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1. Introduction
1.1 About DANMAP 
The Danish Integrated Antimicrobial Resistance 
Monitoring and Research Programme, DANMAP, 
was established in 1995 on the initiative of the Danish 
Ministry of Health and the Danish Ministry of Food, 
Agriculture and Fisheries, as a coordinated national 
surveillance and research programme for antimicrobial 
consumption and antimicrobial resistance in bacteria 
from animals, food and humans. The participants in 
the programme are Statens Serum Institut, the National 
Veterinary Institute, the National Food Institute, and the 
Danish Medicines Agency. The DANMAP programme 
is funded jointly by the Ministry of Health and the 
Ministry of Science, Technology and Innovation.
The objectives of DANMAP are:
•	 to monitor the consumption of antimicrobial agents 
for food animals and humans.
•	 to monitor the occurrence of antimicrobial 
resistance in bacteria isolated from food animals, 
food of animal origin and humans.
•	 to study associations between antimicrobial 
consumption and antimicrobial resistance.
•	 to identify routes of transmission and areas for 
further research studies. 
The monitoring of antimicrobial resistance is based 
on three categories of bacteria: Human and animal 
pathogens, zoonotic bacteria, and indicator bacteria. 
Human and animal pathogens are included because 
these cause infections and they reflect primarily 
resistance caused by use of antimicrobial agents in the 
respective reservoirs. Zoonotic bacteria are included 
because they can develop resistance in the animal 
reservoir, which may subsequently compromise 
treatment effect when causing infection in humans.
Indicator bacteria are included due to their ubiquitous 
nature in animals, food and humans and their ability to 
readily develop antimicrobial resistance in response to 
selective pressure in both reservoirs.
This report, DANMAP 2010, describes the annual 
consumption of antimicrobial agents and the occurrence 
of resistance in different reservoirs in Denmark in 2010. 
Results from the monitoring program as well as from 
selected research projects are presented in overview 
tables and figures. In the Appendices, detailed tables 
of antimicrobial consumption in animals and humans 
and specific MIC distributions are presented, along 
with a list of abbreviations, explanations of terminology 
and description of materials and methods. A list of 
DANMAP publications in the international scientific 
literature in 2010 is also included. 
This DANMAP report is also available at 
www.danmap.org.
1.2 Acknowledgements
The National Food Institute and the National 
Veterinary Institute from the Technical University of 
Denmark would like to thank:
•	 the meat inspection staff and the company 
personnel at the slaughter houses for collecting 
samples from animals at slaughter. Without their 
careful recording of the animals’ farm of origin 
the results would be less useful.
•	 the Laboratory of Swine Diseases, Danish Meat 
Association at Kjellerup for making isolates of 
animal pathogens available to the programme.
•	 the Danish Medicines Agency for collecting and 
transmitting data on veterinary consumption of 
antimicrobial agents from the pharmacies.
•	 the staff of the Regional Veterinary and Food 
Control Authorities for collection of food 
samples and isolation of bacteria.
•	 the staff of the Zoonosis Laboratory at the 
National Food Institute.
•	 the staff of the research group of Antimicrobial 
resistance and molecular typing at the National 
Food Institute.
•	 the staff of the division of Poultry, Fish and Fur 
Animals at the National Veterinary Institute.
Statens Serum Institut would like to thank
 
•	 the Departments of Clinical Microbiology in 
the DANRES group - Danish Study Group for 
Antimicrobial Resistance Surveillance - for 
providing data on resistance in bacteria from 
human clinical samples.
•	 the staff of the Neisseria and Streptococcus 
Typing Unit at SSI.
•	 the staff of the Foodborne Pathogens Unit at SSI.
•	 the staff of the Staphylococcus Laboratory at SSI.
•	 the staff of the Antimicrobial Resistance 
Reference Laboratory and Surveillance Unit at 
SSI.
•	 Maja Laursen and Jan Poulsen from the Danish 
Medicines Agency for providing data on 
consumption of antimicrobials in humans.
•	 Erik Villadsen from the Danish National Board 
of Health for providing data on hospital activity.
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1.3 DANRES
The Danish Study Group for Antimicrobial Resistance 
Surveillance provides data from the Departments of 
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Maria Kristin Bjõrnsdottir
Michael Tvede
DCM, Herlev Hospital:
Magnus Arpi
Hanne Wiese Hallberg
Tina Larsen
DCM, Hillerød Hospital:
Dennis Schrøder Hansen
Lisbeth Nielsen
DCM, Slagelse Hospital:
Ram Dessau
Ole Heltberg
Bent Røder
DCM, Odense University Hospital:
Bente Gahrn-Hansen
Thøger Gorm Jensen
Ulrik Stenz Justesen
DCM, Esbjerg Hospital: 
Kjeld Truberg Jensen
DCM, Vejle Hospital:
Anette Holm
Per Schouenborg
DCM, Herning Hospital:
Helga Schumacher
Marianne Hedegaard Søndergaard
DCM, Skejby Hospital:
Svend Ellermann-Eriksen
Kurt Fuursted
Brian Kristensen
Marianne K. Thomsen
DCM, Viborg Hospital: 
Jørgen Prag
Birgitte Tønning
DCM, Aalborg Hospital: 
Tove Højbjerg
Lena Mortensen
Henrik C. Schønheyder
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2. Summary
2.1 Sammendrag
Dette er den femtende DANMAP rapport. DANMAP 
2010 beskriver det årlige forbrug af antibiotika og fore-
komsten af resistens i forskellige reservoirer. Den konti-
nuerlige overvågning af antibiotikaresistens og -forbrug 
gør det muligt at analysere tendenserne i antibiotikafor-
brug og -resistens over tid.
DANMAP præsenterer antibiotikaforbrug til mennesker 
og dyr på årsbasis. Lægemiddelstyrelsen har overvåget 
forbruget af receptordineret medicin på patientniveau 
siden begyndelsen af 1990erne. Siden 2001 er al anven-
delse af receptordineret medicin til dyr registreret på 
dyreart, aldersgruppe og besætningsniveau i VetStat 
databasen på Veterinærinstituttet, Danmarks Tekniske 
Universitet.
Antibiotikaforbrug til dyr
I 2010 var antibiotikaforbruget til dyr i Danmark på 
126,9 ton, hvilket repræsenterer en 2,1 % reduktion i 
forhold til 2009. Faldet skyldtes hovedsagligt et mindre 
forbrug til svin. Størstedelen af det totale antibiotikafor-
brug kan henføres til svineproduktionen (79 %), mens 
en mindre andel kan tilskrives kvæg- (12 %) og fjerkræ-
produktionen (0,7 %). 
Svin: For første gang siden 2002 er der sket et fald i anti-
biotikaforbruget til svin. Målt i antal antibiotika doser 
per svin produceret, blev forbruget i 2010 reduceret med 
5 % (korrigeret for eksport af 30 kg grise) sammenlignet 
med 2009, men var fortsat højere end forbruget i 2008. 
Antibiotika forbruget pr. svin er steget med 39 % over de 
sidste 10 år.
Faldet i 2010 skete især i forbruget af tetracykliner 
(5 %), med der var også et reduceret forbrug af makro-
lider (2 %), aminoglykosider (16 %), lincosamid/spec-
tinomycin (7 %) og cefalosporiner (48 %). Tetracykliner, 
makrolider og pleuromutiliner, som primært bruges til 
flok-medicinering i foder eller drikkevand, var fortsat de 
mest almindelige antibiotika brugt til svin. Faldet i det 
totale forbrug af antibiotika til svin var for størstedelen 
forbundet med et 11 % fald i ordinering af antibiotika 
til fravænningsgrise med tarminfektioner. Ordinationer 
til so-besætninger (inkl. smågrise) med tarminfektioner 
faldt med 22 %, svarende til et fald på 3 % per so-år.    
Faldet i det totale antibiotikaforbrug relaterer sig kun til 
det andet halvår af 2010. Forbruget steg reelt med 
8 % i de første seks måneder i forhold til samme 
periode i 2009. I juli 2010 modtog 20 % af de danske 
svineproducenter, som havde det højeste forbrug af 
antibiotika, et informationsbrev, der beskrev den nye 
‘Gult kort’ ordning. I samme måned indførte industrien 
et frivilligt stop for brugen af cefalosporiner til svin. 
Samlet er dette en sandsynlig forklaring på den 13 % 
reduktion i antibiotikaforbruget til svin, der blev obser-
veret i anden halvdel af 2010 sammenlignet med samme 
periode året før.   
Kvæg: Antibiotikaforbruget til kvæg var 14,6 ton i 2010, 
og har været relativt stabilt på omkring 14 til 15 ton 
siden 2005. I denne periode er andelen af smalspektrede 
(beta-lactamase følsomme) penicilliner til køer steget 
fra 48 % til 59 % af doser til systemisk behandling, mens 
makrolider faldt fra 11 % til 3 %, hvilket er i overens-
stemmelse med de officielle anbefalinger. Også til kalve 
faldt forbruget af makrolider fra 35 % af forbruget i 2009 
til 24 % af forbruget i 2010, mens forbruget af tetra-
cykliner steg fra 26 % til 30 % af forbruget, hvormed 
tetracykliner igen blev de mest anvendte antibiotika til 
kalve. Der var meget få ordinationer af fluorokinoloner 
i 2010 (1 kg i alt). Forbruget af tredje og fjerde genera-
tions cefalosporiner til intramammær og systemisk be-
handling faldt med hhv. 29 % og 17 % i forhold til 2009. 
Fjerkræ: Det totale antibiotikaforbrug til fjerkræ faldt 
med 18 % i 2010 i forhold til 2009 (fra 1.070 kg til 879 
kg), men niveauet ligger stadig højere end i perioden fra 
2001 til 2008. Antibiotikaforbruget i kyllingeproduk-
tionen er generelt lavt, og sygdomsudbrud hos nogle få 
producenter kan medføre betydelige fluktuationer i det 
totale antibiotikaforbrug. I 2009 var der sygdomspro-
blemer i adskillige fjerkræflokke, hvilket medførte et 
relativt højt forbrug. Disse problemer synes løst i æglæg-
gere samt i opdræt til slagtekyllinger. I slagtekyllinge-
flokkene var antibiotikaforbruget i 2010 fortsat relativt 
højt i forhold til perioden 2001–2008. Forbruget på 
0,14 ADDkg pr. kg kyllingekød produceret er imidlertid 
fortsat lavt i forhold til andre dyrearter, og også meget 
lavt i forhold til forbruget i kyllingeproduktionen i ikke-
skandinaviske lande. 
Antibiotikaforbruget i kalkunproduktionen varierer 
også markant fra år til år. Sygdomsproblemer medførte i 
2009, at forbruget var højt sammenlignet med de forrige 
år. En vaccinationskampagne mod Pasteurella multocida 
synes at have reduceret sygeligheden, og har medført 
at antibiotikaforbruget i 2010 var på det laveste niveau 
siden 2005 (0,62 ADDkg pr. kg kød produceret). 
I 2010 blev fluorokinoloner ikke ordineret til kalkun-, 
æglægger- og i slagtekyllingeproduktionen. Forbruget af 
fluorokinoloner i fjerkræproduktionen har været falden-
de siden 2006, hvor fluorokinoloner udgjorde 7 % af det 
totale forbrug for både kyllinger/høns og kalkuner.
Akvakultur: Det totale forbrug i 2010 var på 3.060 
kg, en 7 % reduktion i forhold til 2009. Faldet skyldes 
primært et skifte i præparatvalg. Havbrug har generelt et 
højt antibiotikaforbrug pr. kg fisk produceret, sammen-
lignet med andre dyregrupper, men forbruget har været 
faldende siden 2006, hvor forbruget toppede med 13 
ADDkg pr. kg fisk produceret, i forbindelse med usæd-
vanligt varm sommer. Antibiotikaforbruget i akvakul-
tur er kraftigt påvirket af vandtemperaturen. Faldet er 
desuden relateret til en markant forbedret vaccinations-
strategi i samme periode (2006-2010), hvor forbruget 
er faldet med 51% i havbruget, til 9 ADDkg pr. kg fisk 
produceret. Forbruget i ferskvandsfisk ligger mere stabilt 
omkring 2 ADDkg pr. kg fisk produceret. Sulfonamid 
kombineret med trimethoprim samt kinoloner (oxolin-
syre) var de mest anvendte antibiotika til fisk.
10                     
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Kæledyr og heste: Antibiotikaforbruget til kæledyr og 
heste var i 2010 på 3 tons. Forbruget er estimeret ud fra 
ordinationer til disse dyrearter samt salg af præparater 
til smådyrs- og hestepraksis. For 2010 blev det totale 
forbrug af fluorokinoloner estimeret til 14 kg, hvoraf 
størstedelen (>13 kg) blev brugt til kæledyr. Dette svarer 
til 72 % af det totale veterinære forbrug af fluorokino-
loner. Amoxicillin kombineret med clavulansyre var 
det mest brugte antibiotika til kæledyr (539 kg), hvilket 
udgør en stigning på 3% sammenlignet med 2009.
I 2010 var forbruget af cefalosporiner til kæledyr på 320 
kg. Dette var primært 1. generations cefalosporiner til 
oral behandling, men forbruget af 3. generations og 4. 
generations cefalosporiner var omkring 3 kg, svarende 
til 1,8 % af det totale veterinære forbrug.
Antibiotikaforbrug til mennesker
Primærsektor og hospitalssektor: Det totale forbrug 
af antibiotika til systemisk brug i mennesker (primær-
sektor og hospitalssektor) steg med 5 %: fra 17,89 DDD 
pr. 1000 indbyggere pr. dag (DID) i 2009 til 18,84 DID 
i 2010. Hospitalsforbruget udgjorde 10 % af det totale 
forbrug. Stigningen i forbruget blev kun observeret i 
primærsektoren. Siden 2001 er det totale forbrug steget 
med 4,54 DID (32 %).  
Primærsektor: I 2010 steg det totale antibiotikaforbrug 
(J01) i primærsektoren med 6 % til 16,93 DID sammen-
lignet med 15,95 DID i 2009. Det er det højeste forbrug, 
der er målt i DANMAPs historie. Beta-laktamase føl-
somme penicilliner repræsenterede den største gruppe 
af antibiotika i 2010 (31 %) og penicilliner (J01C) 
udgjorde 62 % af det totale forbrug i 2010. 
Forbruget af bredspektrede antibiotika var 6,48 DID i 
2010; en stigning på 0,53 DID i forhold til 2009. Forbru-
get af antibiotika steg for alle grupper af antibiotika med 
undtagelse af sulfonamider.
Der kan være flere forskellige forklaringer på det sti-
gende forbrug: 1) en stigning i antallet af behandlede 
patienter; 2) udbrud med Mycoplasma pneumoniae i 
anden halvdel af 2010, som medførte et øget forbrug 
af beta-laktamase sensitive penicilliner til empirisk 
behandling af nedre luftvejsinfektioner og makrolider 
til behandling af bekræftet M. pneumoniae pneumoni – 
ifølge de nationale retningslinjer; og 3) et øget forbrug af 
”kombinationspenicilliner”, sandsynligvis som følge af 
bedre opslutning til de ændringer i behandlingsvejled-
ningerne for patienter med kronisk obstruktive lungeli-
delser, der kom for få år siden.
Siden 2001 er det totale forbrug (J01) i praksis steget 
med 32 %; DDD er den forbrugsindikator, som er steget 
mest, men også antallet af behandlede patienter og antal 
pakninger er steget i samme periode.
Hospitalssektor: Det totale forbrug af antibiotika i hele 
hospitalssektoren (rehabiliteringscentre, hospice, pri-
vat-, psykiatriske-, specialiserede- og somatiske hospita-
ler) lå på 1,91 DID i 2010 (svarende til forbruget i 2009). 
Siden 2001 er det totale forbrug steget med 0,46 DID 
(31 %). Bredspektrede antibiotika udgjorde 67 % af det 
totale forbrug på hospitalerne i 2010 ligesom i 2009.
Somatiske hospitaler: Det totale antibiotikaforbrug steg 
med 3 % opgjort i DDD pr. 100 sengedage (DBD) (fra 
85,03 DBD i 2009 til 87,72 DBD i 2010), mens det faldt 
med 4 % opgjort i DDD pr. 100 indlæggelser (DAD) i 
forhold til 2009 (fra 297,36 DAD til 284,89 DAD). 
Antallet af DDD i 2010 var det samme som i 2009, mens 
antallet af indlæggelser steg og antallet af sengedage 
faldt i forhold til 2009.
For tre grupper af antibiotika steg forbruget fra 2009 til 
2010: kombinationspenicilliner steg med1,48 DBD 
(26 %); carbapenemer steg med 0,88 DBD (28 %) og 
kombinationen af sulfonamider/trimethoprim steg med 
0,76 DBD (34 %). Forbruget faldt fra 2009 til 2010 for 
følgende stofgrupper: penicilliner med udvidet 
spektrum faldt med 0,76 DBD (5 %); beta-laktamase 
følsomme penicilliner faldt med 0,41 DBD (4 %); 
3. generations cefalosporiner faldt med 0,16 DBD 
(11 %); og fluorkinoloner faldt med 0,27 DBD (2 %). I 
2010 udgjorde cefalosporiner 20 % af det totale forbrug 
på de somatiske hospitaler. Penicilliner med udvidet 
spektrum (17 %), fluorkinoloner (12 %) og beta-lakta-
mase følsomme penicilliner (11 %) var andre af de mest 
anvendte antibiotika i 2010. 
Over de sidste 10 år er det totale forbrug steget med 
39,40 DBD (82 %) eller 35,13 DAD (14 %) afhængig af 
nævneren. Det er vigtigt at påpege, at antallet af udskri-
velser er steget med 18 % i løbet af de sidste 10 år, mens 
antallet af sengedage er faldet med 26 % som følge af 
ændringer i hospitalssektoren. 
Resistens i zoonotiske bakterier
Zoonotiske bakterier som Salmonella og Campylobacter 
er sygdomsfremkaldende bakterier, der kan overføres 
fra dyr til mennesker, enten via direkte kontakt med dyr 
eller via kontaminerede fødevarer. 
De højeste niveauer af resistens blev fundet i importeret 
kalkunkød, hvor ingen af de isolerede S. Typhimurium 
isolater var fuldt følsomme overfor alle 16 antibiotika 
inkluderet i testpanelet, og 93 % af isolaterne var multi-
resistente. Desuden steg apramycin, gentamicin og 
streptomycin resistensen signifikant fra 2009 til 2010.
Blandt Salmonella Typhimurium isolater fra danske svin 
blev der fra 2009 til 2010 observeret signifikante stignin-
ger i antibiotikaresistens overfor ampicillin, streptomy-
cin og tetracyklin. Der var ingen signifikante ændringer 
i resistensforekomsten i dansk svinekød, men tetracyk-
linresistensen i S. Typhimurium isolater fra dansk svi-
nekød (27 %) var signifikant lavere end blandt isolater 
fra danske svin (47 %). S. Typhimurium fra importeret 
svinekød havde en højere resistensforekomst (for 8 ud 
Det totale antibiotikaforbrug til dyr faldt i 2010, 
og for første gang siden 2002 faldt forbruget til 
svin. Derimod steg det humane antibiotikaforbrug 
til det højeste niveau siden starten af DANMAP 
programmet i 1995. Stigningen i forbruget blev 
kun observeret i primærsektoren, og kunne delvist 
forklares med en stigning i antallet af behandlede 
patienter og et udbrud med Mycoplasma 
pneumoniae i anden halvdel af 2010.
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af 16 testede antibiotika) sammenlignet med isolater fra 
dansk svinekød. 
I 2010 blev ingen S. Typhimurium isolater fra svin, 
kvæg, dansk svinekød, importeret svinekød og impor-
teret kylligekød fundet resistente overfor cefalosporiner 
eller fluorokinoloner. Kun S. Typhimurium isolater 
fra importeret kalkunkød var resistente overfor disse 
antibiotika. Blandt de humane tilfælde blev der obser-
veret en højere ciprofloxacin resistens hos de rejserelate-
rede tilfælde (14 %) i forhold til de tilfælde, som havde 
erhvervet infektionen i Danmark (4 %). Cefalosporin 
resistens blev kun rapporteret fra rejserelaterede tilfælde 
(3 %), eller hvor oprindelsen af infektionen var uoplyst 
(1 %).
Klonal spredning har haft stor indflydelse på udbredel-
sen af antibiotikaresistens blandt Salmonella bakteri-
erne; dette gælder især for S. Typhimurium. Siden 2005 
har man blandt S. Typhimurium isolater fra svin kunnet 
observere en parallel stigning (14 %) i resistens over-
for ampicillin (A), streptomycin (S), sulfonamid (Su) 
samt tetracyklin (T). Dette resistensmønster (ASSuT) 
forekommer ofte i fagtyperne DT120 og DT193, som er 
almindeligt forekommende i svin. En anden almindeligt 
forekommende klon blandt S. Typhimurium fra svin er 
isolater med resistens overfor ASSuT samt chloramp-
henicol (C), og dette resistensmønster (ACSSuT) rela-
teres primært til fagtypen DT104. Blandt de humane S. 
Typhimurium isolater blev denne sammenhæng mellem 
resistensmønstre og fagtyper også observeret.   
I de seneste år er der udarbejdet et smittekilderegnskab 
for Salmonella, som angiver de vigtigste fødevarebårne 
kilder til human salmonellose i Danmark. Denne model 
blev benyttet til at estimere kilderne til de humane 
infektioner forårsaget af S. Typhimurium med resistens 
overfor ampicillin, sulfonamid og tetracyklin (ASuT). 
Modellen estimerede, at dansk svinekød kunne tilskrives 
et udbruds-relateret ASuT-tilfælde og fem sporadiske 
ASuT–tilfælde, importeret svinekød 41 ASuT-tilfælde, 
endvidere blev et ASuT-tilfælde tilskrevet importeret 
kalkunkød.
Salmonella Enteritidis er relativt sjælden i dansk fjerkræ-
produktion og kun få isolater var til rådighed fra dansk 
fjerkræ og fjerkrækød i 2010. Kun isolater fra importeret 
kyllingekød var resistente overfor nalidixansyre og ci-
profloxacin. Humant var resistensen overfor ciprofloxa-
cin signifikant højere i rejseassocierede tilfælde (21 %) 
end i tilfælde erhvervet i Danmark (8 %).
I 2010 var der ingen signifikante ændringer i resistens-
forekomsten blandt Campylobacter jejuni isolater fra 
danske slagtekyllinger og kvæg eller blandt Campylobac-
ter coli isolater fra svin. Siden 2005 er der sket en svag 
stigning i forekomsten af tetracyklin resistens blandt C. 
jejuni fra danske slagtekyllinger og kvæg samt i C. coli 
fra danske svin. I samme periode var tetracyklin et af de 
mest almindelige antibiotika ordineret til svin. 
Som i de foregående år indeholdt importeret kyllinge-
kød C. jejuni med signifikant højere resistens overfor 
ciprofloxacin (50 %) sammenlignet med dansk kyllinge-
kød (17 %).
 
Blandt de humane C. jejuni isolater fra tilfælde erhvervet 
i Danmark, var der i 2010 ingen signifikante ændringer 
i resistensforekomsten i forhold til 2009. Ciprofloxa-
cin resistensen blandt C. jejuni isolater fra infektioner 
erhvervet herhjemme (25 %) var signifikant lavere end 
blandt isolater fra rejserelaterede tilfælde (80 %). 
Forekomsten af Clostridium difficile i svinebesætnin-
ger, samt hos kvæg og kyllinger på slagterierne blev for 
første gang undersøgt i 2010. C. difficile blev isoleret fra 
15 % af svinebesætningerne, 15 % af kvæget og 3 % of 
kyllingeflokkene. Alle tre toksin-gener blev påvist i 
73 % af svine-isolaterne og 24 % af kvæg-isolaterne, 
mens et eller to toksin-gener blev påvist i de resterede 
isolater. Isolater med tre toksin-gener blev PCR riboty-
pet, og PCR ribotype 078 blev fundet både blandt svine- 
og kvægisolater. Ribotype 078 forekommer hos menne-
sker, mens de resterende PCR ribotyper er sjældent eller 
aldrig fundet i humane isolater i Danmark. Isolaterne 
blev testet for resistens overfor fem antibiotika, og de 
fleste isolater var resistente overfor clindamycin (87 %), 
mens resistens overfor de andre antibiotika var relativ 
lav.
Fundet af C. difficile 078 i svin er forventelig, da denne 
type er almindelig blandt svin. Men nogle af de andre 
typer med alle tre toksin-gener samt deletioner i tcdC 
kan muligvis forårsage alvorlig human sygdom. Den 
potentielle humane risiko ved forekomst af C. difficile 
med tcdA og tcdB toksin-gener i husdyr bør undersøges 
nærmere.
Resistensforekomsten i S. Typhimurium fra svin steg 
i 2010, mens forekomsten i dansk svinekød forblev på 
samme niveau som i 2009. Resistensforekomsten i S. 
Typhimurium fra dansk svinekød og i Campylobacter 
jejuni i dansk kyllingekød var signifikant lavere end 
i isolater fra det importerede kød. Et tilsvarende 
mønster blev observeret blandt de humane S. 
Typhimurium og Campylobacter jejuni infektioner, 
hvor rejserelaterede tilfælde havde signifikant højere 
resistensforekomst sammenlignet med tilfælde som 
havde erhvervet infektionen i Danmark.
Resistens i indikatorbakterier
Indikatorbakterier er inkluderet i overvågningspro-
grammet for at give information om de generelle resi-
stensniveauer i sunde og raske husdyr. 
Blandt Enterococcus faecium isolater fra svin og slagte-
kyllinger blev der observeret signifikante fald i resistens 
overfor tetracyklin, penicillin og ampicillin fra 2009 
til 2010. Desuden faldt forekomsten af streptomycin 
resistens i isolater fra svin, og resistens overfor quinu-
pristin/dalfopristin og avilamycin i isolater fra slagtekyl-
linger. Sammenlignet med importeret kyllingekød var 
resistensforekomsten signifikant lavere i dansk produce-
ret kyllingekød (for 7 ud af 16 testede antibiotika). Ved 
brug af selektive opformeringsmetoder blev der påvist 
vancomycin resistente E. faecium i 47 % af slagtekyllin-
gerne. Dette indikerer udbredt forekomst af VRE i lave 
koncentrationer i en stor del af besætningerne, selv om 
brug af vækstfremmeren avoparcin har været forbudt i 
Danmark siden 1995.
I 2010 havde Enterococcus faecalis isolater fra slagtekyl-
linger signifikant lavere resistens overfor tetracyklin, 
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I Danmark kan slagtekyllinger og kyllingekød være 
et vigtigt reservoir for ESBL-producerende E. coli, 
selvom cefalosporiner ikke benyttes i kyllingepro-
duktionen. Der er stadig en lav forekomst af resistens 
overfor vancomycin og quinupristin/dalfopristin 
blandt E. faecium isolater fra svin, selvom brugen af 
vækstfremmere har været forbudt i mere end ti år.
erythromycin, streptomycin og salinomycin sammenlig-
net med 2009, mens det blandt isolater fra svin kun var 
tetracyklin resistensen, som blev reduceret signifikant. 
Faldet i tetracyklin resistens blandt enterokok isolater 
fra svin kan være relateret til de registrerede fald i for-
bruget af tetracyklin.
En undersøgelse viste, at det var den samme klon af ’høj 
niveau’ gentamicin-resistente E. faecalis (ST16) som blev 
påvist i svin, svinekød, raske personer og fra patienter 
med infektiøs endokardit. Dette indikerer en zoonotisk 
sammenhæng. 
I 2010 var der ingen signifikante ændringer i resistens-
forekomsten blandt indikator E. coli isolater fra svin og 
slagtekyllinger sammenlignet med 2009. Der var en sig-
nifikant stigning i tetracyklin resistensen blandt isolater 
fra kvæg (fra 2 % til 9 %), formentlig relateret til en 10% 
stigning i tetracyklinforbruget til kalve i 2010. I 2010 
blev der ikke observeret fluorokinolon resistens blandt 
E. coli fra danske svin og kvæg, derimod var 8 % af E. 
coli isolater fra slagtekyllinger fluorokinolon resistente. 
I 2002 blev brugen af fluorokinoloner til behandling af 
husdyr begrænset, og forbruget har siden da generelt 
været lavt. Forekomsten af fluorokinolon resistens i kyl-
lingeproduktionen kan hænge sammen med, at forbru-
get her er relativt højere end i de andre husdyrgrupper.
Som for Campylobacter og enterokokker var resistens-
forekomsten i E. coli isolater fra importeret kyllingekød 
signifikant højere end i isolater fra dansk kyllingekød 
(for 13 ud af 16 testede antibiotika), og 60 % af isolater-
ne fra importeret kyllingekød var multiresistente. Cef-
tiofur resistens (og dermed ESBL) blev i 2010 observeret 
for første gang uden brug af selektiv opformering i et E. 
coli isolat fra dansk kyllingekød (1 %). Fluorokinolon 
resistensen var ti gange højere i importeret kyllingekød 
(41 %) end i dansk produceret kyllingekød (4 %).
Blandt E. coli isolater fra dansk svinekød faldt sulfon-
amid resistensen signifikant fra 38 % til 19 %, og i 2010 
var resistens overfor tetracyklin og sulfonamid signi-
fikant lavere i E. coli isolater fra dansk svinekød sam-
menlignet med isolater fra importeret svinekød. Fluoro-
kinolon resistensen i dansk svinekød var fortsat lav (et 
isolat) i forhold til 4 % af E. coli isolaterne fra importeret 
svinekød.
Blandt E. coli isolater fra kvæg og fra dansk og importe-
ret oksekød var resistensen lav.
ESBL-producerende bakterier er resistente overfor bred-
spekterede cefalosporiner, der ofte bruges til behandling. 
Derfor er forekomsten af disse, selv i et lavt niveau, et 
potentielt alvorligt problem. Ved brug af selektive op-
formeringsmetoder blev forekomsten af disse bakterier 
undersøgt i svinebesætninger, hos kvæg og kyllinger på 
slagterierne samt i kød fra detailforretninger og engros-
lagre. Den højeste forekomst af ESBL-producerende E. 
coli hos dyrene blev påvist i kyllingeflokke på slagteriet 
(27 %), på trods af at cefalosporiner ikke har været brugt 
i den danske kyllingeproduktion de sidste ti år. I kød-
prøverne blev de højeste forekomster af ESBL-produce-
rende E. coli påvist i importeret (50 %) og dansk (8.6 %) 
kyllingekød. Forekomsten af ESBL-producerende E. coli 
fra importeret kyllingekød var i 2010 signifikant højere 
end i 2009.
Resistens i bakterier fra diagnostiske indsendelser 
fra mennesker
Rapporteringen af antibiotikaresistens i bakterier 
fra diagnostiske indsendelser fra mennesker er baseret 
på frivillig indsendelse af data fra DANRES gruppen, 
som dækker de klinisk mikrobiologiske afdelinger i 
Danmark. De eneste undtagelser omfatter methicillin 
resistente Staphylococcus aureus og invasive Streptococ-
cus pneumoniae, som er anmeldepligtige. Data vedrø-
rende disse bakterier kommer fra referencelaboratori-
erne på SSI.
Blandt E. coli isolater fra blod var 3. generations cefalo-
sporin resistensforekomsten i 2010 på 7 %, det samme 
niveau som i 2009. Niveauet var højere end i de andre 
nordiske lande i 2009. I 2010 steg gentamicin resistens-
forekomsten til 6 %. Ciprofloxacin resistensen var 14 % 
i 2010 (min 7 %, max 22 % for de individuelle KMAer), 
dette niveau var det samme som i 2009. Ingen E. coli iso-
later fra blodinfektioner var carbapenem resistente. I lø-
bet af de seneste 10 år er resistensen overfor cefuroxim, 
ciprofloxacin og gentamicin steget signifikant. Resistens 
overfor 3. generations cefalosporiner er rapporteret til 
DANMAP siden 2008; i denne periode er resistensfore-
komsten steget.
Blandt E. coli isolater fra urin fra hospitaler var 3. gene-
rations cefalosporin resistensforekomsten på 5 % i 2010, 
det samme niveau som i 2009. For de følgende antibio-
tika var der et lille fald (1 %) i resistensforekomsten: 
ampicillin (41 %), sulfonamid (35 %), ciprofloxacin 
(12 %) og cefuroxim (2. generations cefalosporin) (5 %). 
Blandt E. coli isolater fra urin fra praksis var 3. genera-
tions cefalosporin resistensforekomsten på 5 % i 2010, 
det samme niveau som i 2009. Nalidixansyre resistensen 
steg fra 14 % i 2009 til 15 % in 2010. Fra 2009 til 2010 
var der små fald i resistensforekomsten (1-2 %) for am-
picillin (40 %) og sulfonamid (37 %).
Blandt Klebsiella pneumoniae isolater fra blod var resi-
stensforekomsten for 3. generations cefalosporiner 
9 % (min. 4 %, max 24 %), hvilket er samme niveau som 
i 2009. Denne resistensforekomst var højere, end hvad 
der blev rapporteret til EARS-Net for de andre nordiske 
Tilstedeværelsen af de forskellige ESBL-gener afhang 
af dyrearten. CMY-2 og SHV-2 blev ofte fundet hos 
slagtekyllinger, mens CTX-M-8 kun blev påvist hos 
kvæg. Flere af ESBL-generne i E. coli fra dyr og kød er 
tidligere fundet i humane E. coli isolater. Slagtekyllin-
ger og kyllingekød synes at være et vigtigt reservoir for 
ESBL-producerende E. coli, også i lande som Danmark, 
hvor brugen af cefalosporiner i kyllingeproduktionen 
for længst er ophørt eller aldrig har været brugt.
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Forekomsten af 3. generations cefalosporin resistente E. 
coli og K. pneumoniae fra blod- og urinvejs-infektioner 
var på samme niveau som i 2009. Forekomsten af 
resistens for tredje generations cefalosporiner og 
ciprofloxacin var højere i K. pneumoniae isolater fra 
Sjælland sammenlignet med forekomsten på Fyn og i 
Jylland. Et interventionsstudium på Bispebjerg Hospital 
viste, at det er muligt at nedbringe antallet af resistente 
K. pneumoniae isolater. 
De fleste E. faecium isolater var ampicillinresistente. 
Resistensforekomsten var stadig lav hos 
P. aeruginosa og streptokokker.
Antallet af hospitalserhvervede MRSA var uændret, 
mens stigningen i MRSA infektioner generelt skyldes 
en spredning i samfundet udenfor hospitalerne. Der var 
en stigning i antallet af humane MRSA CC398, en type 
som er associeret med kontakt til svin. 
lande i 2009 og på samme niveau som i flere sydeuropæi-
ske lande. Forekomsten af 3. generations cefalosporin re-
sistens var signifikant højere i den østlige del af Danmark 
(14 %) sammenlignet med den vestlige del (6 %). Både 
fluorkinolon resistensen (ciprofloxacin 11 %, nalidixan-
syre 17 %) og gentamicin resistensen var højere end i de 
andre nordiske lande og på samme niveau som i flere 
sydeuropæiske lande. Fra 2009 til 2010 var der et fald i 
resistensforekomsten for gentamicin, ciprofloxacin og 
cefuroxim; dette fald sås mest for K. pneumoniae isolater 
på Sjælland. Dette kunne delvis forklares ved interven-
tion på hospitaler i Københavnsområdet (Tekstboks 8). 
Ingen K. pneumoniae isolater fra blod var carbapenem 
resistente. 
Blandt Klebsiella pneumoniae isolater fra urin var fore-
komsten af resistens for 3. generations cefalosporiner 
12 % i isolater fra hospitaler og 7 % i isolater fra primær-
sektoren, dette var på samme niveau som i 2009. Både 
for isolaterne fra hospital- og praksis-urinprøverne var 
forekomsten af resistens for 3. generations cefalospo-
riner og ciprofloxacin signifikant højere i den østlige 
del af Danmark (Sjælland) end i den vestlige del (Fyn 
og Jylland). Der var et signifikant fald i forekomsten af 
fluorkinolon resistens i K. pneumoniae urinisolater fra 
hospitalerne fra 2009 til 2010 (i 2010: ciprofloxacin 14 %, 
nalidixansyre 20 %). Sulfonamid resistensen steg til 
29 % blandt urinisolater fra hospitalerne og til 34 % 
blandt isolaterne fra praksis.
Carbapenem (meropenem) resistens var til stede i 
K. pneumoniae urinisolaterne fra både hospitals- og 
praksissektor. Et af de carbapenem resistente isolater 
producerede det nye carbapenemase enzym New 
Delhi Metallo-β-lactamase 1 (NDM-1). Dette isolat 
var resistent overfor alle testede antibiotika undtagen 
tigecyclin og colistin. Forekomsten af carbapenem 
resistens i K. pneumoniae er ikke anmeldepligtig; derfor 
kunne der ikke beregnes en frekvens for carbapenem 
resistens.
ESBL-producerende E. coli og K. pneumoniae er ikke 
anmeldepligtige i Danmark, og de var kun rapporteret 
til DANMAP fra få KMAer; det var derfor ikke muligt at 
beregne forekomsten.
Resistensforekomsten i Pseudomonas aeruginosa isolater 
fra blod var lav for alle de testede antibiotika.
I 2010 var penicillin og erythromycin resistensfore-
komsten stadig lav blandt Streptococcus pneumoniae og 
gruppe A, B, C og G streptokokker.
Forekomsten af ampicillin resistens i Enterococcus 
faecium isolater fra blod steg i 2010 til 92 %. Forekom-
sten af vancomycin resistens var 1.8 % hos E. faecium og 
mindre end 1 % i E. faecalis blodisolater. I 2010 var der 
et udbrud med vancomycin resistente (vanA) E. faecium 
på Aarhus Universitetshospital. Dette udbrud er stadig 
ved at blive undersøgt. Høj niveau gentamicin resistens 
(HLGR) fra blodinfektioner blev kun testet på én afde-
ling for klinisk mikrobiologi. Her var 36 % af de testede 
E. faecalis isolater HLGR og 74 % af de testede E. faecium 
isolater HLGR.
I 2010 blev der indrapporteret 1.418 tilfælde af Staphy-
lococcus aureus bakteriæmi svarende til en incidens på 
24.6 pr. 100.000 indbyggere (uændret fra 2009). I alt 20 
(1.4 %) var forårsaget af methicillin resistente S. aureus 
(MRSA). Dette er på samme niveau som i 2009 og er 
fortsat blandt de laveste incidenser observeret i Europa. 
Frekvensen af resistens overfor fusidinsyre og norfloxacin 
steg, mens frekvensen af resistens overfor øvrige antibio-
tika lå på samme niveau som de foregående år.
Antallet af nye tilfælde af MRSA var i 2010 1.097 sam-
menlignet med 817 i 2009. Antallet var det højeste i mere 
end 25 år. Stigningen blev set både blandt tilfælde erhver-
vet i udlandet (247 vs. 156) og tilfælde erhvervet i Dan-
mark (852 vs. 661). For tilfælde i Danmark skyldes dette 
specielt flere tilfælde i gruppen ”samfundserhvervet, med 
rapporteret kontakt til hospital/plejehjem indenfor de 
sidste 12 måneder” (169 vs. 81). Hos 129 af disse var der 
dog ingen kendt MRSA eksponering; stigningen i denne 
gruppe kan således skyldes bedre rapportering af hospi-
tals-/plejehjemskontakt. Antallet af hospitalserhvervede 
tilfælde er fortsat lavt og på samme niveau som i 2009 
(62 vs. 53). 
For samfundserhvervede tilfælde uden kendt hospitals/
plejehjemskontakt er der set en signifikant ændring, 
således at der i 2010 er betydelig flere, der har rapporte-
ret kendt eksponering for MRSA. Dette gælder både for 
patienter med infektioner samt personer, der er bærere af 
MRSA (screeningsprøver).
Der blev i 2010 set en signifikant stigning i antallet af 
humane MRSA af typen CC398, der har relation til svin; 
fra 40 tilfælde i 2009 til 109 i 2010. I 15 af disse tilfælde 
har personerne ikke haft direkte kontakt til svin eller bor 
i husstand med én, der har direkte kontakt til svin; dette 
kan betyde, at MRSA CC398 er begyndt at adaptere sig, 
således at den lettere smitter fra menneske til menneske. 
Hovedparten af disse 15 personer bor i nærområde til 
andre personer med CC398, eller hvor der er konstateret 
MRSA CC398 i svin. Der er fortsat ingen tegn til spred-
ning til egentlige byområder, og der er således fortsat 
ingen tegn på, at MRSA CC398 spredes via kød.  
I 2010 blev erkendt et nyt gen, der koder for methicillin 
resistens, kaldet mecAlga251. Disse stammer var negative 
med hidtidige detektionsmetoder. I 2010 var der i alt 21 
personer smittet med denne type. Undersøgelse af tidlige-
re års stammer har vist, at disse har spredt sig i Danmark 
siden 2004.
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2.2 Summary
This is the 15th DANMAP report. DANMAP 2010 de-
scribes the annual consumption of antimicrobial agents 
and the occurrence of resistance in different reservoirs. 
The continuous monitoring of antimicrobial resistance 
and consumption makes it possible to analyse trends 
over time.
DANMAP presents the use of antimicrobial agents in 
humans and animals. In humans, the use of prescription 
medicines has been monitored by the Danish Medicines 
Agency at the level of the individual patient since the 
early 1990s. In animals, data on all medicines prescribed 
by veterinarians for use in animals have been registered 
at farm and species level by the VetStat program at the 
Veterinary Institute (Technical University of Denmark) 
since 2001.
Antimicrobial consumption in animals
In 2010, the total veterinary consumption of antimi-
crobial agents amounted to 126.9 tonnes, representing 
a 2.1% decrease relative to 2009, which was attributed 
to a decrease in consumption in pigs. The antimicrobial 
consumption in pigs, cattle and poultry comprised 79%, 
12%, and 0.7% of the total veterinary consumption, 
respectively. 
Pigs: For the first time since 2002, the total antimicrobi-
al consumption in pigs decreased. The decrease in con-
sumption was 5% measured in doses per pig produced 
(adjusted for export of pigs around 30 kg) compared 
with the 2009 level, but remained above the 2008 level 
(by 7%). Over the past decade, the consumption per pig 
produced has increased by 39% (2001–2010).
The decrease in 2010 was mainly in use of tetracyclines 
with a reduction of 100.5 tonnes, representing a 5% 
decrease per pig produced. Also the use of macrolides 
(2%), aminoglycosides (16%), lincosamides/spectino-
mycin (7%) and cephalosporins (48%) was reduced. 
Tetracyclines, macrolides and pleuromutilins mainly 
used for oral therapy, continued to be the most com-
monly used antimicrobial agents in pigs throughout 
2001–2010. 
The overall decrease in consumption was mainly associ-
ated with an 11% decrease in prescription for weaning 
pigs primarily for gastrointestinal infections, but also 
decreasing prescription for sow herds was observed. The 
consumption in sow herds (including piglets) decreased 
by 3% per sow-year, related to a 22% decrease in pre-
scription for gastrointestinal disease.
The decrease in consumption in 2010 was entirely relat-
ed to the second half of the year, while in the first half of 
the year, the consumption increased by 8% compared to  
the same period in 2009. The decrease in use of cepha-
losporins was related to a voluntary ban by the industry 
enforced in July 2010. The same month, the “yellow 
card” intervention was announced with an information 
letter to part of the pig farmers, representing the farms 
with the 20% highest consumption per pig (Textbox 
2). This is a likely explanation for the 13% reduction in 
the second half year compared with the same period in 
2009.
Cattle: In 2010, approximately 14.6 tonnes of antimi-
crobial agents were prescribed for cattle; overall, the 
consumption has been stable since 2005, with a small 
increase in 2009. Since 2005, the proportional use of 
beta-lactamase sensitive penicillins for cows has been 
continuously increasing from 48% to 59%, while use of 
macrolides has decreased from 11% to 3%, in accord-
ance with the official guidelines. In calves, the use of 
macrolides decreased from 35% in 2009 to 24% in 2010, 
while tetracyclines increased from 26% to 30% of the to-
tal consumption, becoming the major drug of choice as 
before 2006. In 2006–2009, macrolides were the major 
drug of choice; the reduction in use of macrolides for 
calves from 35% in 2009 to 24% in 2010, was in accord-
ance with the official guidelines.
The use of fluoroquinolones in cattle was only one 
kg. The use of 3rd and 4th generation cephalosporins 
decreased both for systemic and intramammary use, by 
17% and 29% respectively, as compared to 2009. Over 
the past decade, the highest consumption of 3rd and 4th 
generation cephalosporins for cattle was in 2008 (a total 
of 92 kg).
Poultry: The consumption of antimicrobial agents in 
poultry decreased by 18% to 879 kg in 2010 compared 
with 2009, but was higher than the levels in previous 
years, 2001–2008. 
The antimicrobial consumption in domestic fowl (Gallus 
gallus) is generally at a very low level. Therefore, disease 
outbreaks in a few farms affect importantly the national 
consumption in poultry causing considerable fluctua-
tions. In 2009, increasing disease problems caused a 
steep increase in consumption [DANMAP 2009]. These 
problems appeared to be under control in 2010 for the 
breeding and rearing for layer production, and rearing 
for broiler production. 
For broilers, an additional increase was observed in 
2010, mainly in the prescription of amoxicillin. The 
consumption per broiler produced (including breed-
ing and rearing) was unchanged at 0.14 ADDkg in 2010 
compared with 2009, but this was more than double of 
the consumption during 2001–2008. 
The antimicrobial consumption in turkeys also fluctu-
ates significantly between years. The consumption was 
very high in 2009 compared with previous years but a 
vaccination campaign (Pasteurella multocida) seemed 
to be successful in the combat of the problems, causing 
a decrease in antimicrobial consumption to the lowest 
level since 2005. 
In 2010, fluoroquinolones were used neither in the tur-
key production nor in Gallus gallus; the use of fluoro-
quinolones has been decreasing since 2006 when fluo-
roquinolones comprised 7% of the consumption both in 
Gallus gallus and in turkey production.
                                                                           
       15DANMAP 2010  
2.SUMMARY
Aquaculture: The antimicrobial consumption in aqua-
culture decreased by 7% to 3,060 kg in 2010, continuing 
the decrease observed in 2009. This was mainly due to a 
change in choice of antimicrobial agent towards oxolinic 
acid. The consumption is generally high in salt water 
aquaculture and peaked in 2006 reaching 13 ADDkg/
kg fish produced, due to unusually high summer tem-
peratures. Since then the consumption has decreased 
by 51% to 9 ADDkg/kg fish produced, partly because of 
variation i water temperature, partly due to a gradual 
improvement of vaccination strategies. The consump-
tion in fresh water is more stabile around 2 ADDkg/ 
kg fish produced. In previous years the major class of 
antimicrobial was sulfonamide/trimethoprim, followed 
by quinolones (oxolinic acid). 
Companion animals: The consumption of antimi-
crobial agents in companion animals (pet animals 
and horses) was around 3 tonnes, estimated from the 
prescription for these species and sales for companion 
animal practices. The use of fluoroquinolones in com-
panion animals was estimated to 14 kg in 2010 (>13 
kg for pet animals), corresponding to 72% of the total 
veterinary consumption of fluoroquinolones. The major 
antimicrobial agent used in pet animals was amoxicillin 
in combination with clavulanic acid (539 kg), represent-
ing an increase of 3% compared with 2009. Other agents 
frequently used in pet animals were cephalosporins 
(estimated 320 kg), mainly 1st generation for oral use. 
In pet animals, the consumption of 3rd and 4th genera-
tion cephalosporin was an estimated 3 kg, correspond-
ing to 1.8% of the total veterinary consumption of these 
antimicrobial agents. 
Antimicrobial consumption in humans
Primary health care and hospital care: The total 
consumption of antibacterial agents for systemic use 
(primary health care and hospital care) increased by 5%: 
from 17.89 DDDs per 1,000 inhabitants per day (DID) 
in 2009 to 18.84 DID in 2010. Hospital care contributed 
10% of the total consumption. The increase was noticed 
in primary health care only. Since 2001, the total con-
sumption of antibacterial agents has increased by 4.54 
DID (32%).
Primary health care: The consumption of antibacte-
rial agents for systemic use (J01) in primary health care 
increased by 6% to 16.93 DID as compared with 15.95 
DID in 2009. This is the highest level of consumption 
measured in the history of DANMAP. Beta-lactamase 
sensitive penicillins represented the largest therapeu-
tic group of antibacterial agents consumed (31%), and 
penicillins (J01C) accounted for 62% of the total con-
sumption in 2010. Consumption of broad-spectrum 
agents represented 6.48 DID in 2010, increasing by 0.53 
DID (9%) compared with 2009. Consumption of all 
but one therapeutic group (short-acting sulfonamides) 
increased. Possible explanations for the increased con-
sumption include: 1) an increased number of patients 
treated; 2) an outbreak of Mycoplasma pneumoniae in 
the second half of 2010 with increased consumption of 
beta-lactamase sensitive penicillins as empirical treat-
ment of lower respiratory tract infection and macrolides 
as treatment of confirmed M. pneumoniae pneumonia 
- according to national guidelines; and 3) an increased 
consumption of ‘combination penicillins’ presumably as 
a result of better adherence to the changes in the treat-
ment guidelines for patients with chronic obstructive 
lung diseases that were introduced a few years ago. 
Total antibacterial consumption (J01) in primary health 
care has increased by 32% since 2001, and DDD seems 
to be the indicator that has increased the most. On a 
treated-patient-level both the number of DDDs per 
treated patient and DDDs per prescribed package has 
increased since 2001.
Hospital care: Total consumption (J01) in Danish 
hospital care (rehabilitation centres, hospices, private-, 
psychiatric-, specialised-, and somatic hospitals) added 
up to 1.91 DID in 2010; similar to that of 2009. Since 
2001, the consumption has increased by 0.46 DID 
(31%). Broad-spectrum agents represented 67% of the 
total consumption, as in 2009.
Somatic hospitals: The total consumption (J01) ex-
pressed in DDDs per 100 occupied bed-days (DBD) 
increased by 3% (from 85.03 DBD in 2009 to 87.72 DBD 
in 2010). When expressed as the number of DDDs per 
100 admissions (DAD) it decreased from 297.36 DAD 
to 284.89 DAD (4%). These figures are based on almost 
equal numbers of DDD, but less occupied bed-days and 
more admissions in 2010 compared with 2009. 
In three therapeutic groups, consumption increased 
from 2009 to 2010 when expressed as DBD: ‘combina-
tion penicillins’ increased by 1.48 DBD (26%); carbap-
enems increased by 0.88 DBD (28%) and combinations 
of sulfonamides and trimethoprim increased by 0.76 
DBD (34%). Consumption decreased in other therapeu-
tic groups from 2009 to 2010: penicillins with extended 
spectrum with a decrease of 0.76 DBD (5%); beta-lacta-
mase sensitive penicillins with a decrease of 0.41 DBD 
(4%); 3. generation cephalosporins with a decrease of 
0.16 DBD (11%); and fluoroquinolones with a decrease 
of 0.27 DBD (2%). In 2010, cephalosporins accounted 
for 20% of the total consumption in somatic hospitals. 
Penicillins with extended spectrum (17%), fluoroqui-
nolones (12%) and beta-lactamase sensitive penicillins 
(11%) were the other top four contributing therapeutic 
groups in 2010. 
Over the last decade (2001–2010), somatic hospital con-
sumption has increased by 39.40 DBD (82%) or by 35.13 
DAD (14%) depending on the denominator. It is im-
perative to exemplify that the number of admissions has 
increased by 18% during the last decade and the number 
of bed-days has decreased by 26% as a consequence of 
changes in hospitalization patterns.
Overall, the total antimicrobial consump-
tion in animals decreased during 2010, and for 
the first time since 2002, the consumption in pigs 
decreased. In contrast, the human consumption 
increased to the highest level seen since the start of 
the DANMAP programme in 1995. The increased 
consumption was observed in primary health care, 
and could partly be explained by an outbreak of 
Mycoplasma pneumoniae and increased number of 
treated patients during 2010.
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The level of resistance in S. Typhimurium from 
pigs increased in 2010, whereas the level in Danish 
pork remained the same. The level of resistance in S. 
Typhimurium from Danish pork and Campylobacter 
jejuni from Danish broiler meat was significantly 
lower than in isolates from imported meat. A similar 
pattern was observed among the human S. Typhimu-
rium and Campylobacter jejuni cases, where cases 
associated with a history of travel had significantly 
higher levels of resistance compared to domestically 
acquired cases.
Resistance in zoonotic bacteria
Zoonoses such as salmonellosis or campylobacteri-
osis are infections and diseases that are transmissible 
between animals and humans, either via direct contact 
or indirectly via contaminated food. Data on antimi-
crobial resistance originate from the DANMAP pro-
gramme as well as national surveillance and control 
programmes for Salmonella and Campylobacter.
Among the Salmonella Typhimurium isolates from 
Danish pigs, a significant increase in resistance to 
ampicillin, streptomycin and tetracycline was observed 
from 2009 to 2010. When comparing the resistance 
in Danish pork (27%) to resistance in Danish pigs 
(47%), a significantly higher occurrence of resistance to 
tetracycline was found in the animals. S. Typhimurium 
isolates from imported pork had a significantly higher 
occurrence of resistance to five of the 16 tested anti-
microbial agents than S. Typhimurium isolates from 
Danish pork.
The highest level of resistance was observed in im-
ported turkey meat, where none of the S. Typhimurium 
isolates were fully sensitive, whereas 93% were found 
to be multi-resistant. In addition, a significant increase 
in resistance was seen for apramycin, gentamicin and 
streptomycin resistance in 2010 compared to 2009.
In 2010, no animal isolates of S. Typhimurium or S. 
Enteritidis were found resistant to cephalosporins, 
ciprofloxacin or nalidixic acid. Only S. Typhimurium 
isolates from imported turkey meat were found re-
sistant to these three antimicrobial agents. Among the 
human cases, a higher level of ciprofloxacin resistance 
was observed in the travel-associated infections (14%) 
when compared with the domestically acquired infec-
tions (4%), and resistance to cephalosporins was only 
reported among cases that had travelled abroad (3%) or 
where the origin of the infection was unknown (1%).
 
Clonal dissemination plays an important role in the 
spread of antimicrobial resistant Salmonella spp., par-
ticularly within S. Typhimurium. Since 2005, there has 
been a parallel increase (14%) in pig isolates resistant to 
ampicillin, streptomycin, sulfonamide and tetracycline 
(ASSuT), a resistance pattern often observed in the 
phage types DT120 and DT193. Among the pig isolates 
resistant to ampicillin, chloramphenicol, streptomycin, 
sulfonamide and tetracycline (ACSSuT), the majority 
were phage type DT104. Among the human S. Typh-
imurium cases, the same correlation between resistance 
pattern and phage types was observed.   
A source attribution model is routinely applied to 
estimate the contribution of the major animal-food 
sources to human Salmonella infections in Denmark. 
This model was used to estimate the number of do-
mestically acquired human cases caused by S. Typh-
imurium isolates resistant to ampicillin, sulfonamide 
and tetracycline (ASuT). Overall, one outbreak-related 
and five sporadic ASuT cases were attributed to Danish 
pork, 41 ASuT cases to imported pork and one ASuT 
case to imported turkey meat.
Among Salmonella Enteritidis isolates from human 
cases, a higher level of ciprofloxacin resistance was 
observed in the travel-associated infections (21%) and 
cases of unknown origin (21%) when compared with 
the domestic sporadic cases (8%). 
From 2009 to 2010, no significant changes in resistance 
were observed among isolates of Campylobacter jejuni 
from Danish broilers and Danish cattle nor for Campy-
lobacter coli isolates from pigs. In general, a slightly 
increasing trend has been observed in the occurrence of 
resistance towards tetracycline in C. jejuni from Dan-
ish broilers and Danish cattle, as well as for C. coli from 
Danish pigs since 2005. During the same period, tetra-
cyclines have been the most or second most frequently 
used group of antimicrobial agents for these animal 
species. As in previous years, the level of ciprofloxacin 
resistance in C. jejuni was significantly higher among 
isolates from imported broiler meat (50%) when com-
pared with isolates from Danish broiler meat (17%). 
From 2009 to 2010, no significant changes in resistance 
were observed in C. jejuni isolates from human campy-
lobacteriosis cases acquired domestically. However, C. 
jejuni isolates from cases associated with a history of 
travel have had significantly higher level of ciprofloxacin 
resistance (80%) compared to domestically acquired 
cases (25%). 
Pig farms as well as cattle and broilers at slaughter were 
investigated for the occurrence of Clostridium difficile 
for the first time. Fifteen percent of the pig farms, 15% 
of cattle and 3% of the broiler flocks were positive for C. 
difficile. Isolates with up to three toxin genes were found 
with the highest occurrence among isolates from pig 
farms (73%). The isolates with three toxin genes present 
were ribotyped, and PCR ribotype 078 commonly found 
among pigs was found among pig farm isolates and cat-
tle isolates. The rest belonged to PCR ribotypes rarely 
or not previously found in humans in Denmark. The 
isolates were tested to five antimicrobial agents and most 
isolates were resistant to clindamycin (87%); resistance 
was low to the other antimicrobial agents tested.
Findings of C. difficile 078 in pigs are not surprising 
since this type is known to be common among pigs. But 
other types may also have a potential to cause severe 
disease in humans as types with all three toxin genes 
and deletion in tcdC were found. Moreover, the impor-
tance of C. difficile with tcdA and tcdB in animals should 
be further investigated.
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Resistance in indicator bacteria
Indicator bacteria are included in the DANMAP pro-
gramme to provide information about the general levels 
of resistance in healthy production animals and meat.
Enterococcus faecium isolates from both pigs and broil-
ers showed a significant decrease in the occurrence of 
resistance to tetracycline, penicillin and ampicillin from 
2009 to 2010. In addition, a decrease in the occurrence 
of streptomycin resistance was seen in isolates from 
pigs, and the occurrence of quinupristin/dalfopristin 
and avilamycin resistance in isolates from broilers also 
decreased. When comparing E. faecium isolates from 
Danish and imported broiler meat, a significantly higher 
occurrence of resistance to seven different antimicrobial 
agents was found among isolates from imported broiler 
meat. Using a selective enrichment method, vancomycin 
resistant E. faecium was detected in 47% of the broiler 
samples indicating presence of VRE at low levels, even 
though the use of avoparcin has been banned since 1995 
in Denmark. 
Among Enterococcus faecalis isolates from broilers, a sig-
nificant decrease in resistance was seen for tetracycline, 
erythromycin, streptomycin and salinomycin, while 
among isolates from pigs only a significant decrease in 
tetracycline resistance was observed. The reduced oc-
currence of tetracycline resistance among all enterococci 
isolates from pigs can be related to the reduced con-
sumption of tetracyclines.
The same type (ST16) of high-level gentamicin resistant 
(HLGR) E. faecalis was detected in pigs, pork, healthy 
humans, and from patients with infective endocarditis, 
indicating a zoonotic link.
In indicator E. coli isolates from pigs and broilers, no sig-
nificant changes in the levels of resistance were observed 
from 2009 to 2010; however, the level of resistance to tet-
racycline in bovine isolates increased significantly from 
2% to 9%. In 2010, no fluoroquinolone resistance was 
found in E. coli from Danish pigs and cattle, probably 
reflecting the low consumption since 2002 when the use 
in production animals was restricted by law. In contrast, 
8% of the E. coli isolates from broilers were resistant to 
fluoroquinolone, which corresponds to the relatively 
higher use of fluoroquinolones in the broiler production 
during the last ten years compared with other produc-
tion animal species.
Resistance in E. coli isolates from imported broiler meat 
was significantly higher compared with isolates from 
Danish broiler meat for 13 of the 16 tested antimicro-
bial agents. In 2010, ceftiofur resistance was observed 
for the first time in an isolate from Danish broiler meat, 
obtained without selective enrichment (1%), although 
significantly lower than among E. coli from imported 
broiler meat (7%). The occurrence of fluoroquinolone 
resistance in imported broiler meat (41%) was tenfold 
higher than in Danish broiler meat (4%).
In E. coli from Danish pork, resistance to sulfonamide 
decreased significantly from 38% to 19%. In 2010, 
significantly lower resistance to tetracycline and sulfona-
mide was found in isolates from Danish pork compared 
with imported pork. The resistance to fluoroquinolones 
remained low (one isolate) in Danish pork; in imported 
pork, 4% of the E. coli isolates were resistant to fluoro-
quinolones.
The occurrence of resistance in E. coli from imported 
and Danish beef was low.
ESBL-producing bacteria are resistant to extended-spec-
trum cephalosporins, which are often used for treatment 
of infections. Consequently, even a low occurrence of 
these bacteria can potentially be a serious problem. 
Using selective enrichment methods, the occurrence of 
ESBL-producing E. coli in pig farms, cattle and broilers 
at slaughter and in meat at retail was investigated. In 
production animals, the highest occurrence of ESBL-
producing E. coli was found in broilers at slaughter 
(27%) despite no usage of cephalosporins in the Dan-
ish broiler production for at least a decade. In meat, the 
highest occurrence of ESBL-producing E. coli was found 
in broiler meat of imported (50%) and Danish (8.6%) 
origin. For imported broiler meat, the occurrence was 
significantly higher than in 2009.
The presence of ESBL-genes differed depending on 
animal reservoir. CMY-2 and SHV-2 seemed to be more 
related to the broiler production, whereas CTX-M-8 
was found only in cattle. Several of the ESBL-genes 
detected among E. coli obtained from animals and meat 
can also be detected in E. coli of human origin. Broilers 
and broiler meat seem to be an important reservoir for 
ESBL-producing E. coli, also in countries like Denmark 
with no consumption of cephalosporins in the broiler 
production.
Broilers and broiler meat seem to be an im-
portant source for ESBL-producing E. coli, also in 
countries like Denmark with no consumption of 
cephalosporins in the broiler production. Resistance 
to vancomycin and quinupristin/dalfopristin still 
prevails at low levels among E. faecium isolated from 
pigs even though usage of these growth promoters 
has been banned for more than ten years.
Resistance in human clinical bacteria
Data on antimicrobial resistance in bacteria from diag-
nostic submissions are gathered by voluntary reporting 
from the DANRES group which covers the Depart-
ments of Clinical Microbiology (DCM) in Denmark. 
The only exceptions are methicillin resistant Staphylo-
coccus aureus and invasive Streptococcus pneumoniae 
that are notifiable. Data on these bacteria are obtained 
from the reference laboratories at SSI.
Among E. coli blood isolates, resistance to 3rd genera-
tion cephalosporins was 7% in 2010, the same level as 
reported in 2009, but above the 2009 level in the other 
Nordic countries. Resistance to gentamicin increased to 
6% in 2010. In 2010, ciprofloxacin resistance was 14% 
(min. 7%, max. 22% at the individual DCM), the same 
level as in 2009. No E. coli isolates from blood were 
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primary health care. One of the carbapenem resistant 
isolates produced the new carbapenemase enzyme New 
Delhi metallo-β-lactamase 1 (NDM-1) and was resistant 
towards all tested antimicrobial agents except tigecycline 
and colistin. The occurrence of carbapenem resistance is 
not mandatory reportable and no calculation of the fre-
quency of carbapenem resistance could be made for K. 
pneumoniae. Sulfonamide resistance increased signifi-
cantly among urine isolates from both hospitals (29% in 
2010) and primary health care (34% in 2010). 
ESBL-producing E. coli and K. pneumoniae are not man-
datory reportable in Denmark and were only reported to 
the DANMAP report from a few DCMs; it is therefore 
not possible to calculate the frequency of this resistance.
Antimicrobial resistance in Pseudomonas aeruginosa 
isolates obtained from blood was low for all the tested 
antimicrobial agents.
Resistance to penicillins and erythromycin in Strepto-
coccus pneumoniae and in Group A, B, C and G strepto-
cocci remained low in 2010. 
In 2010, resistance to ampicillin increased to 92% in 
Enterococcus faecium isolates from blood. Vancomycin 
resistance was 1.8% in the E. faecium and less than 1% 
in the E. faecalis blood isolates. During 2010, an out-
break of vancomycin resistant (vanA) E. faecium was 
detected at Aarhus University Hospital. This outbreak is 
still under investigation. Only one of the DCM tested all 
enterococci from bloodstream infections for High-level 
gentamicin resistance (HLGR). Here, 36% of the tested 
E. faecalis isolates were HLGR, as were 74% of the tested 
E. faecium isolates. 
In 2010, 1,418 cases of Staphylococcus aureus bacte-
raemia were reported, corresponding to 24.6 cases per 
100,000 citizens. The number of methicillin resistant S. 
aureus (MRSA) was 20 (1.4%). This is at the same level 
as in 2009 and still among the lowest recorded inci-
dences in Europe. The frequency of resistance towards 
fucidic acid and norfloxacin increased while resistance 
towards other antimicrobials was at the same level as in 
carbapenem resistant. Over the last decade, resistance to 
cefuroxime, ciprofloxacin and gentamicin has increased 
significantly. Resistance to 3rd generation cephalo-
sporins has only been reported since 2008; during this 
period the resistance has increased.
In E. coli urine isolates obtained from hospitals, resist-
ance to 3. generation cephalosporins was 5% in 2010, 
the same level as in 2009. Small decreases (one percent) 
in the occurrence of resistance were observed for the 
following antimicrobial agents: ampicillin (41%), sul-
fonamide (35%), ciprofloxacin (12%) and cefuroxime (2. 
generation cephalosporin) (5%). 
In E. coli urine isolates obtained from primary health 
care, resistance to 3rd generation cephalosporins was 
3% in 2010, the same level as in 2009. Nalidixic acid re-
sistance increased significantly from 14% in 2009 to 15% 
in 2010. From 2009 to 2010, small (1-2%) but significant 
decreases in resistance were observed for ampicillin 
(40%) and sulfonamide (37%).
In Klebsiella pneumoniae blood isolates, 3rd generation 
cephalosporin resistance was 9% (min. 4%, max. 24%), 
the same level as reported in 2009. The level was above 
the level reported to EARS-Net by the other Nordic 
countries and corresponded to the occurrence reported 
by several other European countries in 2009 [EARS-Net 
2009]. In the Eastern part of Denmark (Zealand), the 
occurrence of 3. generation cephalosporin resistant K. 
pneumoniae (14%) was significantly higher than in the 
Western part (Funen and Jutland) (6%). Fluoroquinolo-
ne resistance (ciprofloxacin 11%, nalidixic acid 17%) 
and aminoglycoside (gentamicin) resistance (6%) were 
above the levels reported from the other Nordic coun-
tries and the same as reported to EARS-Net by other 
European countries. When comparing 2009 with 2010, 
significant decreases were observed for gentamicin, 
ciprofloxacin and cefuroxime resistance; this was mostly 
due to decreased occurrence of these resistances in K. 
pneumoniae isolates from Zealand. This could in part 
be explained by interventions at hospitals in the Copen-
hagen area (Textbox 8). In 2010, carbapenem (mero-
penem) resistance was absent in K. pneumoniae blood 
isolates. 
In K. pneumoniae urine isolates, 3rd generation cepha-
losporin resistance was 12% in isolates obtained from 
hospitals, and 7% in isolates obtained from primary 
health care, the same levels as reported in 2009. 3rd gen-
eration cephalosporin resistance in K. pneumoniae iso-
lated from urine was significantly higher in the Eastern 
part of Denmark (Zealand) compared with the Western 
part (Funen and Jutland). A significant decrease in 
fluoroquinolone resistance (in 2010; ciprofloxacin 14%, 
nalidixic acid 20%) was observed from 2009 to 2010 
among K. pneumoniae urine isolates from hospitalized 
patients. In the Eastern part of Denmark (Zealand), the 
occurrence of ciprofloxacin resistant K. pneumoniae in 
urine isolates from both hospitals and primary health 
care was significantly higher than in the Western part 
(Funen and Jutland). 
Carbapenem (meropenem) resistance was present in the 
K. pneumoniae urine isolates from both hospitals and 
The number of new cases of MRSA increased in 2010 
to 1,097 compared with 817 in 2009. The number of 
cases was the highest reported in more than 25 years. 
The increase was recorded both among cases acquired 
abroad (247 in 2010 vs. 156 in 2009) and cases acquired 
in Denmark (852 vs. 661). Among Danish cases the 
increase was most marked in the group categorised as 
health-care associated, but with a community onset 
(HACO, 169 vs. 81). Of these, 129 cases did not report 
any known MRSA exposure and the increase may thus 
be attributed to a better completion of report forms. The 
number of hospital-acquired cases was still low and at 
the same level as in 2009 (62 vs. 53 cases).
Among the community-acquired cases, a significant 
change was recorded. In 2010, considerably more cases 
reported known exposure to MRSA, both patients with 
MRSA infections and carriers. The number of MRSA 
belonging to clonal complex CC398, which is associated 
with pigs, increased from 40 in 2009 to 109 in 2010. In 
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Regarding blood and urinary tract infections 
in humans caused by E. coli and K. pneumoniae, 3rd 
generation cephalosporin resistance was at the same 
level as in 2009. Third generation cephalosporin and 
ciprofloxacin resistance were significantly higher 
in the Eastern part (Zealand) compared with the 
Western part (Funen and Jutland) of Denmark. An 
intervention study at Bispebjerg Hospital has shown 
that it is possible to decrease the number of resistant 
K. pneumoniae isolates. Most of the E. faecium iso-
lates were resistant to ampicillin. The occurrence of 
resistance in P. aeruginosa and Streptococci was low. 
The number of hospital-acquired MRSA cases was 
still low and at the same level as in 2009, whereas the 
number of community-acquired cases increased. An 
increase in the number of human CC398 cases was 
observed, CC398 being associated with contact to 
15 of these cases, no known contact to pigs or people 
with contact to pigs was reported. This may be an adap-
tation of the clone to the human host and the possibil-
ity for a human-to-human spread. The majority of the 
15 persons lived in areas with recorded CC398 cases in 
humans and/or pigs. There are still no signs of spread to 
urban areas or spread through the food chain.
In 2010, a new gene conferring resistance to methicillin 
was recognised (mecAlga251). Previous methods failed 
to detect this new variant. In 2010, a total of 21 persons 
were demonstrated positive with this type. Investigation 
of MRSA strains from previous years showed that these 
strains have been spreading in Denmark since 2004. 
The prevalence of MRSA was investigated in pigs at 
the farms, cattle and broilers at slaughter and in meat 
samples. The prevalence in pigs (16%) was at the same 
level as found among pigs at slaughter in 2009. This is 
lower than observed in some other European countries. 
MRSA was not found among cattle or broilers. The 
MRSA from pigs were CC398, and CC398 was found in 
109 human cases, the majority in persons with con-
tact to pigs. In 15 cases no direct contact was reported, 
whereas the majority was found in persons living in 
rural areas with known occurrence of MRSA CC398 in 
pigs. There are still no sign of spread of CC398 to urban 
areas. Imported meat still has the highest occurrence of 
MRSA (19%) as compared to Danish meat. The relative-
ly frequent occurrence of MRSA in meat combined with 
no/very few cases in urban areas makes it safe to con-
clude that there is very little if any risk for meat being a 
risk for contracting MRSA CC398. Pigs still seem to be 
the most important reservoir for MRSA CC398.
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The distribution of the Danish population in which 
antimicrobial agents were used in 2010 is displayed in 
Figure 3.1 together with the five health care regions and 
the 15 Departments of Clinical Microbiology (DCMs).  
The amount of meat available for consumption in 
Denmark during 2007–2010 is presented in Table 
3.1. Cooled and frozen fresh meat is included as well 
as natural-marinated broiler meat. The amount of 
domestically produced meat available for consumption 
in Denmark is estimated as production minus export. 
Table 3.2 shows the antimicrobial agents that are 
registered for treatment of bacterial infections in 
animals and humans. Growth promoters, which are 
no longer used for animals in Denmark, are shown in 
parentheses. Most of the antimicrobial agents used for 
growth promotion in Denmark had effects on Gram-
positive bacteria. Since 1995, the indicator enterococci 
from animals and meat (and in some years from healthy 
humans) have been used as a measure of resistance to 
the growth promoters.
Table 3.1. Danish and imported meat available for 
consumption (in 100 Tons)(a), Denmark
Source Origin 2007 2008 2009 2010
Pork Danish 1745 2113 1868 1819Import 516 956 833 873
Beef Danish 730 831 845 922Import 800 812 888 1026
Broiler 
meat(b)
Danish 626 478 513 532
Import 304 325 303 427
Turkey 
meat Import 84 83 70 87
a) Source: Statistics Denmark. The volumes of Danish meat are 
estimated as production minus export    
b) Natural-marinated broiler meat included   
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DCM HERNING
DCM VIBORG
DCM AALBORG
DCM ÅRHUS
DCM ESBJERG
DCM VEJLE
DCM ODENSE DCM SLAGELSE
DCM HILLERØD
DCM HVIDOVRE
DCM HERLEV DCM RIGS-
HOSPITALET
DCM SØNDERBORG
DCM SLAGELSE 
(NÆSTVED/NYKØBING F)
DCM SLAGELSE 
(ROSKILDE)
North Denmark Region
No. of inhabitants 579,628 
No. of inhabitants/km2 73        
No. of inhabitants/GP 1647
The Sealand Region
No. of inhabitants 820,564 
No. of inhabitants/km2 113        
No. of inhabitants/GP 1584
The Capital Region of Denmark
No. of inhabitants 1,680,271 
No. of inhabitants/km2 656         
No. of inhabitants/GP 1536
Region of Southern Denmark
No. of inhabitants 1,200,277 
No. of inhabitants/km2 98        
No. of inhabitants/GP 1482
Central Denmark Region
No. of inhabitants 1,253,998 
No. of inhabitants/km2 96        
No. of inhabitants/GP 1498
Source: Statistics Denmark (www.dst.dk) and the Danish Medical Association (www.laeger.dk). GP=general practitioner
DANMAP 2010
Figure 3.1. The five health care regions and 15 Departments of Clinical Microbiology (DCM) of Denmark
Vibeke Frøkjær Jensen and Ulrich Stab Jensen
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Table 3.2.  Antimicrobial agents marketed for systemic and veterinary intramammary therapeutic use in 
animals and humans, Denmark 2010 DANMAP 2010
ATC / ATCvet codes (a) Therapeutic group
Antimicrobial agents within the therapeutic groups
Animals Humans
J01AA / 
QJ01AA,QJ51AA
Tetracyclines Chlortetracycline, doxycycline, 
oxytetracycline
Doxycycline, lymecycline, 
oxytetracycline, tetracycline, 
tigecycline
J01BA / QJ01BA Amphenicols Florfenicol
J01CA / QJ01CA Penicillins with extended 
spectrum
Ampicillin, amoxicillin Ampicillin, pivampicillin, 
amoxicillin, pivmecillinam, 
mecillinam
J01CE / QJ01CE Beta-lactamase sensitive 
penicillins
Benzylpenicillin, 
phenoxymethylpenicillin, 
procaine penicillin, 
penethamate hydroiodide
Benzylpenicillin, 
phenoxymethylpenicillin
J01CF / QJ51CF Beta-lactamase resistant 
penicillins
Cloxacillin, nafcillin Dicloxacillin, flucloxacillin
J01CR / QJ01CR Comb. of penicillins, incl. beta-
lactamase inhibitors
Amoxicillin/clavulanate Amoxicillin/clavulanate, 
piperacillin/tazobactam
J01DB / 
QJ01DB,QJ51DB
First-generation cephalosporins Cefalexin, cefadroxil, cefapirin Cefalexin
J01DC Second-generation 
cephalosporins
Cefuroxime
J01DD / 
QJ01DD,QJ51DD
Third-generation cephalosporins Cefoperazone, ceftiofur, 
cefovecin
Cefotaxime, ceftazidime, 
ceftriaxone
J01DE / QJ51DE Fourth-generation 
cephalosporins
Cefquinome
J01DF Monobactams Aztreonam
J01DH Carbapenems Meropenem, ertapenem, 
doripenem
J01EA Trimethoprim and derivatives Trimethoprim
J01EB / QJ01EQ Short-acting sulfonamides Sulfadimidine Sulfamethizole
J01EE / QJ01EW Comb.of sulfonamides and 
trimethoprim, incl. derivatives
Sulfadiazine/trimethoprim, 
sulfadoxine/trimethoprim
Sulfamethoxazole/trimethoprim
J01FA / QJ01FA Macrolides Spiramycin, tylosin, 
tilmicosin, tylvalosintartrat, 
tulathromycin, gamithromycin
Erythromycin, roxithromycin, 
clarithromycin, azithromycin
J01FF / QJ01FF Lincosamides Clindamycin, lincomycin Clindamycin
J01FG / QJ01XX (b) Streptogramins (Virginiamycin)
J01G / 
QJ01RA,QA07AA
Aminoglycosides Streptomycin, 
dihydrostreptomycin, 
gentamicin, neomycin, 
apramycin
Tobramycin, gentamicin
J01MA / QJ01MA Fluoroquinolones Enrofloxacin, marbofloxacin, 
difloxacin, ibafloxacin
Ofloxacin, ciprofloxacin, 
moxifloxacin
QJ01MB Other quinolones Oxolinic acid
QJ01MQ (b) Quinoxalines (Carbadox, olaquindox)
J01XA,A07AA / 
Not in ATCvet (b, c)
Glycopeptides (Avoparcin) Vancomycin, teicoplanin
J01XB / QA07AA (b) Polypeptides (incl. polymyxins) Colistin, (bacitracin) Colistin
J01XC Steroid antibacterials Fusidic acid 
J01XD,P01AB (c) Imidazole derivatives Metronidazole
J01XE Nitrofurane derivatives Nitrofurantoin 
J01XX / QJ01FF Other antibacterials Spectinomycin Methenamine, linezolid, 
daptomycin
QJ01XQ Pleuromutilins Tiamulin, valnemulin
QP51AG04 Antiprotozoals, sulfonamides Sulfaclozine
Not in ATCvet (b) Oligosaccharides (Avilamycin)
Not in ATCvet (b) Flavofosfolipols (Flavomycin)
a) ATCvet codes starts with a Q   
b) Animal growth promoters used before 1999 are listed in parentheses   
c) Although intestinal antiinfectives (A07AA) and imidazole derivatives for protozoal diseases (P01AB) are used to treat human 
patients, they are not reported by DANMAP   
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4. Antimicrobial consumption in animals
Table 4.1. Production of food animals and the production of meat and milk, Denmark DANMAP 2010
Source: Statistics Denmark (www.dst.dk) and The Danish Directorate for Fisheries. All data include export of live animals for slaughter. 
Export data for poultry from Statistics Denmark (personal communication) and export of 15-50 kg pigs from Danish Agriculture and 
Food
a) The production of farmed fish includes fish transferred from one production facility to another. In 2009, this included 2.7 tonnes 
transferred between freshwater facilities (9.4% of the freshwater production), and 1.9 tonnes transferred from freshwater to salt water 
facilities, corresponding to 18% of the saltwater production
b) Including export of all age groups (not only for slaughter)
c) Export of 15-50 kg pigs. These are included in total number of heads, but antimicrobial use after export until slaughter is not registered 
as it takes place outside Denmark
d) Increase from 2009 to 2010
Year Broilers Turkeys Cattle(slaughtered) Dairy cows Pigs
 Farmed fish(a) 
Fresh 
water
Salt 
water
1000 
heads mill. kg
1000 
heads mill. kg
1000 
heads mill. kg
1000 
heads
mill. Kg
milk
1000 
heads(b)
Export
1000
heads(c)
mill. kg mill. kg mill. kg
1990 94560 116 571 2.5 789 219 753 4542 16425 - 1260 - -
1992 107188 137 761 5.4 862 236 712 4405 18442 - 1442 35 7
1994 116036 152 1091 8.6 813 210 700 4442 20651 - 1604 35 7
1996 107895 149 961 9.3 789 198 701 4494 20424 - 1592 32 8
1998 126063 168 1124 11.6 732 179 669 4468 22738 - 1770 32 7
2000 133987 181 1042 10.3 691 171 636 4520 22414 - 1748 32 7
2001 136603 192 1086 13.2 653 169 623 4418 23199 - 1836 31 8
2002 136350 190 1073 12.8 668 169 611 4455 24203 - 1892 32 8
2003 129861 181 777 11.2 625 161 596 4540 24434 - 1898 34 8
2004 130674 181 1086 19.6 632 165 569 4434 25141 1712 1967 34 9
2005 122179 180 1237 17.4 549 145 559 4449 25758 2720 1988 31 8
2006 106182 163 785 11.3 509 140 556 4492 25763 3204 1957 29 8
2007 107952 178 1009 14.4 512 141 545 4515 26311 3522 2046 31 10
2008 107595 186 1068 12.3 509 138 559 4585 27078 4943 1985 30 10
2009 108851 181 1175 11.1 507 137 569 4734 27603 6642 1898 29 11
2010 117653 187 1184 14.0 519 142 574 4830 28505 7074 1974 - -
Increase 
(%)(d) 8 3 1 26 2 3 1 2 3 7 4.0 - -
4.1 Introduction
4.1.1 Demographic data
In 2010, the production of meat and dairy increased 
compared to 2009 (Table 4.1). The number of pigs 
produced (slaughtered or exported) increased by 3.3%, 
while the production in kg pork produced increased by 
4% (Table 4.1), suggesting a slight increase in average 
weight at slaughter. This may be related to a decrease in 
number of sows in the last quarter. The export of fat-
tening pigs (15–50 kg) has increased over the past years 
and at export, these pigs have received a large amount 
of antimicrobial agents relative to their bodyweight. 
Since 2006, more than 99% of the turkeys produced were 
exported for slaughter.
4.1.2 Policies and regulations of the use of 
antimicrobial agents in animals 
Since the early 1990’ies there has been political and pub-
lic focus on the use of antimicrobial agents in the Dan-
ish animal production. This led to the ban on avoparcin 
for growth promotion in 1994 and voluntary phasing 
out of the remaining antimicrobial agents for growth 
promotion during 1996–1999. In 2002, restricted use 
of fluoroquinolones was enforced. In July 2010, the pig 
industry imposed a voluntary ban on use of cephalo-
sporins. 
Regarding prescription medicines, a number of inter-
ventions affect the present antimicrobial consumption 
pattern in Denmark. Some of this legislation has had an 
evident influence on the prescription pattern, such as a 
steep decrease in consumption from 1994 to 1995 and a 
steep decrease in use of fluoroquinolones from 2001 to 
2003. The effect of other parts of the legislation may be 
less obvious, but are important to keep in mind when 
interpreting the veterinary prescription patterns.
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Order (DK) 142/1993: Restricted the use of extemporaneously prepared medicines; also called the 
cascade rule, imposing mandatory first priority to medicinal products approved for the relevant species, 
subsidiary approved for other species.
Directive (DK) 60/1995: Limits the veterinarians’ profit when distributing medicines to a maximum 
of 5–10% at sales. 
Order (DK) 303/1995 and 304/1995: Limit the veterinary prescription to a maximum of 5 days of 
treatment in production animals. Exceptions only granted when a veterinary advisory service contract 
between the veterinarian and the farmer was signed. In those cases, up to 35 days of treatment is 
allowed for a diagnosed disease or a disease that was expected in the pigs, calves and poultry, on the 
basis of the veterinarian’s knowledge of the herd (revised by Order (DK) 785/2010). By July 2010, 
veterinary advisory service contracts became obligatory for all larger pig and cattle herds in Denmark. 
Order (DK) 303/1995: Treatment allowed only in diseased animals or animals in a well defined 
incubation period (metaphylaxis) and prophylactic use became illegal (revised by Order (DK) 
910/2006).
Mandatory registration by the veterinary practitioners of used, delivered and prescribed drugs to 
farmed animals. The information must be available for inspection by veterinary officials for 3 years). 
Since 2001, reporting into the VetStat database has been mandatory.
Order (DK) 285/1996: Pharmacies and the pharmaceutical industry prohibited from offering 
economic incentives to veterinarians or others for the purpose of increasing product sales.
Order (DK) 119/2002: Flouroquinolones intended for injection were restricted to use by the 
veterinary practitioner only.
Order (DK) 134/2003: Mandatory susceptibility testing in relation to use of fluoroquinolones for 
production animals, documenting the need. Notification of use of fluoroquinolones to the authorities is 
mandatory.
Order (DK) 785/2010: Legal regulation of use of antimicrobial agents for mastitis in cattle 
(recommending using simple penicillins). A similar rule has applied since 2006, for part of the cattle 
herds, with “new health consultancy contract” [Order (DK) 1045/2006].
Order (DK) 1319/2010: The “yellow card” control of antimicrobial use in the pig production, imposing 
preventive measures in the herds with highest consumption per pig. In July 2010, an information letter 
about the upcoming “yellow card” was sent to the pig farmers, using the 20% highest number of ADD’s 
per pig (Textbox 2).
Relevant legislation regarding veterinary use of antimicrobial agents since 1993
Official guidelines for choice of antimicrobial agents in 
pigs and cattle have been available for veterinarians since 
1996. The guidelines provide specific recommendations 
for the selection of the appropriate antimicrobial agents 
for the treatment of all common indications in major 
production animal species. Initially, guidelines were 
developed by the National Veterinary Serum Labora-
tory (presently, the National Veterinary Institute). Since 
2005, the guidelines have been updated by the Danish 
Veterinary and Food Administration (DVFA) in 
collaboration with the National Veterinary Institute, 
the National Food Institute, the Practicing Veterinar-
ians Organization, University experts, and the Danish 
Agriculture and Food Council. The latest update is from 
2010, see Textbox 1.
26                          
                   
DANMAP 2010  
ANTIMICROBIAL CONSUMPTION IN ANIMALS4.
One health evidence based prudent use guidelines for antimicrobial treatment of 
pigs in Denmark
Introduction: New prudent use guidelines for treatment of pigs in Denmark were presented at 
the Annual Meeting for the Danish Veterinary Hyologic Society in 2010. In May 2011, these new 
guidelines were published on-line.
The guidelines are based on available scientific evidence. For every combination of class of 
antimicrobial agents, swine disease and pathogen, an assessment of prudent use will be provided 
by the Danish Veterinary and Food Administration (DVFA) in a simple spreadsheet on-line. The 
spreadsheet presents all currently registered veterinary antimicrobial products for the specific diseases 
in drop-down lists with recommended dosages and treatment periods registered along with a colour 
coding indicating the most prudent choices based on efficiency, susceptibility, pharmacokinetics and 
human importance. The guidelines are dynamic lists, which can be changed on request or if new 
information or new antimicrobial agents emerge. The guidelines in Danish are found on the DVFA 
homepage (http://www.foedevarestyrelsen.dk).
Background: The new guidelines are the third step elaboration of prudent use treatment guidelines; 
the guidelines are part of the ongoing risk management strategy in Denmark for optimisation of 
antimicrobial consumption and reduction of antimicrobial resistance. The DVFA commenced 
elaboration of dynamic prudent use treatment guidelines for food-producing animals, starting with 
swine in 2005, followed by a reviewed concept for treatment guidelines for cattle in 2008 and now 
these new dynamic evidence based prudent use treatment guidelines. 
The guidelines demonstrate the need for collaboration between the human and veterinary side in 
a one health concept in order to combat risk of development of resistant bacteria. The one health 
concept results from a strong collaboration between all stakeholders in a task force hosted by the 
DVFA. Members of the task force are: the Danish Veterinary Association, the Danish Animal 
Health Industry, epidemiologists and risk assessors from the Danish Meat Association and DVFA, 
researchers in pharmacology and swine diseases from the Faculty of Life Sciences, Copenhagen 
University as well as researchers from the Statens Serum Institut, the National Food Institute and the 
National Veterinary Institute. 
Guidelines: Based on the available evidence, the different classes of antimicrobial agents are assessed 
by the following four criteria: a) clinical documentation of efficacy, b) susceptibility based on national 
microbiological data, c) pharmacokinetics and d) risk profiling of the human health concerns 
when the antimicrobial agents are used for veterinary antimicrobial treatment. In the new dynamic 
guidelines, the actual ranking is based on the scoring shown in Table 1, and the documentation for 
the ranking is included in the guideline spreadsheet. 
Textbox 1
Table 1.  Categorisation of antimicrobial agents in the new guidelines, Denmark
Category Scoring
Efficiency 1 = Documented in summary of product characteristics (SPC) 
2 = Documented in peer-revieved papers, EMEA or FDA papers
Susceptibility Percent susceptible, among the isolates sent to the National Food Institute and 
National Veterinary Institute
Pharmacokinetics Score based on MICKill/MIC50: 1 = range 0 - 0.19, 2 = range 0.2 - 0.39, 3 = range 0.4 
- 0.59, 4 = range 0.6 - 0.79 and 5 = > 8.8. Based on estimated MICkill where 80% of 
the dosage are covered by a concentration above MIC50 estimated from the national 
data
Human importance 1 = very high, 2 = high, 3 = mediocre, 4 = low and 5 = very low. Follows FDA and OIE 
guidelines
DANMAP 2010
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Figure 1. Prudent use guidelines for antimicrobial treatment of swine, Denmark
Green indicates antimicrobial agents that are recommended to be used for that specific disease and 
pathogen combination. The green labelled antimicrobial agents will have susceptibility above 80%, good 
pharmacokinetics and a risk profiling of human health consequences assessed to have no or only low 
consequences and preferably also evidence based documentation of clinical efficacy. Examples of green 
labelled antimicrobial agents with good judgement in all four categories for specific diseases and pathogens 
are: benzylpenicillinprocain, tiamulin, valnemulin and colistin sulfas. Yellow indicates antimicrobial agents 
that can be used, but where better alternatives are available. 
Red indicates antimicrobial agents not recommended due high human health consequence or a very low 
susceptibility. Examples of red labelled antimicrobial agents are enrofloxacin, marbofloxacin, cefquinom 
and other cephalosporins, but also other antimicrobial agents with a low score on susceptibility for a 
specific pathogen will be labelled with a red colour.
To be used by the veterinary practitioners: The guidelines are directed towards veterinary practitioners. 
In Denmark, all veterinary medicinal products are prescription only and this places the veterinary 
practitioners as key persons in prudent antimicrobial usage. The veterinary practitioners may use the 
guidelines as a working tool in their counselling of preventive veterinary strategies in herds, thereby 
optimizing antimicrobial usage with due consideration to both human and animal health. They can look up 
a specific disease and pathogen in the guidelines; use the colours to choose a prudent antimicrobial and the 
drop-down lists to find products, dosage and treatment period. If they want to know how or why a certain 
treatment has a good or pour judgement in one or more of the categories, they can use the documentation 
spreadsheets included the guidelines to study the evidence behind. 
 
For further information: Annette Cleveland Nielsen (acln@fvst.dk)
The risk profiling of human health concerns is done according to the principles of FDA guidance 152 
’Evaluating the safety of antimicrobial new animal drugs with regard to their microbial effects on 
bacteria of human health concern’, as well as the principles in OIE-guidelines. For every antimicrobial 
group, it is estimated whether the probability for selection of antimicrobial resistance, exposure of 
humans and human consequences are very high, high, medium, low or very low. Based on these 
estimates, a common estimate for the human health consequences of the use of this antimicrobial group 
for swine is estimated. The common estimate gives a qualitative ranking of the expected future human 
health consequences by antimicrobial usage for swine of the different antimicrobial groups. 
A new feature is that recommendations of usage of antimicrobial classes for the specific diseases (site of 
action) and specific pathogens are indicated by three different colours, green, yellow and red, in order to 
simplify the veterinary practitioner’s choice of a prudent antimicrobial agent (Figure 1).  
 
Recommended 
Better alternatives  
available 
Not recommented 
Evaluation 
Efficiancy 
Susceptability 
Pharmaco- 
kinetics 
human  
importance 
Estimate of 
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The yellow card initiative - special provisions for reduction of the antimicrobial 
consumption in pig holdings 
Background: In order to reverse an increasing trend in antimicrobial consumption in the pig production 
and the related potential risk to human and animal health, the Danish Veterinary and Food Administration 
(DVFA) established the yellow card initiative in 2010.
As more than 80% of the antimicrobial agents used in livestock production in Denmark are used in the pig 
sector, the yellow card initiative was designed to target pig holdings with a high consumption of antimicrobial 
agents, beginning with the 5–10% of the pig producers with the highest antimicrobial consumption. In Oc-
tober 2010, the goal of a 10% reduction in consumption (in kg) in 2013 compared to the 2009 levels was set. 
The yellow card initiative is therefore an incentive for the pig producers to achieve this goal.
The yellow card initiative: Each year, the DVFA will issue threshold limits for antimicrobial consumption in 
three age groups of pigs. The limits for 2010 were as follows:
1. Weaners (7–30 kg): 28 Animal Daily Doses (ADD) per 100 weaners per day
2. Young pigs, including young females (over 30 kg), excluding sows, gilts and boars: 8 ADD   
 per 100 pigs per day
3. Sows, gilts and boars: 5.2 ADD per 100 pigs per day
If the average antimicrobial consumption in a holding within a nine-month period exceeds one or more of 
the above threshold limits, DVFA may issue an order or injunction (the yellow card) compelling the owner of 
the holding, in collaboration with the veterinary practitioner, to reduce the antimicrobial consumption in the 
holding below the threshold limits within nine months. 
In Denmark, prescription-only medicines can only be used and stored for a limited period of time. To pro-
long this period, the veterinarian must re-prescribe the medicine for a new limited period of time. However, 
during the nine-month injunction period, the DVFA may prohibit re-prescription of specific antimicrobial 
agents administered orally. In addition, the DVFA may also carry out one or more unannounced inspection 
visits to the holding during the nine-month period while the injunction is in effect.
If the antimicrobial consumption in the holding has not been reduced below the threshold limits after the ex-
piry of the nine-month period, the DVFA may issue a second injunction compelling the owner of the holding 
to consult another veterinarian for second opinion advice on how to reduce the antimicrobial consumption 
below the threshold limits. This injunction may also be issued if the antimicrobial consumption in the hold-
ing has been reduced below the threshold limits within the nine-month period, but exceed the threshold lim-
its during the succeeding 12-month follow-up period. The expert advice must include an action plan present-
ing specific interventions to reduce the antimicrobial consumption in the holding. As with the yellow card 
injunction, the DVFA may also prohibit re-prescription of specific antimicrobial agents administered orally 
and carry out unannounced inspection visits to the holding to ensure that animal welfare is not compromised 
by reduction in treatment of disease.
If the antimicrobial consumption in the holding has not been reduced below the threshold limits after the 
expiry of the second injunction period, the DVFA may carry out unannounced inspection visits to the hold-
ing within short intervals until the antimicrobial consumption in the holding has been reduced below the 
threshold limits.
The owner of a holding is required to pay a fee for each injunction or prohibition issued and for all inspection 
visits carried out in accordance with the special provisions. All other expenses, including the costs of veteri-
narian expert advice must also be paid by the owner.
Legislation: The requirements of the yellow card initiative are set out in Government Order No. 1319 of De-
cember 1st 2010 on special provisions for the reduction of the consumption of antibiotics in pig holdings.
For further information: Tim Petersen (tipe@fvst.dk)
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For pigs, the adjusted figures are used to de-
scribe temporal trends, while non-adjusted 
figures are used to describe the relative con-
sumption of different antimicrobial agents within 
individual years.
4.1.3 Data sources
Data on antimicrobial use has been collected in Denmark 
since 1996, including historical data back to 1990. Until 
2001, data were available on product level, based on 
report from the pharmaceutical industry of the total 
annual sales. In addition, sales of antimicrobial growth 
promoters and coccidiostatic agents approved as feed 
additives were reported by the feed mills to the Plant 
Directorate before 2001. Since 2001, consumption data 
presented in the DANMAP report have been obtained 
from the national monitoring programme, VetStat. 
Prior to 2001, data were based on overall sales figures 
from the pharmaceutical industry (Table AP1.0). In 
Denmark, all therapeutic drugs are prescription-only 
and VetStat collects data on all medicines prescribed by 
veterinarians for use in animals. Data on consumption 
of antimicrobial feed additives including coccidiostatic 
agents (non-prescription) and antimicrobial growth 
promoters (no longer in use) are also collected by 
VetStat. The VetStat database contains detailed data on 
all prescription medicines for animals, including item ID 
(Nordic Item Number), date of sale, recipient (farm-ID 
or practice ID), prescribing veterinarian (ID), species and 
age group, disease group a.o. (see Appendix 2 for further 
description).
4.1.4 Methods
The measures of antimicrobial consumption are 
numerous. For the description of trends within 
species, the number of Defined Animal Daily doses 
(ADDkg) is preferred, because it describes the exposure 
independent of the choice of drug (see description in 
DANMAP 2009). ADDkg is defined as the assumed 
average maintenance dose per day for treatment of one 
kg animal for the main indication in a specified species; 
correspondingly, the ADDx, is the species specific 
assumed average maintenance dose for a standard body 
weight of x kg. The standard body weight is the assumed 
average body weight at treatment; e.g. for weaning pigs 
(7–30 kg) it is 15 kg, and the consumption for weaning 
pigs can be measured in ADD15 (see further detail in 
DANMAP 2009). However, doses are species specific, 
and have not been defined for all species; therefore, 
grams of active compound are used for measurement of 
overall consumption in DANMAP.
In this report, the production is used as the preferred 
denominator and is measured either in kg-meat-
produced (including export of live animals) or in number 
of animals produced, i.e. slaughtered or exported. 
Population at risk (animal-year-at-risk) is used when 
looking specifically at consumption in sows or in dairy 
cows. 
The number of pigs exported around 30 kg increased 
further by 7%, involving 25% of pigs produced in 2010. 
Because this production type has expanded importantly 
within a few years, it importantly affects the statistics. 
Particular for the evaluation of trends over time, data 
should be adjusted for such changes in production 
structure, as discussed in DANMAP 2009. 
Pigs produced only to 30 kg contribute relatively little 
to the total production (by weight), while the amount 
of antimicrobials used for this part of the production 
(sows, piglets and weaning pigs) comprise two thirds 
of the total antimicrobial consumption for pigs. Thus, 
as illustrated in Figure 4.2, the consumption would 
be underestimated if merely divided by number of 
pigs produced. Conversely, the consumptions would 
be overestimated if the pigs exported at 30 kg were 
included in the production (by weight) (see also 
DANMAP 2009). The adjustment is based on the 
assumption that pigs exported at 30 kg compared 
to those not exported, on average received the same 
amount of antimicrobial agents before export, as other 
pigs from farrowing to 30 kg, giving a more robust 
measure of production (see Section 2.1 in Appendix 2)
4.2 Total antimicrobial consumption
Table 4.2 shows the total antimicrobial consumption in 
production animals from 2001 to 2010, with a decrease 
from 128.3 tonnes in 2009 to 125.5 tonnes in 2010. Due 
to the phasing out of antimicrobial growth promoters 
and legal regulations of the therapeutic use implemented 
in the 1990’ies, the overall antimicrobial consumption 
in production animals decreased importantly in that 
decade (Appendix 1, Figure AP1.1 and table AP1.0). 
During the period 2001–2009, the consumption in 
production animals increased gradually by 36%, but 
in 2010, the consumption was still 40% lower than in 
1994, before the aforementioned interventions had 
been implemented (Table 4.2). In addition, the meat 
production has increased by 17% since 1994 (Table 4.1).
In 2010, the total veterinary consumption of 
antimicrobial agents including companion animals 
amounted to 126.9 tonnes (see details in Table 4.3), 
representing a 2.1% decrease compared to 2009. The 
decrease was mainly attributable to a decrease in 
consumption in pigs despite the increase in production 
(Table 4.1). The distribution of total consumption of 
antimicrobial agents among the major animal species 
has not changed importantly from previous years 
(Figure 4.1). In 2010, the antimicrobial consumption in 
pigs, cattle and poultry comprised 79% (100.5 tonnes), 
12% (14.6 tonnes), and 0.7% of the total veterinary 
consumption, respectively.
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Table 4.2. Estimated total consumption (kg)(a) of prescribed antimicrobial agents for production animals(b), 
Denmark DANMAP 2010
Data source VetStat. Only veterinary drugs are included (including parenteral treatment in companion animals). Veterinary 
drugs almost exclusively used in pets (tablets, capsules, ointment, eye/ear drops) are excluded. Dermal spray with tetracycline, 
extensively used in production animals, is the only topical drug included
a) Kg active compound rounded to nearest 50 for antimicrobial classes and 100 for totals
b) Included also the parenteral use in companion animals
c) Only the major contributing ATCvet groups are mentioned
ATCvet 
groupc) Therapeutic group 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
QJ01AA Tetracyclines 28500 24500 27150 29350 29550 31800 36600 35400 38400 35550
QJ01CE Penicillins, b-lactamase sensitive 16400 17500 18950 20900 22250 22650 23850 23950 25950 27100
QJ01C Other penicillins 8600 9500 10600 12300 11650 10950 10900 10550 12000 12450
QJ01D  cephalosporins  100 150 200 250 250 250 300 300 250 200
QJ01EW Sulfonamides + trimethoprim 9550 10550 10600 11500 12200 13700 13800 13300 14950 13900
QJ01EQ Sulfonamides 950 900 850 850 750 750 700 600 4505 550
QJ01F Macrolides, lincosamides 13400 13650 14000 16150 15300 14350 16500 15250 17350 16800
QJ01XQ Pleuromutilins 4050 4500 5400 6600 6500 6350 6100 9200 10650 10700
QJ01G/
QA07AA Aminoglycosides 11600 11700 11750 11650 10800 10600 8100 6000 6300 6200
Others 900 1600 1400 950 1200 1200 1150 1650 1900 2100
Total 94000 94700 100900 110500 110400 112700 118000 116100 128200 125500
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Table 4.3. Antimicrobial agents sold (kg active compound)(a) by animal species and age group, Denmark 
DANMAP 2010
Therapeutic group(b) Amcol Amglc Ceph FQ Quinol Linco Macro Pleuro Pen-b-sens
Pen-
other
Sulfa-
TMP Tet Others Total
ATCvet groups(c) QJ01B
QJ01
G
QJ01
DA
QJ01
MA
QJ01
MB
QJ01
FF
QJ01
FA
QJ01
XX
QJ01
CE
QJ01
CA
QJ01
E
QJ01
AA
QJ01
X
Pigs, total 150 4950 49 0 0 2663 12978 10661 18323 9011 8914 32318 510 100527
- Sows and piglets 118 2191 41 0 0 692 888 1477 9764 4627 7278 3004 70 30150
- Weaners 23 2449 5 0 0 829 7398 3928 1679 2904 1487 17464 431 38597
- Finishers 9 294 2 0 0 1136 4651 5232 6849 1450 138 11785 7 31552
- Age not given 0 16 0 0 0 6 42 25 31 29 11 65 1 228
Cattle, total (d) 390 832 117 1 0 28 216 16 7754 1361 2063 1845 11 14636
- Intramammaries 0 30 69 0 0 3 0 0 189 157 8 0 2 457
- Cows and bulls 18 374 42 0 0 2 143 0.1 6997 803 1112 1280 1 10773
- Calves<12
  months 362 328 2 0.1 0 6 66 0.2 364 197 474 497 7 2304
- Heifers, Steers 9 21 1 0 0 0.4 5 0 173 26 47 62 0 344
- Age group 
unknown (e) 1 79 3 1 0 16 2 16 32 179 422 5 1 757
Poultry, total 6 4 0 0 0 2 202 12 31 270 109 242 1 879
- Broilers 0 0 0 0 0 0 39 0 19 189 8 82 0 338
- Breeding and 
rearing, broilers 0 0 0 0 0 0 2 0 12 39 3 34 0 91
- Layers               
incl. rearing 0 0 0 0 0 0 13 11 0 21 0 2 1 48
- Turkeys 5 0 0 0 0 0 144 0 0 4 5 94 0 252
- Geese and ducks 0 0 0 0 0 0 0 0 0 0 0.2 14 0 14
- Gamebirds 0.4 4 0.1 2 3 1 0 15 87 11 0.1 124
- Species unknown 0.1 0 0 0.1 0 0 1 0.1 0.1 1 5 5 0 12
Other production animal species
- Small ruminants 0 2 0.1 0 0 0 0.1 1 4 5 2 17 0 31
- Fur animals 0.1 284 0.2 0.4 0 135 579 0 2 1533 382 798 0.4 3714
- Aquaculture 190 0.1 0 0 838 0 0 0 0 5 2026 1 0 3060
- Other production 
animals 0 3 0.2 0.1 0 1 0 0 3 1 14 3 0 25
species unknown(f) 0 0 0 0 0 0.2 -2 0.5 1 3 0.4 1 0.1 3
Companion animals, 
total 8 74 321 14 0 63 30 4 645 674 1047 167 37 3084
- Pet animals 7 55 317 13 0 62 22 2 469 667 456 144 37 2252
- Horses or pets 1 18 3 1 0 0.3 8 2 163 7 484 21 0 708
- Horses 0.1 1 0.4 0 0 1 1 0 12 0.3 106 2 0.1 124
Species unknown(g) 
- Systemic use 0 55 2 3 0 0 -25 8 382 170 133 163 1 892
- Topical drugs 0 4 0 0 0 0 0 0 0 0 0.2 39 6 49
- Intramammaries 0 1 2 0 0 0 0 0 4 7 1 0 0.1 15
Total 744 6209 491 19 838 2891 13978 10703 27149 13038 14691 35595 567 126915
a) Amounts over 0.5 kg are given with one decimal;  amounts of 0.0 kg are given as 0
b) Amcol=amphenicols; Amglc=aminoglycosides; Ceph=cephalosporins; FQ=fluoroquinolones; Quinol=other quinolones; Linco=lincosamides; 
Macro=macrolides; Pleuro=Pleuromutilins; Pen-β-sens=beta-lactamase sensitive penicillins; Pen-other=penicillins with extended spectrum, cloxacillin 
and amoxicillin/clavulanic acid; Sulfa-TMP=sulfonamides+trimethoprim; Tet=tetracyclines. Sulfaclozin (a prescription coccidiostat) is included in the 
sulfonamide/trimethoprim group
c) Only the ATC group contributing mostly to the antimicrobial group is mentioned. Combination drugs are divided into active compounds
d) in 2010, half of the prescribed antimicrobials for cattle was purchased at pharmacies; half was either administered or handed out by veterinary 
practitioners. Reporting from large animal practice on medicines for cattle is validated against data on medicines sold from pharmacies to cattle practice 
(not mixed practice), and the proportion in accordance is included under the respective age groups. Medicines sold to cattle practice, but usage not 
reported by a veterinarian are included under “age group unknown”
e) About 10% of the pharmacy sales for use in practice is not reported (possibly due to factor errors at reporting), when used or sold in practice, 
amounting to 700 kg in 2010. In addition, part of pharmacy sales to farms are lacking age group ID, amounting to 55 kg in 2010
f) Sales to farmers (valid farm ID codes) given, but animal species not identifiable. Negative numbers are due to prescribed antimicrobials that were not 
picked up by the farm owner and where the records the species identity is missing
g) Negative numbers are due to over-reporting by veterinarians of antimicrobial medicines used in practice to specific species
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Figure 4.1. Antimicrobial consumption per kg meat produced from pigs(a), broilers, turkey and 
aquaculture(b), Denmark
DANMAP 2010
a) Export of animals for rearing or slaughter is included. However, data for pig production is not adjusted for the increasing export of pigs at 
30 kg body weight, although the body mass at export is included in the production (see text). Thus, the figures overestimates the increasing 
consumption in the pig production in particular during the last three years
b) In 2006, the consumption reached 262 mg/kg fish produced in salt water, related to unusually warm summer months. The doses for fish 
are defined as 30 mg/kg for sulfonmide-trimethoprim, 10 mg/kg for oxolinic acid and 15 mg for florphenicol (source: Danish Aquaculture)
4.3 Antimicrobial consumption by animal 
species
A comparison of trends in antimicrobial use, per 
species, is shown in Figure 4.1; the trend lines differ 
depending on the unit used. For example, for turkeys 
the peak in 2009 is highest using mg, whereas the peak 
in 2002 is higher using the ADD, due to shift from 
amoxacillin towards tetracyclines. Correspondingly, 
the consumption in aquaculture is extremely high 
compared to other species when measured in mg, but 
more similar to the consumption in pigs (at least in 
some years) when measured in ADDkg, because the 
dominant drug of choice in aquaculture is used in a very 
high dosage (30 mg/kg).Trends may also be affected by 
shifts in the production. In this report, number of pigs 
produced has been used as the denominator, adjusted 
for changes in production as described above. The effect 
of using this measure is shown in Figure 4.2. 
For comparison between species, kg meat produced 
has been used; this measure overestimates the 
selection pressure in species with long lives (e.g. cattle) 
relative to species slaughtered at an early age (e.g. 
poultry). Alternatively, live biomass could be used for 
comparison of selection pressure between species. 
Because cattle in Denmark are almost entirely dairy 
cattle, living many years after reaching the slaughter 
weight, the consumption cannot be directly compared 
with other species using ‘kg meat produced’ as the 
denominator.
4.3.1 Antimicrobial consumption in pigs 
In 2010, the total antimicrobial consumption in 
pigs was 100.5 tonnes active substance (Table 4.3), 
a decrease of 3 tonnes compared to 2009. Relative 
to the meat production, including live export, the 
consumption decreased to 50.9 mg/kg or 4.6 ADDkg/
kg pork produced (Figures 4.1 and 4.2). Consumption 
of antimicrobial agents for systemic use in pigs (2001–
2010), given as Animal Daily Doses (ADDs) to the 
different age groups, are presented in Appendix 1 (Table 
AP1.1). 
In 2010, the overall consumption for pigs decreased by 
5% in ADDkg per pig produced (adjusted for live export, 
Figure 4.2). The decrease was mainly related to a 5% 
decrease in consumption of tetracyclines. However, 
large relative reductions were also observed for 
macrolides (2%), aminoglycosides (16%), lincosamides/
spectinomycin (7%) and cephalosporins (48%) (Figures 
4.3 and 4.4). The 2010 overall decrease in consumption 
was entirely related to the second half of the year. 
During the first six months the consumption increased 
by 8% (in ADDkg) compared to the same period in 2009.
Regarding cephalosporins, the decrease was related 
to a voluntary ban by the industry, enforced in July 
2010 (Figures 4.3 and 4.4). As in previous years, the 
cephalosporins were mainly (86%) prescribed for sow 
herds, including use in piglets for expected outbreaks 
of umbilical infection (DANMAP 2007). Also in July 
2010, an information letter about the upcoming “yellow 
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Figure 4.2. Consumption of antimicrobial agents in sows, weaner pigs(a), finishers(b) and total pig production(c), 
given as Animal Daily Doses (ADDs), Denmark
a) Consumption in sows and weaners is given as ADD25 divided by number of weaning pigs produced
b) Consumption in finishers is given as ADD25 divided by number of finisher pigs produced
c) The” adjusted total” is given with the same units as the total, but adjusted for the increasing export of pigs at 30 kg (see text). 
Consumption per kg meat produced is given as ADDkg divided by meat production including live export
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Figure 4.3. Consumption of 3rd and 4th generation 
cephalosporins in pigs and cattle, Denmark
DANMAP 2010
card” was sent to the pig farmers, using the 20% highest 
number of ADD’s per pig (Textbox 2). This is a likely 
explanation for the overall reduction in consumption 
of 14% in July alone, and a 13% reduction in the second 
half year compared with the same period in 2009 
(measured in ADDkg).
However, since 2001, the consumption has been 
gradually increasing, and during the past decade, the 
total consumption in pigs increased by 39% (adjusted 
for live export, Figure 4.2). Tetracyclines, macrolides 
and pleuromutilins, mainly for oral therapy, continued 
to be the most commonly used antimicrobial agents in 
pigs throughout 2001–2010(Figure 4.3). 
From 2001–2009, the use of tetracyclines in ADD25 per 
pig produced increased by 100% (adjusted), followed by 
the 8% decrease in 2010; both trends have mainly been 
driven by trends in prescription for weaning pigs but 
also in finishers (Figure 4.4). Since 2005, tetracyclines 
have been the most common antimicrobial agent used 
in pigs, likely affected by treatment guidelines launched 
by the veterinary authorities that year, recommending 
that tetracyclines should be preferred over macrolides 
(critically important in human medicine), when a first 
priority agents could not be used. 
Over the past decade, the consumption of 
macrolides has fluctuated between 2.2–2.6 ADD25 per pig produced, with no clear trends. The overall 
consumption of pleuromutilins was similar in 2009 and 
2010, after a 53% increase since 2007 when prices for 
tiamulin were reduced making it price competitive with 
macrolides and tetracyclines. However, the consumption 
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Note: Amphenicols, colistin, fluoroquinolones, intramammaries, gynecologicals and topical drugs are not included in the figure. Data 
from veterinary practice are not included (<1% of the consumption in pigs)
a) ADD25: doses for treatment of 25 kg pigs, to compare treatment across age groups. ADD15: Doses for treatment of 15 kg pigs, the 
assumed average dose for treatment of weaners (7.5–30 kg).  ADD50: Doses for treatment of 50 kg pigs, the assumed average dose 
for treatment of finishers (30–110 kg), estimate based on the number of pigs produced excluding those pigs exported at 15–50 kg. 
ADD200: Doses for treatment of 200 kg pigs:  the medicines are used either in sows (bodyweight>200 kg) or in piglets (<2 kg–7.5 kg)
b) Total pigs produced includes pigs exported at 30 kg, which has increased in numbers from 1.7 million in 2004 to 7.1 million in 2010, 
comprising 25% of the total consumtion, although consumption in these pigs is included only from birth to 30 kg body weight. See 
discussion in the text
c) Beta-lactamase sensitive penicillins
d) Lincosamide/spectinomycin combinations comprise 65% of this group
Figure 4.4. Antimicrobial consumption(a) in the pig production(b), Denmark
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of pleuromutilins increased by 5% in finishers, while 
the consumption in sow herds decreased by 23%. 
Pleuromutilins have been recommended for sanitation 
against Brachyspira hyodysenteriae in sow herds in 
Denmark, and the decrease in use of pleuromutilins 
was related to the overall decrease in prescription for 
gastrointestinal disease in sow herds (Figure 4.4).
The overall decrease in consumption in pigs was 
mainly due to a decrease in consumption in weaning 
pigs but also in sows (Figure 4.4). In both age groups, 
the decrease was related to a decrease in prescriptions 
for gastrointestinal disease. In weaning pigs, the 
prescription for gastrointestinal infections is the major 
indication (70% in 2010), and decreased by 10% from 
6.6 ADD15 in 2009 to 5.9 ADD15 per pig produced 
in 2010, reaching the level from 2008; the overall 
prescription for weaning pigs decreased from 9.1 ADD15 
to 8.4 ADD15 per pig produced. In sow herds, the 
prescription for gastrointestinal disease decreased by 
22% from 2.0 ADD200 to 1.6 ADD200/sow-year, while 
the total consumption decreased from 11.6 ADD200 to 
11.3 ADD200 per sow-year. In finishers, the prescription 
was 2.9 ADD50 per finisher produced both in 2009 and 
2010, and no important changed occurred in indication 
(Figure 4.5). However, a large increase in prescription 
for gastrointestinal disease was seen from 2008 to 2009. 
In all age groups, the prescription for respiratory disease 
has been increasing throughout the last decade (Figure 
4.5). 
It should be noted that these statistics are derived 
from the information on indication (disease group) 
in the VetStat database. The indication is entered by 
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Figure 4.5. Antimicrobial consumption by indication(a) for sows/piglets, weaner and finisher pigs, 
Denmark
DANMAP 2010
a)  The indication given on the prescription. At prescription, VetStat codes are used, representing the target organ system. In this 
figure, indications representing <0.1ADD (per sow year or pig produced) is not shown
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the veterinarian and refers to either the current or 
expected disease within a 30 day period (based on his/ 
her knowledge of the herd). However, the prescribed 
antimicrobial agents may in some cases be used 
for other diseases than originally indicated on the 
prescription, in which case it is re-prescribed by the 
veterinarian at the farm. Such re-prescriptions are not 
registered in VetStat. 
4.3.2 Antimicrobial consumption in cattle
In 2010, it was estimated that14.6 tonnes of 
antimicrobial substance were prescribed for cattle, 
as compared to 15 tonnes in 2009, representing a 3% 
decrease (Table 4.3). These estimates are based on 
pharmacy data, including prescription for cattle and 
cattle practice
Consumption of antimicrobial agents for systemic 
use in cattle (2005–2010), given as Animal Daily 
Doses (ADDs) to different age groups, are presented 
in Appendix 1 (Table AP1.2). For cattle, data are only 
shown for the period 2005–2010, because data quality 
was not acceptable before 2005 due to reporting errors. 
Before 2006, the majority of medicines for cows were 
purchased through veterinary practices, and in 2002–
2006, up to 20% of some of the antimicrobial used in 
practice were missing due to technical errors in the 
amounts reported and the data transmissions. However, 
in 2010, underreporting from veterinary practice 
had reached a level of 5–10%, corresponding to an 
overall 2–5% underreporting on age group level. Thus, 
information about age groups was available for 95–98% 
of the total consumption. 
Pharmacy data have a very high quality, and the 
overall improvement of data quality for cattle is also 
a result of an increasing proportion of the medicine 
being purchased through the pharmacies. In 2010, 
approximately half of the antimicrobial agents for cows 
were purchased through the pharmacies. 
Based on the type of technical errors, we assume that 
the missing data are random, and thus that the data 
from the veterinarians are representative for the relative 
choice of drugs over time. 
From the pharmacy sales, data for cattle practice, and 
thoroughly validated data from veterinary practices, it 
can be concluded that the antimicrobial consumption 
in cattle has been stable, between 14–15 tonnes during 
2005–2009. During this period, the veal and beef pro-
duction has decreased by 2% and the milk production 
has increased by 9% (Table 4.1). 
The temporal trend in choice of drug for systemic use 
is shown in Figures 4.6 and 4.7. In 2010, the relative use 
of beta-lactam sensitive penicillins for systemic use in 
cows increased by 3.5%, mainly related to a relative de-
crease in the usage of tetracyclines (4%) and macrolides 
(29%). The major indication for treatment of cows was 
mastitis (64% of systemic use). Also for intramammary 
treatment, penicillins - mainly narrow spectrum (beta-
lactamase sensitive and beta-lactmase resistant) - was 
the major class, comprising 57% of the treatments (Table 
4.4). Combinations of benzylpenicillins (mainly with 
dihydrostreptomycin) comprised an additional 15%.
In cows and bulls, the proportional use of beta-lacta-
mase sensitive penicilins has increased from 48% in 
2005 to 59% of the overall consumption in 2010, while 
the use of macrolides decreased from 11% to 3% of the 
consumption for systemic use in cows. This is in accord-
ance with the official guidelines. 
The use of intramammary treatment has been stable 
during 2005–2010, while the proportion of narrow 
spectrum penicillins increased from 39% to 57% of 
the treatments (Table 4.4). From 2005 to 2010, the use 
of intramammary treatments has decreased by 2% 
measured in ADD per cow-year.
Table  4.4. Consumption of antimicrobial agents for intramammary application in cattle, Denmark 
a) For intramammary treatment, 1 ADD is defined as the dose to treat one teat for 24 hours
b) Includes benzylpenicillin, cloxacillin, and cloxacillin-ampicillin combinations
c) Mainly dihydrostreptomycin-benzyl benicillin combinations; includes also combinations of penicillin/aminoglycoside with bacitracin or 
nafcillin
d) Lincosamides, neomycin-lincomycin combinations and trimethoprim-sulfonamide combinations
Antimicrobial agents ATCvet classes 2005 2006 2007 2008 2009 2010
ADD (1000's)(a)
Penicillins(b) QJ51CE, QJ51CF, QJ51CR 454 464 454 506 599 671
Aminoglycoside-benzylpenicillin 
combinations(c) QJ51RC 231 203 202 201 220 176
Cephalosporins,
1st generation QJ51DA 206 197 177 169 178 174
Cephalosporins,
3rd and 4th generation QJ51DC, QJ51DD 229 255 262 231 156 105
Others(d) 42 35 31 30 27 44
Total 1163 1153 1126 1138 1180 1170
ADD/cow-year 2.08 2.07 2.07 2.04 2.07 2.04
DANMAP 2010
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Figure 4.6. Proportional consumption (in ADD) of antimicrobial agents(a) for systemic treatment in cows and 
bulls, Denmark
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a) The antimicrobials not shown (amphenicols, fluoroquionolones, lincosamides, aminoglycosides, colistin and pleuromutilins ), each 
account for less than one percent of the consumption
Figure 4.7. Proportional consumption (in ADD) of antimicrobial agents(a) for systemic treatment in calves, 
Denmark
a) The antimicrobials not shown (fluoroquionolones, lincosamides, and pleuromutilins), each account for less than one percent of the 
consumption
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4.3.3 Antimicrobial consumption in poultry
In Denmark, the poultry production is comprised 
mainly of broiler production (Gallus gallus), followed 
by egg layers (Gallus gallus) and turkey production. In 
addition, there is a minor production of ducks, geese, 
and game birds, while pigeons are kept for sports. 
Consumption of antimicrobial agents for systemic 
use in poultry (2001–2010), given as Animal Daily 
Doses (ADDs) to the different species, are presented in 
Appendix 1 (Table AP1.3). 
In 2010, the total antimicrobial consumption in poultry 
was 879 kg active substance (Table 4.3), representing an 
18% decrease compared to 2009. However, this was still 
higher than the levels in previous years (2001–2008). 
In general, increasing disease problems caused a steep 
increase in antimicrobial consumption for poultry in 
2009 (see DANMAP 2009); these disease problems 
seems to be under control in 2010, as indicated by 
the decrease in antimicrobial consumption, both for 
the layers, rearing for broiler production, and the 
turkey production; however, further increased use was 
observed in broilers. 
The antimicrobial consumption in domestic fowl 
(Gallus gallus) is generally at a very low level (Figure 
4.8). Therefore, few disease outbreaks in some farms 
importantly affect the national consumption in 
domestic fowl, causing considerable fluctuations in 
annual consumption.
The total consumption in broilers in 2010 was 429 kg 
including breeding and rearing (Table 4.3). For broilers, 
an additional increase in consumption was observed 
in 2010, mainly in the prescription of amoxicillin, 
which was still the major drug of choice (Figure 
4.8). Prescription for 79 broiler farms was registered, 
corresponding to 28% of the broiler farms [Statistics 
Denmark 2011]. According to some of the major 
poultry practitioners, at least part of the increase in 
antimicrobial consumption was related to outbreaks of 
diarrhoea associated with coccidiosis, due to treatment 
failure (resistance to salinomycin). Due to the decrease 
in consumption in the parent and grandparent flocks 
(breeding and rearing), the overall consumption (0.14 
ADDkg/kg meat produced) in the broiler production 
was at the same level as in 2009, but two–five times 
higher than in previous years (Figure 4.8).
The antimicrobial consumption in the layer production 
(Gallus gallus) is quite low, and the total consumption in 
2010 was only 48 kg (Table 4.3). Measured in ADDkg per 
kg eggs produced, the consumption in layers including 
rearing in 2010 was at the same level as in 2009, a level 
three to four times lower than in the broiler production, 
however the production (meat vs. eggs) is not fully 
comparable (Figure 4.8).
In turkeys, the annual consumption is highly variable. 
In 2010, the consumption again decreased to a relatively 
low level to a total of 252 kg or 0.62 ADDkg/kg meat 
produced (Table 4.3 and Figure 4.8). According to the 
poultry practitioners, the 2009 increase in prescription 
in turkeys was mainly due to Pasteurella multocida 
infections, and a vaccination campaign was conducted 
to control the disease in April–October 2009. Also, 
vaccination against haemorrhagic enteritis (viral) in 
turkeys was initiated in April 2010. 
In 2010, tetracyclines comprised 70% of the 
antimicrobial consumption in turkeys, and have 
from 2008 been the major drug of choice. However, 
before 2007, amoxicillin constituted 70–99% of the 
consumption in turkeys, while the use had decreased 
to 3% in 2010. The changes in prescription occurred 
after the marketing of tetracyclines and other agents 
for use in poultry during 2007–2008. Before 2007, 
only amoxicillin and fluoroquinolones were marketed 
for poultry. Fluoroquinolones were not used in 2010, 
neither in the turkey production nor in Gallus gallus, 
and the consumption has decreased since 2006 when 
fluoroquinolones comprised 7% of the antimicrobial 
consumption in these species.
Measured in ADDkg per kg meat produced, the 
consumption in ducks and geese increased three fold in 
2010, a level approximately three times higher (per kg 
meat produced) than in the broiler production (Figure 
4.8). 
Annual production data are not available for game 
birds. The population was estimated at 1 million 
pheasants, 0.5 million ducks and 0.1 million other 
birds in 2004. Assuming a constant population, the 
antimicrobial consumption in game birds has been 
stable during 2002–2009; around 1 ADDkg/kg meat 
produced (Appendix 1, Table AP1.3). At least part of the 
apparent increase in consumption in 2010 is due to a 
 
In calves, the major drug of choice in 2010 was 
tetracyclines (mainly oxytetracyclines), and the 
consumption increased from 26% in 2009 to 30% in 
2010. From 2006 to 2009, macrolides were the most 
frequently used class, but the use was reduced from 
35% in 2009 to 24% in 2010, in accordance with the 
official guidelines. The major indication in calves was 
respiratory disease (64% of systemic use).
The use of fluoroquinolones in cattle was only 1 kg 
active compound, and has remained at a low level 
since 2003. As in 2009, the consumption of 3rd and 
4th generation cephalosporins decreased in 2010 
both in cows and in calves. Systemic use decreased 
by 17% and intramammary use decreased by 29%. 
Overall since 2008, when the consumption measured 
in kg active substance was highest, the consumption 
of 3rd and 4th generation cephalosporins for systemic 
and intramammary use has decreased by 29% and 
50% (Figure 4.4, Table 4.4). These trends in choice of 
antimicrobial agents for intramammary treatment may 
reflect a response to debate, guidelines and information 
in recent years, about the consequences regarding 
development of ESBL. However, they may also be 
the result of new regulations that require testing for 
antimicrobial resistance in cases where antimicrobial 
agents other than simple penicillins are prescribed for 
mastitis.
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Figure 4.8. Consumption of antimicrobial agents in the poultry production, Denmark
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bias in the previous years of reporting, because missing 
information of poultry species has mostly been related 
to the production of game birds. Thus, the increase in 
registered consumption for game birds is - at least in 
part - related to the decrease in the “species unknown” 
category.
4.3.4 Antimicrobial consumption in fur animals, 
aquaculture and pet animals
The production of fur animals included 14 million 
mink, 34,000 chinchillas and a minor production of 
foxes in 2010 (as in 2009). In 2010, the consumption in 
fur animals increased to 3,714 kg in 2010, representing 
a 16% increase compared with 2009. Please note that 
the data in DANMAP 2009 are not directly comparable, 
when including all data reported from practice, the 
consumption amounted to 3,200 kg in 2009. In 2010, 
aminopenicillins remained the most commonly used 
antimicrobial class in fur animals, increasing to 41% of 
the antimicrobial consumption (kg active substance) 
in 2010. Macrolides, tetracyclines and sulfonamide-
trimethoprim combinations comprised another 56%. 
Fluoroquinolones were not used in 2010. 
The antimicrobial consumption in aquaculture 
decreased by 7% to 3,060 kg in 2010 compared to 
2009 (Figure 4.1). In aquaculture, the major class 
of antimicrobial was sulfonamide/trimethoprim, 
comprising 66% of the consumption in aquaculture. The 
consumption of quinolones (oxolinic acid) comprised 
27% of the consumption in aquaculture in 2010, and has 
increased continuously since 2007. The overall decrease 
was mainly due a change in choice of antimicrobial 
agents towards oxolinic acid (10 mg/kg), which has a 
much lower dosage than sulfonamide-trimethoprim 
(30 mg/kg). The consumption in salt water fish was 
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9 ADDkg/kg fish produced in 2009 and 2010. The 
antimicrobial consumption in salt water aquaculture 
peaked in 2006, reaching 13 ADDkg/kg fish produced, 
due to an unusually warm summer. Fish production is 
very sensitive to water temperatures, but also increasing 
vaccination intensity has caused a gradual 51% decrease 
in antimicrobial use in salt water aquaculture through 
2006–2010 [personal communication: N.H. Henriksen, 
Danish Aquaculture]. Regarding fish produced in fresh 
water, the consumption is more stable around 2 ADDkg 
/kg fish produced; the consumption increased by 8% to 
ADDkg/kg fish produced from 1.8 ADDkg/kg in 2009, 
to 2.0 ADDkg/kg in 2010, when assuming the same 
production volume as in 2009. The increase was most 
likely related to a failure in vaccine deliveries during 
winter 2009–2010 [personal communication: N.H. 
Henriksen, Danish Aquaculture].
The consumption of antimicrobial agents in companion 
animals (pet animals and horses) was 3 tonnes, 
estimated from the prescription for these species and 
sales for companion animal practices. This is higher 
than the estimated 2.2 tonnes in 2009, but this is partly 
due to an underestimation in previous years. Looking 
at oral medicines for pet animals only, the prescription 
did not increase from 2009 to 2010, however, during 
the past decade the veterinary prescription of oral 
medicines increased by 24%. The major antimicrobial 
agent used in pet animals, amoxicillin in combination 
with clavulanic acid, increased by 3% to 539 kg in 2010 
compared to 2009, as part of a continuous increase 
over the past decade. Other frequently used drugs were 
cephalosporins (317 kg), mainly first generation for oral 
use, representing a 9% decrease compared to 2009. In 
pet animals, the consumption of 3rd and 4th generation 
cephalosporin was an estimated 3 kg, corresponding 
to 1.8% of the total veterinary consumption of 
these antimicrobials. The use of fluoroquinolones 
in pet animals was estimated 14 kg in 2010 and this 
corresponded to 72% of the total veterinary use of 
fluoroquinolones in Denmark.
Vibeke Frøkjær Jensen and 
Vibe Dalhoff Andersen
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5. Antimicrobial consumptions in humans
5.1 Introduction
All systemic antimicrobial agents used in Denmark are 
prescription medications only, and all Danish medical 
doctors have the right to prescribe freely what they find 
appropriate for their patients. There are no restrictions 
in the prescribing of antibacterial agents. National 
guidelines exist for the prudent use of antibacterial 
agents, as well as local guidelines from each of the 
Departments of Clinical Microbiology (DCM); taking 
into account the local resistance patterns. 
Throughout the ‘Antimicrobial consumption in 
humans’ section, the consumption of 2010 is compared 
with the consumption of 2009 and of the last decade 
(2001), respectively. Also, combinations of penicillins, 
incl. beta-lactamase inhibitors (J01CR) are referred to 
as ‘combination penicillins’.
Antibacterial agents used for systemic treatment in 
humans (and in animals) are listed in Table 3.2.
Narrow- & Broad-spectrum Agents. Antibacterial 
agents have been classified as either narrow-spectrum 
or broad-spectrum agents according to the width of 
the activity against Gram-positive and Gram-negative 
bacteria (Table 5.1).
Defined Daily Dose (DDD). The DDD is the assumed 
average maintenance dose per day for a drug used for its 
main indication in adults. It should be emphasised that 
DDD is a unit of measurement and does not necessarily 
reflect the recommended or prescribed daily dose 
[http://www.whoc.no]. 
DDD per 1,000 inhabitants per day (DID). 
Consumption in primary health care is presented 
in DID. Also, consumption in hospital care 
(rehabilitation centres, hospices, private-, psychiatric-, 
specialised-, and somatic hospitals) and the merged 
total consumption is presented in DID enabling the 
comparison of the two sectors, and illustrating the 
consumption in hospital care without the activity in 
DANMAP 2010
Table 5.1. Classification of antibacterial agents for systemic use in humans into narrow-spectrum and broad-
spectrum agents, Denmark
a) From the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system
ATC group(a) Therapeutic groupNarrow-spectrum
J01CE                        Beta-lactamase sensitive penicillins     
J01CF                        Beta-lactamase resistant penicillins     
J01DB First-generation cephalosporins (included in data from primary health care as a broad-spectrum agent in the group J01D)
J01DF Monobactams
J01EA                        Trimethoprim and derivatives   
J01EB                        Short-acting sulfonamides       
J01FA                        Macrolides                  
J01FF                        Lincosamides                
J01XA Glycopeptides
J01XC                        Steroid antibacterials (fusidic acid)     
J01XD                        Imidazol derivatives
J01XE Nitrofuran derivatives (nitrofurantoin)
J01XX Other antibacterials
Broad-spectrum
J01AA                        Tetracyclines               
J01CA                        Penicillins with extended spectrum
J01CR                        Combinations of penicillins, incl. beta-lactamase inhibitors   
J01D                        Cephalosporins and related substances (primary health care only)         
J01DC Second-generation cephalosporins
J01DD Third-generation cephalosporins
J01DH Carbapenems
J01EE                        Combinations of sulfonamides and trimethoprim, incl. derivatives 
J01GB Aminoglycosides
J01MA                        Fluoroquinolones            
J01XB                        Polymyxins                 
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the hospitals. Data presented in DID provide a rough 
estimate of the proportion of the population within 
a defined area treated daily with certain drugs. For 
example, 10 DIDs indicates that 1% of the population 
on average gets a certain treatment daily.
Packages per 1,000 inhabitants per year. Assuming 
that one package is prescribed for one prescription, 
packages per 1,000 inhabitants per year serve as a 
surrogate for prescriptions or treatments given to the 
primary health care population.
Treated patients per 1,000 inhabitants per year.
Illustrates the number of patients treated in primary 
health care.
Kilogram. To allow comparison with consumption 
of antibacterial agents in animals, total human 
consumption is also presented in kilograms.
DDD per 100 occupied bed-days (DBD) and DDD 
per 100 admissions (DAD). Consumption in somatic 
hospitals is presented in both DBD and DAD to 
include the activity in hospitals. DAD is introduced in 
this report, since it is the internationally recognised 
abbreviation. It is the same measure as DDD per 100 
discharges (discharged patients) which has been used 
in the previous DANMAP reports.
 
5.2 Total consumption of both primary health 
care and hospital care
Total consumption compared with 2009
In 2010, the total consumption of antibacterial agents 
for systemic use (primary health care and hospital care) 
increased by 5%: from 17.89 DDDs per 1,000 inhabitants 
per day (DID) in 2009 to 18.84 DID in 2010 (Figure 5.1). 
The increase was noticed in primary health care only, 
whereas the consumption in hospital care was similar 
to the year before. Broad-spectrum agents increased by 
7%; representing 7.76 DID of the total consumption in 
2010 compared with 7.24 DID in 2009 (Figure 5.2). The 
percentage of DDDs prescribed in primary health care 
represented 90% of the total human consumption. 
Figure 5.3 shows the distribution of the total number 
of DIDs of antibacterial agents between primary health 
care and hospital care. For example, sulfonamides and 
trimethoprim (J01E) and beta-lactamase resistant 
penicillins (J01CF) had a ratio of consumption in 
primary health care vs. consumption in hospital care of 
around 9/1 and 6/1, respectively.
Total consumption - the last decade
Since 2001, consumption has increased by 4.54 DID 
(32%) (Figure 5.1). Also, broad-spectrum agents have 
increased by 3.3 DID (74%); comprising 41% of the 
total consumption in 2010 compared with 31% in 2001 
(Figure 5.2). During the last decade, the proportion of 
DDDs prescribed in primary health care represented 
89–90% of the total human consumption.
To view the detailed distribution of DIDs among 
antibacterial groups in primary health care and hospital 
care, please refer to Table 5.3 and Table AP1.4 in 
Appendix 1, respectively. 
Total consumption in kilograms
In 2010, 50.67 tonnes of antibacterial agents for systemic 
use were used in humans in Denmark representing an 
increase of 2.06 tonnes (4%) compared with 2009, and 
an increase of 8.67 tonnes (21%) compared with 2001 
(Table 5.2). 
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Figure 5.1. Total consumption of antibacterial agents (J01) in humans by sector, Denmark
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macrolides, lincosamides, glycopeptides, fusidic acid, imidazol derivatives, nitrofuran derivatives and ‘other antibiotics’
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inhibitors, cephalosporins and related substances, combinations of sulfonamides and trimethoprim, aminoglycosides, 
fluoroquinolones and polymyxins         
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Figure 5.3. Distribution of DIDs between primary health care and hospital care, Denmark
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Note: Includes data from both primary health care and hospital care and has been recalculated from original data expressed as DDDs. For 
monitoring in human primary health care and hospital care, the recommended way of expressing consumption is DDDs per 1000 inhabitant-
days and DDDs per 100 occupied bed-days / DDDs per 100 admissions (see Tables 5.3, 5.5 and 5.6)  
a) From the 2010 edition of the ATC classification system         
b) Since 2005, the kg active substance was estimated taking into account the DDD for each route of administration, e.g. cefuroxime parenteral 
DDD = 3 g and cefuroxime oral DDD = 0.5 g. From 2001 to 2004, it was estimated with a DDD corresponding to an average for the various 
routes, e.g. for cefuroxime: 1.75 g         
c) When two different DDDs of an antimicrobial agent existed for different presentations, an average DDD was used. Estimates using the 
lowest and the highest calculated limit are 2473–3603 for 2010        
d) Does not include polymyxins           
Table 5.2. Consumption of antibacterial agents for systemic use in humans (kg active substance), Denmark
ATC group(a) Therapeutic group Year
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
J01AA   Tetracyclines               1475 1501 1542 1636 1748 1835 1855 1884 2039 2161
J01B Amphenicols 1 0 0 0 0 0 0 0 0 0
J01CA                        Penicillins with extended spectrum 5385 5356 5295 5346 5561 5722 6188 6061 6076 6317
J01CE                        Beta-lactamase sensitive penicillins     20730 21263 21630 22230 22520 22760 24003 22466 21744 22301
J01CF                        Beta-lactamase resistant penicillins     3230 3738 4075 4377 4565 4842 5037 5183 5250 5418
J01CR                        
Comb. of penicillins, 
including beta-lactamase 
inhibitors   
146 249 336 480 534 724 1012 1348 1836 2597
J01D                        Cephalosporins and related substances(b)     739 811 830 894 1582 1778 2285 2530 2740 2696
J01EA                        Trimethoprim and derivatives  280 293 307 334 359 382 402 402 399 417
J01EB                        Short-acting sulfonamides       3113 3092 3064 3067 2987 2865 2565 2273 2200 2158
J01EE                        
Comb. of sulfonamides and 
trimethoprim, including 
derivatives 
289 288 273 185 208 208 148 183 193 252
J01FA               Macrolides(c) 4089 4150 3876 3743 3775 3542 3434 3164 2966 3038
J01FF                        Lincosamides(b)              37 40 45 53 52 66 78 94 113 124
J01G Aminoglycosides 30 31 28 31 31 27 27 25 23 24
J01MA                        Fluoroquinolones(b)        398 451 611 722 866 979 1162 1351 1371 1457
J01XA Glycopeptides 36 42 43 46 51 56 61 64 86 89
J01XC                        Steroid antibacterials (fusidic acid)     59 59 58 52 62 65 67 64 62 65
J01XD Imidazoles 168 179 191 195 206 198 202 241 255 258
J01XE Nitrofuran derivatives (nitrofurantoin) 155 163 166 171 180 185 190 192 201 208
J01XX05 Methenamine(b) 1637 1662 1590 1473 1107 1076 1060 1087 1047 1078
J01XX08+09 Linezolid, daptomycin 0 3 4 5 10 14 12 14 14 13
J01 Antibacterial agents for systemic use (total)(d) 41997 43371 43964 45040 46404 47324 49788 48629 48614 50673
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5.3. Primary health care
5.3.1 Total consumption in primary 
health care
Total consumption compared with 2009
In 2010, the total consumption of antibacterial agents 
for systemic use (J01) in primary health care increased 
by 6% to 16.93 DID compared with 15.95 DID in 
2009, and increases were observed for 10/19 of the 
therapeutic groups (Table 5.3). Four therapeutic 
groups constituted most of the increase: macrolides 
(0.23 DID); ‘combination penicillins’ (0.23 DID); 
penicillins with extended spectrum (0.18 DID); 
and beta-lactamase sensitive penicillins (0.13 DID). 
Consumption decreased within only one group: short-
acting sulfonamides 0.01 DID (2%).
The increase this year of 0.98 DID (6%) was the largest 
increase observed, since the DANMAP programme was 
initiated in 1995. Each treated patient, in primary health 
care, used almost equal numbers of DDD compared 
with 2009 (19.6 DDD vs. 19.2 DDD), as demonstrated 
in paragraph 5.3.2. However, more patients were treated 
in 2010 with additional packages prescribed (Tables 
AP1.4, AP1.5 in appendix 1). The fact that more patients 
were treated in 2010 - at least once by an antibacterial 
agent with an equal number of DDDs per patient - has 
led to the increase in consumption.
The observed increase in consumption was markedly 
larger in the second half of 2010, both for total 
consumption (J01), but also for macrolides and beta-
lactamase sensitive penicillins. This coincided with an 
increased burden of lower respiratory tract infections 
(LRTI) in the second half of 2010, confirmed by an 
outbreak of Mycoplasma pneumoniae in the (third 
a) From the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system
DANMAP 2010
Table 5.3. Consumption of antibacterial agents for systemic use in primary health care (DDD/1000 inhabitant-
days), Denmark
ATC 
group(a) Therapeutic group
Year
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
J01AA                        Tetracyclines               0.99 1.04 1.07 1.17 1.28 1.38 1.48 1.54 1.61 1.69
J01CA                        Penicillins with extended spectrum 2.47 2.51 2.52 2.63 2.79 2.95 3.25 3.26 3.29 3.47
J01CE                        Beta-lactamase sensitive penicillins     4.91 5.00 5.07 5.20 5.28 5.40 5.67 5.30 5.12 5.25
J01CF                        Beta-lactamase resistant penicillins     0.65 0.77 0.85 0.92 0.97 1.05 1.09 1.12 1.13 1.17
J01CR                        Combinations of penicillins, including beta-lactamase inhibitors   0.03 0.04 0.05 0.06 0.08 0.12 0.19 0.27 0.45 0.68
J01D                        Cephalosporins and related substances          0.03 0.03 0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.03
J01EA                        Trimethoprim and derivatives   0.35 0.36 0.38 0.41 0.44 0.47 0.49 0.49 0.48 0.51
J01EB                        Short-acting sulfonamides       0.36 0.36 0.36 0.36 0.35 0.35 0.31 0.28 0.27 0.26
J01EE                        Combinations of sulfonamides and trimethoprim, including derivatives 0.04 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01FA                        Macrolides                  2.10 2.15 2.13 2.23 2.41 2.31 2.42 2.28 2.21 2.44
J01FF                        Lincosamides                0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.03 0.03 0.04
J01GB Aminoglycosides 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
J01MA                        Fluoroquinolones            0.17 0.18 0.25 0.28 0.33 0.37 0.44 0.51 0.52 0.57
J01XA Glycopeptides 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01XB                        Polymyxins                 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02
J01XC                        Steroid antibacterials (fusidic acid)     0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01
J01XE Nitrofuran derivatives (nitrofurantoin) 0.39 0.41 0.42 0.43 0.45 0.46 0.47 0.47 0.49 0.51
J01XX Other antibacterials (methenamine >99%) 0.33 0.34 0.32 0.30 0.28 0.27 0.26 0.27 0.26 0.27
J01 Antibacterial agents for systemic use (total) 12.85 13.26 13.53 14.06 14.75 15.23 16.17 15.91 15.95 16.93
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and) fourth quarter of 2010 (Figure 5.11). LRTI’s of 
suspected bacteriological origin are empirically treated 
with beta-lactamase sensitive penicillins, and confirmed 
M. pneumoniae pneumonia by macrolides according 
to guidelines in Denmark. Therefore, it is a likely 
conclusion that the M. pneumoniae pneumonia outbreak 
explains a good part of the increased consumption. 
Unfortunately, indication codes are incomplete, and 
therefore this presumption cannot be verified.
Another important factor was the increased 
consumption of ‘combination penicillins’, contributing 
23% of the total increase. In this therapeutic group, 
indeed more patients were treated in 2010 with 
additional packages pre-scribed (Tables AP1.4 and 
AP1.5 in appendix 1), and additional DDD’s were 
given to each treated patient (Table 5.4). For possible 
explanations to this increase; refer to paragraph 5.3.2.
Beta-lactamase sensitive penicillins still represented 
the largest therapeutic group of antibacterial agents 
consumed (31%) followed by penicillins with extended 
spectrum (20%) and macrolides (15%) (Figure 5.4). 
Penicil-lins (J01C) accounted for 62% of the total 
consumption in 2010. Consumption of broad-spectrum 
agents increased by 0.53 DID (9%) compared with 2009 
(Figure 5.5).
Total consumption - the last decade
Antibacterial consumption (J01) increased by 32% 
from 12.85 DID in 2001 to 16.93 DID in 2010 (Table 
5.3). Broad-spectrum agents represented 6.48 DID 
(38%) of the total consumption in 2010 compared with 
3.75 DID (29%) in 2001; representing an increase of 
73% (Figure 5.5). For all leading groups of antibacterial 
agents (tetracyclines, penicillins with extended 
spectrum, beta-lactamase sensitive penicillins, beta-
lactamase resistant penicillins, ‘combination penicillins’, 
macrolides, and fluoroquinolones) consumption was 
higher in 2010 than 10 years before, and for most 
groups the trend in consumption has been a steady 
increase year by year (Figure 5.6). Only short-acting 
sulfonamides (J01EB) and ‘other antibiotics’ (J01XX) 
were at a lower reported level in 2010 compared with 
2001. 
5.3.2 Measures at treated patient level
Measures at treated patient level compared with 
2009
The total number (J01) of DDDs per treated patient 
was 19.6 in 2010 compared with 19.2 in 2009. Among 
substances with the highest consumption (DID), each 
treated patient received from 11–21 DDDs in 1.4–1.6 
packages with the exception of tetracyclines (45.2 
Figure 5.4. Distribution of the total consumption of antibacterial agents in primary health care, Denmark
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a) Narrow-spectrum includes: beta-lactamase sensitive penicillins, beta-lactamase resistant penicillins, trimethoprim, sulfonamides, 
macrolides, lincosamides, glycopeptides, fusidic acid, imidazol derivatives, nitrofuran derivatives, and ‘other antibiotics’
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Figure 5.6. Consumption of leading antibacterial groups for systemic use in primary health care, Denmark
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tablets could be explanatory for this trend as pointed out 
in DANMAP 2008.
Penicillins with extended spectrum: a few low-strength 
packages (for children) are no longer marketed (higher 
strength packages are prescribed for small children) and 
national guidelines have increased the recommended 
dosage of certain substances over the last decade 
[DANMAP 2008].
Beta-lactamase sensitive penicillins: some low-
strength packages (for children) are no longer marketed 
while packages with higher strength have been 
introduced (higher strength packages are prescribed for 
small children); recommended dosage has increased 
for certain indications over the last decade [DANMAP 
2008].
Beta-lactamase resistant penicillins: no changes 
in packages have occurred over the last decade, but 
national guidelines have introduced new indications of 
treatment for certain infections (mastitis and impetigo) 
over the last decade [DANMAP 2008].
DDDs in 2.0 packages) (Table 5.4 and Table AP1.6 in 
appendix 1). 
Measures at treated patient level - the last decade
Different indicators of antibacterial consumption 
at treated patient level in primary health care are 
available (Figure 5.7). Comparing 2001–2010, DDD’s 
have been the indicator increasing the most; both as 
an increasing number of DDDs per treated patient 
(25%) and as DDDs per prescribed package (20%) 
(Table 5.4). Tetracyclines, ‘combination penicillins’, and 
fluoroquinolones have shown the largest increases.
The nature of these changes in trends found over the 
last decade are not clear, mainly because codes of 
indication are incomplete as pointed out in Textbox 3, 
DANMAP 2008. A list of the changes in packages and 
guidelines that have occurred during the last decade 
that could help to explain these trends is displayed 
below. 
Tetracyclines: the available packages (size and 
strength) have not been altered over the last decade. 
Prescriptions of packages with higher numbers of 
DANMAP 2010
Table 5.4. Number of DDDs and packages per treated patient among leading groups of antibacterial agents in 
primary health care, Denmark
a) From the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system
ATC 
group(a) Therapeutic group Indicator
Year
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
J01AA Tetracyclines               
DDDs / patient 30.6 33.0 34.4 36.9 39.0 40.9 43.0 44.4 45.2 45.9
Packages / patient 1.9 1.9 1.9 1.9 2.0 1.9 2.0 2.0 2.0 2.0
DDDs / package 16.1 17.5 18.1 19.0 19.6 21.0 22.0 22.7 22.7 22.7
J01CA Penicillins with extended spectrum
DDDs / patient 13.0 13.2 13.4 13.6 13.9 14.2 14.4 14.7 14.8 14.9
Packages / patient 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6
DDDs / package 8.1 8.2 8.2 8.4 8.5 8.9 9.0 9.2 9.2 9.0
J01CE Beta-lactamase sensitive penicillins     
DDDs / patient 10.3 10.5 10.7 11.1 11.3 11.5 11.7 11.8 11.8 11.8
Packages / patient 1.4 1.5 1.5 1.5 1.5 1.4 1.4 1.4 1.4 1.4
DDDs / package 7.1 7.2 7.3 7.5 7.7 8.0 8.2 8.2 8.4 8.4
J01CF Beta-lactamase resistant penicillins     
DDDs / patient 12.4 11.8 11.8 12.4 12.7 13.0 13.4 13.7 13.9 14.2
Packages / patient 1.6 1.6 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.5
DDDs / package 7.9 7.5 7.4 7.8 8.0 8.6 8.7 9.0 9.1 9.3
J01CR
Combinations of 
penicillins, incl. beta-
lactamase inhibitors   
DDDs / patient 15.9 14.7 16.6 17.2 16.8 19.3 19.1 19.9 20.4 21.1
Packages / patient 1.7 1.7 1.8 2.0 2.0 1.8 1.6 1.6 1.5 1.5
DDDs / package 9.1 8.6 9.1 9.1 9.3 10.7 11.7 12.4 13.3 13.7
J01FA Macrolides                  
DDDs / patient 11.3 11.7 12.1 12.4 12.4 12.6 12.4 12.5 12.5 12.2
Packages / patient 1.5 1.5 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.5
DDDs / package 7.5 7.6 7.8 7.9 8.0 8.3 8.1 8.1 8.1 8.1
J01MA Fluoroquinolones            
DDDs / patient 8.3 8.6 10.3 9.5 9.6 10.3 10.6 11.0 11.2 11.2
Packages / patient 1.4 1.4 1.6 1.5 1.5 1.5 1.5 1.5 1.5 1.5
DDDs / package 5.9 6.0 6.6 6.4 6.5 6.9 7.0 7.5 7.6 7.6
J01 Antibacterial agents for systemic use (total)
DDDs / patient 15.6 16.0 16.4 17.0 17.5 17.9 17.3 18.9 19.2 19.6
Packages / patient 2.0 2.0 2.1 2.1 2.1 2.0 1.9 2.1 2.1 2.1
DDDs / package 7.8 7.8 7.9 8.1 8.3 8.7 8.9 9.1 9.3 9.3
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‘Combination penicillins’: the proportion of 
children (<15 years) receiving these substances have 
decreased and been replaced by adults as pointed 
out in the DANMAP 2007 report. As a consequence, 
the lowest strength packages are no longer marketed 
and low-strength packages have presumably been 
replaced by packages with higher strength. Also, 
national guidelines have introduced amoxicillin and 
clavulanic acid (J01CR02) as first-choice drug for 
treatment requiring acute exacerbation of chronic 
obstructive pulmonary disease, and for the treatment 
of recurrent/persistent upper respiratory tract 
infections (2007 guideline). In fact, whereas 28% 
of the consumption was dispensed as mixture (for 
children) in 2001, the fraction was only 5% in 2010.
Macrolides: the packages have not changes over the 
last decade, but national guidelines have increased 
the recommended treatment dosage for certain 
indications over the last decade [DANMAP 2008].
Fluoroquinolones: National guidelines only 
recommend these substances as second line choices 
for a limited number of indications, and no changes 
in packages have occurred over the last decade that 
could explain the trends in consumption.
5.3.3 Tetracyclines (J01AA)
Consumption of tetracyclines (J01AA) compared 
with 2009
In 2010, consumption of tetracyclines increased 
by 0.08 DID (5%) compared with 2009 (Table 5.3). 
Tetracycline (0.71 DID (42%)) was the most used 
of the tetracyclines in 2010 followed by doxycycline 
(0.55 DID (33%)), lymecycline (0.36 DID (21%)) and 
oxytetracycline (0.07 DID (4%)), respectively (Figure 
5.8). Within the group, consumption of all substances 
increased in 2010 compared with 2009.
Consumption of tetracyclines (J01AA) - the last 
decade
Since 2001, an extensive increase in the consumption 
of tetracyclines (0.70 DID (70%)) has been observed 
(Table 5.3). As previously pointed out in the DANMAP 
2007 report, a large part of the consumption of 
tetracyclines is prescribed for teenagers and young 
adults, and a binary pattern of consumption has been 
observed (tetracycline and lymecycline with peak 
Figure 5.7. Indicators of antibacterial consumption (J01) in primary health care, Denmark
a) Cumulated number of patients treated with anbacterials (ATC-4 level). The Danish Medicines Agency counts the first treatment 
within each ATC-group for each patient, each year
DANMAP 2010
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values in the spring and autumn, doxycycline with 
peak values in January and June). Also, 43% of the 
tetracycline (J01AA07) consumption is known to be 
prescribed against acne, and 9% of the doxycycline 
(J01AA02) consumption as malaria prophylaxis 
[Textbox 3 DANMAP 2008]. However, a total 
understanding of the increased consumption is not 
possible, as codes of indication are incomplete.
5.3.4 Penicillins (J01C)
Consumption of penicillins (J01C) compared with 
2009
In 2010, consumption of penicillins increased by 0.57 
DID (6%) compared with 2009. The four main groups: 
penicillins with extended spectrum, beta-lactamase 
sensitive penicillins, beta-lactamase resistant penicillins, 
and ‘combination penicillins’ all increased (Table 5.3). 
The only penicillin that did not increase in 2010 was 
pivampicillin (J01CA02) (Figure 5.9).
Consumption of penicillins (J01C) - the last decade
The decreasing consumption of phenoxy-
methylpenicillin and amoxicillin seen in 2009 and 
2008 was not continued in 2010, but a new plateau 
may have been reached (Figure 5.9). This lowered level 
of consumption could be the result of a decreased 
disease burden after the introduction of a heptavalent 
conjugate pneumococcal vaccine (PCV7) in the Danish 
Childhood Immunization Programme in October 
2007, but this has not been documented. Recently, a 
report has demonstrated that the incidence of invasive 
pneumococcal disease has dropped from 20 cases / 
100,000 inhabitants (1,055 cases per year on average) in 
the years prior to the introduction of PCV7 to 18 cases 
/ 100,000 inhabitants (982 cases per year on average) in 
the years after the introduction of PCV7 [EPI-NYT 19, 
2011].
Over the last decade (2001–2010), the consumption of 
penicillins with extended spectrum has increased by 
1.00 DID (40%), beta-lactamase sensitive penicillins 
has increased by 0.35 DID (7%), beta-lactamase 
Figure 5.8. Consumption of tetracyclines in primary health care, Denmark
DANMAP 2010
Figure 5.9. Consumption of leading penicillins in primary health care, Denmark
DANMAP 2010
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resistant penicillins has increased by 0.52 DID 
(80%) and ‘combination penicillins’ has increased 
by 0.65 DID (2277%), respectively (Table 5.3). 
Phenoxymethylpenicillin was still by far the most 
consumed penicillin, but among the other penicillins 
the order has changed during the last decade (Figure 
5.9).
5.3.5 Macrolides (J01FA)
Consumption of macrolides (J01FA) compared with 
2009
The consumption of macrolides increased by 0.23 
DID (10%) from 2009–2010 (Table 5.3). Within the 
group of macrolides, clarithromycin (0.03 DID), 
azithromycin (0.04 DID) and erythromycin (0.04 DID) 
consumption fol-lowed the trends of the previous 
years whereas roxithromycin showed a considerable 
increase of 0.19 DID (Figure 5.10). As in 2004 and 
2005 [Figure 12, DANMAP 2005], part of the increase 
in roxithromycin consumption was likely due to an 
outbreak of Mycoplasma pneumoniae in the (third and) 
fourth quarter of 2010 [Rasmussen et al. 2010. Euro 
Surveill. 15. pii: 19708] (Figure 5.11). In fact, macrolide 
consumption was 0.91 DID (40%) higher in the fourth 
quarter of 2010 compared with the fourth quarter of 
2009.
Consumption of macrolides (J01FA) - the last 
decade
Over the last decade (2001–2010), roxithromycin (0.79 
DID) consumption, and to some extend clarithromycin 
(0.07 DID) and azithromycin (0.02 DID) consumption, 
has increased while erythromycin (0.54 DID) 
consumption has decreased (Figure 5.10). National 
guidelines regarding first-choice macrolide in primary 
health care have changed from erythromycin towards 
first roxithromycin (2004 guideline) and subsequently 
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Figure 5.10. Consumption of macrolides in primary health care, Denmark
DANMAP 2010
DANMAP 2010
Figure 5.11. Monthly consumption of macrolides and PCR positive Mycoplasma pneumoniae tests in 
primary health care, Denmark
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clarithromycin (2007 guideline) [DANMAP 2008], 
but the latter change has not become apparent in the 
distribution of the consumption. Throughout the last 
decade, azithromycin has been recommended for 
urethritis/cervicitis and epididymitis. 
  
5.3.6 Fluoroquinolones (J01MA)
Consumption of fluoroquinolones (J01MA) 
compared with 2009
Fluoroquinolone consumption increased by 0.05 DID 
(10%) compared with 2009 (Table 5.3). Ciprofloxacin 
accounted for 94% of the total fluoroquinolone 
consumption in 2010; ofloxacin and moxifloxacin each 
accounted for 2% and 3%, respectively (Figure 5.12). 
Consumption of fluoroquinolones (J01MA) - the last 
decade
Even though the trend of increasing fluoroquinolone 
consumption seemed to slow down in 2009, 
consumption has increased by 0.40 DID (238%) during 
2001–2010 (Table 5.3). The continuously increasing 
consumption of ciprofloxacin began when the price 
of ciprofloxacin dropped markedly following the 
introduction of generics onto the Danish marked in 
December 2001 [Jensen et al.  2010. J Antimicrob 
Chemother. 65:1286–91].
Figure 5.12. Consumption of leading fluoroquinolones in primary health care, Denmark
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5.4. Hospital care
5.4.1 Introduction
Hospital consumption is presented as both DDD 
per 100 occupied bed-days (DBD) and DDD per 
100 admissions (DAD) to include the activity in 
hospitals, and as DID to compare with primary 
health care and to document the consumption in the 
entire hospital care sector without considering the 
activity in the hospitals. DAD is the internationally 
recognised abbreviation and is the same measure as 
DDD per 100 discharges which has been used in the 
previous DANMAP reports.
Hospital care is the term for all hospitals in the hospital 
care sector of Denmark i.e. rehabilitation centres, 
hospices, private-, psychiatric-, specialised-, and somatic 
hospitals. The majority of antibacterial consumption 
occurs in the somatic hospitals (97% of the total 
consumption in hospital care). Antibiotic consumption 
is therefore correlated to bed-days in and admissions 
to somatic hospitals only, and not to the number of 
bed-days in and admissions in all hospital care, since 
psychiatric hospitals contribute a large proportion of 
bed-days and admissions to all hospital care.
The trends in numbers of occupied bed-days and 
admissions to somatic hospitals 2001–2010 are shown in 
Figure 5.13. The regional numbers of occupied bed-days 
and admissions to somatic hospitals 2010 are displayed 
in table AP1.7 in appendix 1.
In Denmark, the hospitalization pattern has changed 
over the last decade. Today, more people are admitted 
to the somatic hospitals, but each length of stay has 
shortened. Also, outpatient treatment has increased. 
Consequently, the hospital activity and the selection 
pressure for the emergence of resistance are higher than 
10 years ago.
In this report, the number of occupied bed-days and 
admissions of 2001–2009 obtained from the National 
Board of Health has been updated. This update has 
particularly affected the reported consumption of 2009 
and resulted in only minor changes from 2001–2008. 
Due to procedural rearrangements (merging of 
antibacterial agents and infusion liquids) of certain 
chemical substances for infusion, the reporting of 
sales (consumption) by the hospital pharmacies to the 
Danish Medicines Agency has been inaccurate for some 
groups. Consumption of cephalosporins, carbapenems, 
combinations of sulfonamides and trimethoprim and 
imidazole derivates has been corrected, as in previous 
years. In 2010, data were collected from all Danish 
hospital pharmacies. 
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5.4.2 Total consumption in hospital care - DDD 
per 1,000 inhabitants per day (DID)
Total consumption compared with 2009
Total consumption (J01) in Danish hospital care 
(rehabilitation centres, hospices, private-, psychiatric-, 
specialised-, and somatic hospitals) added up to 1.91 
DID in 2010; similar to that of 2009 (Figure 5.14). 
Broad-spectrum agents represented 67% of the total 
consumption, as in 2009.
Figure 5.13. Number of bed-days and admissions in somatic hospitals, Denmark
DANMAP 2010
Total consumption - the last decade
Since 2001, total consumption has increased by 0.46 
DID (31%). Broad-spectrum agents have increased 
by 0.18 DID (37%); comprising 67% of the total 
consumption in 2010 compared with 49% in 2001 
(Figure 5.14 and Table AP 1.8 in appendix 1).
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Figure 5.14. Consumption of antibacterial agents (J01) in hospital care by narrow-spectrum(a) and broad-
spectrum(b) agents, Denmark
a) Narrow-spectrum antibiotics includes: beta-lactamase sensitive penicillins, first-generation cephalosporins, beta-lactamase 
resistant penicillins, monobactams, trimethoprim, sulfonamides, macrolides, lincosamides, glycopeptides, fusidic acid, imidazol 
derivatives, nitrofuran derivatives, and ‘other antibiotics’.        
b) Broad-spectrum includes: tetracyclines, penicillins with extended spectrum, combinations of penicillins incl. beta-lactamase 
inhibitors, second-generation cephalosporins, third-generation cephalosporins, carbapenems, combinations of sulfonamides and 
trimethoprim, aminoglycosides, fluoroquinolones, and polymyxins.       
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Figure 5.15. Distribution of the total consumption of antibacterial agents in somatic hospitals, Denmark
DANMAP 2010
5.4.3 Somatic hospitals - DDD per 100 occupied 
bed-days (DBD)
Somatic hospital consumption (DBD) compared with 
2009
Total consumption (J01) in somatic hospitals increased 
by 2.69 DBD (3%) from 2009 to 2010 (Table 5.5). 
Three therapeutic groups dominated the increase in 
consumption: ‘combination penicillins’ 1.48 DBD (26%), 
carbapenems 0.88 DBD (28%) and combinations of 
sulfonamides and trimethoprim 0.76 DBD (34%), but 
also second-generation cephalosporins, beta-lactamase 
resistant penicillins, macrolides and aminoglycosides 
increased ≥0.10 DBD. The increased consumption of the 
latter three was due to decreasing numbers of bed-days 
and practically equal numbers of DDDs. Regarding 
second-generation cephalosporins, consumption 
measured as DBD went up even though the number of 
DDDs used decreased compared with 2009. 
An intervention at Copenhagen University Hospital, 
Bispebjerg changed the local consumption pattern, 
with lower consumption of cephalosporins and 
fluoroquinolones, but nationally it did not influence the 
consumption much [Textbox 8]. 
Consumption decreased ≥0.10 DBD in four therapeutic 
groups: penicillins with extended spectrum 0.76 DBD 
(5%), beta-lactamase sensitive penicillins 0.41 DBD 
(4%), third-generation cephalosporins 0.16 DBD (11%), 
and fluoroquinolones 0.27 DBD (2%). Regarding all 
four, the decreased consumption was due to both 
decreasing numbers of bed-days and DDDs.
Cephalosporins accounted for 20% of the total 
consumption in somatic hospitals. Penicillins with 
extended spectrum (17%), fluoroquinolones (12%) 
and beta-lactamase sensitive penicillins (11%) were the 
other top four contributing therapeutic groups in 2010 
(Figure 5.15).
Somatic hospital consumption (DBD) – the last 
decade
During 2001–2010, the total consumption (J01) in 
somatic hospitals has increased by 39.40 DBD (82%) 
(Table 5.5). This increase was due to a 35% increase in 
the number of DDDs, and a concurrent 26% decrease in 
the total number of hospital bed-days. 
                                                                           
       57DANMAP 2010  
ANTIMICROBIAL CONSUMPTION IN HUMANS 5.
Table 5.5. Consumption of antibacterial agents for systemic use in somatic hospitals (DDD/100 occupied bed-
days), Denmark
a) From the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system     
ATC group(a) Therapeutic group Year2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
J01AA                        Tetracyclines               0.28 0.32 0.30 0.32 0.33 0.39 0.63 0.78 1.04 1.09
J01CA                        Penicillins with extended spectrum 11.33 11.34 11.55 11.51 12.90 13.00 13.42 13.96 15.37 14.61
J01CE                        Beta-lactamase sensitive penicillins     10.45 11.37 11.85 12.02 12.17 10.67 10.79 9.98 9.90 9.49
J01CF                        Beta-lactamase resistant penicillins     5.90 6.24 6.54 6.78 6.71 6.51 6.70 6.81 7.40 7.71
J01CR                        
Combinations of penicillins. 
incl. beta-lactamase 
inhibitors   
0.17 0.31 0.49 0.84 1.16 1.83 2.95 4.00 5.65 7.13
J01DB                  First-generation cephalosporins 0.11 0.14 0.14 0.17 0.15 0.14 0.13 0.18 0.13 0.13
J01DC Second-generation cephalosporins 5.12 5.79 6.24 6.91 8.39 9.38 12.31 13.32 15.76 16.21
J01DD Third-generation cephalosporins 0.65 0.65 0.67 0.67 0.83 0.83 1.03 1.25 1.42 1.26
J01DF Monobactams 0.01 0.00 0.01 0.00 0.00 0.00 0.04 0.07 0.06 0.09
J01DH Carbapenems 0.42 0.60 0.68 0.85 1.16 1.38 2.13 2.70 3.15 4.02
J01EA                        Trimethoprim and derivatives   0.42 0.41 0.43 0.41 0.41 0.42 0.44 0.44 0.44 0.36
J01EB                        Short-acting sulfonamides       1.22 1.23 1.14 1.06 0.99 0.75 0.34 0.35 0.35 0.33
J01EE                        
Combinations of 
sulfonamides and 
trimethoprim. incl. 
derivatives 
1.33 1.46 1.54 1.86 2.11 2.12 1.52 1.95 2.28 3.04
J01FA                        Macrolides                  3.21 3.21 2.95 2.85 2.89 2.83 3.08 3.06 3.42 3.52
J01FF                        Lincosamides                0.17 0.19 0.22 0.23 0.24 0.31 0.35 0.41 0.50 0.47
J01GB Aminoglycosides 1.82 1.76 1.71 2.00 1.95 1.81 1.79 1.64 1.56 1.71
J01MA                        Fluoroquinolones            2.81 3.52 3.90 4.93 6.14 6.74 8.16 9.53 10.71 10.44
J01XA Glycopeptides 0.32 0.38 0.42 0.47 0.52 0.56 0.63 0.68 0.99 1.07
J01XB                        Polymyxins                 0.03 0.04 0.03 0.06 0.12 0.12 0.05 0.05 0.07 0.10
J01XC                        Steroid antibacterials (fusidic acid)     0.19 0.19 0.22 0.22 0.25 0.28 0.28 0.26 0.31 0.34
J01XD                 Imidazole derivatives 1.94 2.12 2.32 2.43 2.62 2.78 2.62 3.27 3.84 3.93
J01XE Nitrofuran derivatives (nitrofurantoin) 0.28 0.28 0.30 0.28 0.29 0.29 0.28 0.29 0.36 0.31
J01XX05 Methenamine 0.13 0.12 0.08 0.10 0.08 0.11 0.09 0.10 0.09 0.08
J01XX08 Linezolid 0.00 0.04 0.04 0.07 0.15 0.20 0.16 0.21 0.22 0.22
J01XX09 Daptomycin 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.02 0.02
J01 Antibacterial agents for systemic use (total) 48.31 51.73 53.77 57.04 62.58 63.47 69.94 75.28 85.03 87.72
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Figure 5.16 illustrates the steady shift towards increasing 
consumption of ‘newer‘ broad-spectrum antibacterial 
agents - defined as: ‘combination penicillins’ (J01CR), 
cephalosporins (J01DB, DC, DD), carbapenems 
(J01DH) and fluoroquinolones (J01MA) - in Danish 
somatic hospitals. In 2001, consumption of penicillins 
with extended spectrum and beta-lactamase sensitive 
penicillins represented 24% and 22% of total somatic 
hospital antibacte-rial consumption in Denmark, 
respectively. These shares had decreased to 17% and 
11% in 2010. Within the group of the penicillins with 
extended spectrum, the decrease mainly concerned 
ampicillin/pivampicillin/amoxicillin whereas 
consumption of mecillinam/pivmecillinam has 
increased. Consumption of cephalosporins represented 
12% of total somatic hospital antibacterial consumption 
in 2001, rising to 20% in 2010. 
The benefit of these changes in patterns of antibacterial 
consumption over the last decade could be an empirical 
treatment covering more groups of pathogens. 
Nevertheless, this potential gain seems to be rapidly 
counterbalanced by the emergence of resistance towards 
newer classes of antibacterial agents (see chapter 8). 
Importantly, it is interesting that the steeply increasing 
proportion of cephalosporins and fluoroquinolones 
used during the last decade has yielded over the last two 
years.
5.4.4 Somatic hospital consumption - DDD 
per 100 admissions (DAD)
Somatic hospital consumption (DAD) compared 
with 2009
The total consumption (J01) in somatic hospitals 
decreased by 12.47 (4%) from 2009–2010 when 
expressed as the number of DAD (Table 5.6). As 
when measured as DBD, consumption increased 
in the same three therapeutic groups by ≥1 
DAD: ‘combination penicillins’ 3.41 DAD (17%), 
carbapenems 2.06 DAD (28%) and combinations 
of sulfonamides and trimethoprim 1.91 DAD 
(24%). Consumption decreased ≥1 DAD in four 
therapeutic groups: penicillins with extended 
spectrum 6.31 DAD (12%), beta-lactamase 
sensitive penicillins 3.78 DAD (11%), second-
generation cephalosporins 2.47 DAD (4%), and 
fluoroquinolones 3.53 DAD (9%).
Somatic hospital consumption (DAD) – the last 
decade
Antibacterial consumption (J01) has increased by 
14% from 249.76 DAD in 2001 to 284.89 DAD 
in 2010 (Table 5.6). This increase was driven 
by a 35% increase in the number of DDDs, 
but counterbalanced by an 18% increase in the 
number of admissions during the last decade (as a 
consequence of changes in hospitalization patterns). 
The difference between trends in consumption 
measured by DBD and DAD illustrates that the 
interpretation of the measures of consumption is 
highly dependent on the denominator as well as 
the nominator (DDD) and that one indicator is not 
enough to express hospital consumption.
Ulrich Stab Jensen
Figure 5.16. Percentages of total somatic hospital consumption by leading groups of antibacterial agents 
(J01), Denmark
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Table 5.6. Consumption of antibacterial agents for systemic use in somatic hospitals (DDD/100 admitted 
patients), Denmark
a) From the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system     
b) The number of admissions was affectedly low in 2008 due to a major hospital strike      
              
      
DANMAP 2010
ATC group(a) Therapeutic group Year2001 2002 2003 2004 2005 2006 2007 2008(b) 2009 2010
J01AA                        Tetracyclines               1.44 1.58 1.43 1.45 1.45 1.67 2.59 3.19 3.63 3.55
J01CA                        Penicillins with extended spectrum 58.59 56.68 54.88 52.22 56.43 55.13 55.39 57.18 53.76 47.46
J01CE                        Beta-lactamase sensitive penicillins     54.03 56.79 56.33 54.53 53.20 45.26 44.55 40.90 34.61 30.83
J01CF                        Beta-lactamase resistant penicillins     30.50 31.18 31.11 30.77 29.33 27.60 27.64 27.89 25.86 25.04
J01CR                        Comb. of penicillins. incl. beta-lactamase inhibitors   0.88 1.56 2.35 3.82 5.09 7.77 12.17 16.37 19.74 23.15
J01DB                  First-generation cephalosporins 0.58 0.72 0.67 0.76 0.67 0.60 0.55 0.72 0.46 0.43
J01DC Second-generation cephalosporins 26.48 28.95 29.66 31.36 36.70 39.76 50.81 54.55 55.12 52.65
J01DD Third-generation cephalosporins 3.34 3.25 3.17 3.06 3.62 3.53 4.24 5.10 4.98 4.10
J01DF Monobactams 0.05 0.02 0.02 0.02 0.02 0.00 0.18 0.27 0.21 0.29
J01DH Carbapenems 2.16 2.98 3.24 3.85 5.05 5.86 8.78 11.08 11.01 13.07
J01EA                        Trimethoprim and derivatives   2.19 2.07 2.05 1.86 1.78 1.78 1.81 1.80 1.56 1.17
J01EB                        Short-acting sulfonamides    6.33 6.16 5.44 4.82 4.32 3.18 1.41 1.43 1.21 1.09
J01EE                        
Comb. of sulfonamides 
and trimethoprim. incl. 
derivatives 
6.88 7.31 7.32 8.44 9.21 8.98 6.28 7.98 7.96 9.88
J01FA                        Macrolides                  16.58 16.03 14.03 12.92 12.64 12.01 12.70 12.53 11.97 11.45
J01FF                        Lincosamides                0.88 0.94 1.05 1.04 1.05 1.31 1.46 1.69 1.74 1.52
J01GB Aminoglycosides 9.42 8.79 8.14 9.07 8.55 7.68 7.39 6.71 5.45 5.56
J01MA                        Fluoroquinolones            14.51 17.60 18.53 22.38 26.87 28.58 33.66 39.04 37.45 33.92
J01XA Glycopeptides 1.63 1.88 1.97 2.12 2.28 2.38 2.61 2.77 3.48 3.47
J01XB                        Polymyxins                 0.15 0.20 0.14 0.27 0.54 0.53 0.22 0.21 0.24 0.32
J01XC                        Steroid antibacterials (fusidic acid)     1.01 0.97 1.04 1.01 1.11 1.19 1.17 1.05 1.09 1.12
J01XD                 Imidazole derivatives 10.02 10.57 11.03 11.02 11.47 11.81 10.83 13.39 13.43 12.76
J01XE Nitrofuran derivatives (nitrofurantoin) 1.47 1.42 1.41 1.26 1.28 1.24 1.17 1.19 1.27 1.01
J01XX05 Methenamine 0.65 0.61 0.37 0.45 0.36 0.46 0.38 0.43 0.31 0.27
J01XX08 Linezolid 0.00 0.22 0.21 0.34 0.64 0.86 0.68 0.84 0.76 0.72
J01XX09 Daptomycin 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.06 0.06 0.07
J01 Antibacterial agents for systemic use (total) 249.76 258.46 255.59 258.81 273.67 269.18 288.70 308.39 297.36 284.89
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6. Resistance in zoonotic bacteria
Zoonoses are infections and diseases that are 
transmissible between animals and humans, either 
via direct contact or indirectly via contaminated food. 
Zoonotic bacteria such as Salmonella and Campylobacter 
can develop resistance to antimicrobial agents as a 
result of treatment of the animals, which subsequently 
may lead to treatment failure of human infections. A 
more detailed description of the trends and sources of 
zoonoses in Denmark and of national surveillance and 
control programmes can be found in the Annual Report 
on Zoonoses in Denmark 2010 [www.food.dtu.dk].
6.1 Salmonella 
Salmonella is an important zoonotic pathogen with great 
economic significance in both animals and humans. 
The common reservoir of Salmonella is the intestinal 
tract of a wide range of domestic and wild animals. In 
animals, infections are often sub-clinical. Transmission 
of Salmonella to humans often happens through a food 
vehicle which has been contaminated with Salmonella 
and where the organisms have been allowed to multiply 
due to e.g. inadequate storage temperatures, inadequate 
cooking or cross contamination of ready-to-eat food. 
In Denmark, as well as in the European Union, S. 
Enteritidis and S. Typhimurium are the serovars most 
frequently associated with human illness. Human cases 
caused by S. Enteritidis are mostly associated with the 
consumption of contaminated eggs and poultry meat, 
while S. Typhimurium cases are mostly associated with 
the consumption of contaminated pig, poultry and 
bovine meat.
Human salmonellosis is typically characterized by 
the acute onset of fever, abdominal pain, nausea, and 
sometimes vomiting, after an incubation period of 12–
36 hours. Symptoms are often mild and most infections 
are self-limiting. However, in some patients the infection 
may be more serious, and salmonellosis has also been 
associated with long-term and chronic sequelae such as 
reactive arthritis. 
In Denmark, all flocks of laying hens and broilers, 
including breeder flocks, are monitored for Salmonella 
according to the EU requirements. Eggs from Salmonella 
positive laying hen flocks are heat treated or destroyed, 
and meat from broiler flocks found positive at the 
ante-mortem control is heat treated. An extensive 
Salmonella surveillance and control program is also 
running in the Danish pig production (at herd level) 
and samples of pork and beef are collected after chilling 
at the slaughterhouses. Finally, a control program for 
Salmonella in Danish and imported broiler meat, beef 
and pork has been implemented. Human salmonellosis 
is notifiable in Denmark, and all cases are reported to 
the national database at SSI. 
Clonal dissemination plays an important role for 
the spread of antimicrobial resistant Salmonella 
spp., particularly within S. Typhimurium. Examples 
of this are the rapid, global dissemination of the 
penta-resistant S. Typhimurium DT104, which is 
resistant to ampicillin (A), chloramphenicol (C), 
streptomycin (S), sulfonamide (Su) and tetracycline 
(T) (ACSSuT), and the emergence of the monophasic 
“S. Typhimurium-like” strains. In addition, and 
presumably as a consequence of clonal dissemination, 
there also appears to be strong associations between 
certain phage types and particular resistance patterns. 
Again S. Typhimurium DT104 is an example of this, 
and so are the monophasic S. Typhimurium DT193 
and DT120 that are typically resistant to ampicillin (A), 
streptomycin (S), sulfonamide (Su) and tetracycline 
(T), known as the ‘classic DT120 pattern’ or ASSuT. 
However, DT193 and DT120 are also commonly found 
in other lineages, for instance lineages derived from 
DT104, where they may show other resistance patterns 
such as ACSSuT. 
Some phage types (e.g. DT12 and DT66) appear to 
only very slowly acquire resistance - if at all. Rather, 
such phage types appear to be displaced by resistant 
phage types if a selection pressure is put on them due to 
changes in the use of antimicrobial agents.
  
In this report, monophasic Salmonella isolates are 
included as S. Typhimurium, as recently recommended 
by the European Food Safety Authority [EFSA journal 
2010. 8(10): 1826]. For animals and meat, the data 
from 2005 to 2009 have been updated accordingly. See 
definition of multi-resistance in Appendix 2.
6.2 Salmonella from production animals 
For pigs and poultry, the isolates originated mainly 
from national surveillance programs. All Danish 
broiler flocks and table egg layer flocks were tested 
for Salmonella during 2010 (3,773 and 455 flocks, 
respectively), of which 43 broiler flocks and eight layer 
flocks were positive. Overall, nine flocks were found 
positive with S. Typhimurium and five flocks with S. 
Enteritidis [Annual Report on Zoonoses in Denmark 
2010]. S. Typhimurium was isolated from 434 of the 
1,089 pig herds appointed for testing based on results 
from the sero-surveillance. In addition, 21 isolates from 
diagnostic submissions were included. All 18 isolates 
from cattle were from clinical submissions. 
Among the isolates tested for antimicrobial resistance 
in 2010, one isolate per farm was randomly included in 
the report. Insufficient numbers of S. Typhimurium and 
S. Enteritidis isolates (≥15) were obtained for Danish 
broilers and layers, and the results of the susceptibility 
testing is not presented. 
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MIC distributions among S. Typhimurium  from cattle 
and pigs in 2010 are shown in Appendix 1 (Table 
AP1.9). 
In 2010, none of the isolates of S. Typhimurium or S. 
Enteritidis from pigs or cattle were found resistant to 
cephalosporins, ciprofloxacin or nalidixic acid. 
Salmonella Typhimurium in cattle
Of the 18 S. Typhimurium isolates that were 
susceptibility tested, 22% were fully sensitive and 
56% were found to be multi-resistant. The highest 
occurrence of resistance was to streptomycin (67%), 
followed by tetracycline (61%), sulfonamide (56%) and 
ampicillin (56%) (Table 6.1). Nine of the isolates had 
the ASSuT resistance pattern, primarily phage type 
DT193 (6 isolates), but also DT120, DT7 and DTU302.
Salmonella Typhimurium in pigs  
Among the selected 455 S. Typhimurium isolates 
from pigs, the most common phage types were 
DT120 (23%), DT193 (19%), DT12 (9%) and DT104 
(7%). Overall, 38% of the susceptibility tested S. 
Typhimurium isolates from pigs were fully sensitive, 
whereas 53% were found to be multi-resistant. The 
highest occurrence of resistance was to streptomycin 
(56%), followed by sulfonamide (53%), ampicillin 
(49%) and tetracycline (47%) (Table 6.1).
Since 2000, there has been a parallel increase in 
resistance to ampicillin, sulfonamide and tetracycline 
(Figure 6.1). In 2008 and 2009, a temporary reduction 
in tetracycline resistance was observed which has not 
been fully explained; although it was partly related 
to a reduction in DT104 and other phage types 
often resistant to tetracycline. However, in 2010 the 
occurrence of resistance to tetracycline increased 
again (Figure 6.1), which is explained in part by an 
increase in the monophasic DT193 with the resistance 
pattern ASSuT (Figure 6.2). In addition, the significant 
increase in resistance to tetracycline coincided with 
an 5% decrease in consumption of tetracyclines per 
pig produced supporting that the increase is better 
explained by the spread of resistant clones. 
The level of resistance in 2010 was significantly higher 
for ampicillin, streptomycin and tetracycline, as 
compared to the 2009 levels. 
The proportion of S. Typhimurium isolates with the 
ASSuT resistance pattern increased from 15% to 29% 
from 2005 to 2010. The majority of the isolates with 
the ASSuT resistance pattern was DT120, and to 
some extent the monophasic DT193 which increased 
markedly from 2009 to 2010. The increased occurrence 
of the ASSuT resistance pattern in S. Typhimurium 
isolates is primarily a reflection of the increased 
occurrence of these phage types in the Danish pig 
population (Figure 6.2).
Table 6.1. Resistance (%) among Salmonella Typhimurium from cattle, pigs, different types of meat and domestic 
sporadic human cases, Denmark
a) The isolate was categorized as ‘domestic sporadic’ if the patient did not travel one week prior to the infection and was not reported as 
beeing part of an outbreak            
DANMAP 2010 
Antimicrobial agent
Cattle Pigs Pork Broiler meat
Turkey 
meat Human
% % Danish  %
Imported   
%
Imported     
%
Imported     
%
Domestic 
sporadic(a)  
%
Tetracycline 61 47 27 77 6 100 36
Chloramphenicol 6 9 4 21 0 10 7
Florfenicol 6 6 4 10 0 10 6
Ampicillin 56 49 35 73 11 68 42
Ceftiofur 0 0 0 0 0 2 0
Cefotaxime 0 0 0 0 0 2 -
Sulfonamide 56 53 38 84 11 93 44
Trimethoprim 0 8 0 18 0 27 5
Apramycin 0 1 0 0 0 24 1
Gentamicin 0 2 0 0 0 27 1
Neomycin 0 3 0 3 0 24 4
Spectinomycin 6 16 8 24 0 39 9
Streptomycin 67 56 46 87 28 93 43
Ciprofloxacin 0 0 0 0 0 2 4
Nalidixic acid 0 0 0 0 0 2 2
Colistin 0 0 0 0 0 2 1
Number of isolates 18 455 26 62 18 41 227
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Figure 6.1. Resistance (%) in Salmonella Typhimurium(a) 
from pigs, Denmark
a) The number of isolates varies between years (from 216 to 736)  
  
6.2.1 Salmonella in meat
Salmonella isolates from Danish and imported  broiler 
meat, turkey meat, beef and pork are collected as 
part of the national case-by-case control programme. 
Salmonella was not detected in any of the 97 batches 
from Danish broiler meat tested in 2010, whereas it was 
isolated from 12% (58/490) of the batches of imported 
broiler meat. Salmonella was detected in 9% (56/592) 
of the batches of imported turkey meat tested in 2010, 
with several isolates per positive batch. In imported 
beef and pork, 3% (4/127) and 14% (40/296) of the 
batches tested Salmonella positive, respectively [Annual 
Report on Zoonoses in Denmark 2010]. 
 
Salmonella isolates from Danish pork and beef 
originate from the National surveillance programme, 
where carcass swab samples are collected at the 
slaughterhouses. In Danish pork, 22,485 pooled 
samples (each of five carcasses) were analysed in 
2010, and an estimated 1.2% of the pig carcasses 
The proportion of S. Typhimurium isolates with the 
ACSSuT resistance pattern varied between 6% and 8% 
during the period 2005–2009, and was 8% in 2010. The 
majority of the isolates with the ACSSuT resistance 
pattern was DT104 or DT104b, and the changes in 
occurrence of the ACSSuT resistance pattern were 
mainly due to changes in the occurrence of phage type 
DT104, although an increase in ACSSuT resistant 
DTU288 appears to have occurred over the last years 
(Figure 6.2). 
Figure 6.2. Proportional distibution of phage types among Salmonella Typimurium isolates(a) from pigs 
resistant to ampicillin, streptomycin, sulfonamide and tetracycline without or with chloramphenicol 
resistance (ASSuT/ACSSuT), Denmark
DANMAP 2010
a) Total number of isolates included in 2005: n = 752; 2006: n = 509; 2007: n = 577; 2008: n = 502; 2009: n = 386 and 2010: n = 455
b) Isolates with ‘ASSuT’ can also include resistence to other antimicrobial agents except chloramphenicol
c) Isolates with ‘ACSSuT’ all include resistance to chloramphenicol but can also include resistance to other antimicrobial agents
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were Salmonella positive. In addition, 223 individual 
carcasses were tested in smaller slaughterhouses, where 
1.8% of the pig samples were Salmonella positive. 
In Danish beef, 7,660 pooled samples (each of five 
carcasses) were analysed in 2010, and an estimated 
0.3% of the cattle carcasses were Salmonella positive. 
In addition, 162 individual carcasses were tested in the 
smaller slaughterhouses, with no Salmonella positive 
[Annual Report on Zoonoses in Denmark 2010].
 
All susceptibility tested S. Typhimurium and S. 
Enteritidis isolates were included, even in those cases 
where more than one isolate was found per tested 
batch or pooled sample. Insufficient numbers of S. 
Typhimurium isolates (≥15) were obtained for Danish 
broiler meat, Danish beef and imported beef, and the 
results of the susceptibility testing is not presented in 
this report. Due to a low number of isolates, resistance 
data from S. Enteritidis in meat are also excluded. 
MIC distributions among S. Typhimurium from 
imported broiler meat, imported turkey meat and pork 
(Danish and imported) in 2010 are shown in Appendix 
1 (Table AP1.10). 
In 2010, only S. Typhimurium isolates from imported 
turkey meat were found resistant to cephalosporins 
(2%), ciprofloxacin (2%) and nalidixic acid (2%), 
whereas all S. Typhimurium isolates from imported 
broiler meat and pork were sensitive towards these three 
antimicrobial agents (Table 6.1). 
Salmonella Typhimurium in imported broiler meat
There were 18 S. Typhimurium isolates among the 
137 susceptibility tested Salmonella isolates selected 
from imported broiler meat, where the most frequent 
phage type was DTU312 (83%). Overall, 13 (72%) of 
the susceptibility tested S. Typhimurium isolates from 
imported broiler meat were fully sensitive, whereas 
two (11%) were multi-resistant. One isolate (6%) was 
resistant to tetracycline, two isolates (11%) to ampicillin 
and sulfonamide, and five isolates (28%) were resistant 
to streptomycin (Table 6.1). None of the isolates were 
resistant to ciprofloxacin and nalidixic acid. 
Salmonella Typhimurium in turkey meat
The vast majority of Danish turkeys are exported 
for slaughter; therefore, no Salmonella isolates were 
available for susceptibility testing from Danish turkey 
meat in 2010.
Among the 163 susceptibility tested Salmonella isolates 
selected from imported turkey meat, 41 S. Typhimurium 
isolates were found; where the monophasic 
Typhimurium strain 4,5,12:i:- accounted for almost 
half. The most common phage type was DT193 (59%), 
but DT104/104b was also reported. The highest levels 
of resistance was found in the imported turkey meat, 
where none of the susceptibility tested S. Typhimurium 
isolates were fully sensitive, and 93% were found to be 
multi-resistant. In one S. Typhimurium isolates from 
imported turkey meat, resistance was found to all 
tested antimicrobial agents (Table 6.1). All isolates were 
tetracycline resistant, and the occurrence of resistance to 
sulfonamide (93%), streptomycin (93%) and ampicillin 
(68%) was also very high. 
Furthermore, imported turkey meat was the only food 
source where resistant to ceftiofur and cefotaxime was 
found. In 2010, a significant increase in S. Typhimurium 
isolated from imported turkey meat was seen resistant 
to apramycin (from 0% to 24%), gentamicin (from 0% 
to 27%) and streptomycin (from 69% to 93%) compared 
with 2009.
Salmonella Typhimurium in pork
Among the 26 S. Typhimurium isolates from Danish 
pork that were susceptibility tested, the most dominant 
phage types were DT120 (31%) and DT12 (23%), 
followed by DT17 (8%), DT7(8%), DTU66 (4%), 
DT193 (4%) and DTU302 (4%). Overall, 46% of the 
susceptibility tested S. Typhimurium isolates were fully 
sensitive, whereas 35% were found to be multi-resistant. 
Resistance to ampicillin (35%), streptomycin (46%), 
sulfonamide (38%) and tetracycline (27%) was most 
common (Table 6.1). There was no significant change 
in the level of resistance in the susceptibility tested 
S. Typhimurium isolates from Danish pork in 2010 
compared to 2009. When comparing the resistance in 
Danish pork to resistance in Danish pigs, a significantly 
higher occurrence of resistance to tetracycline (27% vs. 
47%) was found in the animals (Table 6.1). 
In imported pork, 99 susceptibility tested Salmonella 
isolates were selected, and among the 62 S. 
Typhimurium isolates the most common phage types 
were DT120 (45%) and DT17 (32%). Overall, 10% of the 
S. Typhimurium isolates were fully sensitive, whereas 
84% were found to be multi-resistant. The highest levels 
of resistance were to streptomycin (87%), sulfonamide 
(84%), tetracycline (77%) and ampicillin (73%) (Table 
6.1). In the isolates from imported pork, none of the 
isolates were resistant to nalidixic acid and ciprofloxacin, 
a significant decrease compared with 2009 (16%). At 
the same time, a significant increase in resistance to 
streptomycin (42%) and trimethoprim (344%, from 5% 
to 18%) was observed. 
S. Typhimurium isolates from imported pork had 
a significant higher occurrence of resistance to 
ampicillin, chloramphinicol, florfenicol, spectinomycin, 
streptomycin, sulfonamide, tetracycline and 
trimethoprim than S. Typhimurium isolates from 
Danish pork (Figure 6.3).
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Figure 6.3. Resistance (%) in Salmonella Typhimurium(a) isolated from Danish and imported pork, Denmark
DANMAP 2010
a) The number of isolates varies between years: for Danish pork from 64 to 103, and imported pork from 21 to 137. For Danish pork, 
data from before 2005 are not shown due to a low number of isolates        
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6.2.2 Salmonella in humans
In 2010, the number of human cases of salmonellosis 
decreased to 1,598 cases (29 per 100,000 inhabitants), 
compared with 2,129 cases reported in 2009. Of 
the 1,598 cases, information on susceptibility to 
antimicrobial agents was available for 1,508 isolates; 
of these, 629 isolates were S. Typhimurium and 364 
isolates were S. Enteritidis. The remaining 515 isolates 
belonged to 97 other serovars.
 
MIC distributions among S. Typhimurium and S. 
Enteritidis from human cases in 2010 are shown in 
Appendix 1 (Tables AP1.11 and AP1.12). 
SSI collected travel information from the patients 
diagnosed with salmonellosis by phone interviews. The 
patients were asked about the date of disease onset and 
whether they had travelled abroad within a seven-day 
period prior to disease. Patients who had travelled were 
asked about their destinations. Cases were categorized 
as “domestically acquired” if the patient had not 
travelled during that time period, and categorized as 
“travel abroad reported” if the patient had travelled. 
Cases with no travel information reported to the 
general practitioners, and where no phone interview 
was conducted, were categorized as “unknown origin”. 
In 2010, travel information was obtained for 80% of the 
Salmonella cases. 
Outbreaks of human salmonellosis are reported in the 
“Annual Report on Zoonoses in Denmark in 2010”. All 
human cases associated with a detected outbreak were 
considered outbreak-related in this report. 
Salmonella Typhimurium in humans
Fifteen percent of human S. Typhimurium cases were 
categorized as travel-related and 70% as domestically 
acquired. Of the domestically acquired, 48% were 
found to be part of an outbreak and 52% were domestic 
sporadic cases. Travel information was not available 
from 15% of the cases (Table 6.2).
 
Of the 217 cases of salmonellosis that were part 
of domestic outbreaks, 90% were caused by S. 
Typhimurium and 1% by S. Enteritidis. Among the 
212 domestic outbreak-related human isolates of S. 
Typhimurium, 78% were phage type DTU323, and the 
remaining cases were caused by phage types DT120, 
DT5, DT7, DTU311, DT104 and DT193. Overall, 8% 
of the human S. Typhimurium isolates from domestic 
outbreaks were fully sensitive whereas 78% were multi-
resistant.
The most commonly reported phage types in domestic 
sporadic human S. Typhimurium isolates were DT193 
(20%), DT120 (15%) and DTU292 (11%). Overall, 
49% of the sporadic domestic human S. Typhimurium 
isolates were fully sensitive whereas 43% were multi-
resistant. For the travel-related cases and cases of 
unknown origin, 32% and 31% of the S. Typhimurium 
isolates were fully sensitive, whereas 63% and 60% were 
multi-resistant, respectively.
Among the human S. Typhimurium isolates, 21% of 
the domestic sporadic cases and 41% of the travel-
related cases had the ASSuT resistance pattern. Among 
the ASSuT isolates, DT193 and DT120 were the most 
common phage types, but DT7 also represented a 
substantial part of the ASSuT isolates associated with 
the domestic outbreaks (Figure 6.5). 
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The ACSSuT resistance pattern was observed in 7% of 
the domestic sporadic cases and in 12% of the travel-
related cases. The dominant phage type was DT104, but 
among the travel associated cases DT120 and DT193 
were also common (Figure 6.5).
In the human S. Typhimurium isolates, the pattern of 
resistance was similar to what is currently observed 
in the rest of Europe, with resistance to ampicillin, 
streptomycin, sulfonamide and tetracycline dominating. 
The occurrence of resistance to these four antimicrobial 
agents was similar among travel-related cases and 
cases with unknown origin. In the domestic cases, 
the occurrence of resistance in the sporadic cases was 
markedly lower for all four antimicrobial agents than 
what was observed in the travel-related cases and the 
cases of unknown origin (Figure 6.4 and Figure 6.5). 
In the domestic outbreak-related cases, tetracycline 
resistance was much lower than what was observed in 
any other source of origin, but resistance to ampicillin, 
streptomycin and sulfonamide was much higher (Table 
6.2). 
Resistance to cefalosporins was only found among the 
isolates from travel-associated cases (3%) or from cases 
where the source of infection was unknown (1%).
The higher level of ciprofloxacin resistance in the travel-
associated S. Typhimurium infections (14%) when 
compared to the domestically acquired infections (4%)
may reflect a higher consumption of fluoroquinolones 
in production animals in the countries of destination. 
The occurrence of resistance to ciprofloxacin was 
higher than to nalidixic acid among human isolates 
due to the occurrence of the plasmid-borne qnrS genes 
which confer resistance to ciprofloxacin only. Of the ten 
human isolates resistant to ciprofloxacin but sensitive 
to nalidixic acid, nine had qnr genes. The four ceftiofur 
resistant isolates, three from travel associated infections 
and one from an unknown infection, were all producing 
the ESBL-enzymes belonging to the CTX-M-1-group.
Figure 6.4. Resistance (%) in Salmonella Typhimurium(a) 
in human cases acquired(b) domestically or associated 
with travel, Denmark
DANMAP 2010
Note: that the shape of the curves are highly influenced by several 
large outbreaks with fully sensitive strains in 2008 and 2009 and a 
large outbreak with a strain resistant to Ampicillin, Streptomycin and 
sulfonamide in 2010. Verified monophasic S. Typhimurium-like isolates 
are included in 2010.   
a) Number of isolates included as domestic and travel related: 2007 = 90 
and 44, 2008 = 1,441 and 103, 2009 = 560 and 58, 2010 = 439 and 95
b) The isolate was categorized as 'domestically acquired' if the patient 
did not travel one week prior to the infection, and it was characterized 
as 'travel abroad reported' if the patient travelled one week prior to the 
infection
ERRATUM: In the printed version of DANMAP 2010 
and in digital versions from before 15. Nov 2011, Figure 
6.4 include 2007-2009 data from all domestic Salmonella 
cases (sporadic and outbreak related), but for 2010 only 
sporadic cases were included. Now all years include 
sporadic and outbreak related Salmonella cases.   
                                                                           
       67DANMAP 2010  
RESISTANCE IN ZOONOTIC BACTERIA 6.
0
2
4
6
8
10
12
14
Domestic, 
sporadic
Domestic, 
outbreak
Travel abroad Unknown 
origin
%
 Is
ol
at
es
DT7 DT104 + DT104b DT120 DT193 Others or unspecified
ACSSuT (c)
0
10
20
30
40
50
Domestic, 
sporadic
Domestic, 
outbreak
Travel 
abroad
Unknown 
origin
%
 Is
ol
at
es
ASSuT(b)
DANMAP 2010
Table 6.2. Resistance (%) in Salmonella Typhimurium(a) from human cases reported(b) as domestically aquired 
(sporadic or outbreak related), associated with travel abroad or as of unknown origin, Denmark
a) Include the monophasic S. Typhimurium isolates        
b) The isolate was categorized as ‘domestically acquired’ if the patient did not travel one week prior to the infection, and it was characterized 
as ‘travel abroad reported’ if the patient travelled one week prior to the infection
c) The higher occurrence of resistance to ciprofloxacin compared to resistance to nalidixic acid in 2010 was in part due to qnr genes 
       
Antimicrobial agent Domestic sporadic
Domestic 
outbreak
Travel abroad 
% 
Unknown  
origin 
% % % %
Tetracycline 36 21 59 54
Chloramphenicol 7 4 13 14
Florfenicol 6 4 12 11
Ampicillin 42 78 60 58
Ceftiofur 0 0 3 1
Cefotaxime - - - -
Sulfonamide 44 87 64 63
Trimethoprim 5 1 8 8
Apramycin 1 0 0 0
Gentamicin 1 0 3 2
Neomycin 4 0 2 4
Spectinomycin 9 4 14 14
Streptomycin 43 87 59 58
Ciprofloxacin(c) 4 4 14 15
Nalidixic acid 2 4 8 13
Colistin 1 0 0 1
Number of isolates 227 212 95 95
DANMAP 2010
Figure 6.5. Proportional distibution of phage types among Salmonella Typimurium isolates(a) from human cases 
resistant to ampicillin, streptomycin, sulfonamide and tetracycline without or with chloramphenicol resistance 
(ASSuT/ACSSuT), Denmark
a) In 2010, a total of 629 S. Typhimurium cases were reported, including the monophasic Typhimurium isolates.   
Domestic sporadic: n = 227; Domestic outbreak: n = 212;  Travel abroad: n = 95 and Unknown origin: n = 95    
b) Isolates with ‘ASSuT’ can also include resistence to other antimicrobial agents except chloramphenicol    
c) Isolates with ‘ACSSuT ‘ all include resistance to chloramphenicol but can also include resistance to other antimicrobial agents  
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Salmonella Enteritidis in humans
In contrast to the few travel-related cases of S. 
Typhimurium, 60% of the human S. Enteritidis cases 
reported travelling abroad, 18% of S. Enteritidis cases 
were domestically acquired and the remaining 22% had 
an unknown origin. Of the domestically acquired cases, 
97% were considered to be sporadic. These were of 
phage types PT2, PT8, PT14c, PT15a and RDNC. 
The majority of S. Enteritidis isolates from domestic 
sporadic cases (91%), travel-related cases (73%) and 
cases of unknown origin (78%) were fully sensitive, 
whereas one (2%) domestic sporadic case, six (3%) 
travel-related cases and one (1%) case of unknown 
origin were multi-resistant.
Of the 388 S. Enteritidis isolates available, 364 isolates 
had valid results from susceptibility testing for all 
antimicrobial agents in the test panel (Table 6.3). Two 
isolates were part of a domestic outbreak, both resistant 
to ciprofloxacin and nalidixic acid. A total of 8% of 
the domestic sporadic isolates were ciprofloxacin and 
nalidixic acid resistant. In contrast, 21% of the cases 
reported to be travel-related or of unknown origin were 
resistant to these two antimicrobial agents. 
 
Humans
Antimicrobial agent
Domestic 
sporadic 
%
Domestic 
outbreak 
%
Travel abroad  
%
Unknown origin 
%
Tetracycline 2 0 5 4
Chloramphenicol 2 0 1 0
Florfenicol 0 0 0 0
Ampicillin 3 0 8 4
Ceftiofur 0 0 0 0
Cefotaxime - - - -
Sulfonamide 2 0 2 0
Trimethoprim 2 0 2 0
Apramycin 0 0 0 0
Gentamicin 0 0 0 0
Neomycin 0 0 0 0
Spectinomycin 0 0 0 1
Streptomycin 2 0 2 1
Ciprofloxacin 8 100 21 21
Nalidixic acid 8 100 19 21
Colistin 16 0 29 16
Number of isolates 64 2 217 81
DANMAP 2010
Table 6.3. Resistance (%) in Salmonella Enteritidis from human cases reported(a) as domestically aquired (sporadic 
or outbreak related), associated with travel abroad or as of unknown origin, Denmark
a) The isolate was categorized as ‘domestically acquired’ if the patient did not travel one week prior to the infection, and it was characterized 
as ‘travel abroad reported’ if the patient travelled one week prior to the infection
6.2.3 Attribution of human S. Typhimurium 
infections (ASuT) to sources of animal origin, 
2007–2010
Salmonella has been among the most important 
foodborne pathogen in Denmark in the last decades. 
To assist prioritization of interventions to reduce the 
burden of human salmonellosis in the country, the 
Danish Zoonosis Centre has routinely applied a source 
attribution model to estimate the contribution of the 
major animal-food sources to human infections of 
Salmonella. 
The principle of the method is to compare the number 
of human cases caused by different Salmonella sero- 
and phage types with the distribution of the same 
subtypes isolated from the various animal-food sources. 
Antimicrobial resistance patterns of S. Typhimurium 
isolates are also included to further distinguish between 
similar phage types found in animals, food and humans 
[Annual Report on Zoonoses in Denmark 2010]. 
In 2010, 642 human S. Typhimurium cases were 
reported, of which 59 (9%) sporadic cases were 
attributed to domestic pork, 68 (11%) to imported 
pork, 13 (2%) to imported poultry products, 133 
(21%) to international travel, 221 (34%) cases were 
associated with outbreaks, and 148 (23%) were 
attributed to “unknown source”. In addition to the 59 
S. Typhimurium sporadic cases attributed to domestic 
pork, there were 172 S. Typhimurium outbreak-related 
cases attributed to this source.
Among the sporadic S. Typhimurium cases attributed 
to domestic pork, five were caused by isolates with 
ASuT resistance pattern (resistant to at least ampicillin, 
sulfonamide and tetracycline but not chloramphenicol 
and one was caused by a S. Typhimurium isolate with 
ACSuT resistance pattern (resistant to at least ampicillin, 
sulfonamide, tetracycline and chloramphenicol). In 
addition, one of the 172 pork related outbreak cases had 
the ASuT resistance pattern (phage type DTU323); most 
of the isolates from these outbreak-related cases were 
resistant to ampicillin, streptomycin and sulfonamide 
only. 
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Figure 6.6. Estimated number of sporadic human Salmonella Typimurium cases(a) resistant to ampicillin, 
sulfonamide and tetracycline(b) without or with chloramphenicol (ASuT/ACSuT), attributed to Danish and 
imported pork by phage type, Denmark
a) Numbers in parentheses indicate the proportion of ASuT/ACSuT cases of all sporadic domestic S. Typhimurium cases attributed 
to Danish and Imported pork during the period. The total number of sporadic domestic Salmonella cases in 2007: n = 776;  2008: n = 
1,235; 2009: n = 802 and 2010: n = 592           
b) Isolates with ‘ASuT’ can also include resistance to other antimicrobial agents except chloramphenicol    
c) Isolates with ‘ACSuT’ all include resistance to chloramphenicol but can also include resistance to other antimicrobial agents  
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Among the 68 sporadic S. Typhimurium cases 
attributed to imported pork, 41 were caused by 
S. Typhimurium ASuT and 10 were caused by S. 
Typhimurium ACSuT. One S. Typhimurium DT193 
with ASuT resistance pattern was attributed to 
imported turkey. 
The Salmonella source attribution model does not 
include results of streptomycin susceptibility testing 
and therefore the results relate to ASuT only. However, 
the majority of the attributed cases with the ASuT +/- 
Chloramphenicol was also resistant to streptomycin.
An analysis of the number of sporadic S. Typhimurium 
ASuT and ACSuT cases attributed to Danish and 
imported pork during the period 2007 through 2010 
showed fluctuations in the relative importance of 
sources and phage types over the years (Figure 6.6). 
The most relevant changes were observed in the 
contribution of Danish and imported pork to human 
sporadic cases caused by both resistance patterns. The 
number of sporadic ASuT cases attributed to Danish 
pork increased markedly from 2007 to 2008, where 
cases were caused by DT120 and unspecified phage 
types in both years. The contribution of domestic pork 
subsequently decreased, and in 2010 was reduced to 
five cases as described above. In contrast, the number 
of sporadic ASuT cases attributed to imported pork 
increased eight-fold from 2007 to 2010. The most 
evident increase was observed in cases caused by phage 
types DT193 but also DT120 (Figure 6.6). 
Among sporadic cases caused by S. Typhimurium with 
ACSuT resistance, the number of cases attributed to 
domestic pork also decreased substantially, from 14 
in 2007 to one in 2010, whereas the number of cases 
attributed to imported pork decreased from 2007 to 
2009, but increased again in 2010 where nine DT104 
or DT104b cases and one non-typeable isolate were 
attributed to this source (Figure 6.6).
 
During the period from 2007 through 2010, one 
sporadic ASuT case was attributed to imported broiler 
meat (95% Credibility Interval (CI): 0 - 3 cases), whereas 
three sporadic ASuT cases (95% CI: 0 - 9) and two 
sporadic ACSuT cases (95% CI: 0-4) were attributed to 
imported turkey. In 2007, five sporadic ASuT cases were 
attributed to Danish beef, and in 2009, one sporadic 
ASuT case was attributed to Danish broiler meat. No 
ACSuT cases were attributed to Danish beef or broiler 
meat during this time period. 
Tina Struve, Helle Korsgaard, 
Sara Pires, Lars Stehr Larsen, 
Eva Møller Nielsen and Tine Hald
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6.2 Campylobacter
Since 2005, Campylobacter have been the most 
commonly reported cause of gastrointestinal bacterial 
infections in humans in Denmark as well as in the 
European Union. 
Human campylobacteriosis is caused by thermotolerant 
Campylobacter spp. The species most commonly 
associated with human infections are C. jejuni followed 
by C. coli, but other species are also known to cause 
infections in humans. In Denmark, 85-95% of the 
human campylobacteriosis cases are caused by C. 
jejuni. Thermotolerant Campylobacter are widespread 
in nature and the most important reservoirs are the 
alimentary tract of wild and domesticated birds and 
mammals. They are prevalent in production animals 
such as poultry, cattle, pigs and sheep; in pets, including 
dogs and cats; in wild birds and environmental water 
sources. The bacteria can readily contaminate various 
foodstuffs. Among sporadic human cases, contact with 
live poultry, consumption of poultry meat, drinking 
water from untreated water sources, and contact with 
pets and other animals have been identified as the 
major sources of infection.
6.2.1 Campylobacter jejuni
Production animals
In 2010, samples from animals were collected at 
slaughter for the DANMAP programme and all further 
testing was performed at the National Food Institute. 
Only one isolate per farm was included in the report. C. 
jejuni from pigs were not included because very few C. 
jejuni isolates were found in pigs.
For broilers, 382 flocks were sampled representing 169 
different farms. A total of 41 C. jejuni were isolated and 
susceptibility tested. Of these, 75% were fully sensitive 
to the antimicrobial agents tested. 
In isolates from Danish broilers, the highest levels of 
resistance were found for ciprofloxacin (19% in 2010 
compared to 13% in 2009) and tetracycline (17% in 
2010 compared to 12% in 2009). An almost continuous 
increase in resistance to ciprofloxacin and tetracycline 
has been observed over the last decade from less than 
10% resistant isolates in 2000 to 19% and 17% in 2010, 
respectively (Figure 6.7). 
Following an increase in consumption of 
fluoroquinolones for rearing and parent flocks in 2009, 
fluoroquinolones were not used in these flocks in 2010. 
A decrease in consumption was also observed for 
amoxicillin, penicillins, sulfonamides and macrolides 
in rearing flocks for the broiler production. However, in 
broiler flocks, the consumption of tetracycline, which 
increased considerably from 2008 to 2009, continued 
to increase in 2010. Second to amoxicillin, tetracycline 
was the most commonly used antimicrobial agent in 
Danish broilers in 2009 and 2010; this is a potential 
explanation for the increasing tetracycline resistance in 
C. jejuni from Danish broilers. Furthermore, from 2009 
to 2010, the consumption of amoxicillin, penicillins and 
sulfonamides in broiler flocks also increased (Figure 
4.8).
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Figure 6.7. Resistance (%) in Campylobacter jejuni from broilers, Danish broiler meat and imported broiler 
meat, Denmark
DANMAP 2010
For cattle, 216 samples were analysed for Campylobacter 
and 98 randomly selected C. jejuni isolates were 
susceptibility tested; 75% of the C. jejuni isolates from 
cattle were fully sensitive to the antimicrobial agents 
tested. 
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Figure 6.8. Resistance (%) in Campylobacter jejuni 
from cattle, Denmark
DANMAP 2010
Meat
The Danish Veterinary and Food Administration 
(DVFA) collected samples from broiler meat, sold at 
wholesale and retail outlets, for Campylobacter testing. 
In 2010, isolates from food were species identified in the 
regional laboratories of DVFA and susceptibility tested 
at the National Food Institute. 
From broiler meat, all isolates verified as C. jejuni (120 
isolates; 52 Danish, 68 imported) were susceptibility 
tested. Only one isolate per sample was reported (Table 
6.4). Among the Danish isolates, 75% were fully sensitive 
to the antimicrobial agents tested, whereas only 37% of 
the isolates from imported meat were fully sensitive.
The observed resistance to ciprofloxacin and tetracycline 
has fluctuated over the last three years, and in 2010 the 
resistance increased, returning to the same levels as 
Table 6.4. Resistance (%) in Campylobacter jejuni from animals, Danish broiler meat, imported broiler meat 
and in domestic and travel related human cases, Denmark
Antimicroial agent
Cattle Broilers Broiler meat Humans
Danish Danish Danish Imported Domestically acquired
“Travel 
abroad”
% % % % % %
Tetracycline 6 17 12 41 13 57
Chloramphenicol 0 0 0 0 0 0
Erythromycin 0 0 2 4 0 0
Gentamicin 0 0 0 0 0 0
Streptomycin 1 2 2 0 2 2
Ciprofloxacin 20 20 17 50 25 80
Nalidixic acid 20 17 13 50 23 80
Number of isolates 98 41 52 68 52 46
DANMAP 2010
reported in 2008. Hence, resistance to ciprofloxacin in 
C. jejuni isolates from Danish broiler meat increased 
significantly from 0% in 2009 to 17% in 2010. However, 
it should be noted that only half as many samples were 
tested in 2009 compared to 2010.
As in previous years, resistance to ciprofloxacin and 
tetracycline was significantly higher in C. jejuni from 
imported broiler meat compared to Danish broiler 
meat (Figure 6.7). In 2009, a significant decrease in 
erythromycin resistance among the tested C. jejuni 
isolates from imported broiler meat was observed. 
Erythromycin resistance has remained at a very low 
level in both domestic and imported broiler meat for 
almost a decade.
MIC distributions among C. jejuni from broiler meat in 
2010 are shown in Appendix 1 (Table AP1.16). 
Resistance to ciprofloxacin among C. jejuni from cattle 
has remained virtually unchanged since 2008, at a level 
around 20% (Figure 6.8). As described in previous 
DANMAP reports, a significant increase in the level of 
fluoroquinolone resistance occurred in 2005 despite low 
consumption of fluoroquinolones in cattle since 2003. 
As in previous years, only few of the fluoroquinolone 
resistant isolates were also resistant to tetracycline in 
2010, indicating that co-selection by tetracycline (one 
of the major drugs for treatment of calves) was not the 
explanation for the high occurrence of fluoroquinolone 
resistance. It has been discussed [DANMAP 2007] 
that clonal spread, particularly between farms, could 
be an explanation for the observed resistance to 
fluoroquinolones. Initially, the fluoroquinolone resistant 
C. jejuni isolates were obtained from cattle farms in 
Southern Jutland, but the occurrence of resistance has 
been moving north from 2007 to 2010 and in 2010, 
85% of the ciprofloxacin resistant C. jejuni isolates 
originated from farms in Jutland, with a high prevalence 
in Northern Jutland.
Since 2005, the resistance to tetracycline in isolates 
obtained from cattle has increased from 0% to 6% and 
the resistance is now at the same level as in 2002 (Figure 
6.8).
MIC distributions among C. jejuni from cattle and 
broilers in 2010 are shown in Appendix 1 (Table 
AP1.14). 
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MIC distributions and the occurrence of antimicrobial 
resistance among C. jejuni from domestically acquired 
human cases and human cases associated with travel are 
shown in Appendix 1 (Table AP1.17).
In 2010, the level of resistance to ciprofloxacin in C. 
jejuni isolates from domestically acquired infections 
remained in between the level of resistance for isolates 
obtained from Danish broiler meat and imported broiler 
meat. The consumption of imported broiler meat has 
continued to increase in Denmark, from 17% in 2003 
to 33% in 2006 to 45% in 2010 [Annual report on 
Zoonoses in Denmark 2010]. It is likely that imported 
broiler meat contribute to the relatively high occurrence 
of ciprofloxacin resistance (25%) in C. jejuni isolates 
from domestically acquired human infections. 
The occurrence of resistance to ciprofloxacin and 
tetracycline continued to be significantly higher in 
travel associated C. jejuni isolates (80% and 57%, 
respectively) compared to isolates from domestically 
acquired infections (25% and 14%, respectively) 
(Figure 6.9). For the other antimicrobial agents tested, 
no significant differences in resistance levels were 
observed. Ciprofloxacin or other fluoroquinolones are 
often used for empiric treatment of adults with severe 
bacterial gastroenteritis. Fluoroquinolones are also 
used in animal husbandry. However, in Denmark the 
consumption of fluoroquinolones in animal husbandry 
has been restricted since 2002. Travelling to or 
consuming meat from countries where fluoroquinolone 
restrictions are not implemented can be associated with 
a higher risk of acquiring infection with ciprofloxacin 
resistant C. jejuni.
Figure 6.9 Resistance (%) in Campylobacter jejuni from human cases, Denmark
Humans
Campylobacter continued to be the most frequent 
cause of bacterial intestinal infections in 2010. A 
total of 4,035 human laboratory confirmed cases of 
campylobacteriosis were reported (73 per 100,000 
inhabitants), representing an increase of 20% compared 
to 2009 [Annual report on Zoonoses in Denmark 
2010]. For the surveillance of antimicrobial resistance, 
the former counties of Northern Jutland, Funen and 
Roskilde were selected, representing approximately 25% 
of all cases in Denmark in 2010. 
Since 2007, SSI has collected information on 
travel history through phone interviews from all 
Campylobacter patients residing in the above mentioned 
counties. Patients were asked about the date of disease 
onset and whether they had travelled abroad within 
a seven-day period prior to the onset of disease. 
Furthermore, patients who had been abroad were asked 
about their destinations. Cases were categorised as 
“domestically acquired” if the patients had not travelled 
within the last week prior to the onset of infection.
In 2010, 141 Campylobacter jejuni isolates were 
submitted to SSI for susceptibility testing continuously 
over the year. The isolates were randomly selected from 
all Campylobacter isolated from stool samples in the 
three counties mentioned above. Among the tested 
isolates, 46 (33%) were from travel-associated cases and 
52 (35%) were considered to be domestically acquired. 
For the remaining 43 cases, it was not known whether 
they were acquired domestically or abroad. Among the 
isolates from domestically acquired infections, 67% were 
fully sensitive to the antimicrobial agents tested, while 
the percentage of fully sensitive isolates was much lower, 
17%, among isolates from travel associated cases (Table 
6.4). 
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6.2.2  Campylobacter coli 
Production animals
For animals, only antimicrobial resistance among C. 
coli isolates from pigs is reported in the DANMAP 
report 2010. MIC distributions and the occurrence of 
antimicrobial resistance among C. coli from pigs are 
shown in Appendix 1 (Table AP1.13).
In 2010, 269 samples from pigs were analysed for 
Campylobacter; 103 randomly selected C. coli isolates 
were susceptibility tested, and 26% were found 
fully sensitive. As in the previous three years, no 
significant changes in fluoroquinolone resistance 
were observed among C. coli from pigs from 2009 
to 2010. Fluoroquinolone resistance was detected in 
approximately 8% of the tested isolates (Figure 6.10) 
despite low consumption of fluoroquinolones in pigs 
since 2003 (Table AP1.1). 
In 2010, erythromycin resistance in C. coli from pigs 
was 15%. A continuous decrease in erythromycin 
resistance in C. coli was observed after withdrawal 
of the growth promoter tylosin from the Danish pig 
production in 1998–1999. However, in the past years, 
the level of resistance has not changed significantly 
and since 2006 the level of resistance has been 10-15% 
(Figure 6.10). In contrast, an increasing trend has been 
observed in the occurrence of resistance to tetracycline 
for C. coli from Danish pigs over the past decade, 
especially during 2004–2010. Overall, the consumption 
of tetracycline has also increased from 2001 to 2009 
(Table AP1.1).
In 2010, streptomycin resistant C. coli isolates from 
pigs increased significantly from 48% to 63%. While 
this increase may reflect that the isolates coincidentally 
originated from producers with high prevalence of 
diseases typically treated with streptomycin (limb, joint, 
CNS and skin), it is noteworthy that the consumption 
of penicillin-streptomycin combinations for finisher 
pigs also increased during this period. However, it 
should be noted that the increase in streptomycin 
consumption represents only a very small fraction of 
the total consumption (Table AP1.1).
Meat
Only one isolate per sample was susceptibility tested 
and reported. In 2010, a total of 47 C. coli isolates 
from broiler meat were susceptibility tested, 20 isolates 
were obtained from Danish broiler meat and 27 were 
obtained from imported broiler meat.
Among the Danish isolates, 11 (55%) were found fully 
sensitive, while only two (7%) isolates from imported 
broiler meat were fully sensitive to the antimicrobial 
agents tested. Significant differences were observed in 
resistance depending on the origin of the meat (Danish/
imported), the MIC values are shown in Appendix 1 
(Table AP1.15). 
Resistance levels in the isolates from Danish 
broiler meat were: No resistance to ciprofloxacin or 
erythromycin, and 35% resistance to tetracycline. The 
corresponding values for the isolates obtained from 
imported meat were: 85% resistance to ciprofloxacin, 
14% resistance to erythromycin, and 82% resistance to 
tetracycline. While there were no significant changes 
observed in the resistance levels in the Danish isolates 
from 2009 to 2010, this was not the case for the 
imported isolates. Thus, 85% of the imported isolates 
were resistant to ciprofloxacin in 2010 compared to 42% 
in 2009. Similarly, the resistance level for erythromycin 
increased from 2% to 15% and resistance to tetracycline 
increased from 51% to 81%. 
Humans
No C. coli isolates from human cases were included in 
the DANMAP report 2010, since there was only a small 
number of C. coli among the Campylobacter isolates 
received at SSI.
Birgitte Borck Høg, Lars Stehr Larsen, 
Eva Møller Nielsen and Anne Mette Seyfarth
Figure 6.10. Resistance (%) in Campylobacter coli 
from pigs, Denmark
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Occurrence of Clostridium difficile in Danish pig farms, and in cattle and broilers at slaughter 
Background: Clostridium difficile is increasingly causing infection in humans and have lately caused outbreaks 
at hospitals in Denmark and other countries as well [DANMAP 2009]. Especially, the virulent C. difficile 027 is 
causing severe infections. Even though, C. difficile can be isolated from animals and meat, its role as a zoonosis 
is not fully understood [Rupnik. 2007. Clin Microbiol Infect. 13: 457-9]. The aim of this study was to investigate 
the occurrence of C. difficile in pig farms, and in cattle and broilers at slaughter to determine if types more likely 
to cause disease in humans were present in animals.
Materials and methods: During June through November 2010, 99 stool samples from slaughter pig pens at 99 
farms, 192 faecal samples from cattle at slaughter and 197 pools of cloacal swabs of broilers at slaughter were 
collected and tested for the presence of C. difficile. The pools of cloacal swabs were added to 2.5 ml of 0.9% NaCl 
and mixed. One milliliter of cells suspended in the 0.9% NaCl or 1 gram of faecal sample was added to 9 ml 
CDMN broth supplemented with 0.1% Sodium taurocholate and incubated anaerobically at 37°C for 7 days. Two 
ml were transferred to 2 ml 99% ethanol and left at room temperature for one hour. After centrifugation, 10 µl of 
pellet was transferred to a CDMN agar plate. The plates were incubated for 44 to 48 hours anaerobically at 37°C. 
Presumptive C. difficile were re-streaked at CDMN agar plates and the presence of C. difficile verified by PCR 
detection of toxin genes (tcdA, tcdB, binary toxin) as previously described [Persson et al. 2008. Clin Microbiol 
Infect. 14: 1057-64]. Isolates positive for all three toxin genes were furthermore PCR ribotyped and tested 
for deletions in tcdC. All isolates containing toxin genes were tested for resistance to clindamyin (1-16mg/l), 
erythromycin (0.5-8 mg/l), metronidazole (4-64 mg/l), moxifloxacin (1-16 mg/l), and vancomycin (4-64 mg/l) 
following CLSI guidelines (see Table 1 for resistance breakpoints). 
Results and discussion: Fifteen (15%) of the pig farm samples were positive for C. difficile. All of the isolates 
were tested for toxin genes and 73% had all three toxin genes whereas 27% had tcdA and tcdB. Twenty-nine 
(15%) of the cattle samples were positive for C. difficile. All of the isolates were tested for toxin genes and 24% 
contained all three genes, 69% contained tcdA and tcdB, and 7% contained only tcdA. Six broiler flocks (3%) 
were positive for C. difficile and all six isolates contained tcdA and tcdB. Six of the eighteen isolates from pigs and 
cattle that contained all three toxin genes belonged to PCR ribotype 078 (two from cattle and four from pigs), 
the rest belonged to PCR ribotypes rarely or not previously found in humans in Denmark. Fifteen of the isolates 
had a 39 bp deletion in tcdC and three had a 54 bp deletion in tcdC. These three isolates all belonged to the same 
PCR ribotype (named DK136) and originated from cattle. One human case with PCR ribotype DK136 has been 
reported in Denmark. More than half of the isolates contained tcdA and tcdB, and approximately one-third of the 
human cases in 2009 were caused by C. difficile with these toxins [DANMAP 2009]. Types found in animals and 
human cases cannot be directly compared since the human isolates are selected for typing based on three criteria 
used to screen for the 027 type: Resistance to moxifloxacin, if the cases have severe clinical manifestations, or if 
cases are suspected to be part of an outbreak. The most common PCR ribotypes in humans in Denmark are 027, 
078, 066 and 023.
The MIC distributions of five antimicrobial agents are presented in Table 1. Most isolates were resistant to 
clindamycin (87%) and all isolates were susceptible to vancomycin and metronidazole. One isolate from pigs 
and one isolate from cattle were resistant to erythromycin. Moreover, one isolate from pigs was resistant to 
moxifloxacin. This isolate contained all three toxin genes and belonged to a PCR ribotype not previously found 
in humans (named DK135). Resistance to moxifloxacin is one out of three criteria used to screen for type 027 in 
Danish hospitals (see above) [DANMAP 2009]. 
In conclusion, the finding of C. difficile 078 in pigs is not surprising since this type is known to be common 
among pigs. However, other types may have a potential to cause severe disease in humans, as isolates with all 
three toxin genes and deletion in tcdC were found. Moreover, the importance of C. difficile with tcdA and tcdB in 
animals should be further investigated.
Yvonne Agersø, Eva Møller Nielsen and Katharina Olsen 
For further information: Yvonne Agersø (yvoa@food.dtu.dk)
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Antimicrobial agent Animal type % Resistant
Distribution (%) of MICs
0.5 1 2 4 8 16 32 64 mg/l
Clindamycin Broilers 100 83 17 
Cattle 81 8 8 4 65 8 8
Pigs 93 7 57 29 7
Erythromycin Broilers 0 66 33
Cattle 4 27 69 4
Pigs 7 7 79 7 7
Metromidazole Broilers 0 100
Cattle 0 100
Pigs 0 100
Moxifloxacin Broilers 0 83 17
Cattle 0 85 12 4
Pigs 7 93 7
Vancomycin Broilers 0 100
Cattle 0 100
Pigs 0 100
Table 1. Resistance (%) in C. difficile from broilers (n = 6), cattle (n = 26) and pigs (n = 14)
Note The resistance breakpoints are indicated with black vertical lines
DANMAP 2010
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7. Resistance in indicator bacteria
Table 7.1. Resistance (%) in Enterococcus faecium from animals and meat of Danish and imported origin, 
Denmark
Antimicrobial agent
Broilers Pigs Broiler meat Beef meat Pork meat
Danish  
 %
Danish  
 %
Danish
%
Imported
%
Danish
%
Danish
%
Tetracycline 6 51 10 43 10 17
Tigecycline 0 0 0 0 0 0
Chloramphenicol 0 0 0 0 0 0
Penicillin 1 3 1 26 0 3
Ampicillin 0 2 1 25 0 0
Erythromycin 26 27 21 63 5 31
Gentamicin 0 0 0 0 0 0
Kanamycin 0 23 1 20 0 3
Streptomycin 1 35 3 37 0 7
Ciprofloxacin - - 0 0 0 0
Vancomycin 0 1 1 0 0 0
Quinupristin/dalfopristin 0 2 1 9 0 0
Avilamycin 0 0 - - - -
Salinomycin 53 0 37 10 0 0
Linezolid 0 0 0 0 0 0
Teicoplanin - - 1 0 0 0
Number of isolates 119 133 145 107 20 29
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Indicator bacteria (Enterococcus faecium, Enterococcus 
faecalis and Escherichia coli) have been included in 
the DANMAP programme since 1995. These bacteria 
are included since they can be isolated from faecal 
samples from animals and humans. During slaughter 
of production animals, meat can be contaminated with 
enterococci and E. coli. Furthermore, enterococci and E. 
coli easily develop antimicrobial resistance in response 
to selective pressure. 
Most of the antimicrobial agents which have been used 
for growth promotion in Denmark (banned in 1998) 
had effect on Gram-positive bacteria like enterococci; 
especially E. faecium. Today, many of the antimicrobial 
agents used in veterinary clinical therapy are broad 
spectrum and are mainly active against Gram-negative 
bacteria, such as Salmonella and E. coli. 
Enterococci are still included in the DANMAP 
programme to follow the persistence of resistance 
after the ban of growth promoters. E. coli is included 
in the programme, since they are more often isolated 
from faecal samples and meat than Salmonella, and 
are therefore a better indicator for occurrence of 
antimicrobial resistance. 
7.1 Enterococci
 
Enterococcus faecium and Enterococcus faecalis were 
isolated from faecal samples from pigs and broilers. 
No enterococci were isolated from cattle. All samples 
included in the DANMAP surveillance programme 
were collected at the time of slaughter. Enterococci from 
food originated from meat sold at wholesale and retail 
outlets, collected randomly in all regions of Denmark 
by the Danish Veterinary and Food Administration 
Regional Laboratories in centrally coordinated 
programmes. The identification and susceptibility 
testing was done at the National Food Institute. The 
MIC distributions and occurrence of resistance among 
E. faecium and E. faecalis are presented in Appendix 1 
(Tables AP1.18, AP1.19, AP1.20 and AP1.21).
7.1.1 Enterococcus faecium in production 
animals
E. faecium was isolated from 18% (136/738) of the 
samples from pigs and 44% (169/382) of the samples 
from broilers. Only one isolate per farm was included 
and a randomly selected subsample of 133 and 119 
isolates from pigs and broilers, respectively, were 
susceptibility tested and reported (Table 7.1).
Pigs
The highest occurrence of resistance was found for 
tetracycline (51%), followed by streptomycin (35%), 
erythromycin (27%) and kanamycin (23%) (Table 
7.1). Both streptomycin and kanamycin belong to 
the aminoglycosides. From 2009 to 2010, significant 
decreases in prevalence of antimicrobial resistance 
among isolated E. faecium from pigs were seen for 
tetracycline, penicillin, ampicillin and streptomycin. 
Both ampicillin and penicillin belong to the beta-
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lactams. The reduced prevalence of tetracycline 
resistance can be related to the reduced usage of 
tetracycline, especially after July 1st 2010 (see chapter 
4.3). The reduction in resistance to the beta-lactams 
(ampicillin and penicillin), however, can be explained 
partly by the high peak observed in 2009 and partly 
by the fact that the epidemiological cut-off value 
recommended by EUCAST does not clearly separate the 
sensitive population from the resistant, and variation 
in methodology can therefore lead to large changes in 
detected prevalence. For streptomycin resistance, which 
has gradually increased over the last decade without 
increased consumption, 95% of the streptomycin 
resistant isolates were also resistant to tetracycline, 
indicating co-resistance between these antimicrobials 
and that the reduced consumption of tetracycline could 
have resulted in lower prevalence of streptomycin 
resistance. Resistance to vancomycin and quinupristin/
dalfopristin still prevails at a low level among E. faecium 
isolated from pigs.
Broilers
The highest occurrence of resistance was found for 
salinomycin (53%) followed by erythromycin (23%) and 
tetracycline (6%) (Table 7.1). Salinomycin is widely used 
as a coccidiostat in the broiler production. Presently 
no cut-off value is recommended by EUCAST. The 
used value is equivalent to the one used in DANMAP 
2009. From 2009 to 2010, a significant decrease in 
prevalence of antimicrobial resistance among E. faecium 
isolated from broilers were seen for tetracycline, 
penicillin, ampicillin, quinupristin/dalfopristin, 
and avilamycin. Resistance to the growth promoter 
avilamycin was not detected for the first time since the 
ban, but the significantly lower occurrence could, as 
for quinupristin/dalfopristin, be a result of the very low 
number of tested isolates in 2009 (n=19) compared to 
the 199 isolates tested in 2010. The reduced prevalence 
of resistance to tetracycline, penicillin and ampicillin 
may be explained as for E. faecium isolated from pigs. 
Using a selective enrichment method, vancomycin 
resistant E. faecium could be detected in 47% of the 
faecal samples even though avoparcin (glycopeptide) 
has been banned since 1995 (Textbox 5). 
7.1.2 Enterococcus faecium in meat
For Danish meat, E. faecium was isolated, from 16% 
(29/184) of the pork samples, 78% (145/187) of the 
broiler meat samples and 17% (20/118) of the beef 
samples. For imported meat, E. faecium was isolated 
from 47% (107/226) of the broiler meat samples. Only 
one isolate per sample was susceptibility tested and 
reported (Table 7.1).
The level of resistances in 2010 was comparable to the 
levels observed in 2009 for Danish pork and broiler 
meat as well as imported broiler meat. When comparing 
E. faecium isolates from Danish and imported broiler 
meat, a significantly higher occurrence of resistance 
to ampicillin, erythromycin, kanamycin, penicillin, 
streptomycin, quinupristin/dalfopristin and tetracycline 
was found in isolates from imported broiler meat, while 
higher occurrence of resistance to salinomycin was 
found among the isolates from Danish broiler meat. 
Significantly lower occurrence of resistance was found 
for tetracycline, kanamycin and streptomycin in E. 
faecium isolates from Danish pork compared to isolates 
from Danish pigs. Significantly lower occurrence of 
resistance to salinomycin was found in isolates from 
Danish broiler meat when compared to Danish broilers.
7.1.3 Enterococcus faecalis in production 
animals
E. faecalis was isolated from 23% (167/738) of the 
samples from pigs and 44% (169/382) of the samples 
from broilers. Only one isolate per farm was included 
and a randomly selected subsample of 157 and 112 
isolates from pigs and broilers, respectively, were 
susceptibility tested and reported (Table 7.2).
Pigs
The highest occurrence of resistance was found for 
tetracycline (78%) followed by erythromycin (44%), 
streptomycin (28%) and kanamycin (21%) (Table 7.2). 
From 2009 to 2010, a significant decrease in prevalence 
of antimicrobial resistance to tetracycline was detected 
as could be explained by reduced usage of tetracycline. 
Using a selctive enrichment method high-level 
gentamicin resistant (HLGR) E. faecalis was detected 
in 11% of the faecal samples from pigs. A recent study 
has shown a possible zoonotic link between HLGR E. 
faecalis from pigs and HLGR E. faecalis isolated from 
endocaditis patients (Textbox 4).
Broilers
The highest occurrence of resistance was observed for 
tetracycline (26%) followed by erythromycin (25%) 
and streptomycin (4%) (Table 7.2). No resistance 
to salinomycin was detected. From 2009 to 2010, 
significant decrease in prevalence of antimicrobial 
resistance was seen for tetracycline, erythromycin, 
streptomycin and salinomycin. Prevalence of 
tetracycline resistance is propably reduced as a 
consequence of reduced consumption.  
As for streptomycin resistance among E. faecium 
isolated from pigs, high (100%) co-resistance between 
streptomycin and tetracycline was detected (only four 
isolates).  No clear co-resistance between erythromycin 
and tetracycline could be detected. Only 55% of the 
erythromycin resistant isolates were tetracycline 
resistant, but since only a limited number of E. faecalis 
(n=19) was tested in 2009, compared to the 119 in 
2010. The observed statistical significant difference for 
erythromycin and salinomycin could be reflected in this 
fact.
7.1.4 Enterococcus faecalis in meat
E. faecalis was isolated from 46% (84/184) of Danish 
pork samples, 32% (59/187) of the Danish broiler meat 
samples and 23% (27/118) of the Danish beef meat 
samples. For imported meat, E. faecalis was isolated 
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Table 7.2. Resistance (%) among Enterococcus faecalis from animals and meat of Danish and imported origin, 
Denmark
Antimicrobial agent Broilers Pigs Broiler meat Beef Pork meat
Danish  
 %
Danish  
 %
Danish
%
Imported
%
Danish
%
Imported
%
Danish
%
Imported
%
Tetracycline 26 78 46 55 22 19 13 34
Tigecycline 0 0 0 0 0 0 0 0
Chloramphenicol 0 16 2 5 0 3 1 3
Penicillin 0 0 2 0 0 0 0 0
Ampicillin 0 0 2 0 0 0 0 0
Erythromycin 25 44 17 39 0 3 1 5
Gentamicin 1 11 0 1 0 0 1 2
Kanamycin 1 21 0 18 4 3 2 3
Streptomycin 4 28 8 24 4 8 0 4
Ciprofloxacin - - 0 1 0 0 0 1
Vancomycin 0 0 0 0 0 0 0 0
Avilamycin 0 0 - - - - - -
Salinomycin 0 0 2 0 0 0 0 0
Linezolid 0 0 0 0 0 0 0 0
Teicoplanin - - 0 0 0 0 0 0
Number of isolates 112 157 59 104 27 36 84 91
DANMAP 2010
from 52% (91/175) of the pork samples, 46% (104/226) 
of the broiler meat samples and 36% (36/99) of the beef 
samples. Only one isolate per sample was susceptibility 
tested and reported (Table 7.2).
Compared to 2009, a significantly lower occurrence 
of resistance to erythromycin was observed among 
isolates from Danish pork and a significantly lower 
occurrence of tetracycline resistance was found among 
isolates from imported pork. Compared to Danish 
pork, a significantly higher occurrence of resistance 
to tetracycline was found in E. faecalis from imported 
pork.
The levels of resistances in 2010 was comparable to the 
levels observed in 2009 for both Danish and imported 
broiler meat; except for tetracycline, where lower 
occurrence was found in Danish broiler meat in 2010 
compared to 2009. A significantly higher occurrence 
of resistance to erythromycin, kanamycin and 
streptomycin was observed in E. faecalis isolates from 
Danish broiler meat compared to isolates from imported 
meat. In imported pork, the level of tetracycline 
resistance was significantly higher than among isolates 
from Danish pork.
Significantly lower occurrence of resistance was found 
for tetracycline, chloramphenicol, erythromycin, 
gentamicin, kanamycin and streptomycin in E. faecalis 
isolates from Danish pork compared to Danish 
pigs. Significantly higher occurrence of resistance to 
tetracycline was found in isolates from Danish broiler 
meat when compared to Danish broilers (Table 7.2).
Lars Bogø Jensen and Lars Stehr Larsen
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Danish pigs are a reservoir of High-level gentamicin resistant Enterococcus faecalis 
associated with infective endocarditis in humans
Background: Infective endocarditis is a life-threatening infection that involves the endocardial surface 
or vascular structures in proximity to the heart. The intrinsic resistance to a number of antimicrobial 
agents makes enterococcal infective endocarditis cumbersome to treat. For decades, the mainstay of 
treatment has been the combination of a cell wall-active agent (ampicillin, penicillin, or vancomycin) 
and gentamicin. High-level resistance to gentamicin hinders, however, the bactericidal activity of such 
combinations. High-level gentamicin resistant (HLGR) E. faecalis has been associated with the hospital 
setting and prior health care exposure, which suggests the existence of a hospital reservoir. Nevertheless, 
enterococci are gut commensals in humans and warm-blooded animals and it is therefore conceivable 
that there may be reservoirs of E. faecalis in the community not directly linked to hospitals. During 
2000–2002, the proportion of HLGR E. faecalis isolates increased from 2% to 6% in the pig population in 
Denmark, which coincided with the emergence of HLGR E. faecalis isolates among infective endocarditis 
patients in the North Denmark Region. We recently undertook a study to determine whether pigs are a 
potential source of E. faecalis infections in Denmark.
Materials and methods: We compared HLGR E. faecalis isolates from Danish pigs (n = 19), Danish pork 
(n = 1), community-dwelling humans (n = 2) and patients with infective endocarditis (n = 2) by multi-
locus sequence typing (MLST) [Larsen et al. 2010. Emerg Infect Dis. 16: 682–4]. 
Results: Twenty-three of the 24 strains belonged to MLST type ST16. The remaining isolate from pigs 
belonged to MLST type ST35. The 23 isolates with MLST type ST16 were further characterised by pulsed 
field gel electrophoresis (PFGE). The PFGE patterns clustered into one major clonal group. 
Discussion: Our study provided the first evidence of existence of a widespread community reservoir of 
HLGR ST16 in Danish pigs, which coincided with the emergence of HLGR ST16 isolates among infective 
endocarditis patients. One isolate was present in pork, which supports foodborne transmission although 
direct transmission from animals to humans is also possible.
Our findings support the results of a study in the United States that identified HLGR E. faecalis isolates 
with similar PFGE patterns from pork and fecal swabs of outpatients [Donabedian et al. 2003. 41: 
1109–13]. These pig-related HLGR isolates in the study from the USA as well as our collection of HLGR 
ST16 isolates carry the aac(6’)Ie-aph(2’’)Ia gene encoding gentamicin resistance. The isolates from pigs 
belonging to ST16 carried pathogenicity island (PAI) genes [Shankar et al. 2006. J Clin Microbiol. 44: 
4200–3]. 
These genes are more frequently detected among E. faecalis isolates recovered from sites of infection 
such as blood and urine or from fecal swabs of inpatients when compared with isolates from fecal swabs 
obtained from healthy humans.
Further studies are required to better understand the human and veterinary epidemiology of this 
zoonosis. Areas of study should include size of the reservoir in pigs as well as in the hospital and other 
health care settings and whether or not other animals, immunocompromised persons, or healthy humans 
constitute a community reservoir of HLGR E. faecalis ST16.
Since 2002, we have observed a continuous increase in the proportion of HLGR E. faecalis isolates in the 
pig population in Denmark (from 6% in 2002 to 20% in 2009). With an annual production of >22 million 
slaughter pigs, Denmark therefore has a large potential reservoir of HLGR ST16. Additional studies 
investigating the clinical impact of this increase are urgently needed.
Jesper Larsen, Henrik C. Schønheyder, Camilla H. Lester, 
Stefan S. Olsen, Lone J. Porsbo, Lourdes Garcia-Migura, 
Lars B. Jensen, Magne Bisgaard and Anette M. Hammerum
For further information: Jesper Larsen (JRL@ssi.dk)
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Detection of vancomycin resistant Enterococcus faecium in Danish broilers 
15 years after the ban of avoparcin
Background: Data on the occurrence of antimicrobial resistance in animal enterococci presented in 
DANMAP are generated by antimicrobial susceptibility testing of one random isolate per herd. It has 
previously been shown that this approach leads to lower resistance frequencies compared to 
antimicrobial selective methods [Heuer et al. 2002. Microb. Drug Resist. 8: 133–138], but generally these 
resistance frequencies are representative for the occurrence in the tested bacterial population [Vieira et 
al. 2008. Antimicrob Agents Chemother. 62: 535–38]. In order to quantify the differences between the 
results obtained by selective and non-selective methods, a subset of the faecal samples collected from pigs, 
broilers and cattle in DANMAP 2010 were additionally analysed for the occurrence of ampicillin and 
vancomycin resistant enterococci by selective enrichment in antimicrobial-containing media.
Materials and methods: Faecal samples from pigs (n = 123), broilers (n = 100) and cattle (n = 100) were 
enriched in 5 ml of Enterococcus Selective Broth containing ampicillin (16 µg/ml) or vancomycin (16 
µg/ml). Following subculture on Slanetz agar containing the same antimicrobial concentration, colonies 
typical of E. faecium and E. faecalis were confirmed by species-specific PCR [Dutka-Malen et al. 1995. J 
Clin Microbiol. 33: 24–27]. Vancomycin-resistant E. faecium (VREF) was confirmed by PCR detection of 
vanA.
Results: Ampicillin and vancomycin resistance was only found in E. faecium. No resistance to these anti-
microbial agents was detected in E. faecalis isolates from all other tested animal reservoirs (pigs, 
broilers and cattle).VREF was isolated at high frequency (47%) in samples from broilers, while no re-
sistant isolates were detected using the non-selective method. None of the samples from pigs and cattle 
were positive for VREF. E. faecium resistant to ampicillin was found in all animal species (28% in broilers, 
4% in cattle and 2% in pigs). 
Discussion and conclusions: The study confirmed marked differences between data generated by selec-
tive and non-selective methods for VREF from broilers. The lack of detection by random isolation is due 
to the relatively low concentration of VREF per gram compared to the total E. faecium 
concentration in broiler faeces. The ratio of vancomycin resistant enterococci to the total enterococci 
count has previously been reported to range from 0.8% to 4.6% in Norwegian broilers 10 years after the 
ban of avoparcin [Sørum et al. 2006. Appl Environ Microbiol. 72: 516–521], which makes VREF 
detection nearly impossible by the current method used in DANMAP. Ampicillin resistant E. faecium 
were isolated from nearly one third of the broiler flocks when using the selective enrichment even though 
ampicillin resistance was not detected in E. faecium isolated by the standard DANMAP 
procedure (see Table 7.1). Resistance to ampicillin and vancomycin was low (≤2%) or absent in samples 
from pigs and cattle, and no significant differences were observed between the two methods in these ani-
mal species. 
The reasons for the long persistence of VREF in Danish broilers 15 years after the avoparcin ban are 
unknown.
The VREF isolates in this study were not multilocus sequenced typed (MLST), but other studies 
have shown that E. faecium isolates of poultry origin cluster together in one cluster (CC9), whereas 
human E. faecium isolates belong to another cluster (CC17) [Willems et al. 2005. Emerg Infect Dis. 11: 
821–8]. However, as shown by a recent in vivo study, E. faecium of poultry origin can act as a donor of 
antimicrobial resistance genes for pathogenic E. faecium of human origin [Lester and Hammerum 2010. J 
Antimicrob Chemother. 65: 1534–6]. 
Manuela Mander, Lars Bogø Jensen, Anette M. Hammerum, 
John Elmerdahl Olsen and Luca Guardabassi
For further information: Luca Guardabassi (lg@life.ku.dk)
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7.2 Escherichia coli
E. coli isolates from healthy production animals 
originated from faecal samples collected for the 
DANMAP programme at the time of slaughter. 
For broilers, isolation and susceptibility testing was 
performed at the National Veterinary Institute and 
for cattle and pigs at the National Food Institute. 
E. coli from meat originated from meat sampled at 
wholesale and retail outlets, collected randomly in 
all regions of Denmark by the Danish Veterinary and 
Food Administration Regional Laboratories in three 
centrally coordinated programs. The susceptibility 
testing was done at the National Food Institute. 
Samples from healthy humans have not been collected 
since 2008. See the definition of multi-resistance in 
appendix 2
7.2.1 Indicator Escherichia coli from 
production animals
E. coli was isolated from 91% (199/219) of the samples 
from pigs and from 92% (122/133) of the samples 
from cattle. For broilers, 382 flocks were sampled, 
representing 153 different farms. Only one isolate was 
included per farm and a randomly selected subsample 
of 160, 106 and 118 isolates from pigs, cattle and 
broilers, respectively, were susceptibility tested and 
reported.
Among animal species, the level of resistance in 
indicator E. coli was lowest in isolates from cattle in 
2010 (Table 7.3). Of the susceptibility tested E. coli 
isolates from cattle, 90% were fully sensitive whereas 
6% were found to be multi-resistant. However, 
among the E. coli isolates from broilers and pigs 
that were susceptibility tested, 57% and 43% were 
fully sensitive, whereas 11% and 33% were found to 
be multi-resistant, respectively. Trends in resistance 
to selected antimicrobial agents in isolates from 
production animals during 2001–2010 are presented in 
Figure 7.1. The MIC distributions for 2010 are shown 
in Appendix 1 (Table AP1.22). In general, the highest 
resistance level was found in E. coli from pigs, except 
for fluoroquinolone (nalidixic acid and ciprofloxacin) 
resistance which was higher in isolates from broilers 
(8%). 
The low level of fluoroquinolone resistance in E. 
coli from Danish pigs and cattle probably reflects 
the low consumption since 2002, when the use 
in production animals was restricted by law. The 
highest fluoroquinolone consumption was seen in 
poultry, decreasing since 2006 however, whereas the 
ciprofloxacin resistance reached the highest observed 
level in 2007 (14.5%). However, fluoroquinolone 
resistance in E. coli from broilers, pigs and cattle has not 
changed significantly over the past decade.
Table 7.3. Resistance (%) in Escherichia coli from animals and meat of Danish and imported origin, Denmark
DANMAP 2010
Antimicrobial agent
Broilers Cattle Pigs Broiler meat Beef Pork meat
Danish   
%
Danish 
 %
Danish
%
Danish   
%
Imported   
%
Danish    
%
Imported  
%
Danish    
%
Imported  
%
Tetracycline 15 9 37 13 46 3 10 24 56
Chloramphenicol 3 1 4 1 21 0 0 3 8
Florfenicol 1 1 0 0 1 0 0 0 2
Ampicillin 21 4 23 16 58 3 5 24 36
Ceftiofur 0 0 1 1 7 0 3 1 0
Cefotaxime 0 0 1 1 7 0 3 1 0
Sulfonamide 20 5 32 15 56 6 5 19 36
Trimethoprim 8 1 21 4 41 3 3 16 30
Apramycin 1 0 1 0 0 0 0 1 0
Gentamicin 0 0 1 0 3 0 3 1 0
Neomycin 1 1 8 1 10 0 0 3 4
Spectinomycin 5 2 25 4 29 0 3 19 14
Streptomycin 14 6 47 15 46 3 5 38 56
Ciprofloxacin 8 0 0 4 41 0 5 1 4
Nalidixic acid 8 0 0 4 38 0 5 1 4
Colistin 0 0 1 0 6 0 0 0 0
Number of isolates 118 106 160 158 177 32 39 68 50
In indicator E. coli from broilers, no significant changes 
in resistance were observed in 2010 compared to 2009 
(Table 7.3). The highest occurrence of resistance was 
seen for ampicillin (21%), while amoxicillin has been 
the most frequently used antibacterial agent in the 
broiler production for at least a decade (Figure 4.8).
Regarding E. coli from pigs, no significant change in 
occurrence of resistance was observed from 2009 to 
2010. For most antimicrobial agents, the consumption 
was similar in 2009 and 2010. However, important 
decreases in consumption was seen for tetracyclines 
(9% per pig produced) and cephalosporins (50% per 
pig produced) in 2010, related to the second half 
year (increase in first half year). Since a time lapse 
is often seen between changes in consumption and 
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isolate per sample was susceptibility tested and reported 
(Table 7.3).
MIC distributions and occurrence of antimicrobial 
resistance in E. coli isolates collected from broiler meat, 
pork and beef sampled at wholesale and retail outlets in 
2010 are presented in Appendix 1 (Table AP1.23). 
Among the indicator E. coli isolates from Danish and 
imported broiler meat that were susceptibility tested, 
58% and 19% were fully sensitive, whereas 7% and 
60% were found to be multi-resistant, respectively. For 
indicator E. coli from Danish broiler meat, the observed 
resistance to sulfonamide increased significantly from 
8% in 2009 to 15% in 2010. As for indicator E. coli from 
broilers, the level of resistance in isolates from broiler 
meat was very low-moderate for all tested agents, with 
the highest level found for ampicillin (16%) (Table 7.3).
In imported broiler meat, the level of resistance was 
significantly higher for 13 of the 16 tested antimicrobial 
agents when compared to E. coli from Danish broiler 
meat, including tetracycline, chloramphenicol, 
ampicillin, cefoxitime, ceftiofur, colistin, sulfonamide, 
trimethoprim, neomycin, spectinomycin, streptomycin, 
ciprofloxacin and nalidixic acid (Table 7.3). 
In 2010, ceftiofur resistance was observed for the first 
time in one isolate from Danish broiler meat obtained 
without selective enrichment (1%); however, this is 
significantly lower than among E. coli from imported 
broiler meat (7%). The occurrence of fluoroquinolone 
resistance in imported broiler meat (41%) was tenfold 
higher than in Danish broiler meat (4%) in 2010 (as in 
2009) (Table 7.3).
In imported pork, two isolates with MIC for nalidixic 
acid <32 µg/ml and for ciprofloxacin >0.06 µg/ml  
were found. One of the isolates contained transferable 
fluoroquinolone resistance encoded by qnrS.
a consequent change in resistance in E. coli [Jensen 
et al. 2006. J Antimicrob Chemother. 58: 101–107], 
a significant decrease in resistance was not expected 
in 2010. In 2010, two ceftiofur resistant E. coli were 
isolated from pigs. In 2009–2010, a supplementary 
investigation of cephalosporin resistant E. coli from pigs 
was performed by use of a selective enrichment method 
(Textbox 7). 
 
Over the past decade, an overall increase in the 
proportion of resistant indicator E. coli isolates from 
pigs has been observed for tetracycline and ampicillin 
resistance, except for an unexplained peak in 2004. 
In the same period, use of tetracycline increased 
dramatically from 2002–2007 and again importantly in 
2009 and first half of  2010. 
In cattle, the overall occurrence of resistance to 
tetracycline increased significantly from 2% in 2009 
to 9% in 2010 (Table 7.3, Figure 7.1), and in calves 
the consumption of tetracyclines increased by 10% 
(Table AP1.2). From 2005 to 2010, the tetracycline 
consumption in calves increased by 7% (absolute 
numbers), from 28% of the total calves consumption 
in 2005 to 30% in 2010; in between, a temporary 
decrease in the tetracycline consumption was observed 
concurrent with a decreasing trend in resistance. 
The steep increase in tetracycline resistance in 2010 
might indicate a low level presence in farms that have 
temporarily stopped using tetracycline during 2006–
2009.
7.2.2 Indicator Escherichia coli from meat 
For Danish meat, E. coli were isolated from 37% 
(68/184) of the pork samples, 27% (32/118) of the beef 
samples, and 84% (158/187) of the broiler samples. For 
imported meat, E. coli were isolated from 29% (50/175) 
of the pork samples, 39% (39/99) of the beef samples 
and 78% (177/226) of the broiler samples. Only one 
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Among the susceptibility tested indicator E. coli 
isolates from Danish and imported pork, 50% and 
36% were fully sensitive, whereas 24% and 38% were 
found to be multi-resistant, respectively. In E. coli 
from Danish pork, sulfonamide resistance decreased 
significantly from 38% to 19%. In 2010, significantly 
lower resistance to tetracycline and sulfonamide was 
found in isolates from Danish pork compared to 
imported pork. Fluoroquinolone resistance remained 
low (one isolate) in Danish pork, probably due to the 
low fluoroquinolone consumption in Danish pigs since 
2002. In imported pork, 4% of the E. coli isolates were 
resistant to fluoroquinolone. Resistance to ceftiofur was 
found in one isolate from Danish pork in 2010, as in 
the two previous years. In 2009–2010, a supplementary 
investigation of cephalosporin resistant E. coli from 
meat was performed by use of a selective enrichment 
method (Textbox 7).
The occurrence of resistance in E. coli isolates obtained 
from Danish and imported beef remained low and 
at comparable levels. Among the susceptibility tested 
indicator E. coli isolates from Danish and imported 
beef, 94% and 87% were fully sensitive, whereas 6% and 
5% were found to be multi-resistant, respectively. No 
significant changes were observed from 2009 to 2010.
7.2.3 Comparison of resistance in Escherichia 
coli from production animals and meat
Data on the occurrence of resistance in E. coli isolates 
from animals and Danish meat are presented in Table 
7.3. For most of the tested antimicrobial agents, the 
level of resistance in Danish meat reflected the level of 
resistance in the corresponding animal species with 
some exceptions.
The occurrence of tetracycline and sulfonamide 
resistance among E. coli from Danish pork was 
significantly lower than what was found among Danish 
pigs. The difference in the level of resistance between 
pork and pigs might be caused by cross contamination 
at the slaughterhouse or due to some resistant isolates 
being less fit to survive through the food production 
chain than susceptible isolates.
Vibeke Frøkjær Jensen and Lars Stehr Larsen
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Zoonotic aspects of E. coli urinary tract infections 
Background: Urinary tract infection (UTI) is one of the most common bacterial infections. The major 
aetiological agent of UTI is Escherichia coli accounting for 80-90% of all infections. Extraintestinal 
pathogenic E. coli (ExPEC) are characterized by carrying a number of virulence genes that enable the 
isolates to cause infection outside the intestinal tract, e.g. by adhering to host surfaces, scavenge iron (or 
other micronutrients), or evade host response. Furthermore, resistance to antibiotics in ExPEC is increasing 
which complicates treatment. Especially, ExPEC belonging to phylogroup B2 and to a lesser extent D cause 
the majority of UTI. Likewise, clonal groups and epidemic strains causing UTI have been identified. The 
E. coli causing UTI is believed to stem from the patient’s own faecal flora. However, the exterior reservoir 
of such E. coli in the human intestines is poorly investigated. The food supply may transmit ExPEC from 
animals to humans. Since the start of DANMAP in 1995, E. coli from food animals at slaughter and fresh 
retail meat have been collected. Furthermore, E. coli isolates have been collected from healthy humans from 
2002 through 2006. DANMAP isolates (from 2004) have recently been compared with E. coli isolates from 
patients with UTI to test the hypothesis if UTI is a zoonosis. 
Materials and methods: A total of 964 geographically and temporally matched E. coli isolates from UTI 
patients, community-dwelling humans, Danish and imported broiler chicken meat, healthy Danish broiler 
chickens, Danish and imported pork and healthy Danish pigs were included. All isolates were investigated 
for phenotypic antimicrobial resistance, for phylogroups (A, B1, B2, D) and for eight ExPEC-related 
virulence genes (kpsM II, papA and papC, iutA, sfaS, focG, afa and hlyD) [Jakobsen et al. 2010. Foodborne 
Pathog Dis. 7: 537–47; Jakobsen et al. 2010. Int J Food Microbiol. 142: 264–72]. Despite many studies 
investigating this hypothesis using molecular characterization, in vivo studies have been lacking. Therefore, 
a subset of B2 E. coli isolates (n = 13) (type 1-fimbriaeted and positive for two or more of the virulence genes 
iutA, kpsM II, papA, papC, focG, sfaS, or hlyA) from animals and meat were investigated for their ability to 
cause infection in a murine model of ascending UTI [Jakobsen et al. 2010. J Clin Microbiol. 48: 2978–80]. 
The model is representative of UTI in humans. Further, D isolates from all origins (n = 158) were screened 
for Clonal group A (CgA) status. This clonal group cause invasive disease in humans, mainly UTI, but the 
distribution and possible sources are poorly investigated. Identified CgA isolates were investigated for clonal 
relationship and virulence in the murine UTI model [Jakobsen et al. 2010. Appl Environ Microbiol. 2010 76: 
8281–4]. 
Figure 1. Distribution (%) of phylogroups and non-typeables among Escherichia coli isolates 
from animals, meat and humans, Denmark
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Results and discussion: Phylogroup B2 and D isolates were detected in different frequencies among 
isolates from all origins, including food animals and retail meat (except for imported pork) (Figure 1). 
Phylogroup B2 was predominant among UTI and community-dwelling human isolates and phylogroup A 
was predominant among animal and meat isolates. Animal and meat isolates were similar to UTI isolates 
based on the phenotypic antimicrobial resistance [Jakobsen et al. 2010. Foodborne Pathog Dis. 7: 537–47]. 
Although B2 and D isolates were found in low frequencies among animal and meat isolates, they may pose 
a risk for acquiring potentially uropathogenic E. coli from these sources. The detection of seven out of eight 
ExPEC-related virulence genes among animal and meat isolates and clustering of animal and meat isolates 
with UTI isolates based on antimicrobial resistance and virulence genes supported this finding [Jakobsen et 
al. 2010. Int J Food Microbiol. 142: 264–72]. All 13 investigated B2 isolates from animal and meat isolates 
were virulent in the murine UTI model with bacterial counts in urine, bladder and often kidneys (n = 9) 
providing solid evidence that UTI is at times a zoonosis [Jakobsen et al. 2010. J Clin Microbiol. 48: 2978–80]. 
This was further supported by the finding of 25 CgA isolates among isolates from broiler chickens and meat, 
community-dwelling humans and UTI patients. Although no CgA animal or meat isolates were clonally 
related to any human isolate, several community-dwelling isolates were related to UTI isolates despite no 
known relation. Retail meat may have been a common source. Like the B2 isolates, the CgA phylogroup D 
animal and meat isolates were virulent in the murine bladder and murine kidneys [Jakobsen et al. 2010. Appl 
Environ Microbiol. 76: 8281–4].
Conclusion: Food animals and fresh retail meat are sources of B2 and D isolates including invasive human 
Clonal group A isolates. Meat and animal isolates are similar to human isolates with respect to resistance and 
virulence genes. Further, animal and meat isolates can cause infection in bladder and kidneys in a murine 
model providing evidence that UTI can be a zoonosis.
For further information: Lotte Jakobsen (lja@ssi.dk) 
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Occurrence of Extended spectrum beta-lactamase (ESBL)-producing Escherichia coli after 
selective enrichment with ceftriaxone in meat and food producing animals
Background: Extended spectrum beta-lactamase (ESBL)-producing bacteria is one of the fastest emerging 
resistance problems worldwide. The resistance type seems to be related to food producing animals and 
may spread to humans via food. June 2010, the use of cephalosporins in the Danish pig production was 
discontinued, but it is still used for systemic and intramammary treatment in cattle. Cephalosporins have not 
been used in the Danish broiler production for at least a decade. The aim of this study was to investigate the 
occurrence of ESBL-producing E. coli in pigs at farm level, in cattle and broilers at slaughter and in meat at 
retail (see Appendix 2 for definition of ESBL).
Materials and methods: During June 2010 through December 2010, stool samples (n = 99) were collected in 
pig farms, fecal samples (n = 192) were taken from cattle at slaughter and pools of five cloacal swabs (n = 197) 
were taken from broiler flocks at slaughter. From January through November 2010, 990 meat samples [Danish: 
Pork (n = 184), broiler meat (n = 187), and beef (n = 118); imported: Pork (n = 176), broiler meat (n = 226), 
and beef (n = 99)] were collected in retail stores and outlets. The samples were randomly selected and for pigs 
each farm was sampled only once. For cattle, one animal represented one farm. For broilers, five animals per 
flock were included in the pooled sample. No broiler flock or cattle herd was sampled more than once in the 
same month.
The meat samples were collected randomly in all regions of Denmark. E. coli was isolated from 1 g of pig stool 
sample, 1 g of cattle feces, pools of five cloacal swabs or 5 g of meat after selective enrichment in McConkey 
media with ceftriaxone (1 µg/ml). The genetic background for ESBL resistance was revealed by use of PCR, 
array and DNA sequencing.
Results: Eleven percent (11/99) of the pig stool samples contained ceftriaxone resistant E. coli (ESBL-producing 
including up-regulation of chromosomal AmpC). Among these isolates, eight (64%) contained CTX-M-1, 
two (18%) contained CTX-M-2, one isolate contained CMY-2 (9%) and one was AmpC up-regulated (9%). 
For cattle, 10% (20/192) of the faecal samples contained ceftriaxone resistant E. coli. Among these isolates, ten 
contained CTX-M-1 (50%), five contained CTX-M-14 (25%), one contained CTX-M-15 (5%), one contained 
CTX-M-8 (5%) and three were AmpC up-regulated (15%). For broilers, 27% (53/197) contained ceftriaxone 
resistant E. coli and these isolates contained CMY-2 (89%) and SHV-2 (11%) (Figure 1). 
Figure 1.  Occurrence (%) of ESBL-genes and AmpC up-regulated Escherichia coli  in broilers, 
cattle and pig farms, Denmark
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From meat samples, the highest prevalence of ceftriaxone resistant E. coli was found among imported poultry 
(50%). Ceftriaxone resistant E. coli were found in 8.6% of isolates from Danish broiler meat and in 0.8 - 2.8% 
of isolates from the other meat catagories. Among the 113 ceftriaxone resistant E. coli from imported broiler 
meat, 42 contained CMY-2 (37%), 50 contained CTX-M-1 (44%), 11 contained SHV-12 (10%), three contained 
CTX-M-2 (3%), five had other mechanisms (4%) (SHV-2a, TEM-52) and two (2%) had unknown mechanisms. 
Among the other meat categories, CMY-2 and CTX-M-1 were found (Figure 2). 
Figure 2. Occurence (%) of ESBL-genes and AmpC up-regulated Escherichia coli in meat, Denmark
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Discussion and conclusions: The use of selective enrichment with ceftriaxone revealed ESBL-producing E. 
coli in food producing animals, which were not found by standard monitoring of indicator E. coli as previously 
described [DANMAP 2009]. The highest prevalence of ESBL was found in broilers; this was surprising since 
cephalosporins are not used in the Danish broiler production. The occurrence of ESBL-producing E. coli found in 
pigs in 2010 corresponded to the occurrence reported for pigs in 2009 [DANMAP 2009]. The occurrence of ESBL 
in cattle at slaughter in 2010 was similar to the occurrence of ESBL producing E. coli in pigs. 
The presence of ESBL-genes differed depending on animal reservoir. CMY-2 and SHV-2 seemed to be more 
related to the broiler production, whereas CTX-M-8 was found only in cattle. Even though ESBL-producing 
E. coli are present in Danish pig farms and in cattle at slaughter, the most important meat source seemed to be 
imported poultry. The presence of ESBL-producing E. coli in imported broiler meat has increased significantly 
from 36% in 2009 to 50% in 2010, mainly due to a higher prevalence of CTX-M-1. The occurrence of ESBL-
producing E. coli in the other meat categories was at the same levels as in 2009. 
Although it seems like the occurrence of ESBL-producing E. coli in Danish broiler meat was higher in 2010 
than in 2009, no statistically significant difference (p = 0.07) was observed. Since broilers and broiler meat seem 
to be an important reservoir for ESBL-producing E. coli, also in countries like Denmark with no consumption 
of cephalosporins in the broiler production, more effort should be done to investigate factors important for 
selection of ESBL in the broiler production.
Several of the ESBL-genes detected among E. coli obtained from animals and meat can also be detected in E. coli 
of human origin; CTX-M-15 is most often detected in ESBL-producing E. coli from both urine and bloodstream 
infections in Danish patients, whereas CTX-M-1, CTX-M-14 and CMY-2 are present to lesser extent [Leihof 
et al. 2011. ECCMID Poster 660; Hansen et al. 2011. ECCMID Poster 662]. CTX-M-14 and CMY-2 have been 
detected in E. coli obtained from faecal samples from healthy Danish military recruits, indicating a human faecal 
reservoir of ESBL-genes in the community [Hammerum et al. 2011. Clin Microbiol Infect. 17: 566–8]. More 
studies are needed to investigate the possible transfer of ESBL-producing E. coli or ESBL-genes between humans 
and animals.
                                                                     For further information: Yvonne Agersø (yvoa@food.dtu.dk)
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8. Resistance in human clinical bacteria
8.1 Escherichia coli
Escherichia coli is part of the normal intestinal flora 
of both humans and animals but also cause infections 
(Textbox 6). In humans, E. coli cause a variety of 
intestinal and extra-intestinal infections such as 
diarrhoea, urinary tract infections, meningitis, and 
bloodstream infections. For E. coli, this report includes 
data from 14 Departments of Clinical Microbiology 
(DCM), representing 95% of the Danish population. 
Data on antimicrobial resistance in blood and urine 
isolates of E. coli in hospitals were obtained from 14 of 
the 15 Danish DCM working with hospital isolates; 13 
DCM of the 14 DCM working with primary health care 
isolates contributed data on antimicrobial resistance in 
urine isolates of E. coli from primary health care (Table 
8.1).
E. coli blood isolates obtained from hospitalised 
patients
The antimicrobial susceptibility of approximately 3,400 
E. coli isolates from blood was reported in 2010 (Table 
8.1 and Figure 8.1).
In 2010, cefuroxime (2nd generation cephalosporin) 
resistance was 8% (min. 3%, max. 15%) the same 
as reported in 2009. Likewise, 7% (min. 4%, max. 
13%) of the isolates were resistant to 3rd generation 
cephalosporin (reported as ceftazidime, ceftriaxone, 
cefpodoxime or cefotaxime) similar to the level in 2009. 
Third generation cephalosporin resistance can be due 
to production of ESBL or AmpC enzymes. The genetic 
background was not reported for the 3rd generation 
cephalosporin resistant E. coli isolates in 2010. A study 
of E. coli from bloodstream infections obtained from 
three DCM in 2009 has shown that ESBL-producing 
enzymes are the most frequent cause of resistance to 3rd 
generation cephalosporins, with CTX-M-15 being the 
most frequent enzyme. In 2009, CTX-M-15 was spread 
due to both clonal and non-clonal strains [Hansen et al. 
2011 ECCMID poster 660].   
In 2010, ciprofloxacin resistance was 14% (min. 7%, max. 
22% at the individual DCM) and nalidixic acid resistance 
was 18% (min. 8%, max. 21%), which is the same level as 
in 2009. 
Table 8.1. Resistance (%) in Escherichia coli isolates from humans, Denmark 2010 DANMAP 2010
Antimicrobial agent Blood isolates, hospitals
(a) Urine isolates, hospitals(b) Urine isolates, primary health care(c)
% % %
Ampicillin 46 41 # 40 #
Mecillinam 9 * 7 6
Sulfonamide 35 # 37 #
Gentamicin 6 * 4 3
Ciprofloxacin 14 12 # 11
Nalidixic acid 18 15 15 *
Cefuroxime 8 5 # 3
3rd generation cephalosporins d) 7 5 3
Meropenem 0
Max. number of isolates tested 3426 36149 29421
*) An asterisk indicates a significant increase from 2009 to 2010        
#) A number sign indicates a significant decrease from 2009 to 2010        
a) 14 DCM reported data on ampicillin, gentamicin and 3rd generation cephalosporin resistance, 13 DCM reported ciprofloxacin and 
cefuroxime resistance, 10 DCM reported mecillinam and nalidixic acid resistance, and 8 DCM reported data on meropenem resistance. Data 
on sulfonamide resistance were not reported        
b) 14 DCM reported data on ampicillin and mecillinam resistance, 12 DCM reported cefuroxime resistance, 10 DCM reported gentamicin 
and 3rd generation cephalosporin resistance, and 9 DCM reported data on sulfonamide, ciprofloxacin and nalidixic acid resistance. No 
comparison of gentamicin resistance in 2009 and 2010 was made, since data were not reported in 2009. Since resistance to meropenem was 
only reported from one DCM, data are not shown      
c) 13 DCM reported data on ampicillin and mecillinam resistance, 11 DCM reported sulfonamide resistance, 9 DCM reported nalidixic 
acid and 3rd generation cephalosporin resistance, 8 DCM reported ciprofloxacin resistance, and 7 DCM reported data on gentamicin and 
cefuroxime resistance. No comparison of gentamicin resistance in 2009 and 2010 was made, since data were not reported in 2009 
d) Tested 3rd generation cephalosporins were ceftazidime, ceftriaxone, cefpodoxime and cefotaxime      
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The level of fluoroquinolone and 3rd generation 
cephalosporin resistance in Denmark was again above 
the level reported to EARS-Net by the other Nordic 
countries and corresponded to the occurrence reported 
by other European countries in 2009 [EARS-Net 2009]. 
A small but significant increase in aminoglycoside 
(gentamicin) resistance was observed from 5% in 2009 
to 6% in 2010. This corresponded to the level reported 
to EARS-Net by the other Nordic countries in 2009 
[EARS-NET 2009]. Among the 10 DCM reporting data 
in both 2009 and 2010, mecillinam resistance increased 
significantly from 5% to 9% (in 2010, min. 2%, max. 
17%).
Over the last decade, resistance to cefuroxime has 
increased from 2% in 2001 to 8% in 2010. Resistance to 
3rd generation cephalosporins has only been reported 
since 2008. Resistance to fluoroquinolones has also 
increased over the last ten years; ciprofloxacin resistance 
increased from 2% in 2001 to 14% in 2010, and nalidixic 
acid resistance from 5% in 2001 to 18% in 2010. 
Aminoglycoside (gentamicin) resistance has increased 
from 1% in 2001 to 6% in 2010. 
In 2010, carbapenem (meropenem) resistance was not 
observed in E. coli blood isolates. 
E. coli urine isolates obtained from hospitalised 
patients 
The antimicrobial susceptibility of approximately 36,000 
E. coli isolates obtained from hospitalised patients with 
a urinary tract infection was reported in 2010 (Table 8.1 
and Figure 8.2).
From 2009 to 2010, smaller but significant decreases in 
resistance were observed for the following antimicrobial 
agents: ampicillin (42% in 2009, 41% in 2010), 
sulfonamide (36% in 2009, 35% in 2010), ciprofloxacin 
(13% in 2009, 12% in 2010) and cefuroxime (2nd 
generation cephalosporin) (6% in 2009, 5% in 
2010). However, over the last decade the occurrence 
of resistance to fluoroquinolones has increased; 
ciprofloxacin resistance has increased from 1% in 2001 
to 12% in 2010, and nalidixic acid resistance from 5% in 
2001 to 15% in 2010.
In 2010, carbapenem (meropenem) resistance was 
observed in two E. coli urine isolates from hospitalised 
patients. The carbapenem resistant isolates were not 
further investigated. The presence of antimicrobial 
resistance in this species is not mandatory reportable, 
and no calculation of the occurrence of carbapenem 
resistance could be made since only one DCM reported 
data on all isolates. 
E. coli urine isolates obtained from primary health 
care
The antimicrobial susceptibility of approximately 29,000 
E. coli isolates obtained from patients with a urinary 
tract infection from primary health care was reported in 
2010 (Table 8.1 and Figure 8.3).
A small but significant increase in nalidixic acid 
resistance was observed from 14% in 2009 to 15% 
in 2010. Also, over the last decade the occurrence 
of resistance to fluoroquinolones has increased; 
ciprofloxacin resistance from 1% in 2001 to 11% in 
2010, and nalidixic acid resistance from 5% in 2001 to 
15% in 2010, respectively.
From 2009 to 2010, smaller but significant decreases in 
resistance were observed for ampicillin (42% in 2009, 
40% in 2010) and sulfonamide (38% in 2009, 37% in 
2010).
In 2010, carbapenem (meropenem) resistance was 
observed in five E. coli urine isolates from primary 
health care. The carbapenem resistant isolates were 
not further investigated. The presence of antimicrobial 
resistance in this species is not mandatory reportable, 
and no calculation of the occurrence of carbapenem 
resistance could be made since the DCM reported data 
on selected isolates only.
Line Skjøt-Rasmussen, Stefan S. Olsen 
and Anette M. Hammerum
Figure 8.1. Resistance (%) in Escherichia coli blood isolates from humans, Denmark
Note: The number (n) in parentheses represents the number of isolates tested for susceptibility in 2010
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Figure 8.2. Resistance (%) in Escherichia coli urine isolates from humans in hospitals, Denmark
Note: The number (n) in parentheses represents the number of isolates tested for susceptibility in 2010
Figure 8.3. Resistance (%) in Escherichia coli urine isolates from humans in primary health care, Denmark
Note: The number (n) in parentheses represents the number of isolates tested for susceptibility in 2010
8.2 Klebsiella pneumoniae
Klebsiella pneumoniae is part of the intestinal flora 
in humans but is often the cause of extra-intestinal 
infections such as urinary tract-, respiratory tract-, 
wound- and bloodstream infections. Many of these 
infections are hospital acquired and can be life 
threatening, especially if the strains are resistant to 
antimicrobial agents. K. pneumoniae is intrinsically 
resistant to aminopenicillins (e.g. ampicillin). 
Therefore, infections caused by K. pneumoniae are 
treated with broad spectrum antimicrobial agents 
such as ciprofloxacin, gentamicin, cephalosporins 
and carbapenems. Data on antimicrobial resistance in 
blood and urine isolates of K. pneumoniae in hospitals 
were obtained from 14 of the 15 Danish DCM working 
with hospital isolates; 13 of the 14 DCM working 
with primary health care isolates contributed data 
on antimicrobial resistance in urine isolates of K. 
pneumoniae.
 
K. pneumoniae blood isolates obtained 
from hospitalised patients
The antimicrobial susceptibility of approximately 800 K. 
pneumoniae isolates from blood was reported in 2010 
(Table 8.2).
Until 2007, the occurrence of antimicrobial resistance 
in K. pneumoniae was low and at the same level as in 
the other Nordic countries (e.g. for 3rd generation 
cephalosporins <5%). However, since 2007 a steady 
increase in resistance has been observed until 2009. 
When comparing 2010 with 2009, a significant decrease 
was observed for gentamicin, ciprofloxacin and 
cefuroxime resistance; this was mostly due to decreased 
occurrence of these resistances in K. pneumoniae 
isolates from Zealand. This could in part be explained 
by interventions at hospitals in the Copenhagen area 
(Textbox 8).
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In 2010, 3rd generation cephalosporin resistance 
(reported as ceftazidime, ceftriaxone, cefpodoxime 
or cefotaxime) was 9% (min. 4%, max. 24%); this 
was at the same level as in 2009 (12%). In 2010, 3rd 
generation cephalosporin resistance was above the level 
reported to EARS-Net by the other Nordic countries 
and corresponded to the occurrence reported by several 
other European countries in 2009 [EARS-Net 2009]. In 
the Eastern part of Denmark (Zealand), 3rd generation 
cephalosporin resistance in K. pneumoniae (14%) was 
significantly higher than in the Western part (Funen 
and Jutland) (6%). Third generation cephalosporin 
resistance can be due to production of ESBL or AmpC 
enzymes. The genetic background was not reported 
for the 3rd generation cephalosporin resistant K. 
pneumoniae isolates in 2010. In a study from 2008, 
it was observed that 3rd generation cephalosporin 
resistant K. pneumoniae from bloodstream infections 
in Danish hospitals was mostly due to spread of two 
clones (ST15 and ST16) producing the ESBL-enzyme 
CTX-M-15 among hospitals in Zealand. Both clones 
have been reported in other countries before, indicating 
international spread [Lester et al. 2011, Int J Antimicrob 
Agents. 38(2): 180-2]. 
The occurrence of fluoroquinolone resistance 
(ciprofloxacin 11%, nalidixic acid 17%) and 
aminoglycoside (gentamicin) resistance (6%) was above 
the level reported from the other Nordic countries and 
the same as reported to EARS-Net by other European 
countries in 2009 [EARS-Net 2009].  
In 2010, carbapenem (meropenem) resistance was not 
observed in K. pneumoniae blood isolates. 
DANMAP 2010
Table 8.2. Resistance (%) in Klebsiella pneumoniae 
isolates from blood, Denmark
DANMAP 2010
Table 8.3. Resistance (%) in Klebsiella pneumoniae 
urine isolates from humans in hospitals, Denmark
a) 12 DCM reported data on mecillinam, sulfonamide and 
ciprofloxacin resistance, 8 DCM reported nalidixic acid and 3rd 
generation cephalosporin resistance, and 1 DCM reported data on 
meropenem resistance (not shown). Gentamicin and cefuroxime 
resistance was not reported    
b) 14 DCM reported data on mecillinam resistance, 12 DCM 
reported cefuroxime resistance, 10 DCM reported gentamicin 
and 3rd generation cephalosporin resistance, 9 DCM reported 
sulfonamide, ciprofloxacin and nalidixic acid resistance, and 1 
DCM reported data on meropenem resistance (not shown)  
c) Tested 3rd generation cephalosporins were cefpodoxime and 
cefotaxime   
Antimicrobial agent 2009
(a) 2010(b)
% %
Mecillinam 13.3 14.3
Sulfonamide 27.0 28.6
Gentamicin 7.3
Ciprofloxacin 17.3 13.9
Nalidixic acid 21.9 19.6
Cefuroxime 12.8
3rd gen. cephalosporins (c) 12.8 12.0
Max. number of isolates tested 6394 5740
K. pneumoniae urine isolates obtained 
from hospitalised patients
The antimicrobial susceptibility of approximately 5,500 
K. pneumoniae isolates obtained from hospitalised 
patients with a urinary tract infection was reported in 
2010 (Table 8.3).
The occurrence of 3rd generation cephalosporin 
resistance was 12% (reported as cefpodoxime or 
cefotaxime) and corresponded to the occurrence 
reported in 2009 (13%). In the Eastern part of Denmark 
(Zealand), 3rd generation cephalosporin resistance in K. 
pneumoniae (20%) was significantly higher than in the 
Western part (Jutland) (7%).
Fluoroquinolone resistance decreased from 2009 to 
2010; ciprofloxacin resistance decreased from 17% to 
14%, and nalidixic acid resistance decreased from 22% 
to 20%. In the Eastern part of Denmark (Zealand), 
the occurrence of ciprofloxacin resistance (16%) was 
significantly higher than in the western part (Jutland 
and Funen) (7%).
In 2010, carbapenem (meropenem) resistance was 
observed in seven K. pneumoniae urine isolates from 
hospitalised patients. The seven isolates were tested for 
the presence of carbapenem resistance genes. One of 
the seven isolates produced the new carbapenemase 
enzyme New Delhi metallo-β-lactamase 1 (NDM-1) 
and was resistant towards all tested antimicrobial agents 
except tigecycline and colistin. This isolate was obtained 
from urine from a colonised patient [Hammerum et 
al. 2010, Lancet Infect Dis 10: 829-30]. The patient had 
been travelling to Bosnia and Herzegovina; a Balkan 
link has also been found in other countries with the 
Antimicrobial agent 2008
(a) 2009(b) 2010(c)
% % %
Gentamicin 7.6 9.0 6.0
Ciprofloxacin 16.1 18.1 11.3
Nalidixic acid 22.2 21.8 17.4
Cefuroxime 15.2 17.1 12.8
3rd gen. cephalosporins (d) 9.6 12.0 9.2
Meropenem 0.2 0 0
Max. number of isolates tested 788 886 799
a) 14 DCM reported data on gentamicin resistance, 13 DCM 
reported ciprofloxacin and cefuroxime resistance, 11 DCM reported 
3rd gen. cephalosporin resistance, 10 DCM reported nalidixic acid 
resistance, and 9 DCM reported data on meropenem resistance
b) 14 DCM reported data on ciprofloxacin and gentamicin 
resistance, 13 DCM reported cefuroxime resistance, 12 DCM 
reported 3rd gen. cephalosporin resistance, 10 DCM reported 
nalidixic acid resistance and 9 DCM reported data on meropenem 
resistance
c) 14 DCM reported data on gentamicin and 3rd gen. cephalosporin 
resistance, 13 DCM reported cefuroxime resistance, 11 DCM 
reported ciprofloxacin resistance, 10 DCM reported nalidixic acid 
resistance and 8 DCM reported data on meropenem resistance
d) Tested 3rd generation cephalosporins were ceftazidime, 
ceftriaxone, cefpodoxime and cefotaxime
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first NDM-1 isolates [Struelens et al. 2010, Euro 
Surveill. 15 pii: 19716]. Another of the seven isolates 
was positive for VIM-1, whereas the remaining five 
carbapenem resistant isolates were not positive for 
any of the known carbapenem resistance genes. The 
presence of antimicrobial resistance in this species is 
not mandatory reportable, and no calculation of the 
occurrence of carbapenem resistance could be made 
since only one DCM reported data on all isolates. 
Sulfonamide resistance increased significantly from 
27% in 2009 to 29% in 2010.
K. pneumoniae urine isolates obtained 
from primary health care
The antimicrobial susceptibility of approximately 3,000 
K. pneumoniae isolates obtained from patients with a 
urinary tract infection from primary health care was 
reported in 2010 (Table 8.4). 
The occurrence of 3rd generation cephalosporin 
resistance was 7% (reported as cefpodoxime or 
cefotaxime) and corresponded to the occurrence 
reported in 2009 (8%). In the Eastern part of Denmark 
(Zealand), 3rd generation cephalosporin resistance 
in K. pneumoniae (11%) was significantly higher than 
in the Western part (Jutland) (4%). Resistance to 3rd 
generation cephalosporins in K. pneumoniae from 
urine from general practice patients was significantly 
lower than the occurrence of resistance detected in 
isolates from both blood and urine from hospitalised 
patients.
Fluoroquinolone resistance was 20% for nalidixic 
acid and 12% for ciprofloxacin, corresponding to 
the occurrences observed in 2009. However, in the 
Eastern part of Denmark (Zealand), the occurrence of 
ciprofloxacin resistance (21%) was significantly higher 
than in the western part (Jutland and Funen) (7%). 
Ciprofloxacin resistance in K. pneumoniae from urine 
from general practice patients was significantly lower 
than the occurrence of resistance detected in isolates 
from urine from hospitalised patients.
In 2010, carbapenem (meropenem) resistance was 
observed in one K. pneumoniae urine isolate from 
primary health care. The carbapenem resistant 
isolate was not further investigated. The presence 
of antimicrobial resistance in this species is not 
mandatory reportable, and no calculation of the 
occurrence of carbapenem resistance could be made 
since the DCM reported data on selected isolates only.
Sulfonamide resistance increased significantly from 
30% in 2009 to 34% in 2010. Resistance to mecillinam 
was 16% (min. 7%, max. 24%). Both resistance to 
sulfonamide and mecillinam was significantly higher in 
the urine isolates from general practice patients than in 
the urine isolates from hospitalised patients, probably 
reflecting the usage of sulfonamide and mecillinam in 
the treatment of urinary tract infections in primary 
health care.
Anette M. Hammerum, Stefan S. Olsen
and Line Skjøt-Rasmussen
DANMAP 2010
Table 8.4. Resistance (%) in Klebsiella pneumoniae 
urine isolates from humans in primary health care, 
Denmark
a) 11 DCM reported data on mecillinam and sulfonamide 
resistance, 9 DCM reported ciprofloxacin resistance, and 7 
DCM reported nalidixic acid and 3rd generation cephalosporin 
resistance. Meropenem resistance was only reported for selected 
isolates and therefore not shown. Gentamicin and cefuroxime 
resistance was not reported   
b) 13 DCM reported data on mecillinam resistance, 11 DCM 
reported sulfonamide resistance, 9 DCM reported nalidixic acid 
and 3rd generation cephalosporin resistance, 8 DCM reported 
ciprofloxacin resistance, and 7 DCM reported gentamicin and 
cefuroxime resistance. Meropenem resistance was only reported 
for selected isolates and therefore not shown  
c) Tested 3rd generation cephalosporins were cefpodoxime and 
cefotaxime   
Antimicrobial agent 2009
(a) 2010(b)
% %
Mecillinam 15.1 16.3
Sulfonamide 30.2 33.9
Gentamicin 3.5
Ciprofloxacin 13.2 11.9
Nalidixic acid 19.9 19.7
Cefuroxime 8.6
3rd gen. cephalosporins (c) 8.1 7.0
Max. number of isolates tested 3200 3200
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Reduction in the prevalence of ESBL-producing Klebsiella pneumoniae after 
changing the antibiotic policy and antimicrobial consumption at Bispebjerg Hospital
In 2008, an increasing prevalence of ESBL-producing Klebsiella pneumoniae and E. coli was 
observed in the Copenhagen City area. Especially, ESBL-producing Klebsiella pneumoniae was 
increasing in two hospitals. At the end of 2009, more than 40% of the K. pneumoniae isolates were 
ESBL-producing at these two hospitals. This increased level was seen in spite of numerous infection 
control initiatives such as reintroducing chlorine cleaning and focusing on isolation precautions.
An intervention was prepared for the 600 bed University Hospital, Bispebjerg Hospital, where the 
usage of cephalosporins was restricted to surgical prophylaxis and to the empirical treatment of 
meningitis, and the usage of quinolones was to be decreased significantly. In Bispebjerg Hospital 
and the other hospitals in the area served by the DCM Hvidovre Hospital, the use of penicillins 
was preferred in all cases possible, e.g. Staphylococcus aureus was treated with dicloxacillin, and the 
use of quinolones avoided. The intervention was a multidisciplinary exercise planned by a clinical 
microbiologist and a clinical pharmacologist and carried out in collaboration with the infections 
control team and the quality organisations in the hospital. Focus was set on diagnostic initiatives, 
isolation precautions and use of small spectrum antimicrobial agents when possible. Numerous 
teaching lectures were given, and written information and guidelines were distributed to all clinical 
working employees in brochures and electronically.
The rate of patients at Bispebjerg Hospital with ESBL-producing K. pneumoniae decreased from 
43% in January 2010 to 16% in November 2010 (p = 0.007), and the rate of patients with ESBL-
producing E. coli was unchanged at app. 12%. The number of bed-days with patients under isolation 
precautions for patients with ESBL-producing K. pneumoniae and E. coli was reduced from more 
than 260 per month to less than 50 (p < 0.001). The compliance to the new guidelines was almost 
complete; the consumption of cephalosporins decreased by 76% from 2,410 DDD/month in 2009 
to 581 in 2010. Likewise, for fluoroquinolones a 16% reduction from 1,477 DDD/month in 2009 to 
1,244 in 2010 was observed. The number of bed-days with patients under isolation precautions was 
also reduced significantly.
These outstanding effects of the intervention have resulted in a permanent change in the routine 
guidelines for the Bispebjerg Hospital to the above described. The effect of improved antimicrobial 
stewardship in the other hospital in the area with similar problems with ESBL-producing 
K. pneumoniae also resulted in a decrease in incidence of patients with ESBL-producing K. 
pneumoniae.
Jenny Dahl Knudsen and Stig E. Andersen
 for the Bispebjerg Intervention Group
For further information: Jenny Dahl Knudsen 
(jenny.dahl.knudsen@hvh.regionh.dk)
Textbox 8
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8.3 Pseudomonas aeruginosa
Pseudomonas aeruginosa is an opportunistic pathogen 
of immunocompromised individuals. P. aeruginosa 
typically infects the pulmonary tract, urinary tract, 
burns, wounds, and also causes other bloodstream 
infections. It is the most frequent coloniser of medical 
devices (e.g. catheters). P. aeruginosa infection is a 
serious problem in patients hospitalised with cancer, 
cystic fibrosis and burns. The case fatality rate in these 
patients is high.
P. aeruginosa blood isolates obtained from 
hospitalised patients
For P. aeruginosa, this report includes data from 
14 Departments of Clinical Microbiology (DCM), 
representing 95% of the Danish population. The 
antimicrobial susceptibility of approximately 375 P. 
aeruginosa isolates from blood was reported in 2010. 
Not all DCM tested for the same antimicrobial agents 
(Table 8.5). The occurrence of resistance was low for 
all the tested antimicrobial agents and compared to the 
other countries reporting to the EARS-Net  among the 
lowest.
Anette M. Hammerum, Stefan S. Olsen 
and Line Skjøt-Rasmussen
Table 8.5. Resistance (%) in Pseudomonas aeruginosa blood isolates from humans, Denmark DANMAP 2010
Antimicrobial agent 2007 2008 2009 2010% % % %
Ciprofloxacin 5.7 4.5 5.3 5.8
Gentamicin 1.2 <1 <1 1.3
Ceftazidime 2.4 3.4 3.6 2.8
Meropenem 2.3 <1 2.5 3.1
Piperacillin / Tazobactam 3.4 2.3 1.8 3.9
Max. number of isolates tested 417 426 440 375
8.4 Streptococci 
Streptococci are part of the normal commensal flora 
of the mouth, skin, intestine, and upper respiratory 
tract of humans, but streptococci also cause infections 
such as otitis media, tonsillitis, bacterial pneumonia, 
bacteremia/sepsis, endocarditis and meningitis.
In this report, data on resistance in invasive (from 
blood or cerebrospinal fluid) streptococcal isolates 
were obtained from the Neisseria and Streptococcus 
Reference laboratory covering all DCM in Denmark. 
In Denmark, penicillins and macrolides are often used 
for treatment of infections caused by streptococci. All 
invasive non-duplicate Streptococcus pneumoniae and 
group A, B, C and G streptococci were susceptibility 
tested against erythromycin and penicillin. 
Streptococcus pneumoniae
Streptococcus pneumoniae is a leading cause of bacterial 
pneumonia, otitis media, bacteraemia and meningitis. In 
2010, susceptibility testing was performed on 960 non-
duplicate S. pneumoniae isolates from invasive infections 
(Figure 8.4).
Macrolide resistance in S. pneumoniae isolates from 
blood and cerebrospinal fluid was 4.2% (n = 40) in 2010. 
The occurrence of macrolide resistant S. pneumoniae 
has been around 6% from 2000 to 2008, but decreased 
significantly from 6.6% in 2008 to 3.6% in 2009. The 
decrease in the number of erythromycin resistant S. 
pneumoniae may be related to the introduction of 
the pneumococcal conjugated vaccine in the Danish 
childhood vaccination program in October 2007. The 40 
macrolide resistant S. pneumoniae from 2010 belonged 
to 15 different serotypes and the most commonly 
found serotypes were type 19A (30%), 11A (15%) and 
14 (12.5%). In previous years, serotype 14 was the 
dominant erythromycin resistant serotype.
As in previous years, no resistance to penicillin in group 
B, C or G isolates from invasive infections was reported 
in 2010.
The percentage of S. pneumoniae invasive isolates being 
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Figure 8.4. Resistance (%) in Streptococcus pneumoniae 
blood and spinal fluid isolates from humans, Denmark
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non-susceptible (resistant and intermediary resistant) 
to penicillin was 3.5% (n = 34) in 2010 compared 
with 3.2% in 2007, 3.0% in 2008, and 3.6% in 2009. 
The 34 penicillin non-susceptible S. pneumoniae from 
2010 belonged to 16 different serotypes, and the most 
commonly found serotypes were type 19A (38%), 15A 
(8.8%) and 6C (8.8%). In previous years, serotype 19A 
was present in a lower percentage whereas serotype 9V 
was a dominant type also in 2006 and 2007.   
The occurrence of resistance to erythromycin and 
penicillin was similar to the occurrence in other 
Scandinavian countries but much lower than reported 
in many of the other European countries reporting to 
EARS-Net [EARS-Net 2009]. 
According to EUCAST, one (0.1%, MIC = 4 μg/ml) of 
the 960 tested isolates was resistant to penicillin (MIC 
> 2 μg/ml). However, according to the CLSI penicillin 
breakpoint for susceptibility testing of isolates from 
patients with invasive disease treated with intravenous 
penicillin, except for patients with meningitis, (2 μg/
ml < MIC < 8 μg/ml) this isolate would be reported as 
non-susceptible intermediary resistant.
Group A Streptococci
In 2010, 155 invasive GAS (Streptococcus pyogenes) 
isolates were susceptibility tested. As in previous 
years, no resistance to penicillin in GAS isolates from 
invasive infections was reported in 2010. Erythromycin 
resistance was detected in two isolates (1.3%) as 
compared to six of 143 isolates (4.5%) in 2009 and two 
of 136 (1.5%) in 2008. 
Group B, C and G Streptococci
In 2010, 110 invasive group B streptococci 
(Streptococcus agalactiae) isolates from invasive 
infections were tested. Erythromycin resistance was 
detected in 14 isolates (12.7%) compared with 12.8% in 
2009, and 11.4% in 2008. 
Fifty-three isolates of invasive group C streptococci 
were tested in 2010. One isolate (1.9%) was resistant to 
erythromycin compared with three isolates (8.1%) in 
2009 and 4% in 2008.
Seventeen (12%) of the tested 142 invasive group G 
streptococci were resistant to erythromycin compared 
with 4.8% in 2009, 10% in 2008, and 8% in 2007.
Lotte M. Lambertsen
8.5 Enterococci
Enterococci are part of the normal intestinal flora of 
both humans and animals but can also cause infections. 
Important clinical infections caused by Enterococcus 
species include urinary tract infections, bacteremia 
and bacterial endocarditis. E. faecalis and E. faecium 
can cause life-threatening infections in humans, 
especially in the hospital environment. The naturally 
high level of antimicrobial resistance found in E. 
faecalis and E. faecium makes infections difficult to 
treat. Antimicrobial therapy for serious enterococcal 
infections requires the use of synergistic combinations 
of a cell-wall-active agent such as penicillin (ampicillin) 
and an aminoglycoside (gentamicin) or a glycopeptide 
(vancomycin). 
For E. faecalis and E. faecium, data from 14 of the 15 
DCM were obtained, representing 95% of the Danish 
population. 
Enterococcus faecium and Enterococcus faecalis 
blood isolates obtained from hospitalised patients
In 2010, a maximum of 506 E. faecium isolates and 
535 E. faecalis isolates from blood were tested for 
antimicrobial susceptibility.
Ampicillin resistant E. faecium increased significantly 
from 87% in 2009 to 92% in 2010. Treatment with 
fluoroquinolones, cephalosporins or carbapenems has 
been described as a risk factor for development of an E. 
faecium infection. An increasing consumption of these 
antimicrobial agents has been observed in hospitals 
in Denmark during the past years. The antimicrobial 
pressure in a hospital environment might be a reason 
for the increasing frequency of ampicillin resistant E. 
faecium as a cause of bloodstream infections.
 
Only one of the DCM (Aalborg Hospital) tested all 
enterococcal blood isolates for High-level gentamicin 
resistance (HLGR). Among the tested E. faecalis isolates 
at DCM Aalborg, 36% were HLGR, whereas 74% of the 
tested E. faecium isolates were HLGR. The occurrence of 
HLGR E. faecalis was similar to the occurrence detected 
in many countries reporting to EARS-Net in 2009 
(including Spain, Portugal and Norway) [EARS-Net 
2009].
Vancomycin resistance was detected in 1.8% of the 
E. faecium isolates (n = 9) and 0.7% of the E. faecalis 
isolates (n = 3) from bloodstream infections. During 
2010, an outbreak of vancomycin resistant (vanA) E. 
faecium was detected at Aarhus University Hospital. 
This outbreak is under investigation (Brian Kristensen, 
personal communication).
The occurrence of vancomycin resistant E. faecium and 
vancomycin resistant E. faecalis was at the same level 
or lower compared to most other countries in Europe 
[EARS-Net 2009].
Since 2005, SSI has asked all the DCM to send 
presumable vancomycin resistant enterococcal isolates 
from both invasive and non-invasive infections 
for national surveillance on vancomycin resistant 
98                          
                   
DANMAP 2010  
RESISTANCE IN HUMAN CLINICAL BACTERIA8.
8.6 Staphylococcus aureus 
Staphylococcus aureus is part of the normal flora from 
skin and mucosa in approximately 50% of humans. 
Some people only carry S. aureus intermittently 
whereas others carry S. aureus for longer time. 
However, S. aureus also cause infections ranging from 
superficial skin infections i.e. impetigo and boils, 
to invasive infections such as post operative wound 
infections, infections related to intravenous catheters 
and prosthetic devices, arthritis, bacteremia and 
endocarditis. 
In Denmark, Methicillin Resistant S. aureus (MRSA) 
has been both laboratory and clinical notifiable since 
November 2006. In recent years, S. aureus, belonging 
to clonal complex 398 (CC398), has attracted special 
attention as this type has been closely connected to 
livestock animals, especially pigs, and has affected 
people in direct contact with pigs.  
Surveillance of bacteremia
In 2010, 1,418 S. aureus bacteremia cases corresponding 
to 24.6 per 100,000 inhabitants were reported from 
the Departments of Clinical Microbiology (DCM) in 
Denmark. Twenty (1.4%) of the cases were caused by 
MRSA. This is at the same level as in previous years 
enterococci. Besides the vanA E. faecium isolates from 
the outbreak at Aarhus University hospital, 19 vanA E. 
faecium, 7 vanB E. faecium and 5 vanB E. faecalis isolates 
were received during 2010.  
As described above, most of the E. faecium isolates from 
bloodstream infections were resistant to ampicillin; 
these infections can therefore not be treated with 
ampicillin but will often be treated with vancomycin 
instead. This might in part, together with the increased 
number of MRSA infections, explain the increased 
consumption of glycopeptides (vancomycin) in 
hospitals, which has been observed during the last years. 
Anette M. Hammerum, Stefan S. Olsen 
and Line Skjøt-Rasmussen
Table 8.6. Resistance (%) in isolates from Staphylococcus aureus bacteraemia cases, Denmark
Antimicrobial agent 2005 2006 2007 2008 2009 2010% % % % % %
Methicillin 1.6 1.4 0.6 1.3 1.6 1.4
Penicillin 78 80 78 77 77 75
Erythromycin 5 5 4 5 7 5
Clindamycin 4 4 3 4 6 4
Tetracycline 3 3 2 3 2 3
Fusidic acid 10 10 9 9 9 13
Rifampicin <1 <1 <1 <1 <1 <1
Norfloxacin 3 2 1 2 2 3
Kanamycin 2 1 <1 1 1 1
Mupirocin 0 0 <1 <1 <1 <1
Number of isolates 1428 1329 1345 1344 1480 1418
DANMAP 2010
and very low compared to most of the other countries 
participating in EARS-Net [EARS-Net 2009]. Resistance 
in S. aureus bacteremia isolates from 2005–2010 is 
presented in Table 8.6. 
Multi-resistance defined as resistance to at least 1, 
2 or 3 other antimicrobials in addition to penicillin 
was demonstrated in 22%, 7% and 2% of the cases, 
respectively. In 2010, resistance to fusidic acid and 
norfloxacin increased compared with 2009. Eleven 
(0.8%) of the bacteremia cases belonged to CC398, the 
strain type associated to livestock. None of these were 
MRSA and any association to pig farming is not known. 
The corresponding numbers were ten in 2009, six in 
2008 and five in 2007.
Surveillance of Methicillin Resistant S. aureus 
In 2010, 1,097 new MRSA cases were detected (19.8 
per 100,000 inhabitants). Here, a case is a patient found 
positive for the first time with a specific MRSA strain 
regardless whether the patient was infected or colonised. 
This is a large increase (34%) compared with 817 in 
2009 and is the highest number of cases observed in 
over 25 years (Figure 8.5). In 2010, five persons were 
found with two different MRSA strains. At the time of 
diagnosis, 646 (59%) of the new cases had infection, this 
was at the same level as in 2009 (486 cases (60%)). The 
proportion of bloodstream infections with MRSA was 
1.4% in 2010 (see surveillance of S. aureus bacteremia). 
The incidence rate of new MRSA cases per year for each 
DCM in the last four years is shown in Table 8.7. The 
incidence varied from 30.9 per 100,000 inhabitants in 
the greater Copenhagen area (Greater Copenhagen is 
served by three DCM, and is shown as one) to 10.6 per 
100,000 inhabitants in Vejle.
The total number of cases and the number of cases 
presenting with infection according to epidemiological 
classification are shown in Table 8.8. Most of the cases 
(77%) were acquired in Denmark. The epidemiological 
classification of MRSA infections 2006–2010 is shown in 
Figure 8.6. An increase was seen among cases classified 
as health-care associated, with community onset 
(HACO) from 49 cases in 2009 to 132 cases in 2010 
(Figure 8.6). Only 16 of the HACO infections could be 
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Figure 8.5. Number of MRSA cases, with a three years moving average, Denmark
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Figure 8.6. Number of MRSA cases presenting with infection according to epidemiological classification, 
Denmark
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Table 8.7. Incidence rate of new MRSA cases per 100,000 inhabitants per Department of Clinical 
Microbiology, Denmark
a) Rigshospitalet (national referral hospital), Hvidovre and Herlev    
b) Statens Serum Institut is no longer serving former Roskilde County   
c) Including isolates from former Roskilde County    
 
Department of Clinical 
Microbiology 2007 2008 2009 2010
Greater Copenhagen(a) 17.7 23.6 26.9 30.9
Hillerød 11.7 21.8 16.5 27.0
Statens Serum Institut(b) 3.9 17.6 17.6 –
Slagelse(c) 15.3 19.3 15.1 17.9
Næstved 8.8 12.1 8.8 19.8
Odense 7.1 12.9 8.9 16.3
Sønderborg 8.1 11.1 12.8 25.8
Esbjerg 14.5 8.8 6.2 11.8
Vejle 23.4 20.0 11.6 10.6
Herning 2.5 7.7 7.3 15.1
Århus 10.1 6.0 10.1 11.6
Viborg 8.2 18.5 9.1 11.0
Aalborg 8.2 10.7 7.6 16.6
Denmark total 12.1 15.5 14.7 19.8
DANMAP 2010Table 8.8. Epidemiological classification of new MRSA cases, Denmark
Note: Numbers shown in bold are totals        
a) Epidemiological classification missing for 5 cases        
b) Epidemiological classification missing for 6 cases        
Epidemiologic classification Exposure
2009 2010
No. of 
cases(a)
No. (%) of 
cases with 
infections 
No. of 
cases(b)
No. (%) of 
cases with 
infections 
Imported (IMP) 156 97 (62) 247 163 (66)
Hospital-acquired (HA) 53 30 (57) 62 34 (55)
Health-care associated,  
community onset (HACO)
with health care risk 81 169
      with known exposure 25 12 (48) 40 16 (40)
      without known exposure 56 37 (66) 129 116 (90)
Health care worker 18 5 (28) 35 8 (23)
Community-acquired (CA) without health care risk 491 578
      with known exposure 176 37 (21) 331 100 (30)
      without known exposure 315 265 (84) 247 210 (85)
Unclassified 4 3 (75) 0 0 (0)
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Table 8.9. The ten most prevalent spa types 
demonstrated in MRSA cases, Denmark 2010
a) CC = Clonal complex
spa type CC group(a) No. of cases No. causing  infections (%)
t002 CC5 110 67 (61)
t034 CC398 93 32 (34)
t008 CC8 90 63 (70)
t024 CC8 80 53 (66)
t019 CC30 73 59 (81)
t032 CC22 39 26 (67)
t044 CC80 34 27 (79)
t127 CC1 33 11 (33)
t041 CC22 25 10 (40)
t437 CC59 24 19 (79)
associated with a known exposition, 8 from hospitals, 
3 from nursing homes and the remaining 5 from other 
sources. The remaining 116 cases of infection classified 
as HACO were registered with a possible association 
to health-care institutions without known exposition, 
of these were 62 cases with an association to hospitals, 
and 32 cases with an association to nursing homes 
and private home care. The increase in the number of 
HACO infections without any known exposition may 
reflect a better completion of the report forms where 
any contact to health-care institutions within the 
previous 12 months is registered. 
Without such information, the cases would have been 
categorised as community-acquired (CA) infections. 
CA infections remained at the same level as in 2009 
despite the increase in the number of infections. 
In 2010, more CA cases reported known exposure 
compared to 2009, both for patients with infections and 
carriers, the latter representing contact screening.
Molecular typing of the MRSA strains
The number of isolates belonging to the 10 dominating 
spa types isolated in 2010 is shown in Table 8.9. They 
constituted 55% of the total number of MRSA isolates. 
Seven spa types constituted 51% of the 646 clinical 
infections with MRSA (out of 141 different spa types 
associated with clinical infection). Most prevalent 
spa types causing clinical infections were t002, t008, 
t019, t024, t034, t044 and t032. Of the 451 strains 
isolated from asymptomatic carriers, t034 was the most 
prevalent spa type (n = 61), followed by t002 (n = 43), 
t008 (n = 27), t024 (n = 27) and t127 (n = 22). The 
number of CC398 isolates (the clonal complex related 
to pigs) increased from 40 in 2009 to 109 in 2010. 
Among the CC398 isolates, the most frequent spa type, 
t034, increased from 27 in 2009 to 93 in 2010. Thirty-
two of the 93 t034 cases represented infections (Table 
8.9).
An EU funded research programme, PILGRIM, 
performed screening in 2010 for MRSA CC398 among 
pig farmers and their family, workers on pig farms and 
veterinarians. The number of cases from the targeted 
screening constituted 20 cases. t034 and other CC398 
spa types were also seen in 15 cases without any known 
contact to pigs or other livestock, although the persons 
lived in areas with a high density of pig production 
facilities. They may represent an adaption of CC398 
to the human host and the possibility of human-to-
human spread. So far there are still no signs of spread 
through the food chain.
Resistance among MRSA isolates
The occurrence of resistance to tetracycline and 
mupirocin increased when comparing all MRSA 
isolates in 2010 with all MRSA isolates in 2009 (Table 
8.10). The increase in tetracycline  resistance reflects 
the increased number of t034 in 2010. The resistance 
pattern varied considerably between spa types (Table 
8.10). In 2010, 100% of CC398 spa type t034 isolates 
were resistant to tetracycline and 100% of CC22 spa 
type t032 were resistant to norfloxacin. 
In contrast, the majority of t019, a primarily 
community-acquired spa type, were susceptible to all 
tested antimicrobial agents except for beta-lactams. 
Even though differences in antimicrobial resistance 
were demonstrated between spa types, the success of 
antimicrobial treatment cannot be predicted based 
on spa type or epidemiological classification. Multi-
resistance, defined as resistance to at least 1, 2 or 3 
other antimicrobials in addition to cefoxitin/penicillin, 
was demonstrated in 72%, 58% and 38% of the cases, 
respectively. In Table 8.11, the most common resistance 
patterns and any frequent spa types are shown. 
Andreas Petersen, Marit Sørum, 
Robert L. Skov and Anders Rhod Larsen
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Table 8.10. Resistance (%) in the six most prevalent spa types demonstrated in MRSA cases compared with 
all MRSA cases, Denmark 2010
spa type t002 t034 t008 t024 t019 t032 All cases
Clonal complex CC5 CC398 CC8 CC8 CC30 CC22
% % % % % % %
Erythromycin 42 47 64 94 4 64 44
Clindamycin 39 77 7 88 3 64 38
Tetracycline 14 100 10 0 0 3 28
Fusidic acid 27 4 6 11 0 3 15
Rifampicin 4 0 0 0 1 0 3
Norfloxacin 34 19 55 24 1 100 31
Kanamycin 23 0 67 4 0 3 30
Linezolid 0 0 0 0 0 0 0
Mupirocin 1 0 1 0 0 3 3
Number of isolates 110 93 90 80 72 39 1097
DANMAP 2010
Table 8.11. Resistance markers in addition to cefoxitin demonstrated in MRSA cases, Denmark 2010
a) T = tetracycline, N = norfloxacin, F = fusidic acid, K = kanamycin, E = erythromycin, C = clindamycin, R = rifampicin
No. of markers No. of cases Frequent patterns (no. of isolates) Any frequent spa type (no. of isolates)
0 306 – –
1 150 T(41) t034(17)
N(38) t032(12)
F(35) t002(12), t021(10)
K(30)
2 222 E,C(97) t024(51), t002(16)
C,T(25) t034(19)
F,N(22) t002(14)
3 252 E,N,K(59) t008(34), t657(14)
E,C,N(52) t032(24)
E,C,T(49) t034(35)
T,F,K(40) t044(20)
4 93 E,C,T,K(35) t437(16), t127(8)
E,C,N,K(22) t002(8)
5 63 E,C,N,K,M(28) t041(25)
E,C,T,N,K(18) t037(6), t189(5)
6 10 E,C,T,R,N,K(4)
7 1 E,C,T,F,R,N,K(1) t987(1)
DANMAP 2010
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Methicillin resistant Staphylococcus aureus (MRSA) in Danish pig herds, broilers and cattle at 
slaughter, and in Danish and imported retail meat
Background: Methicillin resistant Staphylococcus aureus (MRSA), especially belonging to the clonal 
complex CC398, has since 2003 emerged in livestock worldwide. The occurrence in Danish pigs at 
slaughter was investigated in 2009, and 13% of the pigs were found positive [DANMAP 2009]. As MRSA 
can be transmitted between animals during transportation and prior to slaughter, the occurrence found 
in the slaughterhouses may not be equivalent to the occurrence of MRSA positive farms [Broens et al. Vet 
J. 2010 (ahead of print)]. MRSA has also been found in many other animal species and in 2009, MRSA 
CC398 was found in a Danish beef sample. MRSA has not previously been found in cattle in Denmark. The 
aim of this study was to investigate the occurrence of MRSA at the pig farm level and to see if this differed 
significantly from that found at slaughter in 2009. We also wanted to investigate whether MRSA could be 
found in cattle and broilers at slaughter. Meat samples were collected to follow changes in occurrence when 
compared to data from 2009.
Materials and methods: During June through November 2010, pools of five nasal swab samples (n = 
99) were taken from five slaughter pigs in five different pens in 99 farms in Denmark. Cattle, mainly 
young bulls, were tested at slaughter by taking skin swabs between leg and udder/testis of 192 animals, 
representing at least 174 different farms. One hundred ninety-seven pools of five throat swabs from broilers 
at the same farm were tested. Meat samples of Danish origin: pork (n = 183), broiler meat (n = 186), and 
beef (n = 118) as well as imported: pork (n = 176), broiler meat (n = 225), and beef (n = 99) were collected 
in retail stores and outlets. The meat samples were collected randomly in all regions of Denmark. MRSA 
was isolated from each pool of nasal/throat swabs, skin swabs or from 25 g of meat after pre-enrichment 
in Mueller-Hinton medium with 6.5% NaCl followed by selective enrichment in tryptone soya broth 
supplemented with 4 mg/L cefoxitin and 75 mg/L aztreonam. Ten µl were transferred to brilliance MRSA 
agar and colonies with typical S. aureus morphology were confirmed to be MRSA by PCR and the isolates 
were spa typed.
Results and discussion: Sixteen (16%) of the pig farms were positive for MRSA. All isolates except one 
were spa typed and all 15 isolates had spa types corresponding to CC398. The occurrence of MRSA in pig 
farms was not significantly different from what was found in pigs at slaughter in 2009 (13%). In 2009, 95% 
had spa types corresponding to CC398.
No MRSA were found among the 192 cattle and 197 broilers at slaughter. A study of MRSA in broilers 
using a similar sampling method found 6.9% MRSA positive broilers in The Netherlands [Mulders et al. 
Epidemiol Infect. 2010. 38: 743–55]. It can therefore be concluded that the occurrence of MRSA in Danish 
broilers is lower/absent compared to the Netherlands. 
The absence of MRSA in cattle may be due to sampling method or that MRSA is not present. A Dutch 
study found that testing for MRSA by use of skin swabs between udder and legs of dairy cows was the most 
efficient method compared to testing of nasal swabs or milk. The use of skin swabs between udder/testis as 
in the present study may not have been so efficient, since the slaughter cattle were mainly young bulls and 
this sampling method has been tested for dairy cows (personal communication).
From meat samples, the highest occurrence of MRSA was found in imported broiler meat (19%), followed 
by Danish pork (6.0%), imported pork (5.7%) and imported beef (4.0%). No MRSA were found in Danish 
broiler meat or Danish beef. All except two isolates from meat were spa typed. From imported broiler meat, 
89% corresponded to CC398, one isolate corresponded to CC5, one to CC7 and three corresponded to a 
new spa type. From Danish pork, only CC398 was found; from imported pork, CC398 was predominant, 
one isolate corresponded to CC1 and three isolates had a spa type not previously found. From imported 
beef, three isolates corresponded to CC398 and one isolate corresponded to CC7 (Figure 1). 
MRSA CC398 was found in 109 human cases in 2010, the majority in persons with close contact to pigs or 
being a household member to a person with close contact to pigs. In 15 cases no such direct contact could 
be found - the majority of these were in persons living in rural areas with known occurrence of MRSA 
CC398 in pigs. There are still no sign of spread of CC398 to urban areas.
Textbox 9
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Conclusions: This investigation showed that 16% of Danish pig farms were MRSA positive, this 
is at approximately the same level as found in 2009 for pigs at slaughter. The occurrence of farms 
positive for MRSA is therefore still much lower compared to pig farms in The Netherlands and 
some other European countries. No MRSA was found in Danish broilers or cattle. In meat, MRSA 
was often found in imported broiler meat (19%), but not in Danish broiler meat. In pork, MRSA 
was found at the same level in Danish and imported meat (5-6%). In beef, MRSA was detected in 
imported but not in Danish meat. The relatively frequent occurrence of MRSA in meat combined 
with no/very few cases in urban areas makes it safe to conclude that there is very little if any risk for 
meat being a risk for contracting MRSA CC398. Pigs still seem to be the most important reservoir 
for MRSA CC398.
Yvonne Agersø, Karl Pedersen and Robert L. Skov
For further information: Yvonne Agersø
(yvoa@food.dtu.dk)
Figure 1. Occurrence (%) of MRSA in meat, Denmark
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Detection of a new mecA homologue in methicillin resistant S. aureus from human samples 
with a possible link to cattle
Methicillin resistance in Staphylococcus aureus (MRSA) is encoded by the mecA gene located on a mobile 
element called Staphylococcal Cassette Chromosome (SCC). Detection of the mecA gene is therefore “the golden 
standard” for MRSA confirmation. A new mecA homologue was however recently discovered by a group in 
Cambridge headed by Professor Mark Holmes. It was designated mecAlga251, according to the strain Lga251 in 
which it was found. The Lga251 isolate originated from bulk milk and a second milk isolate carrying mecAlga251 
was also found. Another 13 isolates with mecAlga251were found in a collection of 940 bovine isolates and a 
subsequent survey in humans revealed the first identified human isolates in England.
Except for betalactams, the mecAlga251 containing isolates are in general susceptible to other antimicrobials 
(gentamicin, neomycin, ciprofloxacin, tetracycline, erythromycin, clindamycin, fusidic acid, rifampicin and 
teicoplanin). The mecAlga251 gene is located in a novel Staphylococcal Cassette Chromosome designated 
SCCmec XI and shares only 60% nucleotide homology with the conventional mecA gene. The low homology 
means that the isolates have been unrecognised by published MRSA PCRs and genotypic detection systems 
GeneOhm™ StaphSR (Becton Dickinson), GeneXpert™ MRSA (Cepheid) and NucliSENS EasyQ MRSA 
(bioMérieux) [Oliveira et al. 2002. Antimicrob Agents Chemother. 46: 2155–61; Kondo et al. 2007. Antimicrob 
Agents Chemother. 51: 264–74]. Likewise, the latex agglutination assays directed against PBP2a fail to detect the 
protein encoded by mecAlga251.
In Denmark, we became aware of the new gene in January 2011 after searching the isolate collections at SSI 
to identify isolates carrying the gene. The search included isolates being phenotypically resistant to cefoxitin 
but mecA negative from the years 2004 through 2010 (n = 149). Among these strains previously determined as 
borderline resistant (BORSA) or modified resistant (MODSA), we found 67 isolates to carry the mecAlga251 
gene. Furthermore, searching our bacteremia database (including data collected since 1958 on more than 40,000 
isolates) revealed a curiosum: a mecAlga251 positive strain dating back to 1975.
The geographic distribution of the isolates is shown in Table 1. Five persons were detected in the same 
Department of Clinical Microbiology (Slagelse) in 2010 and person to person transmission seems very likely. 
Isolates in which mecAlga251 have been found belong to four genetic lineages within clonal complex 130: spa 
type t847 being the predominant. CC130 isolates have not been found in humans before but have previously been 
associated with bovine samples [Sung et al. 2008. Microbiology. 154: 1949–59]. We have not obtained any clinical 
information indicating that the affected Danish patients have had any contact to cattle.
Future studies should be addressed to elucidate the possible link between cattle and humans of this new mecA 
analogue, since so far no isolates from Danish cows have been detected.
Anders Rhod Larsen and Robert Skov
                                                                                              For further information: Anders Rhod Larsen (arl@ssi.dk)
Table 1. mecAlga251 cases per Department of Clinical Microbiology, Denmark DANMAP 2010
Department of Clinical 
Microbiology 2004 2005 2006 2007 2008 2009 2010 Total
Slagelse 3 2 1 1 5 12
Aalborg 1 2 3 1 1 2 10
Vejle 2 2 1 3 8
Sønderborg 2 1 2 1 6
Herlev 2 1 3
Næstved 2 1 1 1 5
Århus 2 3 5
Herning 3 3
Hillerød 1 1 2 4
Viborg 1 1 1 3
Esbjerg 2 2
Odense 1 1 2
SSI 1 1 2
Hvidovre 1 1
Nykøbing F. 1 1
Denmark total 6 10 12 6 5 7 21 67
Textbox 10
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Resistance in diagnostic submissions from animals
The DANMAP programme monitors antimicrobial 
resistance in Escherichia coli O149 from diagnostic 
submissions from pigs, and E. coli F5 (K99) from 
diagnostic submissions from cattle. E. coli was isolated 
from faecal samples, typically from pigs or calves 
with diarrhoea. The number of isolates available at 
the National Veterinary Institute has been decreasing 
annually due to outsourcing of the diagnostic tasks. In 
2010, 33 E. coli (O149) were isolated from pigs and the 
distribution of MICs and occurrence of resistance in E. 
coli O149 from pigs is presented in Appendix 1 (Table 
AP1.24).
In 2010, only 14 cattle isolates of E. coli F5 (K99) 
were available and therefore these were not reported. 
Staphylococcus hyicus has not been reported since 2008 
due to low number of available isolates. 
9.1 Escherichia coli from pigs
Trends in resistance to selected antimicrobial agents in 
E. coli O149 isolates from pigs are presented in Figure 
9.1. The isolates were mainly from weaning pigs with 
diarrhoea (>7.5 to 30 kg). Most isolates from diagnostic 
submissions originated from animals in antimicrobial 
therapy or with a history of recent antimicrobial 
therapy. For this reason, a higher frequency of 
resistance is expected in bacteria from diagnostic 
submissions compared to bacteria originating from 
healthy animals sampled at slaughter. In 2010, only one 
isolate (3%) was fully susceptible.
As in previous years, high levels of resistance (70%–
80%) were found to tetracycline, sulfonamide and 
streptomycin. Sulfonamide and streptomycin are not 
used for weaning pig diarrhoea, and the consumption 
in weaning pigs has been stable at a low level (Figure 
4.3); however, the resistance to these agents may be co-
selected with tetracycline resistance, as tetracyclines are 
the most commonly used antimicrobials for weaning 
pigs (Figure 4.4). 
In 2010, the only significant increase was seen for 
ciprofloxacin and nalidixic acid resistance, with 
24% resistance to ciprofloxacin in 2010; all but two 
isolates (i.e. 6/8 isolates) were also resistant to the 
commonly used antimicrobials, tetracyclines and 
extended spectrum penicillins. The consumption of 
fluoroquinolones has been at a very low level in the pig 
production since 2003, but the resistance persists due to 
co-selection.  
In 2010, one E. coli O149 isolate was resistant to 
cefotaxime and ceftiofur. 
 Vibeke Frøkjær Jensen and Lars Stehr Larsen
Figure 9.1. Resistance (%) in Escherichia coli O149 from diagnostic submissions from pigs, Denmark
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Figure AP1.1. Consumption of antimicrobial agents and growth promoters in animal production and 
prescribed antibacterials in humans, Denmark
Sources: Human therapeutics: The Danish Medicines Agency. Veterinary consumption: 1990–2000, data based on reports from the 
pharmaceutical industry of total annual sales. (Data 1990–1994:  Use of antibiotics in the pig production. Federation of Danish pig producers 
and slaughterhouses. N. E. Rønn (Ed.). 1996–2000: Danish Medicines Agency and Danish Plant Directorate). 2001–2009: Data from VetStat.   
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Table AP1.0. Estimated total consumption (kg active compound) of prescribed antimicrobials for production 
animals 1990–2000, Denmark
Data based on reports from the pharmaceutical industry of total annual sales. 1990–1994:  Data on use of antibiotics in the pig 
production. Federation of Danish pig producers and slaughterhouses. N. E. Rønn (Ed.). 1996–2000: Danish Medicines Agency. Only 
veterinary drugs are included. Veterinary drugs almost exclusively used in pets (tablets, capsules, ointment, eye/ear drops) are excluded 
a) Only the major contributing ATCvet groups are mentioned.  Kg active compound rounded to nearest 50 for antimicrobial classes and 
100 for totals          
b) Consumption in aquaculture was only partially included before 2001         
         
ATCvet 
group(a) Therapeutic group 1990 1992 1994 1995 1996 1997 1998 1999 2000
QJ01AA Tetracyclines 9300 22000 36500 9000 12900 13700 12100 16200 24000
QJ01CE Penicillins, b-lactamase sensitive 5000 6700 9400 8800 7200 11200 14300 14700 15100
QJ01C/
QJ01D
Other penicillins, 
cephalosporins  1200 2500 4400 4500 5800 6100 6700 6600 7300
QJ01EW Sulfonamides + trimethoprim 3800 7900 9500 6300 4800 6900 7700 6800 7000
QJ01EQ Sulfonamides 8700 5900 5600 1800 2100 1400 1000 1000 1000
QJ01F Macrolides, lincosamides, pleuromutilins 10900 12900 11400 9500 7600 6600 7100 8700 15600
QJ01G/ 
QA07AA Aminoglycosides, colistin 7700 8500 8600 7600 7100 6100 7800 7500 10400
Others(b) 6700 6800 4400 2100 600 650 650 350 300
Total 53300 73200 89800 49600 48100 52800 57350 61900 80700
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Year Sows/piglets (1000’s ADD200 )
2001 1046 0 1574 719 38 803 763 428 291 1 93 597 533 6886
2002 1072 0 1793 894 60 965 764 555 252 26 51 643 498 7574
2003 1104 8 2039 993 99 1116 690 568 234 35 23 703 953 8567
2004 1135 9 2256 1080 113 1269 719 580 215 35 3 669 1027 9110
2005 1092 10 2344 1059 132 1366 724 567 167 35 4 661 845 9006
2006 1232 9 2371 1056 149 1434 780 542 152 35 7 647 955 9368
2007 1697 10 2589 1184 244 1568 1315 615 101 47 6 662 1300 11338
2008 1660 11 2647 1195 300 1635 1242 558 38 57 0 631 1842 11814
2009 1764 31 2865 1404 219 2033 1355 535 48 85 0 685 1726 12751
2010 1620 45 2796 1462 114 2092 1320 447 55 92 0 694 1287 12023
Weaner pigs (1000’s ADD15 )
2001 36163 0 2249 7158 60 3446 48410 13187 27324 75 531 1933 15230 155766
2002 31476 4 2552 8308 147 3987 44195 16575 23752 3172 188 2152 18255 154763
2003 32349 112 3015 10654 254 4185 39308 18691 22032 4377 17 2211 19779 156984
2004 39194 141 4144 13899 263 5516 49768 21189 21288 4531 8 3075 24984 188001
2005 45858 96 4258 12115 267 6192 48252 18269 19633 3994 5 3588 26747 189272
2006 56166 48 4050 10017 291 4698 46666 15881 19464 4212 11 3513 25496 190514
2007 76701 90 4472 9914 407 4192 54522 16203 10586 5299 0 3439 22655 208481
2008 83718 256 4144 9730 400 4559 51676 16597 2857 6727 0 3445 30834 214943
2009 98866 149 4618 11902 358 4668 59205 17823 2981 6862 0 3782 39241 250456
2010 91435 122 4775 11361 181 3939 56090 16636 2169 7349 0 4018 41232 239305
Finisher pigs (1000’s ADD50 )
2001 9223 0 4149 1505 16 173 10840 3131 262 1 129 296 7047 36773
2002 8936 0 4630 1756 36 206 11027 3693 220 22 69 351 7568 38515
2003 11492 30 5249 1995 56 177 11605 4233 192 28 6 423 8522 44008
2004 12689 43 6502 2835 60 237 11599 4447 124 22 4 380 10371 49313
2005 14074 35 7488 2674 62 247 12033 4223 236 20 2 368 12121 53582
2006 16231 33 7702 2275 50 159 10316 3524 213 27 1 297 10846 51673
2007 19320 20 7917 2155 54 172 10362 3194 109 20 0 226 8806 52354
2008 18824 20 7544 1547 53 152 10006 2637 5 43 0 158 12993 53983
2009 20000 16 8195 1651 39 120 11823 2737 13 30 0 129 15194 59948
2010 19581 10 8991 1671 22 112 11942 2695 38 32 0 210 16353 61657
Age group not given (1000’s ADD50 )
2001 1137 0 556 424 9 268 1471 545 584 0 89 139 806 6030
2002 800 2 444 296 7 202 929 330 209 22 20 82 630 3975
2003 768 5 491 305 9 210 951 376 149 39 0 98 676 4077
2004 915 7 557 289 9 154 1125 419 170 29 3 69 986 4731
2005 874 4 563 276 10 184 841 324 85 32 0 85 729 4007
2006 1168 2 510 315 11 177 755 279 144 34 0 69 722 4187
2007 675 1 254 101 11 84 369 186 48 27 0 26 395 2177
2008 398 1 147 94 9 56 235 90 8 35 0 8 287 1368
2009 233 0 110 78 10 43 205 56 2 24 0 10 187 958
2010 83 1 35 34 3 12 114 35 3 7 0 10 85 423
Table AP1.1. Consumption of antimicrobial agents(a) for systemic use in pigs given as Animal Daily 
Doses (ADDs)(b), Denmark
a) Data includes sales from pharmacies and feed mills. Consumption in veterinary practice comprises less than 1% of the total 
consumption in pigs and are not included, except for the use of fluoroquinolones. Local intrauterine and intramammary use is not 
included, and comprised less than 0.1‰ of the ADDs used in sows. Topical treatment is not included    
b) Animal Standard weight is an assumed average weight at treatment, used to calculate numbe of ADD (Animal Daily Doses giving an 
estimated number of animals treated) from number of ADDkg (mass of animal treated, measured in kg animal bodyweight)   
c) Includes a small proportion (< 1‰) of combinations with aminopenicillin and clavulanic acid      
d) 3rd and 4th generation cephalosporins          
e) Lincosamides and combnations between spectinomycin and lincosamides       
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Table AP1.2. Consumption of antimicrobial agents(a) for systemic use in cattle given as Animal Daily 
Doses (ADDs)(b), Denmark
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Year Cows and bulls (1000’s ADD600)
2005 186 1 58 490 71 65 112 2 19 0 0 22 1027
2006 193 1 57 498 64 61 116 2 9 0 0 22 1021
2007 235 1 68 610 79 73 91 2 2 0 0 28 1189
2008 257 1 80 702 85 75 65 1 1 0 0 34 1302
2009 279 2 84 804 73 73 53 1 2 0 0 36 1407
2010 269 1 79 835 70 73 38 0 2 0 0 42 1410
Calves (1000’s ADD100)
2005 574 61 193 170 33 162 562 19 127 39 2 142 2083
2006 534 67 145 180 30 141 879 13 108 7 1 136 2242
2007 561 96 131 183 37 154 881 16 92 8 1 131 2290
2008 528 129 105 168 30 133 804 13 77 11 0 113 2111
2009 556 150 102 173 22 166 768 9 95 10 0 117 2167
2010 615 180 123 166 20 193 475 12 100 15 0 120 2018
Heifers and steer (1000’s ADD300)
2005 18 0 5 27 3 3 8 1 0 0 0 2 67
2006 19 0 3 26 3 3 9 0 0 0 0 3 67
2007 24 1 6 33 4 3 10 2 0 0 0 4 86
2008 26 1 5 36 4 3 9 2 0 0 0 4 90
2009 26 1 5 37 3 3 6 1 0 0 0 5 88
2010 25 1 5 37 3 4 5 0 0 0 0 5 86
age group unknown  (1000’s ADD600)
2005 7 0 4 5 1 2 6 1 2 0 0 1 29
2006 21 1 13 14 2 4 31 6 5 1 0 2 99
2007 16 0 5 13 2 2 13 2 1 0 0 2 57
2008 2 0 1 3 1 0 2 0 0 0 0 0 10
2009 1 0 0 3 0 0 1 0 0 0 0 0 6
2010 1 0 0 4 0 1 1 0 0 0 0 0 7
a) Data includes sales from pharmacies and use for cattle in veterinary practice, including sales to the farmer. The consumption in           
calves is underestimated by up to 5% and consumption in cows is underestimated by up to 17% in individual years, because the use              
in cattle practice was underestimated by up to 20%. This error was decreasing with time (10% underestimation in  2010). Therefore, the 
numbers  not fully representatrends over years, but reflects the choice of drug in individual years.     
b)  Animal Standard weight is an assumed average weight at treatment, used to calculate numbe of ADD (Animal Daily Doses giving an 
estimated number of animals treated) from number of ADDkg (mass of animal treated, measured in kg animal bodyweight)   
c) Includes a small proportion (< 1‰) of combinations with aminopenicillin and clavulanic acid      
d) 3rd and 4th generation cephalosporins          
e) Lincomycin and lincomycin/spectinomycin combinations        
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Table AP1.3. Consumption of antimicrobial agents for systemic use in poultry given as Animal Daily 
Doses (ADDkg)(a), Denmark
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Broilers (1000’s ADDkg)
2001 0 36 2777 0 90 16 250 13 0 3181 192 0.03
2002 0 0 3352 0 69 0 680 0 0 4101 190 0.04
2003 0 70 3052 0 8 0 270 0 0 3399 181 0.03
2004 100 116 4617 8 43 44 650 75 46 5699 181 0.07
2005 0 32 3984 22 58 3 661 0 100 4860 180 0.05
2006 0 0 3356 6 40 0 620 0 6 4029 163 0.06
2007 0 0 1718 0 168 289 130 0 36 2341 178 0.03
2008 0 429 4086 0 83 133 20 0 80 4830 186 0.07
2009 0 5200 6988 439 75 560 20 60 80 13422 181 0.15
2010 0 5469 13543 1158 135 522 0 0 20 20846 187 0.14
Rearing for broiler production (1000’s ADDkg)
2001 0 0 1392 0 30 0 230 0 0 1652 -
Included 
in broiler 
production 
above
2002 0 88 2025 0 96 0 660 0 0 2869 -
2003 0 0 1361 0 0 0 80 0 0 1441 -
2004 0 0 6464 0 0 0 490 0 0 6954 -
2005 0 0 3348 0 0 0 400 0 0 3748 -
2006 0 0 6238 0 15 0 114 0 0 6367 -
2007 0 0 2659 0 43 22 190 0 0 2914 -
2008 0 400 6913 0 100 322 0 0 10 7745 -
2009 0 2067 7738 2851 80 289 440 0 290 13754 -
2010 0 2267 2825 719 44 33 0 0 0 5888
Layers and layer rearing (1000’s ADDkg)(d)
2001 0 19 434 0 196 16 50 13 0 727 69 0.01
2002 0 285 670 0 171 0 100 0 0 1226 70 0.02
2003 0 540 350 0 328 0 0 0 0 1218 69 0.02
2004 0 2 819 2 215 6 30 0 230 1303 72 0.02
2005 0 8 680 4 243 0 0 3 30 967 69 0.01
2006 0 28 376 0 140 11 0 0 0 555 67 0.01
2007 0 0 1150 0 96 0 0 0 150 1396 67 0.02
2008 0 12 2563 0 100 0 0 0 70 2745 68 0.04
2009 0 713 1475 0 15 2 0 0 488 2693 61 0.04
2010 0 133 1488 0 8 171 0 275 395 2469 62 0.04
Turkeys (1000’s ADDkg)
2001 0 0 10477 0 0 0 90 0 0 10567 13.2 0.80
2002 0 0 26829 0 0 0 0 0 0 26829 12.8 2.10
2003 0 0 10900 0 58 0 360 4568 0 15885 11.2 1.42
2004 200 0 4873 0 76 16 1560 0 0 6725 19.6 0.34
2005 150 60 8963 0 68 0 780 0 0 10020 17.4 0.58
2006 100 150 15193 0 45 0 1160 0 0 16648 11.3 1.47
2007 518 1654 6788 278 0 2547 2430 0 728 14941 14.4 1.04
2008 0 5767 1038 0 4 811 190 0 531 8340 12.3 0.68
2009 0 11771 4563 491 0 2538 0 0 536 19899 11.1 1.79
2010 0 6119 300 0 86 1922 0 0 253 8680 14.0 0.62
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Table AP1.3 (Continued). Consumption of antimicrobial agents for systemic use in poultry given as 
Animal Daily Doses (ADDkg)
(a), Denmark
Ducks and geese (1000’s ADDkg)
2001 0 2 0 0 1 11 50 3 0 67 4.5 0.01
2002 0 12 36 0 0 30 0 0 0 77 4.9 0.02
2003 0 8 257 0 0 0 0 0 0 265 4.2 0.06
2004 0 14 400 0 13 11 150 3 0 591 4.2 0.14
2005 0 0 525 0 0 14 0 3 0 542 4.1 0.13
2006 0 0 1125 0 0 0 0 0 0 1125 4.5 0.25
2007 0 0 100 0 0 0 0 0 2 102 2.4 0.04
2008 0 36 250 0 1 0 0 0 0 287 2.6 0.11
2009 0 24 0 0 10 200 0 0 0 234 2.2 0.11
2010 0 914 0 0 3 0 0 0 0 917 2.0 0.45
Game birds (1000’s ADDkg)
2001 0 77 768 0 205 146 85 5 84 1370 - -
2002 125 177 1466 0 346 289 10 10 94 2518 - -
2003 150 128 923 0 318 273 1 933 0 2725 - -
2004 250 148 1003 0 460 113 30 18 0 2022 - -
2005 160 98 1939 0 403 177 0 13 14 2803 - -
2006 110 86 1863 0 258 39 11 5 42 2413 - -
2007 2 126 1425 0 542 37 0 0 73 2203 - -
2008 110 80 1825 0 256 39 11 0 38 2360 - -
2009 0 270 901 18 664 46 10 0 172 2080 - -
2010 3 267 1083 0 1443 44 10 25 161 3036 - -
Production type unknown (e) (1000’s ADDkg)
2001 1 155 3814 0 441 306 475 10 18 5219 - -
2002 29 95 2909 0 315 272 93 5 0 3718 - -
2003 300 91 2370 0 348 186 391 5 0 3690 - -
2004 450 106 3654 0 440 90 131 3 4 4878 - -
2005 0 58 2978 0 192 3 121 5 46 3403 - -
2006 50 144 3059 0 182 4 110 0 0 3549 - -
2007 0 140 1321 72 518 118 34 8 58 2267 - -
2008 0 374 863 0 263 148 3 3 39 1692 - -
2009 2 794 486 0 182 22 11 5 56 1557 - -
2010 0 142 97 0 85 11 12 3 14 363 - -
a) ADDkg is the dose necessary for treating 1 kg body-weight        
b) Includes sulfaclozin (a coccidiostat/antibacterial) and sulfonamide/trimethoprim combinations     
c) Includes  QA07AA10 (colistin), QJ01FF (lincosamides, including combinations with spectinomycin), QJ01B (amphenicols) and 
QJ01R (penicillin/streptomycin combinations)          
d) For layers and layer rearing, only the production of eggs for consumption is included (not the slaughter/export of hens)  
e) Includes prescription with erraneous farm id or farms with more than one poultry species; for 2009–2010 this was mainly pigeons 
and game birds.             
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Table AP1.4. Consumption of antibacterial agents for systemic use in primary health care (No. 
packages/1000 inhabitants/year), Denmark
a) From the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system     
ATC 
group(a) Therapeutic group
Year
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
J01AA            Tetracyclines               22.4 21.7 21.6 22.5 23.8 23.9 24.5 25.0 25.9 27.2
J01CA            Penicillins with extended spectrum 110.9 111.8 111.5 115.3 119.9 119.7 131.3 130.0 130.2 140.2
J01CE            Beta-lactamase sensitive penicillins     251.0 254.4 254.5 253.7 251.1 243.3 253.0 235.9 223.2 228.2
J01CF            Beta-lactamase resistant penicillins     30.1 37.5 41.9 43.0 44.4 44.0 45.8 45.4 45.2 45.9
J01CR            Combinations of penicillins, including beta-lactamase inhibitors   1.2 1.7 2.0 2.5 3.0 4.0 5.8 8.0 12.3 18.0
J01D            Cephalosporins and related substances          1.3 1.4 1.3 1.4 1.6 1.7 1.8 2.1 2.1 2.1
J01EA            Trimethoprim and derivatives   8.2 8.8 9.3 10.2 10.6 10.7 11.5 12.4 10.9 11.3
J01EB            Short-acting sulfonamides       47.8 47.6 47.9 48.3 47.5 45.8 41.0 36.0 34.6 34.3
J01EE            Combinations of sulfonamides and trimethoprim, including derivatives 1.4 1.3 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
J01FA            Macrolides                  102.2 102.8 99.8 102.7 110.3 101.8 108.6 103.3 99.6 110.5
J01FF            Lincosamides                0.5 0.6 0.6 0.7 1.1 1.4 1.6 2.0 2.5 2.8
J01GB Aminoglycosides 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
J01MA        Fluoroquinolones            10.6 11.0 13.8 16.2 18.3 19.4 22.9 25.1 25.0 27.4
J01XA Glycopeptides 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.4
J01XB            Polymyxins                 2.1 2.0 2.0 2.1 2.0 1.5 0.8 0.8 0.9 0.9
J01XC            Steroid antibacterials (fusidic acid)     0.8 0.8 0.7 0.6 0.7 0.7 0.7 0.8 0.7 0.7
J01XE Nitrofuran derivatives (nitrofurantoin) 10.4 11.1 11.3 11.7 12.3 12.5 11.9 12.2 12.6 12.4
J01XX05 Methenamine 3.2 3.2 2.6 2.4 2.3 2.0 1.9 2.0 1.9 1.9
J01XX08 Linezolid 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
J01  Antibacterial agents for systemic use (total) 604.4 618.0 622.3 633.6 649.3 632.6 663.5 641.2 628.0 664.4
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Table AP1.5. Consumption of antibacterial agents for systemic use in primary health care (No. treated 
patients/1000 inhabitants/year), Denmark
a) From the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system     
b) Total no. of patients treated with an antibiotic is lower than the sum of all antibiotic classes. This is because the Danish Medicines 
Agency only counts the first treatment for each patient, each year               
    
ATC 
group(a) Therapeutic group
Year
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
J01AA            Tetracyclines               11.8 11.5 11.4 11.6 12.0 12.3 12.5 12.7 13.0 13.4
J01CA            Penicillins with extended spectrum 69.4 69.2 68.8 70.6 73.0 75.8 82.1 81.3 81.1 85.1
J01CE            Beta-lactamase sensitive penicillins   173.3 173.4 172.6 171.2 170.2 171.3 177.1 164.4 158.8 162.9
J01CF            Beta-lactamase resistant penicillins   19.2 23.9 26.4 27.1 27.8 29.4 29.7 29.9 29.9 30.0
J01CR            Combinations of penicillins, including beta-lactamase inhibitors  0.7 1.0 1.1 1.3 1.5 2.3 3.6 5.0 8.0 11.7
J01D                        Cephalosporins and related substances          0.4 0.4 0.4 0.5 0.5 0.5 0.5 0.5 0.5 0.5
J01EA            Trimethoprim and derivatives   4.2 4.5 4.6 5.0 5.4 5.6 5.9 5.9 5.8 6.0
J01EB            Short-acting sulfonamides       33.2 33.0 33.1 33.3 32.7 33.0 29.7 26.3 25.4 25.0
J01EE            Combinations of sulfonamides and trimethoprim, including derivatives 0.8 0.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0
J01FA            Macrolides                  67.7 66.9 64.1 65.9 70.7 67.0 71.4 66.9 64.5 72.7
J01FF            Lincosamides                0.2 0.3 0.3 0.4 0.4 0.5 0.6 0.8 1.0 1.3
J01GB Aminoglycosides 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
J01MA            Fluoroquinolones            7.5 7.7 8.9 10.8 12.2 13.1 15.2 17.1 16.9 18.5
J01XA Glycopeptides 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
J01XB            Polymyxins                 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
J01XC            Steroid antibacterials (fusidic acid)     0.5 0.4 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.3
J01XE Nitrofuran derivatives (nitrofurantoin) 5.7 6.1 6.2 6.4 6.7 7.0 6.5 6.8 7.0 6.9
J01XX05 Methenamine 0.5 0.6 0.5 0.5 0.5 0.4 0.4 0.4 0.4 0.4
J01XX08 Linezolid - 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
J01(b) Antibacterial agents for systemic use (total) 300.6 301.5 301.4 302.6 308.0 310.3 320.4 308.2 303.1 315.5
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DANMAP 2010
ATC 
group(a) Therapeutic group Indicator
Year
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
J01AA Tetracyclines               
DDDs / patient 30.6 33.0 34.4 36.9 39.0 40.9 43.0 44.4 45.2 45.9
DDDs / package 16.1 17.5 18.1 19.0 19.6 21.0 22.0 22.7 22.7 22.7
Packages / patient 1.9 1.9 1.9 1.9 2.0 1.9 2.0 2.0 2.0 2.0
J01CA Penicillins with extended spectrum
DDDs / patient 13.0 13.2 13.4 13.6 13.9 14.2 14.4 14.7 14.8 14.9
DDDs / package 8.1 8.2 8.2 8.4 8.5 8.9 9.0 9.2 9.2 9.0
Packages / patient 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6
J01CE Beta-lactamase sensitive penicillins     
DDDs / patient 10.3 10.5 10.7 11.1 11.3 11.5 11.7 11.8 11.8 11.8
DDDs / package 7.1 7.2 7.3 7.5 7.7 8.0 8.2 8.2 8.4 8.4
Packages / patient 1.4 1.5 1.5 1.5 1.5 1.4 1.4 1.4 1.4 1.4
J01CF Beta-lactamase resistant penicillins     
DDDs / patient 12.4 11.8 11.8 12.4 12.7 13.0 13.4 13.7 13.9 14.2
DDDs / package 7.9 7.5 7.4 7.8 8.0 8.6 8.7 9.0 9.1 9.3
Packages / patient 1.6 1.6 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.5
J01CR Combinations of penicillins,incl. beta-lactamase inhibitors   
DDDs / patient 15.9 14.7 16.6 17.2 16.8 19.3 19.1 19.9 20.4 21.1
DDDs / package 9.1 8.6 9.1 9.1 9.3 10.7 11.7 12.4 13.3 13.7
Packages / patient 1.7 1.7 1.8 2.0 2.0 1.8 1.6 1.6 1.5 1.5
J01D Cephalosporins and related substances          
DDDs / patient 25.5 24.9 18.3 18.6 21.7 20.7 21.9 23.8 22.7 24.7
DDDs / package 8.4 7.8 5.6 6.1 6.2 5.8 6.1 5.8 5.7 5.8
Packages / patient 3.0 3.2 3.3 3.0 3.5 3.5 3.6 4.1 4.0 4.3
J01EA Trimethoprim and derivatives   
DDDs / patient 30.4 29.3 30.0 29.9 30.2 30.6 30.5 30.2 30.7 30.7
DDDs / package 15.6 14.9 14.9 14.8 15.3 15.9 15.7 14.5 16.1 16.4
Packages / patient 2.0 2.0 2.0 2.0 2.0 1.9 1.9 2.1 1.9 1.9
J01EB Short-acting sulfonamides       
DDDs / patient 4.0 4.0 4.0 3.9 3.9 3.9 3.9 3.8 3.8 3.8
DDDs / package 2.7 2.7 2.7 2.7 2.7 2.8 2.8 2.8 2.8 2.8
Packages / patient 1.4 1.4 1.4 1.5 1.5 1.4 1.4 1.4 1.4 1.4
J01EE
Combinations of sulfonamides 
and trimethoprim. incl. 
derivatives 
DDDs / patient 19.4 15.6 18.3 - - - - - - -
DDDs / package 10.4 8.4 11 - - - - - - -
Packages / patient 1.9 1.9 1.67 - - - - - - -
J01FA Macrolides                  
DDDs / patient 11.3 11.7 12.1 12.4 12.4 12.6 12.4 12.5 12.5 12.2
DDDs / package 7.5 7.6 7.8 7.9 8.0 8.3 8.1 8.1 8.1 8.1
Packages / patient 1.5 1.5 1.6 1.6 1.6 1.5 1.5 1.5 1.5 1.5
J01FF Lincosamides                
DDDs / patient 15.2 11.1 11.1 13.9 13.4 13.8 13.3 12.8 12.6 11.4
DDDs / package 7.3 6.1 6.1 7.6 4.9 4.8 4.9 5.0 5.0 5.2
Packages / patient 2.1 1.8 1.8 1.8 2.8 2.9 2.7 2.5 2.5 2.2
J01GB Aminoglycosides
DDDs / patient 121.7 121.7 156.5 172.2 135.6 128.0 152.7 157.6 151.5
DDDs / package 18.3 36.5 47.0 51.7 27.1 26.0 32.2 37.8 43.4
Packages / patient 6.7 3.3 3.3 3.3 5.0 4.9 4.9 4.2 3.5
J01MA Fluoroquinolones            
DDDs / patient 8.3 8.6 10.3 9.5 9.6 10.3 10.6 11.0 11.2 11.2
DDDs / package 5.9 6.0 6.6 6.4 6.5 6.9 7.0 7.5 7.6 7.6
Packages / patient 1.4 1.4 1.6 1.5 1.5 1.5 1.5 1.5 1.5 1.5
J01XB Polymyxins                 
DDDs / patient 183 243.3 243.3 192.3 196.7 205.6 219.3 202.8 202.8 199.4
DDDs / package 3.5 3.7 3.7 3.7 3.9 5.5 10.0 10.0 10.0 10.0
Packages / patient 52.5 66.7 66.7 52.5 50.0 37.5 21.9 20.3 20.3 19.9
J01XC Steroid antibacterials (fusidic acid)     
DDDs / patient 7.6 8.7 11.1 14.4 16.0 15.1 17.1 18.5 18.7 18.8
DDDs / package 4.6 4.6 5.2 7.2 7.6 7.6 8.0 7.3 6.8 7.7
Packages / patient 1.7 1.9 2.1 2.0 2.1 2.0 2.1 2.5 2.8 2.4
J01XE Nitrofuran derivatives (nitrofurantoin)
DDDs / patient 24.8 24.5 24.8 24.3 24.3 24.1 26.3 25.4 25.4 26.8
DDDs / package 13.7 13.5 13.6 13.3 13.3 13.5 14.4 14.2 14.1 15.0
Packages / patient 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8
J01XX05 Methenamine
DDDs / patient 227.3 225.6 220.4 221.6 222.9 233.1 237.5 239.9 227.2 234.1
DDDs / package 37.6 38.8 44.9 45.2 44.6 49.0 50.1 50.0 50.0 50.0
Packages / patient 6.0 5.8 4.9 4.9 5 4.8 4.7 4.8 4.5 4.7
J01 Antibacterial agents for systemic use (total)
DDDs / patient 15.6 16.0 16.4 17.0 17.5 17.9 17.3 18.9 19.2 19.6
DDDs / package 7.8 7.8 7.9 8.1 8.3 8.7 8.9 9.1 9.3 9.3
Packages / patient 2.0 2.0 2.1 2.1 2.1 2.0 1.9 2.1 2.1 2.1
a) From the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system
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Source: The National Board of Health (www.sst.dk)      
a) Excluding private hospitals, psychiatric hospitals, specialized clinics, rehabilitation centres and hospices    
b) Compared to the previous year no. bed-days have decreased by 3.4% and no. admissions have increased by 4.0%   
   
Region No. bed-days somatic hospitals(a) No. admissions somatic hospitals(a)
The Capital Region of Denmark 1514665 450077
The Sealand Region 591364 210413
Region of Southern Denmark 839553 258316
Central Denmark Region 869636 278195
North Denmark Region 454664 117661
Denmark(b) 4269882 1314662
DANMAP 2010
Table AP1.8. Consumption of antibacterial agents for systemic use in hospital care (DDD/1000 inhabitant-
days), Denmark
a) From the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system     
ATC 
group(a) Therapeutic group
Year
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
J01AA            Tetracyclines               0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.03 0.03
J01CA            Penicillins with extended spectrum 0.34 0.33 0.33 0.32 0.35 0.35 0.35 0.35 0.35 0.32
J01CE            Beta-lactamase sensitive penicillins     0.32 0.33 0.34 0.33 0.33 0.29 0.28 0.25 0.23 0.21
J01CF            Beta-lactamase resistant penicillins     0.18 0.18 0.18 0.19 0.18 0.18 0.18 0.17 0.17 0.17
J01CR            Combinations of penicillins, incl. beta-lactamase inhibitors  0.01 0.01 0.01 0.02 0.03 0.05 0.08 0.10 0.13 0.15
J01DB            First-generation cephalosporins 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01DC            Second-generation cephalosporins 0.15 0.17 0.17 0.19 0.22 0.23 0.31 0.33 0.37 0.35
J01DD           Third-generation cephalosporins 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.03 0.03
J01DF            Monobactams 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01DH            Carbapenems 0.01 0.02 0.02 0.02 0.03 0.03 0.05 0.07 0.07 0.08
J01EA            Trimethoprim and derivatives  0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
J01EB            Short-acting sulfonamides       0.04 0.04 0.03 0.03 0.03 0.02 0.01 0.01 0.01 0.01
J01EE            
Combinations of 
sulfonamides and 
trimethoprim, incl. derivatives 
0.04 0.04 0.04 0.05 0.05 0.05 0.04 0.05 0.05 0.06
J01FA            Macrolides                  0.10 0.09 0.09 0.08 0.08 0.08 0.08 0.08 0.08 0.08
J01FF            Lincosamides                0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
J01GB Aminoglycosides 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.04 0.04 0.04
J01MA        Fluoroquinolones            0.08 0.10 0.11 0.13 0.16 0.18 0.21 0.24 0.24 0.22
J01XA Glycopeptides 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02
J01XB            Polymyxins                 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01XC            Steroid antibacterials (fusidic acid)     0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
J01XD            Imidazol derivatives 0.06 0.06 0.06 0.07 0.07 0.07 0.07 0.06 0.05 0.08
J01XE Nitrofuran derivatives (nitrofurantoin) 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
J01XX Other antibacterials 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01
J01 Antibacterial agents for systemic use (total) 1.45 1.51 1.51 1.56 1.67 1.70 1.81 1.87 1.91 1.91
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Table AP1.13. Distribution of MICs and resistance (%) in Campylobacter coli from pigs (n=103), Denmark
Vertical solid lines indicate EUCAST epidemiological cut-off values. EUCAST/CLSI clinical breakpoints indicated as vertical dotted 
lines if different from the corresponding epidemiological cut-off values. See table AP2.2 for further details    
White fields represent the range of dilutions tested. MIC values equal to or lower than the lowest concentration tested are presented as 
the lowest concentration. MIC values greater than the highest concentration in the range are presented as one dilution step above the 
range              
Antimicrobial 
agent
%
 Resistant
95% 
Confidence 
interval
Distribution (%) of MICs
0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 >128
Tetracycline 11.7 [6.2-19.5] 52.4 24.3 9.7 1.9 2.9 1.0 1.0 6.8
Chloramphenicol 0 [0-3.5] 20.4 59.2 18.4 1.9
Erythromycin 15.5 [9.1-24.0] 23.3 24.3 26.2 10.7 15.5
Streptomycin 63.1 [53.0-72.4] 28.2 8.7 3.9 59.2
Gentamicin 0 [0-3.5] 9.7 58.3 32.0
Ciprofloxacin 7.8 [3.4-14.7] 28.2 43.7 20.4 7.8
Nalidixic acid 7.8 [3.4-14.7] 7.8 35.9 33.0 15.5 1.9 5.8
DANMAP 2010
Table AP1.14. Distribution of MICs and resistance (%) in Campylobacter jejuni from broilers (n=41) and 
cattle (n=98), Denmark
Vertical solid lines indicate EUCAST epidemiological cut-off values. EUCAST/CLSI clinical breakpoints indicated as vertical dotted 
lines if different from the corresponding epidemiological cut-off values. See table AP2.2 for further details    
White fields represent the range of dilutions tested. MIC values equal to or lower than the lowest concentration tested are presented as 
the lowest concentration. MIC values greater than the highest concentration in the range are presented as one dilution step above the 
range              
     
Antimicrobial 
agent
Animal 
species
% 
Resistant
95% 
Confidence 
interval
Distribution (%) of MICs
0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 >128
Tetracycline Broilers 17.1 [7.2-32.1] 61.0 17.1 4.9 2.4 14.6
Cattle 6.1 [2.3-12.9] 59.2 32.7 1.0 1.0 6.1
Chloramphenicol Broilers 0 [0-8.6] 58.5 36.6 4.9
Cattle 0 [0-3.7] 76.5 22.4 1.0
Erythromycin Broilers 0 [0-8.6] 46.3 26.8 19.5 7.3
Cattle 0 [0-3.7] 33.7 48.0 17.3 1.0
Streptomycin Broilers 2.4 [0.06-12.9] 97.6 2.4
Cattle 1.0 [0.03-5.6] 98.0 1.0 1.0
Gentamicin Broilers 0 [0-8.6] 46.3 46.3 4.9 2.4
Cattle 0 [0-3.7] 42.9 48.0 9.2
Ciprofloxacin Broilers 19.5 [8.8-34.9] 12.2 46.3 19.5 2.4 19.5
Cattle 20.4 [12.9-29.7] 10.2 59.2 9.2 1.0 20.4
Nalidixic acid Broilers 17.1 [7.2-32.1] 7.3 53.7 17.1 4.9 17.1
Cattle 20.4 [12.9-29.7] 5.1 59.2 13.3 2.0 20.4
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Table AP1.15. Distribution of MICs and resistance (%) in Campylobacter coli from broiler meat (Danish n=20; 
imported n=27), Denmark
Vertical solid lines indicate EUCAST epidemiological cut-off values. EUCAST/CLSI clinical breakpoints indicated as vertical dotted lines 
if different from the corresponding epidemiological cut-off values. See table AP2.2 for further details    
White fields represent the range of dilutions tested. MIC values equal to or lower than the lowest concentration tested are presented as the 
lowest concentration. MIC values greater than the highest concentration in the range are presented as one dilution step above the range 
              
   
Antimicrobial 
agent Origin
% 
Resistant
95%  
Confidence 
interval
Distribution (%) of MICs
0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 >64
Tetracycline Danish 35.0 [15.4-59.2] 45.0 15.0 5.0 35.0
Imported 81.5 [61.9-93.7] 14.8 3.7 81.5
Chloramphenicol Danish 0 [0-16.8] 45.0 40.0 15.0
Imported 0 [0-12.8] 14.8 59.3 22.2 3.7
Erythromycin Danish 0 [0-16.8] 40.0 50.0 10.0
Imported 14.8 [4.2-33.7] 25.9 18.5 29.6 11.1 14.8
Streptomycin Danish 20.0 [5.7-43.7] 70.0 10.0 20.0
Imported 0 [0-12.8] 85.2 14.8
Gentamicin Danish 0 [0-16.8] 50.0 35.0 15.0
Imported 0 [0-12.8] 18.5 51.9 29.6
Ciprofloxacin Danish 0 [0-16.8] 5.0 60.0 25.0 10.0
Imported 85.2 [66.3-95.8] 7.4 7.4 85.2
Nalidixic acid Danish 0 [0-16.8] 10.0 70.0 15.0 5.0
Imported 85.2 [66.3-95.8] 7.4 7.4 85.2
DANMAP 2010
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Table AP1.16. Distribution of MICs and resistance (%) in Campylobacter jejuni from broiler meat (Danish n=52; 
imported n=68), Denmark
Vertical solid lines indicate EUCAST epidemiological cut-off values. EUCAST/CLSI clinical breakpoints indicated as vertical dotted lines 
if different from the corresponding epidemiological cut-off values. See table AP2.2 for further details    
White fields represent the range of dilutions tested. MIC values equal to or lower than the lowest concentration tested are presented as the 
lowest concentration. MIC values greater than the highest concentration in the range are presented as one dilution step above the range  
               
Antimicrobial 
agent Origin
% 
Resistant
95%         
Confidence 
interval
Distribution (%) of MICs
0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 >64
Tetracycline Danish 11.5 [4.4-23.4] 59.6 23.1 1.9 3.8 11.5
Imported 41.2 [29.4-53.8] 29.4 26.5 1.5 1.5 41.2
Chloramphenicol Danish 0 [0-6.8] 73.1 21.2 5.8
Imported 0 [0-5.3] 41.2 38.2 11.8 8.8
Erythromycin Danish 1.9 [0.05-10.3] 34.6 34.6 25.0 3.8 1.9
Imported 4.4 [0.9-12.4] 17.6 52.9 17.6 7.4 4.4
Streptomycin Danish 1.9 [0.05-10.3] 98.1 1.9
Imported 0 [0-5.3] 94.1 5.9
Gentamicin Danish 0 [0-6.8] 48.1 50.0 1.9
Imported 0 [0-5.3] 33.8 52.9 13.2
Ciprofloxacin Danish 17.3 [8.2-30.3] 3.8 63.5 11.5 1.9 1.9 1.9 15.4
Imported 50.0 [37.6-62.4] 7.4 22.1 13.2 4.4 2.9 50.0
Nalidixic acid Danish 13.5 [5.6-25.8] 13.5 57.7 13.5 1.9 1.9 11.5
Imported 50.0 [37.6-62.4] 4.4 33.8 5.9 5.9 50.0
                                                                           
       127DANMAP 2010  
APPENDIX 1.
D
A
N
M
A
P 
2
0
1
0
Ta
bl
e 
A
P
1
.1
7.
 D
is
tr
ib
ut
io
n 
of
 M
IC
s 
an
d 
re
si
st
an
ce
 (
%
) 
in
 C
am
py
lo
ba
ct
er
 je
ju
ni
 f
ro
m
 h
um
an
 c
as
es
 r
ep
or
te
d 
as
 
do
m
es
ti
c 
sp
or
ad
ic
 (
n=
5
2
),
 a
ss
os
ia
te
d 
w
it
h 
tr
av
el
 a
br
oa
d 
(n
=
4
6
) 
an
d 
of
 u
nk
no
w
n 
or
ig
in
 (
n=
4
3
),
 D
en
m
ar
k
Ve
rt
ic
al
 so
lid
 li
ne
s i
nd
ic
at
e E
U
CA
ST
 ep
id
em
io
lo
gi
ca
l c
ut
-o
ff 
va
lu
es
. E
U
CA
ST
/C
LS
I c
lin
ic
al
 b
re
ak
po
in
ts 
in
di
ca
te
d 
as
 v
er
tic
al
 d
ot
te
d 
lin
es
 if
 d
iff
er
en
t f
ro
m
 th
e 
co
rr
es
po
nd
in
g 
ep
id
em
io
lo
gi
ca
l c
ut
-o
ff 
va
lu
es
. S
ee
 ta
bl
e A
P2
.2
 fo
r f
ur
th
er
 d
et
ai
ls 
 
 
 
W
hi
te
 fi
eld
s r
ep
re
se
nt
 th
e r
an
ge
 o
f d
ilu
tio
ns
 te
ste
d.
 M
IC
 v
al
ue
s e
qu
al
 to
 o
r l
ow
er
 th
an
 th
e l
ow
es
t c
on
ce
nt
ra
tio
n 
te
ste
d 
ar
e p
re
se
nt
ed
 as
 th
e l
ow
es
t c
on
ce
nt
ra
tio
n.
 M
IC
 
va
lu
es
 g
re
at
er
 th
an
 th
e h
ig
he
st 
co
nc
en
tr
at
io
n 
in
 th
e r
an
ge
 ar
e p
re
se
nt
ed
 as
 o
ne
 d
ilu
tio
n 
ste
p 
ab
ov
e t
he
 ra
ng
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
nt
im
ic
ro
bi
al
 
ag
en
t
O
rig
in
%
 
Re
sis
ta
nt
95
%
 
C
on
fid
en
ce
 
in
te
rv
al
D
ist
rib
ut
io
n 
(%
) o
f M
IC
s
0.
06
0.
12
5
0.
25
0.
5
1
2
4
8
16
32
64
12
8
>1
28
Te
tr
ac
yc
lin
e
D
om
es
tic
al
ly
 ac
qu
ire
d
13
.5
[5
.6
-2
5.
8]
69
.2
15
.4
1.
9
13
.5
Tr
av
el 
ab
ro
ad
 re
po
rt
ed
56
.5
[4
1.
1-
71
.1
]
26
.1
13
.0
2.
2
2.
2
56
.5
U
nk
no
w
n 
or
ig
in
20
.9
[1
0.
0-
36
.0
]
46
.5
23
.3
9.
3
20
.9
Ch
lo
ra
m
ph
en
ic
ol
D
om
es
tic
al
ly
 ac
qu
ire
d
0
[0
-6
.8
]
73
.1
26
.9
Tr
av
el 
ab
ro
ad
 re
po
rt
ed
0
[0
-7
.7
]
45
.7
30
.4
21
.7
2.
2
U
nk
no
w
n 
or
ig
in
0
[0
-8
.2
]
67
.4
25
.6
7.
0
Er
yt
hr
om
yc
in
D
om
es
tic
al
ly
 ac
qu
ire
d
0
[0
-6
.8
]
44
.2
48
.1
7.
7
Tr
av
el 
ab
ro
ad
 re
po
rt
ed
0
[0
-7
.7
]
43
.5
43
.5
10
.9
2.
2
U
nk
no
w
n 
or
ig
in
0
[0
-8
.2
]
41
.9
46
.5
7.
0
4.
7
St
re
pt
om
yc
in
D
om
es
tic
al
ly
 ac
qu
ire
d
1.
9
[0
.0
5-
10
.3
]
98
.1
1.
9
Tr
av
el 
ab
ro
ad
 re
po
rt
ed
2.
2
[0
.0
6-
11
.5
]
95
.7
2.
2
2.
2
U
nk
no
w
n 
or
ig
in
2.
3
[0
.0
6-
12
.3
]
95
.3
2.
3
2.
3
G
en
ta
m
ic
in
D
om
es
tic
al
ly
 ac
qu
ire
d
0
[0
-6
.8
]
69
.2
28
.8
1.
9
Tr
av
el 
ab
ro
ad
 re
po
rt
ed
0
[0
-7
.7
]
63
.0
34
.8
2.
2
U
nk
no
w
n 
or
ig
in
2.
3
[0
.0
6-
12
.3
]
46
.5
48
.8
2.
3
2.
3
Ci
pr
ofl
ox
ac
in
D
om
es
tic
al
ly
 ac
qu
ire
d
25
.0
[1
4.
0-
38
.9
]
19
.2
48
.1
5.
8
1.
9
1.
9
23
.1
Tr
av
el 
ab
ro
ad
 re
po
rt
ed
80
.4
[6
6.
1-
90
.6
]
6.
5
10
.9
2.
2
80
.4
U
nk
no
w
n 
or
ig
in
41
.9
[2
7.
0-
57
.9
]
9.
3
32
.6
11
.6
2.
3
2.
3
2.
3
39
.5
128                   
                   
DANMAP 2010  
APPENDIX1.
0
10
20
30
40
50
60
70
80
0
20
40
60
80
100
94 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10
To
nn
es
 a
ct
ive
 s
ub
st
an
ce
%
 re
si
st
an
t I
so
la
te
s
Macrolides for pigs Pigs - E. Faecium Pigs - E. Faecalis
DANMAP 2010
Figure AP1.3. Resistance (%) to erythromycin among Enterococcus faecium and Enteroccus faecalis from 
pigs and the the consumption of macrolides in pigs, Denmark
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Figure AP1.4. Resistance (%) to streptogramins in Enterococcus faecium from broilers and the 
consumption of virginiamycin, Denmark
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Figure AP1.2. Resistance (%) to tetracycline among Enterococcus faecium and Enteroccus faecalis from 
pigs and the consumption of tetracyclines in pigs, Denmark
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Figure AP1.5. Resistance (%) to avoparcin in Enterococcus faecium and Enterococcus faecalis from 
broilers and the consumption of avoparcin, Denmark
DANMAP 2010
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Figure AP1.6. Resistance (%) to streptogramins in Enterococcus faecium from pigs and the comsumption of 
virginiamycin, Denmark
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Figure AP1.7. Resistance (%) to avoparcin in Enterococcus faecium and Enterococcus faecalis from pigs 
and the consumption of avoparcin, Denmark
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List of abbreviations
ACD  Defined Animal Course Dose
ADD  Defined Animal Daily Dose
ADDkg  Defined Animal Daily Dose per kg animalAGP  Antimicrobial Growth Promoter
ATC  Anatomical Therapeutic Chemical Classification System
CHR  Central Husbandry Register
CI  Confidence Interval
CNS  Central Nervous System
CPR  Danish Civil Registry
DAD  Defined Daily Doses per 100 admissions
DBD  Defined Daily Doses per 100 occupied bed-days
DCM  Department of Clinical Microbiology
DID  Defined Daily Doses per 1,000 inhabitants per day
DDD  Defined Daily Dose
DMA  Danish Medicines Agency
DTU  Technical University of Denmark
DVFA  Danish Veterinary and Food Administration
EARS-Net  The European Antimicrobial Resistance Surveillance Network
ESBL  Extended Spectrum Beta-Lactamase 
GI  Gastrointestinal 
GP  General Practitioner
HLGR  High-level gentamicin resistance
MIC  Minimum Inhibitory Concentration
MRSA  Methicillin-resistant Staphylococcus aureus
N  Number of samples
n  Number of isolates tested for antimicrobial susceptibility
OIE  World Organisation for Animal Health 
PMWS  Postweaning multisystemic wasting syndrome
RFCA  Regional Veterinary and Food Control Authorities
SSI  Statens Serum Institut
VetStat  Danish Register of Veterinary Medicines
VRE  Vancomycin Resistant Enterococci
WHO  World Health Organization
WT  Wild type
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List of words
Anatomical Therapeutic Chemical (ATC) classification.  International classification system for drug 
consumption studies. The ATC code identifies the therapeutic ingredient(s) of each drug for human use 
according to the organ or system on which it acts and its chemical, pharmacological and therapeutic 
properties. Antibacterials for systemic use are known as ATC group J01. The ATC classification is 
maintained by the WHO Collaborating Centre for Drug Statistics and Methodology (Oslo, Norway) (http://
www.whocc.no/atcddd/indexdatabase/). The ATC classification for veterinary medicinal products, ATCvet, 
is based on the same main principles as the ATC classification system for medicines for human use and 
is also maintained by the WHO Collaborating Centre for Drug Statistics and Methodology (http://www.
whocc.no/atcvet/database/).
Antibacterial agents. Synthetic (chemotherapeutics) or natural (antibiotics) substances that destroy 
bacteria or suppress bacterial growth or reproduction [Source: Dorland’s Illustrated Medical Dictionary]. 
Antimycobacterial agents are not included. Only antibacterial agents for systemic use are included (J01 in 
the ATC system) in the section on human consumption.    
Antimicrobial agents. The term ‘antimicrobial agents’ covers antibacterial, antiviral, coccidiostatic and 
antimycotic agents. In the section on veterinary consumption, the broad term ‘antimicrobial agents’ is 
usually used because coccidiostats are included. Antiviral substances are not used in veterinary medicine, 
and antimycotics are only registered for topical veterinary use and used mainly in companion animals. 
Antimycobacterial agents are not included. The term ’antibacterial agents’ is only used in the veterinary 
section for precision, to distinguish from use of coccidiostats as feed additives (poultry only). 
Broiler. A type of chicken raised specifically for meat production. In Denmark, the average weight after 
slaughter is 1.66 kg.
Central Husbandry Register (CHR). This is a register of all Danish farms defined as geographical sites 
housing production animals. It contains numerous information concerning ownership, farm size, animal 
species, age groups, number of animals and production type. Each farm has a unique farm identity number 
(CHR-number).
Defined Daily Dose (DDD). This is the assumed average maintenance dose per day in adults. It should 
be emphasised that the Defined Daily Dose is a unit of measurement and does not necessarily reflect the 
recommended or prescribed daily dose. DDDs provide a fixed unit of measurement independent of price 
and formulation, enabling the assessment of trends in drug consumption and to perform comparisons 
between population groups. The DDDs are defined and revised yearly by the WHO Collaborating Centre for 
Drug Statistics and Methodology (http://www.whocc.no/atcddd/indexdatabase/). DDD/1,000 inhabitant-
days is called DID.
Defined Animal Daily Dose (ADD and ADDkg). This is a national veterinary equivalent to the DDD. 
This is an assumed average daily dose per animal, defined as the daily maintenance dose for a drug used 
for its main indication in a specified species. The dose is defined for a ”standard animal”, i.e. an animal with 
an estimated average weight within a specified age group. In VetStat, ADDs are calculated for each age 
group. Otherwise, the general principles for standardisation of dosage for animals are similar to that used 
by the WHO Collaborating Centre for Drug Statistics and Methodology to calculate Defined Daily Dose 
(DDD) in humans [Jensen et al. 2004. Prev Vet Med. 64: 201-215]. The ADDkg is the ADD per kg animal. 
Consumption calculated in ADDkg allows summation of consumption across different age groups and 
animal species.
Defined Animal Course Dose (ACD and ACDkg). The duration of the treatment related to one application 
may vary substantially between antimicrobial drugs. To correct for this, total course dose has been 
introduced as unit of measurement for antimicrobial usage. As a standard, the length of the course is here 
defined as 6 days, if nothing else is stated. Course doses are assigned per kilogram (live weight) of the 
animal species (ACDkg) or age group of the relevant species (ADCxx) and are based on the corresponding 
ADDkg or ADDxx, respectively, for the relevant animal species and drug formulations. 
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ESBL. In this DANMAP report ‘ESBL’ describes the clinically important acquired beta-lactamases with 
activity against extended-spectrum cephalosporins; including the classical class A ESBLs (CTX-M, SHV, 
TEM), the plasmid-mediated AmpC and OXA-ESBLs [Giske et al. 2009. J Antimicrob Chemother. 63: 1-4]. 
Finishers. Pigs from 30 kilogram live weight to time of slaughter at app. 100 kilogram live weight.
Fully sensitive. See definition of multi-resistance. 
Heifer. A young female cow before first calving. 
Intramammaria. Antimicrobial agents for local application in the mammary gland (udder) to treat mastitis.
Intramammary syringe. A one dose applicator for use in the udder.
Layer. A hen raised to produce eggs for consumption.
Minimum Inhibitory Concentration (MIC). This is the lowest concentration of antimicrobial agent in a 
given culture medium, e.g. broth or agar, below which growth of the bacteria is not inhibited.
Multi-resistant. A Salmonella or E. coli isolate is assumed multi-resistant if resistant to three or more of 
the following ten antimicrobial groups: Tetracyclines (tetracycline), phenicoles (chloramphenicol and/
or florfenicol), penicillins (ampicillin), cephalosporins (ceftiofur and/or cefotaxime), sulfonamides 
(sulfonamide), trimethoprim (trimethoprim), aminoglycosides - except streptomycin (gentamicin), 
streptomycin (streptomycin), quinolones (ciprofloxacin and/or nalidixic acid) and polymycins (colistin). An 
isolate will be referred to as fully sensitive if susceptible to all the above listed antimicrobial groups.
Pet animals. Dogs, cats, birds, mice, guinea pigs and more exotic species kept at home for pleasure, rather 
than one kept for work or food; does not include horses.
Piglet. The newborn pig is called at piglet from birth till they are permanently separated from the sow at 3-4 
weeks of age. The weight of the piglet at weaning is approximately 7 kilogram. 
Poultry. The major production species are fowl - Gallus gallus (broilers, layers, including breeding and 
rearing) and turkey.  Regarding antimicrobial consumption, ‘poultry’ also includes domesticated ducks, 
geese, game birds and pigeons. In DANMAP 2010, the poultry isolates originated from Gallus gallus and 
broiler meat, and a minor part originated from imported turkey meat. 
 
Significant. When written in the text, significant differences imply statistically significant differences where 
p<0.05 using Chi-square or Fisher’s Exact Test when the number of samples is low (<25).  
Sow. Any breeding female pig that has been served and is on the farm.
Steer. Castrated male cattle, usually young animal.
Weaner. Any pig, 7–30 kilogram live weight. 
Wild type. The typical form of an organism, strain, gene, or characteristic as it occurs in nature. 
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Materials and methods
1. General information
For the 2010 DANMAP report, the population and 
geographical data were obtained from Statistics 
Denmark (www.dst.dk) and the data on general 
practitioners from the Danish Medical Association 
(www.laeger.dk). 
In this report, the epidemiological unit for pigs, 
cattle and broilers was defined as the individual farm, 
meaning that only one isolate per bacterial species 
per farm was included in the report. For humans, the 
epidemiological unit was defined as the individual 
patient and the first isolate per patient per year was 
included. For food, the epidemiological unit was 
defined as the individual meat sample. 
2. Data on antimicrobial consumption
Antimicrobial agents used for humans and animals in 
Denmark are presented in Table 3.2.
2.1. Antimicrobial consumption in animals
Since 2001, consumption data presented in this report 
were obtained from the national monitoring program, 
VetStat. Prior to 2001, data were based on overall 
sales figures from the pharmaceutical industry (Table 
AP1.0). 
In Denmark, all therapeutic drugs are prescription-
only and VetStat collects data on all medicines 
prescribed by veterinarians for use in animals. In 
addition, data on consumption of coccidiostatics as 
feed additives (non-prescription) and antimicrobial 
growth promoters (no longer in use) are collected by 
VetStat. Data on coccidiostatics were reported until 
2004, but due to problems in data transfer data were 
not reported in 2005 and 2006. Data on coccidiostatics 
for 2007–2010 will be presented in later reports 
following validation of data. 
Until 2007, antimicrobial agents could only be 
purchased at the pharmacy or in medicated feed from 
the feed mills. In 2010, sales from feed mills comprised 
almost entirely prescriptions for aquaculture and 
sales of zinc chloride for the pig production. The 
pharmacy either sells the medicines to veterinarians 
for own use in practice or for re-sale to farmers, or 
sells the medicines directly to the animal holder on 
presentation of a prescription. By law, the profit that 
veterinarians may make on the sale of medicine is very 
small (5%), thereby limiting the economic incentive 
to sell medicine. Hence, in 2010, only 10% of the 
antimicrobial agents used for animals were used or 
distributed by veterinarians.
From April 2007, the monopoly was suspended and 
private companies (two in 2010) can now, on certain 
conditions (identical to the pharmacies), sell prescribed 
veterinary medical products for production animals. In 
addition, price setting was liberalised, which allowed for 
discounts corresponding to lower administration cost 
related to sale of large quantities to the veterinarians. In 
2010, the animal owners and veterinarians purchased 
the antimicrobial agents equally from the pharmacies 
(49%) and the veterinary drug trading companies 
(49%), while only 2.4% was purchased from the feed 
mills. 
Data on all sales of veterinary prescription medicine 
from the pharmacies, private companies, feed mills 
and veterinarians are sent electronically to VetStat. 
Veterinarians are required by law to report to VetStat 
the use of all prescription medicines in production 
animals on a monthly basis. For most veterinarians, the 
registration of data is linked to the writing of invoices. 
For the DANMAP report the amount of drugs reported 
by the veterinary practitioners is validated against 
pharmacy data on the total sales of therapeutic drugs 
for use in practice. The electronic registration of the 
sales at the pharmacies is linked to the billing process, 
which ensures a high data quality regarding amounts 
and identity of drugs.
The VetStat database contains detailed information 
about source and consumption for each prescription 
item: date of sale, identity of prescribing veterinarian, 
source ID (identity of the pharmacy, feed mill, or 
veterinarian reporting), package identity code and 
amount, animal species, age-group, disease category 
and code for farm-identity (CHR - Danish Central 
Husbandry Register). The package code is a unique 
identifier, relating to all information on the medicine, 
such as active ingredient, content as number of unit 
doses (e.g. number of tablets), package size, and code 
of the antimicrobial agent in the Veterinary Anatomical 
Therapeutic Chemical (ATCvet) classification system.
Knowledge of the target animal species enables the 
presentation of consumption data in Defined Animal 
Daily Doses (ADD). The ADD system is a national 
veterinary equivalent to the international Defined Daily 
Doses (DDD) system applied in the human field [www.
whocc.no]. See further about the ADD system in the 
DANMAP 2009 report. 
The consumption is compared with production in 
kg meat or number of animals produced. Due to an 
increasing number of pigs exported around 30 kg, 
involving 25% of pigs produced in 2010, an adjusted 
measure of consumption per pig was calculated. 
The adjustment is based on the assumption that pigs 
exported at 30 kg, on average received the same amount 
of antimicrobial agents before export, as other pigs from 
farrowing to 30 kg:
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Antimicrobial use per pig produced (adjusted)= 
(ADDs *(Nf/Nw)+ ADDw *(Nf/Nw) + ADDf) / Nf,
where ADDs = Amounts of antimicrobial used in sow 
herds, measured in ADDkg ; ADDw = Amounts of 
antimicrobial used in weaning pigs herds, measured 
in ADDkg ; ADDf = Amounts of antimicrobial used in finisher pigs, measured in ADDkg ; Nw = Number of pigs produced to 30 kg bodyweight, including pigs exported 
at 15-50 kg (mostly at 30 kg); Nf = Number of pigs 
produced to slaughter, whether exported domestically 
or exported.
2.2. Antimicrobial consumption 
in humans
Consumption data presented in this report were 
obtained from the Danish Medicines Agency (DMA) 
(http://www.laegemiddelstyrelsen.dk). The DMA has 
the legal responsibility for monitoring the consumption 
of all human medicinal products. This is carried out by 
monthly reporting of consumption from all pharmacies 
in Denmark, including hospital pharmacies, to the 
DMA. Data from the primary health care sector have 
been collected since 1994, whereas data on consumption 
in hospitals are available from 1997.
Certain categories of hospitals were excluded when 
the consumption was measured by occupied bed-days 
and admissions. This year, data from private hospitals 
and clinics, psychiatric hospitals, specialised non-acute 
care clinics, rehabilitation centres and hospices were 
excluded from DANMAP (representing approximately 
3% of the antimicrobial consumption at hospitals and of 
the number of bed-days).
In Denmark, all antimicrobial agents for human use are 
prescription-only medicines and are sold by pharmacies 
in defined packages. Each package is uniquely identified 
by a code which can be related to package size, content 
as number of unit doses (e.g. number of tablets), content 
as number of Defined Daily Doses (DDD), code of the 
antimicrobial agent in the Anatomical Therapeutic 
Chemical (ATC) classification system, and producer. 
In addition, the following information is collected 
for each transaction: social security number (CPR 
number) of the patient, code identifying the prescribing 
physician, date and place (pharmacy, hospital pharmacy, 
institution) of the transaction, and information 
regarding reimbursement of cost, if applicable. 
Information on the indication for the prescription is not 
yet available. The data are transferred monthly to the 
DMA in an electronic format. 
The present report includes data on the consumption 
of antibacterial agents for systemic use, or group J01, of 
the 2010 update of the ATC classification, in primary 
health care and in hospitals. As recommended by the 
World Health Organization (WHO), consumption of 
antibacterial agents in primary health care is expressed 
as a number of DDDs per 1,000 inhabitants and per day 
(DDD/1,000 inhabitant-days). Consumption in primary 
health care is also reported as a number of packages per 
1,000 inhabitants. Consumption of antibacterial agents 
in hospitals is expressed as a number of DDDs per 1,000 
inhabitants and per day (DDD/1000 inhabitant-days) 
to compare with primary health care and as a number 
of DDDs per 100 occupied bed-days and per day 
(DDD/100 occupied bed-days). Since antimicrobial 
consumption expressed as DDD/100 occupied bed-
days does not necessarily reflect changes in hospital 
activity and production, consumption in hospitals is 
also presented as DDD/100 admitted patients. 
The number of occupied bed-days is calculated as 
the date of discharge minus the date of admission 
(minimum one day), and the number of admissions 
is calculated as one admission whenever a patient 
is admitted to one specific ward (one patient can be 
registered as admitted multiple times if transferred 
between wards during one hospital stay). Data on the 
number of occupied bed-days (or patient-days) and 
number of admissions in each hospital were obtained 
from the National Patient Registry at the National 
Board of Health [http://www.sst.dk].
3. Collection of bacterial isolates
3.1. Animals
Animal isolates included in DANMAP 2010 from 
healthy production animals at slaughter, were 
Escherichia coli, Enterococcus faecium, Enterococcus 
faecalis, Campylobacter coli and Campylobacter jejuni. 
Isolates of E. coli O149 and E. coli F5 (K99) were 
collected from diagnostic submissions and Salmonella 
isolates were collected from subclinical infections as 
well as from cases of clinical salmonellosis.
Campylobacter, indicator E. coli and enterococci. 
Samples from healthy pigs, cattle and broilers were 
collected at slaughter for the DANMAP programme by 
meat inspection staff or company personnel and sent 
for examination to the National Food Institute. For 
broilers, cloacal swab samples were collected weekly 
throughout the year representing all broiler flocks 
in Denmark (approximately 400 samples per year). 
In Denmark, a farm consists typically of more than 
1 flock (2–12 flocks), and even though most of the 
flock samples were analysed only one isolate per farm 
of each bacterial species was finally included in the 
DANMAP report. 
For pigs and cattle, the slaughter plants included in 
the DANMAP programme accounted for 94% and 
90%, respectively, of the total number of animals 
slaughtered in Denmark during 2010. The number of 
pig and cattle samples taken at the slaughter plant was 
proportional to the number of animals slaughtered at 
each plant per year and samples were collected once 
a month from January through November as ceacum 
samples from pigs and rectum samples from cattle. 
As for broilers, only one isolate per farm of each 
bacterial species was included in the DANMAP report. 
Accordingly, the bacterial isolates may be regarded 
as representing a stratified random sample of the 
respective populations, and the observed prevalence 
of resistant isolates provides an estimate of the true 
occurrence in the population. 
An overview of the number of samples analysed, the 
                                                                           
       147DANMAP 2010  
APPENDIX 2.
Note: Data in this table should not be used for reportation of prevalences of the bacterial species     
Table AP2. 1. Number of DANMAP samples, isolates and MIC-tests from healthy production animals at 
slaughter, Denmark
E. coli E. faecium E. faecalis C. jejuni  C. coli  
Pigs No. of samples analysed (1 per farm) 219 738 738 269 269
No. of isolates 199 136 167 - -
No. of isolates MIC-tested/reported 160 133 157 0 103
Cattle No. of samples analysed (1 per farm) 133 - - 216 216
No. of isolates 122 - - - -
No. of isolates MIC-tested/reported 106 - - 98 0
Broilers No. of samples analysed (no. of flocks) 382 382 382 382 382
No. of farms represented  153 169 169 169 169
No. of isolates MIC-tested/reported 118 119 112 41 0
DANMAP 2010
Isolates from diagnostic submissions were collected 
for the DANMAP programme at both the National 
Food Institute and at the Laboratory of Swine Diseases, 
the Danish Agriculture & Food Council, Kjellerup. E. 
coli O149 from diarrhoeic pigs and E. coli F5 (K99) 
from diarrhoeic cattle were included, with no more 
than one isolate representing each farm.  However, E. 
coli F5(K99) was not reported in 2010 due to the low 
number of isolates available. Staphylococcus hyicus 
isolates from skin infections in pigs were also collected, 
but not reported in 2009 and 2010 due to the low 
number of isolates. Data on S. hyicus collected over 
three years are expected to be reported in the next 
DANMAP report.
Salmonella. The National Food Institute is the national 
reference laboratory for Salmonella in animals, feeding 
stuffs and food, and therefore receives all isolates for 
typing. Among all serotyped Salmonella isolates, one 
isolate per farm was selected for the DANMAP report. 
Only isolates of S. Typhimurium and S. Enteritidis 
were included in DANMAP. In general, isolates of S. 
Typhimurium include the monophasic variants with 
antigenic formulas S. 4,5,12:i:- and S. 4,12:i:-.  
The majority of the Salmonella isolates from pigs 
(95% in 2010) originated from the Danish Salmonella 
surveillance programmes: The results of a serological 
surveillance at the slaughterhouses and in all breeding 
herds appointed risk herds to be further examined 
by analysing pen-faecal samples: 1) finisher herds at 
level 2 and level 3 farms (i.e. farms with high level 
of S. Typhimurium antibodies in three successive 
months in meat juice samples taken at slaughter), 2) 
related (supplying) sow herds, and finally 3) breeding 
and multiplier herds with high serum levels in three 
monthly samples. In 2010, 1,089 pig herds were 
appointed as risk herds from the sero-surveillance one 
or more times and S. Typhimurium was isolated from 
434 of these herds (including the monophasic variants). 
In addition, Salmonella in samples from pig herds 
investigated due to clinical disease (not necessarily 
salmonellosis) were included (21 isolates in 2010). 
For broilers, all flocks were sampled before slaughter 
as part of the Salmonella surveillance programme; 
this includes flocks intended for export. Samples were 
collected 15-21 days before slaughter. Since 2008, an 
additional AM (ante mortem)-testing of broiler flocks 
was introduced 7-10 days prior to slaughter. In 2010, 
3,773 broiler flocks were analysed of which 43 were 
positive for Salmonella. Data are not presented in tables 
due to the low number of isolates in 2010.
For cattle, a total of 144 different herds were examined 
based on clinical indication. A total of 26 Salmonella 
were isolated, including seven S. Dublin and 18 S. 
Typhimurium isolates (including the monophasic 
variants S. 4,5,12:i:- and S. 4,12:i:- with six and one 
isolate, respectively).
Further details on the sampling procedures in the 
Salmonella surveillance programmes are described in 
the Annual Report on Zoonoses in Denmark, 2010.
3.2. Meat 
Campylobacter, indicator E. coli and Enterococci. 
The meat isolates originated from meat samples 
collected at wholesale and retail outlets by the Regional 
Veterinary and Food Control Authorities (RFCA) in 
all regions of Denmark. The samples were collected 
during the course of routine inspection carried out 
by the authorities or on specific request from the 
Danish Veterinary and Food Administration (DVFA) 
for the DANMAP programme. The collected material 
consisted of both Danish and imported meat. Indicator 
E. coli and enterococci were collected from beef, pork 
and poultry meat (118, 184 and 187 Danish samples; 
and 99, 175 and 226 imported samples, respectively). 
Campylobacter were only collected from poultry 
meat (72 Danish samples and 95 imported  samples). 
The meat samples were collected according to the 
guidelines for microbiological examination of food 
from the DVFA [Vejledning nr. 9613 af 20. Dec. 2002 
om offentlig mikrobiologisk kontrol af fødevarer]. Only 
one isolate per bacterial species per meat sample was 
selected for DANMAP. 
number of isolates obtained and the number of MIC-
determinations for pigs, cattle and broilers is presented 
in Table AP2.1. For Campylobacter, the isolation rate of 
C. jejuni from pigs and of C. coli from cattle and broilers 
was low and MIC-determinations were therefore not 
performed. Samples from cattle were not analysed for 
enterococci.
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Salmonella. The Salmonella isolates from Danish pork 
and beef originated from the Salmonella surveillance 
programme, comprising swab samples of pork and beef 
carcasses taken at the slaughterhouses after cooling. 
In Danish pork, 22,485 pooled samples (each of five 
carcasses) were analysed in 2010, and an estimated 
1.2% of the pig carcasses were Salmonella positive. In 
addition, 223 single animals were tested in smaller 
slaughterhouses, where 1.8% of the pig carcasses were 
Salmonella positive. In Danish beef, 7,660 pooled 
samples (each of five carcasses) were analysed in 2010, 
and an estimated 0.3% of the cattle carcasses were 
Salmonella positive. In addition, 162 single animals 
were tested in the smaller slaughterhouses, and here 
none of the cattle carcasses were Salmonella positive 
[Annual Report on Zoonoses in Denmark 2010]. All 
isolates of S. Typhimurium and S. Enteritidis from a 
positive batch of meat were included in this report.
Salmonella isolates from imported poultry meat and 
other imported fresh meats originated from a case-by-
case risk assessment programme (Danish Veterinary 
and Food Administration). For each tested batch of 
meat, 12 pooled samples (1–60 single samples) were 
tested for Salmonella. All isolates of S. Typhimurium 
and S. Enteritidis within one batch of meat were 
included in this report. In 2010, 58 of 490 batches of 
imported broiler meat, 56 of 592 batches of imported 
turkey meat, 40 of 296 batches of imported pork, and 
four of 127 batches of imported beef were Salmonella 
positive. As the sampling is risk based, the findings are 
not indicative of the prevalence at retail [Annual Report 
on Zoonoses in Denmark 2010]. 
Isolates of S. Typhimurium include the monophasic 
variants with antigenic formula 4,5,12:i:- and 4,12:i:-.  
3.3. Humans
Salmonella enterica serovars Typhimurium and 
Enteritidis and Campylobacter jejuni. Antimicrobial 
susceptibility was performed on human faecal 
isolates submitted to Statens Serum Institut (SSI). 
Campylobacter isolates were submitted from 
Departments of Clinical Microbiology (DCM) covering 
three geographical regions: Northern Jutland, Funen 
and Roskilde/Køge. Information on travel history was 
obtained for these patients. Salmonella isolates were 
submitted from all DCM in Denmark. Exact figures 
of the proportion tested and the sampling strategy for 
the different species can be found in the corresponding 
chapters of this report. 
Staphylococcus aureus. All blood isolates were referred 
to the Staphylococcus reference laboratory at SSI on a 
voluntary basis. In November 2006, methicillin resistant 
S. aureus (MRSA) became a notifiable disease in 
Denmark and since then it has been mandatory to send 
all MRSA isolates to the reference laboratory. 
Invasive Streptococcus pneumoniae, Streptococcus 
pyogenes (group A streptococci), group B, C and 
G streptococci. Invasive pneumococcal disease is a 
notifiable disease in Denmark, and therefore all blood 
and spinal fluid isolates nationwide are sent to SSI for 
determination or confirmation as well as susceptibility 
testing and typing. Group A, B, C and G streptococcal 
isolates are referred to SSI on a voluntary basis. 
E. coli, Klebsiella pneumoniae, Pseudomonas 
aeruginosa, invasive Enterococcus faecium and 
invasive Enterococcus faecalis. Data were provided 
on all isolates recorded from either blood samples (E. 
coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, 
E. faecium and E. faecalis) or urine samples (E. coli, 
Klebsiella pneumoniae) submitted for susceptibility 
testing to the participating DCM at the following 
hospitals: Rigshospitalet, Hvidovre, Herlev, Hillerød, 
Slagelse, Næstved, Roskilde, Odense, Esbjerg, Vejle, 
Herning, Aarhus, Viborg, and Aalborg. 
In 2010, no samples were collected from healthy 
humans.
4. Isolation and identification of 
bacteria
4.1. Animals 
Salmonella. Examination of samples was done by 
non-selective pre-enrichment of 25 g material in a 
1:10 dilution with buffered peptone water (BPW) and 
incubated 16-20 hours at 37°C. A plate with Modified 
Semi-solid Rappaport-Vassiliadis (MSRV) medium 
was inoculated with 0.1 ml of BPW deposited as 3 
drops. After incubation overnight at 41.5°C, material 
from MSRV swarming zones were inoculated onto 
Brilliant Green Agar. Overnight incubation at 37°C 
was followed by serotyping of suspect colonies by slide 
agglutination. For cattle samples, in addition 1.0 ml 
of the BPW suspension was incubated in 9 ml selenite 
cystine broth overnight at 41.5°C before inoculation on 
MSRV agar. 
Campylobacter. Samples from pigs and poultry were 
examined by direct inoculation on mCCD agar (Oxoid, 
Denmark) followed by incubation in micro-aerophilic 
atmosphere for 2-4 days at 41.5°C. For cattle, selective 
enrichment in Preston broth at a ratio of 1:10 
incubated in microaerophilic atmosphere for 24 h at 
41.5°C was performed followed by inoculation of 10 µl 
of the enrichment broth to mCCD agar. Campylobacter 
suspect colonies were verified by microscopy and 
oxidase activity (oxidase strips, Oxoid). Species-
identification was performed by catalase activity and 
the ability to hydrolyse indoxyl acetate and hippurate. 
All isolates of C. jejuni and C. coli were stored (-80°C).  
E. coli  from healthy animals (indicator E. coli). The 
material was inoculated directly onto Drigalski agar 
(SSI Diagnostica, Denmark) and incubated at 37°C 
overnight. Yellow colonies were inoculated onto BBL 
CHROMagar Orientation Medium (Becton Dickinson, 
Germany) and red colonies were identified as E. coli 
after incubation at 37°C overnight. 
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Enterococci.  One drop of material suspended in 2 ml 
sodium chloride (0.9%) was spread on Slanetz-Bartley 
agar and incubated for two days at 42°C. Up to four 
colonies with morphology typical of E. faecalis / E. 
faecium were sub-cultivated on blood agar. Colonies 
were identified by the following criteria: Colour, 
motility, arginine dihydrolase testing and the ability 
to ferment mannitol, sorbitol, arabinose, raffinose and 
melibiose. All isolates of E. faecium and E. faecalis were 
stored (-80°C). Like in previous years, no samples from 
cattle were investigated for enterococci.
Pathogens. The diagnostic submissions were 
examined according to the standard procedures at the 
participating laboratories. 
4.2. Meat
Salmonella was isolated according to the guidelines for 
microbiological examination of food from the Danish 
Veterinary and Food Administration [NMKL No. 187, 
2007]. Sero- and phage-typing was performed for all 
isolates at the National Food Institute. 
Campylobacter was isolated according to the guidelines 
for microbiological examination of food from the 
DVFA [NMKL No. 119, 3rd ed., 2007]. Identification 
was performed at the Regional Veterinary and Food 
Control Authorities (RFCA) by microscopy or test kit 
DRO150M (Oxoid), and oxidase activity (except for 
one of the laboratories), catalase activity, and the ability 
to hydrolyse indoxyl acetate and hippurate. All isolates 
of C. jejuni, C. coli and C. lari were stored (-80°C) and 
sent to the National Food Institute for MIC-testing of C. 
jejuni and C. coli.
Indicator E. coli was isolated by adding 5 g of the 
sample to 45 ml of MacConkey- or laurylsulfphate-
broth, which was incubated overnight at 44°C, and 
subsequently streaked onto violet red bile agar and 
incubated for 24h at 44°C by RFCA. Presumptive E. coli 
were further identified by CHROMagar Orientation 
Medium (one laboratory) or by indole- and lactose 
testing in laurylsulphate-broth culture incubated 
overnight at 44°C. E. coli isolates were sent to the 
National Food Institute for MIC-testing. All isolates 
were stored (-80°C).
Enterococci were isolated by adding 5 g of the sample 
to 45 ml of azide dextrose broth, which was incubated 
overnight at 44°C and subsequently streaked onto 
Slanetz-Bartley agar. After incubation at 44°C for 48 
hours, colonies typical of E. faecium and E. faecalis were 
further identified by the following criteria: Colour of 
material, motility, arginine dihydrolase testing and the 
ability to ferment mannitol, sorbitol, arabinose, raffinose 
and melibiose. All isolates of E. faecium and E. faecalis 
were stored (-80°C) and sent to the National Food 
Institute for MIC-testing.
4.3. Humans
Salmonella. isolates were serotyped according to the 
Kauffman-White Scheme. 
Campylobacter. Species identification was performed 
using a species specific PCR assay [Klena et al. 2004, J 
Clin Microbiol. 42: 5549-5557]. 
Staphylococcus aureus. Sequencing of the S. 
aureus specific spa gene was used both for species 
conformation and typing purposes. Any spa negative 
isolates were confirmed as S. aureus by MALDI-TOF.  
The spa typing [Harmsen et al. 2003. J Clin Microbiol. 
41: 5442-5448] and additional typing by multi locus 
sequence typing (MLST) was performed [Enright et al. 
2000. J Clin Microbiol. 38: 1008-1015] and annotated 
using eBURST v.3 software (www.mlst.net). Based on 
the spa and MLST typing, each isolate was assigned to 
a clonal complex (CC). For MRSA isolates, presence 
of the mecA methicillin resistance gene was confirmed 
by PCR [Larsen et al. 2008. Clin Microbiol Infect. 14: 
611-614].
5. Susceptibility testing
  
MIC-testing 
Antimicrobial susceptibility testing of Salmonella, 
Campylobacter, indicator E. coli, Enterococcus 
and the veterinary pathogens was performed as 
microbroth dilution MIC with the Sensititre system 
(Trek Diagnostic Systems Ltd., East Grinstead, United 
Kingdom). Inoculation and incubation procedures were 
in accordance with the CLSI guidelines. The following 
quality control strains were used for internal control: 
Staphylococcus aureus ATCC 29213, Escherichia coli 
ATCC 25922, Pseudomonas aeruginosa ATCC 27853, 
Enterococcus faecalis ATCC 29212 and Campylobacter 
jejuni ATCC 33560. 
Table AP2.2 presents an overview of the interpretation 
of MIC-values used for all combinations of bacteria 
and antimicrobial agents. Since 2007, MIC-data were 
interpreted using EUCAST epidemiological cut-off 
values with a few exceptions as explained by footnotes 
in Table AP2.2. In addition, corresponding clinical 
breakpoints are also presented in Table AP2.2 and 
shown in all MIC-distributions in order to visualize the 
impact of using epidemiological cut-off values contra 
clinical breakpoints. In most cases, data from previous 
years presented in this DANMAP report are not 
corrected for changes in interpretation (e.g. all data are 
presented with use of the interpretation applied for the 
year in question). 
All isolates from animals and meat were MIC-tested 
at the National Food Institute. The Salmonella and 
Campylobacter isolates of human origin were tested 
at SSI. From 1998–2007, a performance test for 
susceptibility testing was carried out once a year to 
ascertain the quality and comparability of susceptibility 
testing in the laboratories providing MIC-data. In 
2002, MIC-testing at the National Food Institute was 
accredited by DANAK (the Danish national body 
for accreditation), and the SSI is awaiting the same 
accreditation. Both laboratories participate in European 
ring trials to ensure MIC-data of constantly high 
quality.
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Table AP2.2. EUCAST epidemiological cut-off values (blue fields) and corresponding clinical breakpoints used 
as interpretation criteriae for MIC-determination
*   EUCAST epidemiological cut-off value or EUCAST clinical breakpoint. Clinical breakpoints defined by CLSI (unmarked) were listed if a 
clinical breakpoint was not defined by EUCAST         
a) The EUCAST epid. value of >1 was not applied according to investigations presented in DANMAP 2006 (trade name synercid)  
b) The EUCAST epid. value of >4 was not applied, since the purpose was to look for high level ciprofloxacin resistance as  described by 
Werner et al. 2010 (Int J Antimicob Agents. 35: 119-125)              
             
Antimicrobial agent
Salmonella E. coli E. faecium E. faecalis C. jejuni  C. coli  
Epid
cut-off
μg/ml
Clin 
break
μg/ml
Epid
cut-off
μg/ml
Clin
break
μg/ml
Epid
cut-off
μg/ml
Clin
break
μg/ml
Epid
cut-off
μg/ml
Clin
break
μg/ml
Epid
cut-off
μg/ml
Clin
break
μg/ml
Epid
cut-off
μg/ml
Clin
break
μg/ml
Ampicillin >8* >8* >8* >8* >4* >8* >4* >8*
Apramycin >16 >16
Avilamycin >16* >8*
Cefotaxime >0.5* >2* >0.25* >2*
Cefoxitin
Ceftiofur >2* >1*
Chloramphenicol >16* >16 >16* >16 >32* >16 >32* >16 >16* >16*
Ciprofloxacin >0.06 * >1* >0.03* >1* >16  b) >8  b) >1* >1* >1* >1*
Colistin >2* >2* >2* >2*
Erythromycin >4* >4 >4* >4 >4* >4* >16* >16
Florfenicol >16* >16*
Gentamicin >2* >4* >2* >4* >32*  >512 >32* >512 >1* >2*
Kanamycin >1,024 >1,024
Linezolid >4* >4* >4* >4*
Nalidixic acid >16* >16 >16* >16 >16* >32*
Neomycin >4* >8*
Penicillin >16* >8 >16* >8
Quinupristin/
dalfopristin >4  a) >4*
Salinomycin >4 >4
Spectinomycin >64 >64*
Streptomycin >16* >16* >128* >512* >2* >4*
Sulfonamide >256 >256 >256 >256
Teicoplanin >2* >2* >2* >2*
Tetracycline >8* >8 >8* >8 >4* >8 >4* >8 >2* >8 >2* >8
Tiamulin
Tigecycline >0.25* >0.5* >0.25* >0.5*
Trimethoprim >2* >4* >2* >4*
Vancomycin >4* >4* >4* >4*
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One isolate per bacterial species per farm, per meat 
sample, or per patient was tested for antimicrobial 
susceptibility. For animal isolates in excess numbers 
(typically for indicator E. coli, enterococci and 
Campylobacter from healthy production animals), a 
random selection of 100 to 150 isolates was appointed 
to MIC-testing. Due to low number of isolates, C. jejuni 
from pigs, C. coli from cattle, C. coli from broilers, and S. 
hyicus from pigs (clinical cases) were not susceptibility 
tested.
Staphylococcus aureus from humans
Susceptibility testing was performed by disc diffusion 
according to EUCAST methodology using discs 
from Oxoid (Ballerup, Denmark) on Mueller-Hinton 
Agar (SSI, Copenhagen, Denmark). The following 
antimicrobials were tested: Erythromycin, clindamycin, 
kanamycin, rifampicin, penicillin, cefoxitin, fusidic acid, 
norfloxacin, linezolid, tetracycline and mupirocin. In 
addition, MRSA isolates were screened for susceptibility 
towards glycopeptides by spot test on Brain-Heart 
infusion (BHI) agar (Becton Dickinson, Germany) 
with teicoplanin (5 mg/L) and confirmed by Etest® 
(AB Biodisk, Solna, Sweden) on BHI with inoculum of 
McFarland 2.0. In case of MIC ≥ 8 mg/L for vancomycin 
and teicoplanin or an MIC ≥12 mg/L for teicoplanin, 
population analysis profile against vancomycin 
was performed [Wootton et al. 2001. J Antimicrob 
Chemother. 47: 399-403].
Invasive Streptococcus pneumonia from humans 
Screening for penicillin-resistant S. pneumoniae was 
performed using a 1 μg oxacillin tablet (Neo-Sensitabs®, 
A/S Rosco, Taastrup, Denmark) on 10% horse blood 
agar (SSI Diagnostika, Hillerød, Denmark), and for 
erythromycin-resistant S. pneumoniae using a 78 
μg erythromycin tablet (Neo-Sensitabs®, A/S Rosco, 
Taastrup, Denmark) on 10% horse blood agar (SSI 
                                                                           
       151DANMAP 2010  
APPENDIX 2.
Diagnostika). The breakpoints used are defined by 
the CLSI. Penicillin and erythromycin MICs were 
determined using STP6F plate, Sensititre (Trek 
Diagnostic Systems Ltd., East Grinstead, United 
Kingdom) as recommended by the manufacturer. The 
breakpoints used are defined by EUCAST. Resistant 
isolates were defined as both fully and intermediary 
resistant isolates.  
Invasive Streptococcus pyogenes (group A), group B, C 
and G streptococci from humans 
Screening for penicillin-resistant streptococci was 
performed using a 1 μg oxacillin disk (Oxoid, Greve, 
Denmark) on 10% horse blood agar (SSI Diagnostika, 
Hillerød, Denmark), and for erythromycin-resistant 
streptococci using a 78 μg erythromycin tablet (Neo-
Sensitabs®, A/S Rosco, Taastrup, Denmark) on 10% 
horse blood agar (SSI Diagnostika). Erythromycin 
resistant streptococci were tested with a 15 μg 
erythromycin disk (Oxoid) and a 2 μg clindamycin 
disk (Oxoid) on Mueller-Hinton Agar (Mueller-Hinton 
plate, 5% blood, 20 mg beta-NAD, SSI Diagnostika). 
Erythromycin MICs were determined using the Etest® 
(AB Biodisk, Solna, Sweden) on Mueller-Hinton 
incubated at 36°C, 5% CO2. The breakpoints used are defined by the EUCAST. Resistant isolates were defined 
as both fully and intermediary resistant isolates. 
E. coli, K. pneumoniae, P. aeruginosa, invasive E. 
faecium and E. faecalis from humans 
In 2010, the DCM at hospitals in Næstved, Odense 
and Viborg, and Rigshospitalet, that is the national 
referral hospital, used the tablet diffusion method 
(Neo-Sensitabs®, A/S Rosco) on Danish Blood Agar 
(Resistensplade, SSI Diagnostika) and the breakpoints 
defined for this medium by A/S Rosco. 
However, the DCM at Odense Hospital used Neo-
Sensitabs® on Mueller-Hinton agar (SSI Diagnostica) 
when testing urine isolates and Columbia agar with 
4.5% NaCl (SSI Diagnostika) when testing staphylococci 
for oxacillin resistance. The DCM at Vejle Hospital 
used the Neo-Sensitabs® on Mueller-Hinton agar (SSI 
Diagnostica) and the breakpoints defined for this 
medium by A/S Rosco. The DCM at Esbjerg Hospital 
used the tablet diffusion method (Neo-Sensitabs®, A/S 
Rosco) on Mueller-Hinton agar (SSI Diagnostika) 
when testing E. coli. The DCM at Aalborg Hospital 
used the Neo-Sensitabs® on Mueller-Hinton agar (SSI 
Diagnostika) in combination with the tablet diffusion 
method (A/S Rosco) and the breakpoints defined by 
the Swedish Reference Group for Antibiotics (SRGA) 
(available from: URL: http://www.srga.org/). The only 
exception from SRGA was that the wild type population 
of E. coli was deemed susceptible for ampicillin instead 
of intermediary susceptible.
In 2010, the DCM at Hillerød and Hvidovre Hospitals 
used the disk diffusion method (Oxoid, Basingstoke, 
UK) on Iso-Sensitest (ISA) medium (Oxoid). The 
DCM at Slagelse Hospital used the same disks on Iso-
Sensitest (ISA) medium with or without 5% horse blood 
(Oxoid) according to test material and bacterial species. 
Laboratories performing the disk diffusion method 
used the breakpoints defined by the SRGA. In 2010, the 
DCM at Herlev, Herning and Aarhus Hospitals changed 
to methods described by EUCAST (DCM at Aarhus 
and Herning hospitals per February and May 2010, 
respectively). 
All submitting laboratories participate in national and 
international quality assurance collaborations such 
as the United Kingdom National External Quality 
Assessment Schemes (NEQAS).
Quinupristin/dalfopristin breakpoint  
The epidemiological cut-off value suggested by EUCAST 
for quinupristin/dalfopristin when testing E. faecium 
is >1 μg/ml. In DANMAP, E. faecium isolates with 
MICs >4 μg/ml are reported resistant to quinupristin/
dalfopristin due to an evaluation study presented in the 
DANMAP 2006 report, page 49-50.
6. Data handling
6.1. Animal  
  
The results from the primary examination of samples 
from slaughterhouses and primary production for the 
bacteria of interest - positive as well as negative findings 
- and of the susceptibility testing were stored in an 
Oracle Database 8i Enterprise Edition® at the National 
Food Institute. The susceptibility data were stored 
as continuous values (MIC) as well as categorised as 
susceptible or resistant, respectively, as defined by the 
relevant epidemiological cut-off value. Each isolate was 
identified by the bacterial species, including subtype as 
applicable and by the date of sampling and the species 
of animal. Information on the farm of origin was also 
recorded. All handling and evaluation of results was 
carried out using SAS®Software, SAS Enterprise Guide 
3.0.
6.2. Meat
  
Results from the analysis of food samples were reported 
via the database administrated by the Danish Veterinary 
and Food Administration, except for the data on 
Salmonella, which were reported to and extracted from 
the laboratory database at the National Food Institute. 
For each bacterial isolate, information was available 
on the food type, bacterial species, date and place of 
sampling, date of examination of the sample, country 
of slaughter, the RFCA that collected and processed 
the sample, and an identification number, which makes 
it possible to obtain further information about the 
isolate from the Authority. Furthermore, more detailed 
information about the country of origin was recorded 
whenever possible. 
6.3. Human
  
Salmonella and Campylobacter. Data on Salmonella 
and Campylobacter infections are stored in the 
Danish Registry of Enteric Pathogens (SQL database) 
maintained by SSI. This register includes only one 
isolate per patient within a window of six months and 
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includes data on susceptibility testing of gastrointestinal 
pathogens.
Staphylococcus aureus. For MRSA, data on the 
characteristics of the isolates and the clinical/
epidemiological information were obtained from the 
Danish MRSA register at SSI (mandatory reportable). 
In this database, patients were only registered the first 
time they were diagnosed with MRSA regardless of 
whether it was colonisation or infection. Based on the 
reported information, MRSA cases were classified as 
colonisation/active screening (i.e. surveillance samples 
to detect nasal, throat, gut or skin colonisation), 
imported infection (i.e. acquired outside Denmark), 
infection acquired in a Danish hospital, defined as 
diagnosed >48 hours after hospitalisation with no sign 
of infection at admittance (HA-MRSA) or infection 
diagnosed outside hospitals (community onset). 
MRSA cases with community onset were further 
classified according to risk factors during the previous 
12 months as either health-care associated with 
community onset (HACO) or community-acquired 
(CA). Health-care associated risk factors included 
prior hospitalisations or stay in long-term care facilities 
within 12 months prior to MRSA isolation and being a 
health-care worker. Community risk factors included 
known MRSA positive household members or other 
close contacts. Non-Danish origin defined as the person 
or one of the parents being born outside Denmark was 
investigated through the Danish Civil Registry. 
Streptococcus pneumoniae, Streptococcus pyogenes 
(group A streptococci), group B, C and G 
streptococci. Data on susceptibility testing of isolates 
were stored as MICs in a Microsoft® Access database 
placed at a SQL server at SSI. Analysis including 
selection of isolates from blood and spinal fluid samples 
and removal of duplicate isolates was performed in 
Microsoft® Access. 
E. coli, K. pneumoniae, P. aeruginosa, invasive E. 
faecium and invasive E. faecalis. Fourteen DCM 
provided data on resistance levels in E. coli, Klebsiella 
pneumoniae, Pseudomonas aeruginosa, invasive E. 
faecium and invasive E. faecalis isolates. Data were 
extracted from the following laboratory information 
systems:
- ADBakt (Autonik AB, Skoldinge, Sweden) for the 
DCM at Hvidovre, Herlev and Aalborg Hospitals.
- MADS (DCM, Skejby Hospital, Aarhus, Denmark) 
for the DCM at Rigshospitalet and Slagelse, Næstved, 
Roskilde, Odense, Esbjerg, Vejle, Herning, Aarhus 
(Skejby) and Viborg Hospitals.
- SafirLIS Microbiology (Profdoc Lab AB, Borlänge, 
Sweden) for the DCM at Hillerød Hospital.
Resistance data on the first isolate per patient per year 
were included. Generally, resistance data were excluded 
if susceptibility to a certain antimicrobial agent was 
tested on only a selected number of isolates. 
7. Calculation of confidence limits
Estimation of exact 95% (two-sided) confidence 
intervals for proportions were based on binomial 
probability distributions as described in Armitage & 
Berry [Statistical Methods in Medical Research, 4th 
ed. 2001, Oxford: Blackwell Scientific Publications]. 
Significance tests of differences between proportions of 
resistant isolates were calculated using SAS®Software, 
SAS Enterprise Guide 3.0 or StatCalc in EpiInfo™ v. 6. 
In the text, significant differences imply statistically 
significant differences where p<0.05 using Chi-square, 
or Fisher’s Exact Test when the number of samples is 
low (<25). 
Anne Mette Seyfarth (animal and meat data) 
and Line Skjøt-Rasmussen (human data)
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